valproic acid has been researched along with Bipolar Disorder in 1344 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topiramate, a structurally novel anticonvulsant, is being evaluated for other neurological conditions such as migraine, neuropathic pain, and essential tremor, and also for psychiatric conditions such as bipolar disorder, bulimia, post-traumatic stress disorder, and schizoaffective disorder, in addition to obesity." | 10.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "Lithium carbonate is the drug of choice for the management of bipolar disorder, but 20% to 40% of patients do not exhibit adequate response to this agent." | 10.16 | Non-lithium treatment for bipolar disorder. ( Post, RM, 1990) |
| "Patients with bipolar disorder treated with lithium often require additional antipsychotics or anticonvulsants." | 9.69 | Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes. ( Bowden, CL; Calabrese, JR; Friedman, ES; Fung, V; Iosifescu, DV; Ketter, TA; Kocsis, JH; Köhler-Forsberg, O; McElroy, SL; McInnis, M; Nierenberg, AA; Ostacher, MJ; Shelton, RC; Sylvia, LG; Thase, M; Tohen, M, 2023) |
| " There is little evidence indicating the efficacy of celecoxib adjuvant therapy in treatmenting of manic episodes of bipolar disorder." | 9.69 | Does celecoxib with sodium valproate have an augmentation effect on acute mania in bipolar disorder? A double-blind controlled clinical trial in Iran. ( Ahrari, S; Eslamzadeh, M; Faridhosseini, F; Khadem-Rezaiyan, M; Pourgholami, M; Salimi, Z; Shahini, N; Talaei, A, 2023) |
| "The effects of long-term consequences of lithium, valproic acid, carbamazepine and antipsychotic agents on the development of dementia or cognitive impairments in patients with bipolar disorder were investigated." | 9.41 | [Effects of lithium, valproic acid, carbamazepine and antipsychotic agents on cognition in bipolar disorders-A systematic review]. ( Leopold, S; Quante, A, 2023) |
| " In/outpatients (n = 68) aged 18-70, experiencing mania or hypomania, were assigned to 3 weeks ebselen (600 mg bd) (n = 33) or placebo (n = 35)." | 9.34 | A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. ( Cowen, PJ; Godlewska, BR; Holder, AA; MacDonald, O; Shanyinde, M; Sharpley, AL; Singh, N; Williams, C, 2020) |
| "In the present study, an effort was made to investigate the effect of lamotrigine on cognitive function and serum inflammatory factors in patients with depression of recurrent bipolar disorder and to explore its possible mechanism." | 9.27 | Effect of lamotrigine on cognitive function and serum inflammatory factors in patients with depression of recurrent bipolar disorder. ( Li, L; Shi, S; Song, L; Wang, X, 2018) |
| "We previously conducted a randomized, double-blind, controlled, 12-week study evaluating the effect of add-on dextromethorphan (DM), a noncompetitive N-methyl-D-aspartate receptor antagonist, on patients with bipolar disorder (BD) treated using valproate (VPA), which showed negative clinical differences." | 9.24 | The COMT Val158Met Polymorphism Is Associated With Response to Add-on Dextromethorphan Treatment in Bipolar Disorder. ( Chang, YH; Chen, KC; Chen, PS; Chen, SL; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, TY; Yang, YK, 2017) |
| " Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder." | 9.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| "Ziprasidone, adjunctive to either lithium or valproate, has previously been shown to be associated with a significantly lower risk of relapse in bipolar disorder compared with lithium or valproate treatment alone." | 9.17 | Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: clinical and methodological implications. ( Bowden, CL; Gundapaneni, BK; Karayal, ON; O'Gorman, C; Schwartz, JH, 2013) |
| "Patients with bipolar disorder and past suicide attempts (N=98) were randomly assigned to treatment with lithium or valproate, plus adjunctive medications as indicated, in a double-blind 2." | 9.15 | Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. ( Burke, AK; Currier, D; Galfalvy, HC; Grunebaum, MF; Harkavy-Friedman, J; Mann, JJ; Oquendo, MA; Parsey, RV; Sher, L; Sublette, ME; Sullivan, GM, 2011) |
| "Based on our findings, folic acid seems to be an effective adjuvant to sodium valproate in the treatment of the acute phase of mania in patients with bipolar disorder." | 9.14 | Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial. ( Asadi, S; Behzadi, AH; Chalian, M; Ghadiri, M; Omrani, Z, 2009) |
| "To pilot the efficacy and safety data of lamotrigine adjunctive therapy to lithium and divalproex in patients with rapid-cycling bipolar disorder (RCBD) and a recent substance use disorder (SUD)." | 9.14 | Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. ( Calabrese, JR; Chan, PK; Conroy, C; Fang, Y; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE; Serrano, MB; Wang, Z, 2010) |
| " We used different keywords, including bipolar disorder, lithium and valproic acid, inositol role in bipolar disorder, side effects, inositol depletion, supplementation of inositols under lithium treatment, inositol role in metabolism, hypothyroidism, renal and cardiac functionality." | 9.12 | Combined treatment of myo-inositol and d-chiro-inositol (80:1) as a therapeutic approach to restore inositol eumetabolism in patients with bipolar disorder taking lithium and valproic acid. ( D'Ambrosio, F; Di Lorenzo, C; Janiri, L, 2021) |
| "l-carnitine had no effect on mean weight loss compared with placebo (-1." | 9.12 | Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. ( Elmslie, JL; Hunt, PJ; Joyce, PR; Mann, JI; Porter, RJ, 2006) |
| " The combination of risperidone and divalproex sodium is used to treat the manic phase of bipolar disorder." | 9.11 | Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder. ( Alexander, J; Lacroix, D; Ravindran, A; Silverstone, P; van Schaick, E; Vermeulen, A, 2004) |
| "Prior work reported elevated gray matter (GM) lactate and Glx (glutamate + glutamine + GABA) concentrations in unmedicated patients with bipolar disorder (BP) compared with healthy controls (HC)." | 9.11 | Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. ( Dager, SR; Demopulos, C; Dunner, DL; Friedman, SD; Hirashima, F; Lyoo, IK; Parow, A; Renshaw, PF; Stoll, AL, 2004) |
| "The objective of this study was to determine the clinical and quality of life outcomes associated with adjunctive treatment of olanzapine added to either lithium or valproic acid/divalproex sodium in patients with bipolar disorder." | 9.11 | Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. ( Breier, A; Namjoshi, MA; Risser, R; Shi, L; Tohen, M, 2004) |
| "These pilot data, from the first prospective comparison study of risperidone and olanzapine in bipolar disorder, suggest that adjunctive administration of either agent may reduce depressive symptom severity." | 9.11 | The antidepressant effects of risperidone and olanzapine in bipolar disorder. ( Kennedy, SH; Konarski, JZ; Mancini, DA; McCann, S; McIntyre, RS; Srinivasan, J, 2004) |
| "Divalproex maintenance treatment for bipolar disorder resulted in comparable medical costs, clinical and QOL outcomes compared with lithium." | 9.11 | Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial. ( Ahearn, EP; Hirschfeld, RM; Keck, PE; Palmer, C; Revicki, DA; Weisler, RH, 2005) |
| "The authors tested the hypothesis that divalproex would be more effective than lithium in the long-term management of patients with recently stabilized rapid-cycling bipolar disorder." | 9.11 | A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. ( Bilali, S; Calabrese, JR; Findling, RL; Ganocy, SJ; Jackson, K; Rapport, DJ; Shelton, MD; Youngstrom, EA, 2005) |
| "This study compared the efficacy, safety, and tolerability of divalproex and olanzapine in the treatment of acute mania associated with bipolar disorder." | 9.10 | A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. ( Sachs, G; Sommerville, KW; Swann, AC; Weisler, R; Wozniak, P; Zajecka, JM, 2002) |
| "The medical records of all inpatients with bipolar disorder at the Connecticut Mental Health Center in 1997 were examined to compare length of stay for patients who began monotherapy with divalproex (27 treatment starts) and lithium (20 treatment starts)." | 9.09 | Effects of divalproex versus lithium on length of hospital stay among patients with bipolar disorder. ( Baker, CB; Dalkilic, A; Diaz, E; Pearsall, HR; Woods, SW, 2000) |
| "A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers." | 9.09 | A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. ( Ghaemi, SN; Guille, C; Sachs, GS, 2000) |
| "[corrected] To assess efficacy and safety of gabapentin in the treatment of bipolar disorder." | 9.09 | Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. ( Crockatt, JG; Janney, CA; Pande, AC; Tsaroucha, G; Werth, JL, 2000) |
| "Resolution of hyperammonemia caused by Valproic acid therapy may be enhanced with the administration of L-carnitine." | 8.95 | Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report. ( Ballabio, M; Cattaneo, CI; D'Innella, P; Fornaro, M; Ressico, F; Valsesia, R, 2017) |
| "The mood stabilizers lithium and valproic acid (VPA) are traditionally used to treat bipolar disorder (BD), a severe mental illness arising from complex interactions between genes and environment that drive deficits in cellular plasticity and resiliency." | 8.89 | Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. ( Chiu, CT; Chuang, DM; Hunsberger, JG; Wang, Z, 2013) |
| "This paper reviews the current treatment guidelines for the treatment of bipolar disorder and examines the rationale behind the use of aripiprazole in combination with mood stabilizers for acute and long-term treatment of bipolar disorder." | 8.88 | Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance. ( de Bartolomeis, A; Perugi, G, 2012) |
| " We review the clinical literature which suggests that tolerance can develop to most treatment approaches in bipolar illness and present an animal model of tolerance development to anticonvulsant effects of carbamazepine or lamotrigine on amgydala-kindled seizures." | 8.87 | Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders. ( Post, RM; Weiss, SR, 2011) |
| "The mood stabilizers lithium, valproate and lamotrigine are traditionally used to treat bipolar disorder." | 8.87 | Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. ( Chuang, DM; Fessler, EB; Wang, ZF, 2011) |
| "Oxcarbazepine, a keto derivative of the 'mood stabiliser' carbamazepine, may have efficacy in the treatment of acute episodes of bipolar disorder." | 8.87 | Oxcarbazepine for acute affective episodes in bipolar disorder. ( Geddes, J; Macritchie, K; Vasudev, A; Vasudev, K; Watson, S; Young, AH, 2011) |
| "Olanzapine was licensed in the USA by the Food and Drug Administration in 2003 for the prevention of relapse in patients with bipolar disorder when the acute manic episode had responded to treatment with olanzapine." | 8.86 | Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. ( Cipriani, A; Geddes, JR; Rendell, J, 2010) |
| "Randomised controlled trials comparing olanzapine with placebo or other active treatment in long-term treatment of bipolar disorder." | 8.85 | Olanzapine in long-term treatment for bipolar disorder. ( Cipriani, A; Geddes, J; Rendell, JM, 2009) |
| "The preclinical and clinical MRS findings were generally supportive of the involvement of myo-inositol in bipolar disorder and its treatment." | 8.82 | Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. ( Kim, H; McGrath, BM; Silverstone, PH, 2005) |
| "Carbamazepine and valproate are used in the treatment of acute bipolar mania and as maintenance treatments for bipolar disorder." | 8.81 | Carbamazepine and valproate in the maintenance treatment of bipolar disorder. ( Keck, PE; McElroy, SL, 2002) |
| "Although lithium has been the most commonly used maintenance treatment in bipolar disorder for several decades, valproate is being used increasingly - especially in the United States of America." | 8.81 | Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. ( Geddes, JR; Goodwin, GM; Haslam, DR; Macritchie, KA; Scott, J, 2001) |
| "Lithium and certain anticonvulsants, including carbamazepine and valproic acid, are effective antimanic drugs for treating bipolar disorder, but their mechanisms of action remain uncertain." | 8.81 | Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? ( Bosetti, F; Rapoport, SI, 2002) |
| "As clinical experience with lithium treatment of bipolar disorders accumulates, factors predictive of nonresponse are emerging." | 8.79 | Lithium therapy: limitations and alternatives in the treatment of bipolar disorders. ( Calabrese, JR; Woyshville, MJ, 1995) |
| "The research literature on alternative drug treatments to lithium therapy for the prevention of recurrences in bipolar disorders is discussed." | 8.78 | Alternative prophylactic treatments to lithium in bipolar disorders. ( Altamura, AC; Mauri, MC; Percudani, M; Regazzetti, MG, 1990) |
| "Valproic acid (VPA) is used for the treatment of epilepsy and bipolar disorder (BD)." | 8.12 | Long-term use of valproic acid reduced mortality in bipolar disorder patients in a Taiwanese population: An association analysis using the national health insurance research database (NHIRD). ( Hsieh, TC; Lin, CC; Wu, LS, 2022) |
| "Bipolar disorder and treatment with lithium, antipsychotics, valproate, and lamotrigine." | 8.12 | Association of Lithium Treatment With the Risk of Osteoporosis in Patients With Bipolar Disorder. ( Köhler-Forsberg, O; Nierenberg, AA; Rohde, C; Østergaard, SD, 2022) |
| "In a nation-wide population-based longitudinal register linkage study for the first time 1) to investigate long-term response to lithium in patients with bipolar disorder with and without comorbid epilepsy, and 2) within patients with bipolar disorder and comorbid epilepsy to compare differences in responses between lithium, valproate and lamotrigine." | 8.12 | Response to lithium and anticonvulsants among patients with bipolar disorder with and without comorbid epilepsy - A nation-wide population-based longitudinal study. ( Budtz-Jørgensen, E; Gerds, T; Kessing, LV; Ziersen, SC, 2022) |
| "Although valproate and lithium are most commonly prescribed for bipolar disorder patients, studies comparing their effects on the risk of dementia are limited." | 8.12 | Effect of valproate and lithium on dementia onset risk in bipolar disorder patients. ( Ji, E; Kim, KW; Kwon, JS; Moon, W; Shin, J, 2022) |
| "The aim of this study was to compare the outcomes of monotherapy in individuals with bipolar disorder who are prescribed lithium, valproate, quetiapine, olanzapine, venlafaxine, or citalopram in private psychiatric practices in Germany." | 8.02 | Bipolar Disorder and Outcomes of Monotherapy with Lithium, Valproate, Quetiapine, Olanzapine, Venlafaxine, and Citalopram. ( Bauer, M; Bohlken, J; Kostev, K; Riedel-Heller, S, 2021) |
| "Although mood stabilizers such as lithium (LIT), valproate (VAL), and lamotrigine (LMT) appear to be efficacious treatments for bipolar disorder (BD) in research settings, the long-term response to these mood stabilizers in clinical practice is highly variable among individuals." | 7.96 | Clinical correlates associated with the long-term response of bipolar disorder patients to lithium, valproate or lamotrigine: A retrospective study. ( Bahk, WM; Jung, YE; Kim, MD; Kwon, YJ; Lee, J; Lee, JG; Lee, K; Nam, B; Seo, JS; Song, JH; Wang, SM; Woo, YS; Yoon, BH, 2020) |
| "These findings suggest that carnitine deficiency is associated with the VPA dose and the serum VPA level in patients with bipolar disorder." | 7.96 | Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder. ( Ishioka, M; Kubo, K; Miyazaki, K; Nakagami, T; Shimoda, K; Sugawara, N; Tarakita, N; Yasui-Furukori, N; Yokoyama, S, 2020) |
| "The cancer incidence of bipolar disorder patients treated with VPA was no significant difference than treated with lithium and other anticonvulsants." | 7.88 | Long-term use of valproic acid and the prevalence of cancers in bipolar disorder patients in a Taiwanese population: An association analysis using the National Health Insurance Research Database (NHIRD). ( Hsieh, TC; Lin, CC; Wu, LS, 2018) |
| "Valproic acid (VPA) provides a common treatment for both epilepsy and bipolar disorder; however, common cellular mechanisms relating to both disorders have yet to be proposed." | 7.88 | Diacylglycerol kinase (DGKA) regulates the effect of the epilepsy and bipolar disorder treatment valproic acid in ( Kelly, E; Sharma, D; Wilkinson, CJ; Williams, RSB, 2018) |
| "We conducted an observational retrospective cohort study between January 1 and December 31, 2013, which included patients with a diagnosis of bipolar disorder treated with lithium carbonate in 25 Colombian cities; we evaluated socio-demographic variables, lithium dose, co-medication, drug interactions and adverse reactions." | 7.85 | [Profile of lithium carbonate use in patients with bipolar disorder in Colombia]. ( Alzate-Carvajal, C; Machado-Alba, JE; Machado-Duque, ME; Zapata-Castañeda, K, 2017) |
| " The aim of this study was to determine the influence of valproic acid (VPA) treatment on adiponectin, leptin levels and oxidative stress in bipolar disorder (BD)." | 7.85 | Evaluation of adiponectin and leptin levels and oxidative stress in bipolar disorder patients with metabolic syndrome treated by valproic acid. ( Akgün, S; Kahraman, A; Köken, T, 2017) |
| "Valproic acid (VPA) is an FDA-approved medication widely prescribed for seizures, migraines, and mixed or manic episodes in bipolar disorder." | 7.85 | Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report. ( Birur, B; Fargason, RE; Landry, KB; Patel, N, 2017) |
| "Valproic acid (VPA) is widely used for treating patients with bipolar disorder; however, it has adverse effects on cognitive function." | 7.83 | Effect of valproic acid on dementia onset in patients with bipolar disorder. ( Chiu, CH; Huang, CJ; Liu, IC; Tsai, PS; Wang, MY, 2016) |
| "Valproic acid (VPA) is approved by the Food and Drug Administration (FDA) for the treatment of manic or mixed episodes associated with bipolar disorder." | 7.83 | Reversible Valproic Acid-Induced Parkinsonism and Cognitive Impairment in an Elderly Patient With Bipolar Disorder I. ( Hassamal, S; Reese, K; Testa, C; Waller, S, 2016) |
| "Valproic acid, a branched short-chain fatty acid, has numerous action mechanisms which turn it into a broad spectrum anticonvulsant drug and make its use possible in some other pathologies such as bipolar disorder." | 7.80 | Hyperammonemia associated with valproic acid concentrations. ( Alvariza, S; Fagiolino, P; Guevara, N; Ibarra, M; Magallanes, L; Maldonado, C; Olano, I; Olmos, I; Vázquez, M, 2014) |
| " Divalproex loading was as well tolerated or better tolerated than the other active treatments as measured by adverse events and changes in laboratory parameters." | 7.80 | The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. ( Baker, JD; Hirschfeld, RM; Sommerville, KW; Tracy, K; Wozniak, P, 2003) |
| "The primary objective of this study was to assess patient and treatment variables that have an impact on inpatient antipsychotic treatment continuation and 30-day hospital readmission rates in patients with bipolar disorder treated with aripiprazole or quetiapine." | 7.79 | An evaluation of inpatient treatment continuation and hospital readmission rates in patients with bipolar disorder treated with aripiprazole or quetiapine. ( Coley, KC; Fabian, TJ; Haskett, R; Kreys, TJ; Saul, MI, 2013) |
| "Mood stabilizers used for treating bipolar disorder (BD) selectively downregulate arachidonic acid (AA) turnover (deacylation-reacylation) in brain phospholipids, when given chronically to rats." | 7.79 | Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: a potential drug for bipolar disorder. ( Basselin, M; Bialer, M; Coleman, RA; Li, LO; Modi, HR; Rapoport, SI; Taha, AY, 2013) |
| "Carbamazepine (CBZ) has been used in the treatment of bipolar disorder, both in acute mania and maintenance therapy, since the early 1970s." | 7.78 | Carbamazepine treatment of bipolar disorder: a retrospective evaluation of naturalistic long-term outcomes. ( Chen, CH; Lin, SK, 2012) |
| "We present a patient who developed pancytopenia while taking valproic acid for bipolar illness." | 7.77 | Successful reintroduction of valproic acid after the occurrence of pancytopenia. ( Stewart, JT, 2011) |
| "Valproic acid, a conventional antiepileptic drug, is also used in the treatment of bipolar disorder, to provide rapid stabilization of the patient." | 7.77 | A rare occurrence of isolated neutropenia with valproic acid: a case report. ( Chakraborty, J; Chakraborty, S; Ghosal, MK; Mandal, S, 2011) |
| "Risperidone, as all atypical antipsychotics, can cause hyperprolactinemia which can in turn lead to galactorrhea." | 7.76 | Galactorrhea - side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder. ( Grahovac, T; Pavlović, E; Peitl, MV; Peitl, V, 2010) |
| "We report a case of severe restless legs syndrome (RLS) that occurred as a side effect of olanzapine therapy." | 7.75 | Refractory restless legs syndrome likely caused by olanzapine. ( Khalid, I; Khalid, TJ; Rana, L; Roehrs, T, 2009) |
| " We investigated the association of exon 26 C3435T genetic variants of MDR1 gene with susceptibility to bipolar disorder and serum valproic acid concentration." | 7.75 | Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid. ( Alatas, G; Herken, H; Kursunluoglu, R; Kurt, E; Oral, T; Sengul, C; Turgut, G; Turgut, S, 2009) |
| "To compare clinical responses of patients with pediatric bipolar disorder being treated with risperidone versus divalproex." | 7.74 | Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder. ( Gonzalez-Heydrich, JM; Korndörfer, SR; MacMillan, CM; Mrakotsky, C; Tilley, CA; Withney, JE, 2008) |
| "This study investigated the association between 2 mood stabilizers (carbamazepine and valproate) and other medications (including other anticonvulsants) and the risks of erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) among patients with bipolar disorder." | 7.74 | The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study. ( Chang, CJ; Chao, PF; Gau, CS; Gau, SS; Lin, YJ, 2008) |
| "To determine the incidence, characteristics, and predictors of clozapine-induced fever in a sample of patients in a local psychiatric unit." | 7.74 | The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong. ( Chan, WF; Chung, KF; Lai-wah Dunn, E; Pui-yin Chung, J; Shiu-yin Chong, C; Wai-nang Tang, O, 2008) |
| "This case report describes two children who developed hyperammonemia together with frank manic behavior during treatment with a combination of valproic acid and risperidone." | 7.74 | Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania. ( Caplan, R; Carlson, T; Reynolds, CA, 2007) |
| "To analyze, from a payer perspective, the net pharmaceutical and medical costs of prescribing divalproex sodium extended-release (DVPX-ER) versus valproic acid (VPA) in patients with bipolar disorder." | 7.74 | Cost analysis of divalproex sodium extended-release compared to valproic acid in the treatment of bipolar disorder. ( Cramer, JA; Gupta, SR; Schumock, GT; Walton, SM, 2007) |
| "Inositol-1,4,5-trisphosphate (InsP3) depletion has been implicated in the therapeutic action of bipolar disorder drugs, including valproic acid (VPA)." | 7.73 | Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure. ( Adley, K; Chadborn, NH; Eickholt, BJ; Eikel, D; Harwood, AJ; Nau, H; Ryves, WJ; Towers, GJ; Williams, RS; Ylinen, LM, 2005) |
| "Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective phospholipase A(2)." | 7.73 | Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder. ( Bazinet, RP; Rapoport, SI; Rosenberger, TA; Weis, MT, 2006) |
| "A patient with a treatment-refractory bipolar disorder with ultradian cycling responded to adjunctive topiramate." | 7.73 | Adjunctive topiramate in ultradian cycling bipolar disorder: case report with 3-year follow-up. ( Karama, S; Lal, S, 2006) |
| "A 30-year-old man with bipolar disorder and HIV initiated treatment with lopinavir/ritonavir, zidovudine, and lamivudine." | 7.73 | Possible interaction between lopinavir/ritonavir and valproic Acid exacerbates bipolar disorder. ( Allan, J; Brouillette, MJ; Delisle, MS; Sheehan, NL, 2006) |
| "Divalproex (DVP) and oxcarbazepine (OXC) are used to treat pediatric bipolar disorder (PBPD) with severe aggression but these agents have not been compared in head to head trials." | 7.73 | A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder. ( Fleisher, CA; Gonzalez-Heydrich, J; Korndörfer, SR; MacMillan, CM; Mezzacappa, E; Rao, S, 2006) |
| "To assess the efficacy of lamotrigine combined with either divalproex or lithium for the treatment of bipolar disorder." | 7.73 | Lamotrigine combined with divalproex or lithium for bipolar disorder: a case series. ( Bowden, CL; Jamison, KL; Redmond, JR, 2006) |
| "The purpose of the present paper was to remind physicians that hypothermia is a possible side-effect of combining zotepine, valproate,and benzodiazepine." | 7.72 | Two case studies of hypothermia induced by an increased dosage of zotepine in a combination therapy. ( Chen, KC; Chen, PS; Yang, MJ; Yang, YK; Yeh, TL, 2003) |
| "Levetiracetam (LEV) is a novel anticonvulsant that is currently investigated in bipolar disorder." | 7.72 | Levetiracetam in the treatment of rapid cycling bipolar disorder. ( Bräunig, P; Krüger, S, 2003) |
| "To evaluate whether valproic acid (VPA) can cause thrombocytopenia and impaired platelet function in young patients with new-onset bipolar disorder." | 7.72 | Thrombocytopenia during valproic acid treatment in young patients with new-onset bipolar disorder. ( Campanella, D; De Berardis, D; Ferro, FM; Gambi, F; Grimaldi, MR; La Rovere, R; Matera, V; Pacilli, AM; Salerno, RM; Sepede, G, 2003) |
| "Lithium is one of the most widely used mood-stabilizing agents for the treatment of bipolar disorder." | 7.72 | Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. ( Brune, K; Fox, N; Li, B; Liu, F; Ni, B; Paul, S; Ryder, J; Solenberg, P; Su, Y; Wu, X; Zhou, Y, 2004) |
| "This case suggests the potential utility of lamotrigine in treatment-resistant menstrually-related rapid cycling bipolar disorder, and raises the possibility that lamotrigine might be able to treat pathological entrainment of mood with the menstrual cycle." | 7.72 | Lamotrigine therapy in treatment-resistant menstrually-related rapid cycling bipolar disorder: a case report. ( Becker, OV; Glenn, T; Ketter, TA; Marsh, WK; Rasgon, NL, 2004) |
| "A nondiabetic young male patient in hypomanic phase of bipolar disorder on maintenance treatment with sodium valproate, developed transient episode of acute pancreatitis and diabetic ketoacidosis after addition of chlorpromazine and halopridol." | 7.72 | Acute pancreatitis and diabetic ketoacidosis in non-diabetic person while on treatment with sodium valproate, chlorpromazine and haloperidol. ( Gupta, SB; Laghate, VD, 2004) |
| "The pharmacokinetics of valproic acid (VPA) were studied in nine patients with bipolar disorder who were receiving VPA as prophylactic therapy, following the full daily dose (400-1500 mg), on which the patients had been maintained for at least the past 3 months." | 7.71 | Pharmacokinetics of valproic acid in patients with bipolar disorder. ( Das, S; Goswami, U; Tayal, G; Vasudev, K, 2001) |
| "A 47-year-old man suffering from a bipolar disorder and intermittent myoglobinuria presented with acute rhabdomyolysis with renal failure after starting therapy with valproic acid." | 7.71 | Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. ( Glocker, FX; Jaksch, M; Ketelsen, UP; Kottlors, M; Lücking, CH; Weiner, S, 2001) |
| "A potential model for bipolar disorder, quinpirole-induced biphasic locomotion, was used for a preliminary evaluation of behavioral effects of oral anticonvulsant treatment." | 7.71 | Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. ( Belmaker, RH; Einat, H; Shaldubina, A; Shimon, H; Szechtman, H, 2002) |
| " The authors present a bipolar disorder patient with dose-dependent valproic acid thrombocytopenia and suggest treatment strategies." | 7.70 | Dose-dependent valproic acid thrombocytopenia in bipolar disorder. ( Gerner, R; Kaufman, KR, 1998) |
| "Lithium, carbamazepine and sodium valproate are mood stabilizers used in the treatment of bipolar disorder, and although their mechanisms of action remain unknown, signal transduction systems and the associated modulation of gene expression may constitute significant actions." | 7.70 | Modulation of carbachol-stimulated AP-1 DNA binding activity by therapeutic agents for bipolar disorder in human neuroblastoma SH-SY5Y cells. ( Jope, RS; Pacheco, MA, 1999) |
| "Inositol uptake was measured at concentrations of 25, 40 and 50 microM in human astrocytoma cell cultures treated for 1-3 weeks with pharmacologically relevant concentrations of LiCl, valproic acid or carbamazepine as well as in control cultures that had not been treated with any drug." | 7.70 | Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. ( Belmaker, RH; Bersudsky, Y; Hertz, L; Simkin, M; Wolfson, M; Zinger, E, 2000) |
| "A 28-year-old patient with a 5-year history of bipolar disorder developed signs of encephalopathy 2 weeks after the addition of valproic acid to his treatment regimen of doxepine, risperidone, and biperidene." | 7.70 | [Valproic acid in prophylaxis of bipolar disorder. A case of valproate-induced encephalopathy]. ( Rottach, KG; Schmauss, M; Weiss-Brummer, J; Wieland, U, 2000) |
| "Alterations in choline and myo-inositol metabolism have been noted in bipolar disorder, and the therapeutic efficacy of lithium in mania may be related to these effects." | 7.70 | Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex. ( Babb, SM; Breeze, JL; Cohen, BM; Frederick, BB; Gruber, SA; Hennen, J; Moore, CM; Renshaw, PF; Stoll, AL; Villafuerte, RA; Yurgelun-Todd, DA, 2000) |
| "We report two cases of severe bipolar disorder in which there was a dramatic response to the combination of lithium and sodium valproate." | 7.69 | Combining lithium and sodium valproate for bipolar disorder. ( Hickie, I; Jacobs, G; Mitchell, P; Withers, K, 1994) |
| "To test the hypothesis that, although typical neuroleptics are commonly used in the treatment of bipolar disorder, newer atypical antipsychotic agents, like risperidone, may be more effective and better-tolerated." | 7.69 | Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. ( Baldassano, CF; Ghaemi, SN; Sachs, GS; Truman, CJ, 1997) |
| "Memantine is an NMDA receptor antagonist with anti-inflammatory effects." | 6.84 | Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder. ( Chang, HH; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, SY; Lu, RB; Wang, TY; Yang, YK, 2017) |
| "This study reviewed all published valproic acid (VPA) population pharmacokinetic (PPK) models in adult patients and assessed them using external validation methods to determine predictive performance." | 6.82 | Published population pharmacokinetic models of valproic acid in adult patients: a systematic review and external validation in a Chinese sample of inpatients with bipolar disorder. ( de Leon, J; Dong, F; Guo, W; Li, AN; Ruan, CJ; Zang, YN, 2022) |
| "Dextromethorphan (DM) is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that may be neuroprotective for monoamine neurons." | 6.77 | The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder. ( Chang, YH; Chen, SH; Chen, SL; Chu, CH; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, CL; Yang, YK; Yeh, TL, 2012) |
| "Co-morbid diagnoses, such as disruptive behavior disorders (DBDs) and high levels of aggression, are extremely common among youth with pediatric bipolar disorder (PBD) and may interfere with treatment response; however, they have rarely been examined as predictors of response to pharmacotherapy." | 6.76 | Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. ( Celio, CI; Henry, D; Pavuluri, MN; Weinstein, SM; West, AE, 2011) |
| "To determine whether there is a pharmacokinetic drug interaction between quetiapine fumarate and divalproex sodium." | 6.73 | Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. ( Davis, PC; DeVane, CL; Ennis, DJ; Figueroa, C; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2007) |
| "Aripiprazole is an atypical antipsychotic compound that is approved by the U." | 6.73 | Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. ( Blow, FC; Cassidy, KA; Coconcea, N; Hays, RW; Ignacio, RV; Meyer, WJ; Sajatovic, M, 2008) |
| "Lamotrigine was used at a mean +/- SD dose of 185." | 6.68 | Lamotrigine in rapid-cycling bipolar disorder. ( Calabrese, JR; Fatemi, SH; Rapport, DJ; Thuras, P, 1997) |
| "Valproic acid (VPA) is a commonly used antiepileptic drug (AED)." | 6.61 | Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. ( Kashyap, A; Rashid, M; Undela, K, 2019) |
| " In the present paper, I review studies in unanaesthetized rats using a neuropharmacological approach, combined with kinetic, biochemical and molecular biology techniques, demonstrating that chronic administration of three commonly used mood stabilizers (lithium, valproic acid and carbamazepine), at therapeutically relevant doses, selectively target the brain arachidonic acid cascade." | 6.45 | Is the brain arachidonic acid cascade a common target of drugs used to manage bipolar disorder? ( Bazinet, RP, 2009) |
| "Lamotrigine has emerged as a first line treatment for bipolar depression, which is an area of weakness for other mood stabilizers." | 6.42 | Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders. ( Goodwin, FK; Lieberman, DZ, 2004) |
| "Topiramate, a structurally novel anticonvulsant, is being evaluated for other neurological conditions such as migraine, neuropathic pain, and essential tremor, and also for psychiatric conditions such as bipolar disorder, bulimia, post-traumatic stress disorder, and schizoaffective disorder, in addition to obesity." | 6.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "Lithium carbonate is the drug of choice for the management of bipolar disorder, but 20% to 40% of patients do not exhibit adequate response to this agent." | 6.16 | Non-lithium treatment for bipolar disorder. ( Post, RM, 1990) |
| "Lithium carbonate was not associated with an increased risk of Parkinson-like events, but was related to these events in patients taking sodium valproate." | 5.72 | Relationship between lithium carbonate and the risk of Parkinson-like events in patients with bipolar disorders: A multivariate analysis using the Japanese adverse drug event report database. ( Nabekura, T; Uwai, Y, 2022) |
| "Patients with bipolar disorder treated with lithium often require additional antipsychotics or anticonvulsants." | 5.69 | Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes. ( Bowden, CL; Calabrese, JR; Friedman, ES; Fung, V; Iosifescu, DV; Ketter, TA; Kocsis, JH; Köhler-Forsberg, O; McElroy, SL; McInnis, M; Nierenberg, AA; Ostacher, MJ; Shelton, RC; Sylvia, LG; Thase, M; Tohen, M, 2023) |
| " There is little evidence indicating the efficacy of celecoxib adjuvant therapy in treatmenting of manic episodes of bipolar disorder." | 5.69 | Does celecoxib with sodium valproate have an augmentation effect on acute mania in bipolar disorder? A double-blind controlled clinical trial in Iran. ( Ahrari, S; Eslamzadeh, M; Faridhosseini, F; Khadem-Rezaiyan, M; Pourgholami, M; Salimi, Z; Shahini, N; Talaei, A, 2023) |
| "Olanzapine is a second-generation antipsychotic." | 5.51 | Generalised tonic-clonic seizures on the subtherapeutic dose of olanzapine. ( Chachar, AS; Mansoor, M; Mesiya, MH, 2019) |
| "Hypothermia is a rare but serious condition that has been associated with various psychiatric medications." | 5.46 | Severe recurrent hypothermia in an elderly patient with refractory mania associated with atypical antipsychotic, valproic acid and oxcarbazepine therapy. ( Ajayi, OO; Holroyd, S, 2017) |
| "The effects of long-term consequences of lithium, valproic acid, carbamazepine and antipsychotic agents on the development of dementia or cognitive impairments in patients with bipolar disorder were investigated." | 5.41 | [Effects of lithium, valproic acid, carbamazepine and antipsychotic agents on cognition in bipolar disorders-A systematic review]. ( Leopold, S; Quante, A, 2023) |
| " In parallel, adenosine deficit is increasingly recognized in epilepsy pathophysiology." | 5.41 | Bipolar mania and epilepsy pathophysiology and treatment may converge in purine metabolism: A new perspective on available evidence. ( Boison, D; Daniels, SD, 2023) |
| " In/outpatients (n = 68) aged 18-70, experiencing mania or hypomania, were assigned to 3 weeks ebselen (600 mg bd) (n = 33) or placebo (n = 35)." | 5.34 | A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. ( Cowen, PJ; Godlewska, BR; Holder, AA; MacDonald, O; Shanyinde, M; Sharpley, AL; Singh, N; Williams, C, 2020) |
| "We accepted him as type 1 diabetes mellitus (DM type 1)." | 5.33 | Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus type 1 in a patient treated with valproate and lithium. ( Alpaslan, T; Bulent, C; Cengiz, T; Mithat, B, 2005) |
| "He presented coma requiring tracheal intubation and mechanical ventilation at 11 hours and central diabetes insipidus." | 5.33 | [Transient central diabetes insipidus during a valproic acid poisoning]. ( Corne, P; Jonquet, O; Lemaire, X, 2006) |
| "Topiramate is an antiepileptic drug, recently also used in the treatment of psychiatric diseases." | 5.33 | Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. ( Gaudreau, PO; Gobbi, G; Leblanc, N, 2006) |
| "Risperidone, an atypical antipsychotic medication, is recommended as a first line treatment for acute mania in patients with bipolar disorder I (BD I)." | 5.30 | Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. ( Bertolin, S; Lam, RW; Qian, H; Valdes, M; Wong, H; Yatham, LN, 2019) |
| "In the present study, an effort was made to investigate the effect of lamotrigine on cognitive function and serum inflammatory factors in patients with depression of recurrent bipolar disorder and to explore its possible mechanism." | 5.27 | Effect of lamotrigine on cognitive function and serum inflammatory factors in patients with depression of recurrent bipolar disorder. ( Li, L; Shi, S; Song, L; Wang, X, 2018) |
| "Lamotrigine has acute antidepressant effects in patients with bipolar disorder." | 5.24 | Correlation between the Efficacy of Lamotrigine and the Serum Lamotrigine Level during the Remission Phase of Acute Bipolar II Depression: A Naturalistic and Unblinded Prospective Pilot Study. ( Aiba, T; Hiraki, K; Kikkawa, A; Kitamura, Y; Sendo, T, 2017) |
| "We previously conducted a randomized, double-blind, controlled, 12-week study evaluating the effect of add-on dextromethorphan (DM), a noncompetitive N-methyl-D-aspartate receptor antagonist, on patients with bipolar disorder (BD) treated using valproate (VPA), which showed negative clinical differences." | 5.24 | The COMT Val158Met Polymorphism Is Associated With Response to Add-on Dextromethorphan Treatment in Bipolar Disorder. ( Chang, YH; Chen, KC; Chen, PS; Chen, SL; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, TY; Yang, YK, 2017) |
| " Evidence supporting the use of aripiprazole, olanzapine, quetiapine, valproate and lamotrigine for treatment of rapid cycling bipolar disorder was found." | 5.22 | Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review. ( Roosen, L; Sienaert, P, 2022) |
| " Three groups of patients were studied: (A) epileptic under phenytoin monotherapy (n = 31); (B) with bipolar disorder under valproic acid treatment (n = 28); (C) elderly (n = 41)." | 5.22 | Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia. ( Fagiolino, P; González, R; Guevara, N; Maldonado, C; Queijo, C; Vázquez, M, 2016) |
| " Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder." | 5.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| ", Text Revision (DSM-IV-TR) diagnosis of bipolar disorder, manic, hypomanic, or mixed episode, were recruited over a 6 year period from two academic outpatient programs for a double-blinded, placebo-controlled trial in which subjects were randomized in a 2:2:1 ratio to risperidone solution, valproic acid, or placebo." | 5.20 | Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder. ( Altaye, M; Delgado, S; Kowatch, RA; Lagory, D; Monroe, E; Scheffer, RE, 2015) |
| "Memantine, a noncompetitive N-methyl-d-aspartate receptor antagonist with a mood-stabilizing effect, and an association between bipolar disorder and proinflammatory cytokine levels have been reported." | 5.19 | The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial. ( Chang, YH; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, TY; Wang, YS; Yang, YK; Yeh, TL, 2014) |
| "Ziprasidone, adjunctive to either lithium or valproate, has previously been shown to be associated with a significantly lower risk of relapse in bipolar disorder compared with lithium or valproate treatment alone." | 5.17 | Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: clinical and methodological implications. ( Bowden, CL; Gundapaneni, BK; Karayal, ON; O'Gorman, C; Schwartz, JH, 2013) |
| "Aripiprazole plus a mood stabilizer has minimal impact on metabolic changes in predominantly overweight/obese BPD patients over a 52-week period." | 5.17 | Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine. ( Baker, RA; Carlson, BX; De Hert, M; Eudicone, JM; Fyans, P; Kemp, DE; Marler, SV; Rahman, Z, 2013) |
| "The current study examined the impact of risperidone and divalproex on affective and working memory circuitry in patients with pediatric bipolar disorder (PBD)." | 5.16 | Risperidone and divalproex differentially engage the fronto-striato-temporal circuitry in pediatric mania: a pharmacological functional magnetic resonance imaging study. ( Fitzgerald, JM; Passarotti, AM; Pavuluri, MN; Sweeney, JA; Wegbreit, E, 2012) |
| "To compare the maintenance efficacy of lamotrigine (Lam) to combination therapy of Lam+divalproex ER (Div) in recently depressed patients with bipolar disorder (BD)." | 5.16 | Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression. ( Bowden, CL; Chang, X; Mintz, J; Quinones, M; Singh, V; Thompson, P; Weisler, R, 2012) |
| "TEAM was a multi-site, 8-week, randomized clinical trial of risperidone, lithium, or divalproex in 279 medication-naïve patients, aged 6 through 15 years, with a DSM-IV diagnosis of bipolar disorder currently in manic or mixed phase." | 5.16 | Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) study. ( Axelson, DA; Birmaher, B; Emslie, G; Joshi, P; Luby, J; Riddle, MA; Robb, A; Ryan, ND; Tillman, R; Vitiello, B; Wagner, KD; Walkup, JT; Yenokyan, G, 2012) |
| "Efficacy and tolerability of valproate and lithium were shown to be comparable in the management of bipolar disorder in the VALID study." | 5.15 | Estimation of resource utilisation difference between lithium and valproate treatment groups from the VALID study. ( Aggarwal, SK; Li, SC, 2011) |
| "Patients with bipolar disorder and past suicide attempts (N=98) were randomly assigned to treatment with lithium or valproate, plus adjunctive medications as indicated, in a double-blind 2." | 5.15 | Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. ( Burke, AK; Currier, D; Galfalvy, HC; Grunebaum, MF; Harkavy-Friedman, J; Mann, JJ; Oquendo, MA; Parsey, RV; Sher, L; Sublette, ME; Sullivan, GM, 2011) |
| "This study compares the metabolic effects of olanzapine and risperidone in a prospective, randomized, open-label trial in 160 patients with DSM-IV-TR schizophrenia, schizoaffective disorder, or bipolar disorder after 1, 3, 6, and 12 months' treatment." | 5.15 | A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. ( Bobo, WV; Bonaccorso, S; Chen, Y; Jayathilake, K; Meltzer, HY, 2011) |
| "Based on our findings, folic acid seems to be an effective adjuvant to sodium valproate in the treatment of the acute phase of mania in patients with bipolar disorder." | 5.14 | Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial. ( Asadi, S; Behzadi, AH; Chalian, M; Ghadiri, M; Omrani, Z, 2009) |
| "Two hundred two adults, aged 18 to 60 years, who met DSM-IV-TR criteria for bipolar disorder with a current mixed episode and had been taking divalproex for >or=14 days at levels of 75 to 125 microg/mL with inadequate efficacy (21-item Hamilton Depression Rating Scale [HDRS-21] and Young Mania Rating Scale [YMRS] scores >or=16) were randomly assigned to olanzapine 5 to 20 mg/d versus placebo augmentation." | 5.14 | Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. ( Degenhardt, EK; Houston, JP; Jamal, HH; Ketter, TA; Liu, LL; Tohen, M, 2009) |
| "Lithium carbonate and valproate semisodium are both recommended as monotherapy for prevention of relapse in bipolar disorder, but are not individually fully effective in many patients." | 5.14 | Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. ( Alder, N; Azorin, JM; Cipriani, A; Geddes, JR; Goodwin, GM; Juszczak, E; Morriss, R; Ostacher, MJ; Rendell, J, 2010) |
| "Valnoctamide could be an important valproate substitute for women of childbearing age with bipolar disorder who may become pregnant." | 5.14 | Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. ( Agam, G; Applebaum, J; Belmaker, RH; Bersudsky, Y; Gaiduk, Y; Mishory, A; Podberezsky, A; Sharony, L, 2010) |
| "To pilot the efficacy and safety data of lamotrigine adjunctive therapy to lithium and divalproex in patients with rapid-cycling bipolar disorder (RCBD) and a recent substance use disorder (SUD)." | 5.14 | Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. ( Calabrese, JR; Chan, PK; Conroy, C; Fang, Y; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE; Serrano, MB; Wang, Z, 2010) |
| " We used different keywords, including bipolar disorder, lithium and valproic acid, inositol role in bipolar disorder, side effects, inositol depletion, supplementation of inositols under lithium treatment, inositol role in metabolism, hypothyroidism, renal and cardiac functionality." | 5.12 | Combined treatment of myo-inositol and d-chiro-inositol (80:1) as a therapeutic approach to restore inositol eumetabolism in patients with bipolar disorder taking lithium and valproic acid. ( D'Ambrosio, F; Di Lorenzo, C; Janiri, L, 2021) |
| "Despite the increasing use of lamotrigine (LTG) in bipolar disorder, little is known about its impact on cognition in bipolar patients." | 5.12 | Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results. ( Benabarre, A; Colom, F; Comes, M; Daban, C; Goikolea, JM; Martínez-Arán, A; Sánchez-Moreno, J; Torrent, C; Vieta, E, 2006) |
| "l-carnitine had no effect on mean weight loss compared with placebo (-1." | 5.12 | Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. ( Elmslie, JL; Hunt, PJ; Joyce, PR; Mann, JI; Porter, RJ, 2006) |
| "Breakthrough manic episodes are the rule in bipolar disorders; valproate and olanzapine are considered first-line treatments for manic episodes, nevertheless the two drugs have only been compared in monotherapy studies." | 5.12 | Valproate or olanzapine add-on to lithium: an 8-week, randomized, open-label study in Italian patients with a manic relapse. ( Albert, U; Bogetto, F; Maina, G; Mancini, M; Salvi, V, 2007) |
| "Thirty patients with bipolar disorder, currently hypomanic, were randomized to receive oxcarbazepine or divalproex as add-on or monotherapy for 8 weeks." | 5.12 | Comparison of two anticonvulsants in a randomized, single-blind treatment of hypomanic symptoms in patients with bipolar disorder. ( Curley, E; Foster, B; Hynan, LS; Kelly, DI; Snow, DE; Suppes, T; Sureddi, S, 2007) |
| " The combination of risperidone and divalproex sodium is used to treat the manic phase of bipolar disorder." | 5.11 | Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder. ( Alexander, J; Lacroix, D; Ravindran, A; Silverstone, P; van Schaick, E; Vermeulen, A, 2004) |
| "Prior work reported elevated gray matter (GM) lactate and Glx (glutamate + glutamine + GABA) concentrations in unmedicated patients with bipolar disorder (BP) compared with healthy controls (HC)." | 5.11 | Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. ( Dager, SR; Demopulos, C; Dunner, DL; Friedman, SD; Hirashima, F; Lyoo, IK; Parow, A; Renshaw, PF; Stoll, AL, 2004) |
| "The objective of this study was to determine the clinical and quality of life outcomes associated with adjunctive treatment of olanzapine added to either lithium or valproic acid/divalproex sodium in patients with bipolar disorder." | 5.11 | Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. ( Breier, A; Namjoshi, MA; Risser, R; Shi, L; Tohen, M, 2004) |
| "These pilot data, from the first prospective comparison study of risperidone and olanzapine in bipolar disorder, suggest that adjunctive administration of either agent may reduce depressive symptom severity." | 5.11 | The antidepressant effects of risperidone and olanzapine in bipolar disorder. ( Kennedy, SH; Konarski, JZ; Mancini, DA; McCann, S; McIntyre, RS; Srinivasan, J, 2004) |
| "This prospective 6-month open trial examined the safety and efficacy of two combination therapies for manic or mixed episodes of pediatric bipolar disorder: (1) divalproex sodium plus risperidone (DVPX+Risp), or (2) lithium plus risperidone (Li+Risp)." | 5.11 | Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. ( Carbray, JA; Henry, DB; Janicak, PG; Naylor, MW; Pavuluri, MN; Sampson, G, 2004) |
| "To determine whether divalproex sodium (DVPX) was superior to lithium carbonate (Li+) in the maintenance monotherapy treatment of youths diagnosed with bipolar disorder who had been previously stabilized on combination Li+ and DVPX (Li+/DVPX) pharmacotherapy." | 5.11 | Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. ( Calabrese, JR; Findling, RL; Gracious, BL; McNamara, NK; Reed, MD; Stansbrey, R; Youngstrom, EA, 2005) |
| "This study examined direct treatment costs based on medication and service use data collected in a 47-week multi-center, double-blind, randomized clinical trial of olanzapine versus divalproex for patients with bipolar disorder and and experiencing acute mania." | 5.11 | Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial. ( Baker, RW; Lage, MJ; Shi, L; Tohen, M; Tunis, SL; Zhao, Z; Zhu, B, 2005) |
| "Divalproex maintenance treatment for bipolar disorder resulted in comparable medical costs, clinical and QOL outcomes compared with lithium." | 5.11 | Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial. ( Ahearn, EP; Hirschfeld, RM; Keck, PE; Palmer, C; Revicki, DA; Weisler, RH, 2005) |
| " We examine the cellular distribution and activation of PKC and receptor-G protein coupling in blood platelets from normal controls, patients with BD mania or schizophrenia during treatment-free state, and after lithium or valproic acid administration." | 5.11 | Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. ( Friedman, E; Hahn, CG; Koneru, R; Levinson, DF; Wang, HY, 2005) |
| "The authors tested the hypothesis that divalproex would be more effective than lithium in the long-term management of patients with recently stabilized rapid-cycling bipolar disorder." | 5.11 | A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. ( Bilali, S; Calabrese, JR; Findling, RL; Ganocy, SJ; Jackson, K; Rapport, DJ; Shelton, MD; Youngstrom, EA, 2005) |
| " The aim of this study is to determine the effectiveness and safety of olanzapine as an add-on therapy in patients with bipolar disorder with a rapid cycling course during a dysphoric mania episode." | 5.10 | Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine. ( Fernandez-Corres, B; Gonzalez-Pinto, A; Gutierrez, M; Lalaguna, B; Micó, JA; Pérez-Heredia, JL; Tohen, M, 2002) |
| "This study compared the efficacy, safety, and tolerability of divalproex and olanzapine in the treatment of acute mania associated with bipolar disorder." | 5.10 | A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. ( Sachs, G; Sommerville, KW; Swann, AC; Weisler, R; Wozniak, P; Zajecka, JM, 2002) |
| " Recent data suggest that valproic acid, a commonly prescribed mood stabilizer, may be associated with polycystic ovarian syndrome (PCOS)." | 5.10 | Valproate, bipolar disorder and polycystic ovarian syndrome. ( Kennedy, SH; Mancini, DA; McCann, S; McIntyre, RS; Srinivasan, J, 2003) |
| "This 47-week, randomized, double-blind study compared flexibly dosed olanzapine (5-20 mg/day) to divalproex (500-2500 mg/day) for manic or mixed episodes of bipolar disorder (N=251)." | 5.10 | Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. ( Altshuler, L; Baker, RW; Brown, E; Frye, M; Ketter, TA; Risser, RC; Schuh, LM; Suppes, T; Tohen, M; Zajecka, J; Zarate, CA, 2003) |
| "Lithium carbonate (Li) or divalproex sodium (DVPX) may be effective for some juveniles with bipolar disorder." | 5.10 | Combination lithium and divalproex sodium in pediatric bipolarity. ( Branicky, LA; Calabrese, JR; Demeter, CA; Findling, RL; Fisher, KE; Gracious, BL; McNamara, NK; Reed, MD; Stansbrey, RJ; Youngstrom, EA, 2003) |
| "This 3-week randomized, double-blind, placebo-controlled study included 156 bipolar disorder patients with a current manic or mixed episode who received a mood stabilizer (lithium or divalproex) and placebo, risperidone, or haloperidol." | 5.10 | Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. ( Bowden, CL; Ghaemi, SN; Grossman, F; Okamoto, A; Sachs, GS, 2002) |
| "Omega3 fatty acids may inhibit neuronal signal transduction pathways in a manner similar to that of lithium carbonate and valproate, 2 effective treatments for bipolar disorder." | 5.09 | Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. ( Cress, KK; Diamond, E; Freeman, MP; Marangell, LB; Rueter, S; Severus, WE; Stoll, AL; Zboyan, HA, 1999) |
| "Twenty-two female outpatients with a DSM-IV diagnosis of bipolar disorder who were between the ages of 18 and 45 years (inclusive) and who were taking lithium and/or divalproex (10, divalproex monotherapy; 10, lithium monotherapy; 2, divalproex/lithium combination therapy) were evaluated." | 5.09 | Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. ( Altshuler, LL; Burt, VK; Gudeman, D; Hendrick, V; Korenman, S; Rasgon, NL; Tanavoli, S, 2000) |
| "The medical records of all inpatients with bipolar disorder at the Connecticut Mental Health Center in 1997 were examined to compare length of stay for patients who began monotherapy with divalproex (27 treatment starts) and lithium (20 treatment starts)." | 5.09 | Effects of divalproex versus lithium on length of hospital stay among patients with bipolar disorder. ( Baker, CB; Dalkilic, A; Diaz, E; Pearsall, HR; Woods, SW, 2000) |
| "A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers." | 5.09 | A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. ( Ghaemi, SN; Guille, C; Sachs, GS, 2000) |
| "[corrected] To assess efficacy and safety of gabapentin in the treatment of bipolar disorder." | 5.09 | Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. ( Crockatt, JG; Janney, CA; Pande, AC; Tsaroucha, G; Werth, JL, 2000) |
| "Anticonvulsant agents such as carbamazepine and valproate are alternatives to lithium in treating subjects with bipolar disorder." | 5.09 | Topiramate as add-on treatment for patients with bipolar mania. ( Atzert, R; Brar, JS; Chengappa, KN; Delaney, J; Levin, H; Levine, J; Moffa, N; Parepally, H; Rathore, D; Solai, L, 1999) |
| "In a double-blind, placebo-controlled study, 117 outpatients with DSM-III-R bipolar disorder, depressive phase, were randomly assigned to treatment with paroxetine (N=35), imipramine (N=39), or placebo (N=43) for 10 weeks." | 5.09 | Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. ( Bowden, CL; Evans, DL; Gergel, IP; Gyulai, L; Nemeroff, CB; Oakes, R; Pitts, CD; Sachs, GS, 2001) |
| ", who received at least 6 weeks of add-on olanzapine treatment for psychotic mood disorders (schizoaffective disorders [bipolar and depressive type], bipolar disorders [I, II, and NOS], and major depressive disorder)." | 5.09 | Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. ( Grace, JJ; Narendran, R; Pato, MT; Pristach, CA; Valenti, AM; Young, CM, 2001) |
| "After a < or = 1-day screening period, 36 consecutive hospitalized patients with bipolar disorder, manic or mixed phase and with psychotic features, were randomly assigned to receive either divalproex 20 mg/kg/day or haloperidol 0." | 5.08 | A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. ( Bennett, JA; Keck, PE; McElroy, SL; Stanton, SP; Strakowski, SM; Tugrul, KC, 1996) |
| "Valproic acid is added to the lithium regimens of many patients with bipolar disorder, especially those with mania refractory to lithium treatment." | 5.08 | Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. ( Cavanaugh, JH; Granneman, GR; Schneck, DW; Witt, GF, 1996) |
| "Bupropion (BUP) may be less likely than other antidepressants to cause switches into mania and rapid cycling, suggesting utility in bipolar disorder." | 5.08 | Carbamazepine but not valproate induces bupropion metabolism. ( Callahan, AM; Chao, J; George, MS; Hinton, ML; Jenkins, JB; Ketter, TA; Marangell, LB; Pazzaglia, PJ; Post, RM; Schroeder, DH, 1995) |
| "Some outpatients with bipolar disorder refractory to lithium and carbamazepine received clinically relevant prophylactic benefit from valproate when used with lithium or in triple therapy." | 5.08 | Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. ( Ali, SO; Bryan, AL; Denicoff, KD; Post, RM; Smith-Jackson, EE, 1997) |
| "Nineteen patients with bipolar disorder, manic phase, received divalproex sodium 20 mg/kg/day in divided dosages for 5 days, without other psychotropic agents except lorazepam up to 4 mg/day." | 5.07 | Valproate oral loading in the treatment of acute mania. ( Bennett, JA; Keck, PE; McElroy, SL; Tugrul, KC, 1993) |
| "Lithium remains the mainstay of therapy for most patients with bipolar disorder." | 5.07 | Dysphoric mania. ( Clothier, J; Freeman, T; Swann, AC, 1992) |
| "Thirty-five patients, all with major depressive illness, bipolar disorder, or schizoaffective disorder, were retrospectively identified as having received valproate either alone or in combination with lithium, after having failed to adequately respond to previous lithium and/or carbamazepine treatment." | 5.06 | Long-term use of valproate in primary psychiatric disorders. ( Hayes, SG, 1989) |
| "Valproic acid is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder." | 4.95 | The pharmacogenomics of valproic acid. ( Chen, XP; Li, HL; Luo, J; Shi, LH; Zhang, ZL; Zhu, MM, 2017) |
| "Resolution of hyperammonemia caused by Valproic acid therapy may be enhanced with the administration of L-carnitine." | 4.95 | Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report. ( Ballabio, M; Cattaneo, CI; D'Innella, P; Fornaro, M; Ressico, F; Valsesia, R, 2017) |
| "Valproic acid is approved for treatment of seizures and manic episodes of bipolar disorder, and continues to be one of the most commonly prescribed antiepileptic drugs in the world." | 4.90 | Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity. ( Felker, D; Johnson, DE; Lynn, A; Wang, S, 2014) |
| " Several treatments [monoamine oxidase inhibitors (MAOIs), ziprasidone, aripiprazole and risperidone] have limited or no therapeutic activity in bipolar depression." | 4.90 | Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. ( Cornelius, V; Smith, L; Taylor, DM; Young, AH, 2014) |
| " Ziprasidone may be a good alternative for patients with bipolar disorder experiencing a suboptimal response or intolerance to olanzapine in combination with a mood stabilizer because of its mood-stabilizing effect and minimal propensity for clinically significant body weight gain and metabolic disturbances." | 4.89 | The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study. ( Bahk, WM; Kim, MD; Kwon, YJ; Lee, HB; Lee, JG; Woo, YS; Yoon, BH, 2013) |
| "The mood stabilizers lithium and valproic acid (VPA) are traditionally used to treat bipolar disorder (BD), a severe mental illness arising from complex interactions between genes and environment that drive deficits in cellular plasticity and resiliency." | 4.89 | Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. ( Chiu, CT; Chuang, DM; Hunsberger, JG; Wang, Z, 2013) |
| "This paper reviews the current treatment guidelines for the treatment of bipolar disorder and examines the rationale behind the use of aripiprazole in combination with mood stabilizers for acute and long-term treatment of bipolar disorder." | 4.88 | Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance. ( de Bartolomeis, A; Perugi, G, 2012) |
| " We review the clinical literature which suggests that tolerance can develop to most treatment approaches in bipolar illness and present an animal model of tolerance development to anticonvulsant effects of carbamazepine or lamotrigine on amgydala-kindled seizures." | 4.87 | Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders. ( Post, RM; Weiss, SR, 2011) |
| "The mood stabilizers lithium, valproate and lamotrigine are traditionally used to treat bipolar disorder." | 4.87 | Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. ( Chuang, DM; Fessler, EB; Wang, ZF, 2011) |
| "Oxcarbazepine, a keto derivative of the 'mood stabiliser' carbamazepine, may have efficacy in the treatment of acute episodes of bipolar disorder." | 4.87 | Oxcarbazepine for acute affective episodes in bipolar disorder. ( Geddes, J; Macritchie, K; Vasudev, A; Vasudev, K; Watson, S; Young, AH, 2011) |
| "Olanzapine was licensed in the USA by the Food and Drug Administration in 2003 for the prevention of relapse in patients with bipolar disorder when the acute manic episode had responded to treatment with olanzapine." | 4.86 | Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. ( Cipriani, A; Geddes, JR; Rendell, J, 2010) |
| "Randomised controlled trials comparing olanzapine with placebo or other active treatment in long-term treatment of bipolar disorder." | 4.85 | Olanzapine in long-term treatment for bipolar disorder. ( Cipriani, A; Geddes, J; Rendell, JM, 2009) |
| "Starting with carbamazepine and valproate in the eighties, several anticonvulsant have been established as a treatment option in bipolar disorder." | 4.84 | [Anticonvulsants in the treatment of bipolar disorder]. ( Grunze, H, 2007) |
| "Lithium, valproate, lamotrigine and olanzapine are effective as maintenance therapy for the prevention of relapse in bipolar disorder." | 4.84 | A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. ( Barbieri, M; Beynon, S; Bravo Vergel, Y; Duffy, S; Dunn, G; Geddes, J; Gilbody, S; Palmer, S; Soares-Weiser, K; Woolacott, N, 2007) |
| "Valproic acid (2-n-propylpentanoic acid, VPA) is well-established as a mood-stabilizer for bipolar disorder, in addition to its application as a treatment in neurological disorders such as epilepsy, migraine headaches, and chronic neuropathic pain." | 4.84 | Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review. ( Rasgon, NL; Reynolds, MF; Sisk, EC, 2007) |
| "Valproate, lamotrigine and carbamazepine have a valuable place in the management of bipolar disorder." | 4.83 | Anticonvulsants in bipolar disorder. ( Bowden, CL; Karren, NU, 2006) |
| "Randomised trials comparing haloperidol with placebo or other active treatment in the treatment of acute manic or mixed episodes in patients with bipolar disorder or schizoaffective disorder." | 4.83 | Haloperidol alone or in combination for acute mania. ( Cipriani, A; Geddes, JR; Rendell, JM, 2006) |
| "At present there are three compounds in clinical trials in patients with epilepsy that can be regarded as second-generation VPA: valproyl glycinamide, 3-methylbutanamide or isovaleramide and SPD421 (DP-VPA)." | 4.82 | New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? ( Bialer, M; Isoherranen, N; Yagen, B, 2003) |
| " Weight gain and pharmacokinetic interaction with lamotrigine are perhaps the most consistent problems in use." | 4.82 | Valproate. ( Bowden, CL, 2003) |
| "The role of lithium carbonate in the maintenance treatment of bipolar disorder is well established." | 4.82 | Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder. ( Freeman, MP; Gelenberg, AJ; Gnanadesikan, M, 2003) |
| "To evaluate the clinical and cost-effectiveness of quetiapine, olanzapine and valproate semisodium in the treatment of mania associated with bipolar disorder." | 4.82 | A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. ( Bagnall, AM; Bridle, C; Darba, J; Duffy, S; Palmer, S; Riemsma, R; Sculpher, M, 2004) |
| "The preclinical and clinical MRS findings were generally supportive of the involvement of myo-inositol in bipolar disorder and its treatment." | 4.82 | Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. ( Kim, H; McGrath, BM; Silverstone, PH, 2005) |
| "Although monotherapy with lithium or divalproex is the recommended initial therapy for bipolar disorder, these agents are associated with prolonged favorable outcomes in only 30% of patients." | 4.82 | Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. ( Bowden, CL, 2005) |
| "Shire is developing DP-VPA, a prodrug of valproic acid (VPA) licensed from D-Pharm, for the potential treatment of severe forms of epilepsy, including status epilepticus, acute repetitive seizures in children and possibly manic depression and migraine [242649], [385958]; the drug is also being developed for bipolar disorder and migraine prophylaxis [385862]." | 4.81 | DP-VPA D-Pharm. ( Labiner, DM, 2002) |
| "Carbamazepine and valproate are used in the treatment of acute bipolar mania and as maintenance treatments for bipolar disorder." | 4.81 | Carbamazepine and valproate in the maintenance treatment of bipolar disorder. ( Keck, PE; McElroy, SL, 2002) |
| "The introduction of lithium salts to treat bipolar disorder (BPD) revolutionized the therapy of psychiatric illnesses, but the pathogenesis of the disease and the mechanism of lithium action remain unknown." | 4.81 | Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. ( Gurvich, N; Klein, PS, 2002) |
| "Although lithium has been the most commonly used maintenance treatment in bipolar disorder for several decades, valproate is being used increasingly - especially in the United States of America." | 4.81 | Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. ( Geddes, JR; Goodwin, GM; Haslam, DR; Macritchie, KA; Scott, J, 2001) |
| " Alternative and adjunctive treatments to lithium in bipolar disorder have been sought and the anticonvulsants carbamazepine and valproate show promise." | 4.81 | Developments in mood stabilisers. ( Ferrier, IN, 2001) |
| "Lithium and certain anticonvulsants, including carbamazepine and valproic acid, are effective antimanic drugs for treating bipolar disorder, but their mechanisms of action remain uncertain." | 4.81 | Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? ( Bosetti, F; Rapoport, SI, 2002) |
| "In an attempt to find the key to reducing the excessive morbidity and mortality seen with mood disorders, our laboratory has been extensively investigating lithium's mechanisms of action in an integrated series of clinical and preclinical studies." | 4.80 | Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. ( Bebchuk, JM; Chen, G; Glitz, D; Hasanat, KA; Manji, HK; Moore, GJ, 1999) |
| "Mood-stabilizing drugs including lithium, anticonvulsants, and antipsychotics have established effects in the management of bipolar disorder, especially in mania." | 4.80 | Mood-stabilizing drugs in depression. ( Shelton, RC, 1999) |
| "Three man, aged 66, 60 and 26 years with bipolar disorder and long periods (20-5 years) of effective lithium prophylaxis had relapses on lithium discontinuation." | 4.80 | [Risk of inducing resistance upon stopping and restarting lithium after long-term usage]. ( Hoenderboom, AC; Kupka, RW; Nolen, WA; Oostervink, F, 2000) |
| "As clinical experience with lithium treatment of bipolar disorders accumulates, factors predictive of nonresponse are emerging." | 4.79 | Lithium therapy: limitations and alternatives in the treatment of bipolar disorders. ( Calabrese, JR; Woyshville, MJ, 1995) |
| "Outcome studies of bipolar disorder, the majority of which were conducted before the use of lithium, divalproex, and carbamazepine, generally found that only 50 to 60% of patients achieved good recovery 6 to 12 months after a manic episode." | 4.79 | Outcome in the pharmacologic treatment of bipolar disorder. ( Keck, PE; McElroy, SL, 1996) |
| "Although lithium remains the preferred treatment of bipolar disorder, only 60 to 80% of patients with the classic presentation have an adequate response to this drug." | 4.79 | Predictors of response to mood stabilizers. ( Calabrese, JR; Fatemi, SH; Kujawa, M; Woyshville, MJ, 1996) |
| " We describe the phenomenon of amygdala-kindled seizures episodically breaking through effective daily pharmacotherapy with carbamazepine and valproate, suggesting that these observations could reflect the balance of pathological vs compensatory illness-induced changes in gene expression." | 4.79 | A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. ( Post, RM; Weiss, SR, 1996) |
| "Alopecia is a common side effect in patients managed on the mood stabilizers lithium, valproate, and carbamazepine." | 4.79 | Alopecia and mood stabilizer therapy. ( DeVane, CL; Finkenbine, RD; McKinney, PA, 1996) |
| "Published reports regarding the time course of onset, clinical factors associated with response, and health-economic impact of the treatment of acute mania with lithium, valproate, and carbamazepine were reviewed (PAPERCHASE data base, 1966 to present, terms: bipolar disorder, drug treatment, lithium, valproate, and carbamazepine)." | 4.79 | Health-economic implications of the onset of action of antimanic agents. ( Bennett, JA; Keck, PE; McElroy, SL, 1996) |
| "Lithium is the primary treatment for bipolar disorder." | 4.78 | Valproate in bipolar disorder: the Canadian perspective. ( Joffe, RT, 1993) |
| "The acute and chronic pharmacotherapy of bipolar disorder requires an understanding of the pharmacology of very dissimilar compounds--the mood stabilizers (lithium, carbamazepine and valproate) and several classes of antidepressants." | 4.78 | Pharmacological issues in the treatment of bipolar disorder: focus on mood-stabilizing compounds. ( Ketter, TA; Potter, WZ, 1993) |
| ", carbamazepine, valproate, clonazepam, oxcarbazepine, and electroconvulsive therapy (ECT), for patients with bipolar disorder." | 4.78 | Anticonvulsants in the treatment of bipolar disorder. ( Keck, PE; McElroy, SL; Nemeroff, CB, 1992) |
| "The research literature on alternative drug treatments to lithium therapy for the prevention of recurrences in bipolar disorders is discussed." | 4.78 | Alternative prophylactic treatments to lithium in bipolar disorders. ( Altamura, AC; Mauri, MC; Percudani, M; Regazzetti, MG, 1990) |
| "The anticonvulsants, especially carbamazepine and valproate, offer new clinical and theoretical perspectives in the treatment of lithium-refractory bipolar disorders." | 4.77 | Emerging perspectives on valproate in affective disorders. ( Post, RM, 1989) |
| "Valproic acid is an effective mood stabilizer, registered for the treatment of bipolar disorder and epilepsy." | 4.31 | [A severe, reversible encephalopathy after prolonged use of valproic acid]. ( Bloemkolk, D; Gerritse, FL; Rundervoort, RS; van Haaren, PCF, 2023) |
| "Treatment with valproate and antipsychotics-but not with lithium and lamotrigine-was associated with increased risk of DM in a real-world cohort of patients with bipolar disorder." | 4.31 | Pharmacological treatment of bipolar disorder and risk of diabetes mellitus: A nationwide study of 30,451 patients. ( Köhler-Forsberg, O; Nierenberg, AA; Rohde, C; Østergaard, SD, 2023) |
| "Patients prescribed mood stabilizers (lithium, carbamazepine, valproic acid, or lamotrigine) for a psychiatric condition other than bipolar disorder (codes F31." | 4.31 | Clinical use of mood stabilizers beyond treatment for bipolar disorder: The REAP-MS study. ( Avasthi, A; Chee, KY; Chemi, N; Chen, CK; Chong, MY; Grover, S; Hayakawa, K; Jang, OJ; Javed, A; Kallivayalil, RA; Kato, TA; Khan, MNS; Lin, SK; Maramis, M; Oo, T; Ouyang, WC; Pariwatcharakul, P; Park, SC; Park, YC; Sartorius, N; Seneviratne, L; Shinfuku, N; Sim, K; Tan, CH; Tang, WK; Xiang, YT; Yang, SY; Zhu, X, 2023) |
| "Valproic acid (VPA) is used for the treatment of epilepsy and bipolar disorder (BD)." | 4.12 | Long-term use of valproic acid reduced mortality in bipolar disorder patients in a Taiwanese population: An association analysis using the national health insurance research database (NHIRD). ( Hsieh, TC; Lin, CC; Wu, LS, 2022) |
| "Bipolar disorder (BD) effects on cognition are confounded by the putative cognitive impact of its major pharmacological treatments, given the neurotrophic potential of mood stabilizers, particularly lithium." | 4.12 | Bipolar disorder, mood stabilizers and cognitive flexibility: Translationally dissecting illness from drug effects. ( Anyfandi, E; Ferentinos, P; Kalogerakou, S; Nikolakopoulou, M; Owens, DA; Papakosta, VM; Psarros, C; Tsaltas, E, 2022) |
| "Bipolar disorder and treatment with lithium, antipsychotics, valproate, and lamotrigine." | 4.12 | Association of Lithium Treatment With the Risk of Osteoporosis in Patients With Bipolar Disorder. ( Köhler-Forsberg, O; Nierenberg, AA; Rohde, C; Østergaard, SD, 2022) |
| "In a nation-wide population-based longitudinal register linkage study for the first time 1) to investigate long-term response to lithium in patients with bipolar disorder with and without comorbid epilepsy, and 2) within patients with bipolar disorder and comorbid epilepsy to compare differences in responses between lithium, valproate and lamotrigine." | 4.12 | Response to lithium and anticonvulsants among patients with bipolar disorder with and without comorbid epilepsy - A nation-wide population-based longitudinal study. ( Budtz-Jørgensen, E; Gerds, T; Kessing, LV; Ziersen, SC, 2022) |
| "Although valproate and lithium are most commonly prescribed for bipolar disorder patients, studies comparing their effects on the risk of dementia are limited." | 4.12 | Effect of valproate and lithium on dementia onset risk in bipolar disorder patients. ( Ji, E; Kim, KW; Kwon, JS; Moon, W; Shin, J, 2022) |
| "The aim of this study was to compare the outcomes of monotherapy in individuals with bipolar disorder who are prescribed lithium, valproate, quetiapine, olanzapine, venlafaxine, or citalopram in private psychiatric practices in Germany." | 4.02 | Bipolar Disorder and Outcomes of Monotherapy with Lithium, Valproate, Quetiapine, Olanzapine, Venlafaxine, and Citalopram. ( Bauer, M; Bohlken, J; Kostev, K; Riedel-Heller, S, 2021) |
| "Although mood stabilizers such as lithium (LIT), valproate (VAL), and lamotrigine (LMT) appear to be efficacious treatments for bipolar disorder (BD) in research settings, the long-term response to these mood stabilizers in clinical practice is highly variable among individuals." | 3.96 | Clinical correlates associated with the long-term response of bipolar disorder patients to lithium, valproate or lamotrigine: A retrospective study. ( Bahk, WM; Jung, YE; Kim, MD; Kwon, YJ; Lee, J; Lee, JG; Lee, K; Nam, B; Seo, JS; Song, JH; Wang, SM; Woo, YS; Yoon, BH, 2020) |
| "These findings suggest that carnitine deficiency is associated with the VPA dose and the serum VPA level in patients with bipolar disorder." | 3.96 | Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder. ( Ishioka, M; Kubo, K; Miyazaki, K; Nakagami, T; Shimoda, K; Sugawara, N; Tarakita, N; Yasui-Furukori, N; Yokoyama, S, 2020) |
| "Use of carbamazepine and valproic acid, but not lithium and lamotrigine, is associated with increased risk of stroke in patients with bipolar disorder." | 3.91 | Mood stabilisers and risk of stroke in bipolar disorder. ( Chang, CK; Chen, CC; Chen, PH; Kuo, CJ; Pan, CH; Su, SS; Tsai, SY, 2019) |
| "Valproic acid (VPA) and lithium are widely used in the treatment of bipolar disorder." | 3.91 | Gene expression effects of lithium and valproic acid in a serotonergic cell line. ( Balasubramanian, D; Kennedy, MA; Pearson, JF, 2019) |
| "This retrospective observational study was performed to investigate electroencephalogram abnormalities in clozapine-treated patients with refractory schizophrenia or bipolar disorder." | 3.91 | Association between electroencephalogram changes and plasma clozapine levels in clozapine-treated patients. ( Chung, IW; Jeong, SH; Jeong, SW; Jung, HY; Kim, HS; Kim, KK; Kim, SH; Kim, YS; Youn, T, 2019) |
| "We found increased risks of cataract development in long-term users of lithium, lithium combined with other MS and valproic acid combined with other MS for more than two years among patients with BD and schizophrenia." | 3.88 | Associations between use of mood stabilizers and risk of cataract: A population-based nested case-control study. ( Chou, PH; Chu, CS; Lan, TH; Lin, CH, 2018) |
| " This limitation and high risks of neural tube and other major teratogenic effects, especially of valproate, indicate the need for great caution in the use of valproate and carbamazepine to treat bipolar disorder in women of child-bearing age." | 3.88 | Mood-Stabilizing Anticonvulsants, Spina Bifida, and Folate Supplementation: Commentary. ( Baldessarini, RJ; Patel, N; Viguera, AC, 2018) |
| "The aim of the study was to evaluate proliferation capacity and susceptibility to apoptosis of T lymphocytes of patients with bipolar disorder (BD) and to investigate in vitro influence of two standard mood stabilizers: lithium and valproic acid on these parameters using flow cytometry." | 3.88 | Proliferation and apoptosis of T lymphocytes in patients with bipolar disorder. ( Grabowski, K; Landowski, J; Lisowska, KA; Pietruczuk, K; Witkowski, JM, 2018) |
| "The cancer incidence of bipolar disorder patients treated with VPA was no significant difference than treated with lithium and other anticonvulsants." | 3.88 | Long-term use of valproic acid and the prevalence of cancers in bipolar disorder patients in a Taiwanese population: An association analysis using the National Health Insurance Research Database (NHIRD). ( Hsieh, TC; Lin, CC; Wu, LS, 2018) |
| "Valproic acid (VPA) provides a common treatment for both epilepsy and bipolar disorder; however, common cellular mechanisms relating to both disorders have yet to be proposed." | 3.88 | Diacylglycerol kinase (DGKA) regulates the effect of the epilepsy and bipolar disorder treatment valproic acid in ( Kelly, E; Sharma, D; Wilkinson, CJ; Williams, RSB, 2018) |
| "Valproic acid is one of the most widely prescribed drugs for the treatment of epilepsy and bipolar disorder." | 3.88 | [Valproic acid toxicity due to misinterpretation of plasma levels: increase in unbound fraction caused by hypoalbuminaemia and renal dysfunction]. ( Dols, A; Jacobs, GE; Nauta, KJ; Ruiter-Visser, R; Smulders, YM, 2018) |
| "Two hundred and thirty-four outpatients with bipolar disorders receiving prophylactic treatment with lithium, valproate, carbamazepine, or their combination were followed up for at least 18 months in two Italian psychiatric centers specialized in mood disorders." | 3.88 | Lithium, valproate, and carbamazepine prescribing patterns for long-term treatment of bipolar I and II disorders: A prospective study. ( Benedetti, A; Cambiali, E; Del Grande, C; Dell'Osso, L; Massimetti, G; Musetti, L; Pergentini, I; Tundo, A, 2018) |
| "We conducted an observational retrospective cohort study between January 1 and December 31, 2013, which included patients with a diagnosis of bipolar disorder treated with lithium carbonate in 25 Colombian cities; we evaluated socio-demographic variables, lithium dose, co-medication, drug interactions and adverse reactions." | 3.85 | [Profile of lithium carbonate use in patients with bipolar disorder in Colombia]. ( Alzate-Carvajal, C; Machado-Alba, JE; Machado-Duque, ME; Zapata-Castañeda, K, 2017) |
| " The aim of this study was to determine the influence of valproic acid (VPA) treatment on adiponectin, leptin levels and oxidative stress in bipolar disorder (BD)." | 3.85 | Evaluation of adiponectin and leptin levels and oxidative stress in bipolar disorder patients with metabolic syndrome treated by valproic acid. ( Akgün, S; Kahraman, A; Köken, T, 2017) |
| "Valproic acid (VPA) is an FDA-approved medication widely prescribed for seizures, migraines, and mixed or manic episodes in bipolar disorder." | 3.85 | Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report. ( Birur, B; Fargason, RE; Landry, KB; Patel, N, 2017) |
| "Lithium is a first line treatment option in bipolar disorder, but several alternative treatments have been introduced in recent years, such as antiepileptic and atypical antipsychotic drugs." | 3.83 | Changes in mood stabilizer prescription patterns in bipolar disorder. ( Karanti, A; Kardell, M; Landén, M; Lundberg, U, 2016) |
| "To compare rates of self-harm, unintentional injury, and suicide in patients with bipolar disorder who were prescribed lithium, valproate sodium, olanzapine, or quetiapine fumarate." | 3.83 | Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study. ( Geddes, JR; Hayes, JF; King, M; Marston, L; Osborn, DP; Pitman, A; Walters, K, 2016) |
| "Valproic acid (VPA) is widely used for treating patients with bipolar disorder; however, it has adverse effects on cognitive function." | 3.83 | Effect of valproic acid on dementia onset in patients with bipolar disorder. ( Chiu, CH; Huang, CJ; Liu, IC; Tsai, PS; Wang, MY, 2016) |
| " We included patients who had a diagnosis of bipolar disorder and were prescribed lithium (n = 2148), valproate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376) as maintenance mood stabilizer treatment." | 3.83 | Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study. ( Geddes, JR; Hayes, JF; King, M; Marston, L; Osborn, DP; Walters, K, 2016) |
| " Although various mechanisms may be responsible for the results, the data support the utilization of lithium or valproate, rather than SGAs, as the initial antimanic treatment in bipolar disorder." | 3.83 | A population-based study of the comparative effectiveness of second-generation antipsychotics vs older antimanic agents in bipolar disorder. ( Bajor, LA; Bauer, MS; Lee, A; Li, M; Miller, CJ, 2016) |
| "Valproic acid (VPA) is approved by the Food and Drug Administration (FDA) for the treatment of manic or mixed episodes associated with bipolar disorder." | 3.83 | Reversible Valproic Acid-Induced Parkinsonism and Cognitive Impairment in an Elderly Patient With Bipolar Disorder I. ( Hassamal, S; Reese, K; Testa, C; Waller, S, 2016) |
| "We present the case of a 47-year-old man who had bipolar disorder for ten years and treated with valproic acid." | 3.83 | Valproic Acid and Hepatic Steatosis: A Possible Link? About a Case Report. ( Masmoudi, J; Mnif, L; Sellami, R, 2016) |
| "Valproic acid is often used in psychiatry to treat schizophrenia and other conditions outside of indication ("off-label")." | 3.81 | [Use of valproic acid in long stay units of psychiatry]. ( Chillerón-Cuenca, R; Esplá-González, S; Hernández-Pérez, P; Herraiz-Robles, P; Martínez-Lazcano, MT; Pol-Yanguas, E, 2015) |
| "Valproic acid, a branched short-chain fatty acid, has numerous action mechanisms which turn it into a broad spectrum anticonvulsant drug and make its use possible in some other pathologies such as bipolar disorder." | 3.80 | Hyperammonemia associated with valproic acid concentrations. ( Alvariza, S; Fagiolino, P; Guevara, N; Ibarra, M; Magallanes, L; Maldonado, C; Olano, I; Olmos, I; Vázquez, M, 2014) |
| "Plasma samples of bipolar disorder patients (n = 69) on a stable dose of aripiprazole 20 mg/day were analyzed by a liquid chromatography-mass spectrometry method in a routine therapeutic drug monitoring setting." | 3.80 | Effect of valproate on the plasma concentrations of aripiprazole in bipolar patients. ( Eryilmaz, G; Gül, IG; Hizli Sayar, G; Karamustafalioğlu, O; Özten, E; Yorbik, Ö, 2014) |
| " Divalproex loading was as well tolerated or better tolerated than the other active treatments as measured by adverse events and changes in laboratory parameters." | 3.80 | The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. ( Baker, JD; Hirschfeld, RM; Sommerville, KW; Tracy, K; Wozniak, P, 2003) |
| "We describe the case of an adult man aged 49, without personal antecedents, or family psychiatric history, treated for bipolar disorder since 1995 and stabilised in the last 8 years by valproic acid, who presented in January 2010 an acute drug-induced pancreatitis." | 3.79 | [Acute pancreatitis induced by valproic acid]. ( Douki, S; Jomli, R; Nacef, F, 2013) |
| "The primary objective of this study was to assess patient and treatment variables that have an impact on inpatient antipsychotic treatment continuation and 30-day hospital readmission rates in patients with bipolar disorder treated with aripiprazole or quetiapine." | 3.79 | An evaluation of inpatient treatment continuation and hospital readmission rates in patients with bipolar disorder treated with aripiprazole or quetiapine. ( Coley, KC; Fabian, TJ; Haskett, R; Kreys, TJ; Saul, MI, 2013) |
| "Case one describes an adult male who developed hyperammonemia after acute exposure to valproic acid as a treatment for his bipolar disorder-manic episode." | 3.79 | Hyperammonemia induced by interaction of valproate and quetiapine. ( Haddad, R; Halaby, A; Naja, WJ, 2013) |
| "Mood stabilizers used for treating bipolar disorder (BD) selectively downregulate arachidonic acid (AA) turnover (deacylation-reacylation) in brain phospholipids, when given chronically to rats." | 3.79 | Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: a potential drug for bipolar disorder. ( Basselin, M; Bialer, M; Coleman, RA; Li, LO; Modi, HR; Rapoport, SI; Taha, AY, 2013) |
| "Patients with major affective disorders are more likely to complete suicide than patients in any other medical group." | 3.79 | Anticonvulsant therapy and suicide risk in affective disorders. ( Goodwin, FK, 1999) |
| " The present study examines the hypothesis that the three antiepileptics approved for bipolar disorder (carbamazepine, lamotrigine, and valproate) are associated with an elevated risk of suicide attempts and suicides." | 3.78 | Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study. ( Coryell, WH; Endicott, J; Fiedorowicz, JG; Keller, MB; Leon, AC; Li, C; Solomon, DA, 2012) |
| "Data were derived from the national Department of Veterans Affairs registries for older patients with bipolar disorder (≥65 years) with a new start of an atypical antipsychotic (risperidone, olanzapine, or quetiapine) or valproic acid and derivatives during fiscal years 2001-2008." | 3.78 | Mortality risk with the use of atypical antipsychotics in later-life bipolar disorder. ( Bhalerao, S; Chiang, C; Kales, HC; Kavanagh, J; Kim, HM; Seyfried, LS, 2012) |
| "Carbamazepine (CBZ) has been used in the treatment of bipolar disorder, both in acute mania and maintenance therapy, since the early 1970s." | 3.78 | Carbamazepine treatment of bipolar disorder: a retrospective evaluation of naturalistic long-term outcomes. ( Chen, CH; Lin, SK, 2012) |
| "It has been reported that fewer patients with unipolar mania respond to lithium prophylaxis as do those with classical bipolar disorder." | 3.78 | [Unipolar mania: a distinct entity or characteristic of manic preponderance?]. ( Cakır, S; Yazıcı, O, 2012) |
| "Combination therapy with valproic acid plus quetiapine is recommended as one of the first-line approaches to treatment of manic or mixed episodes in patients with bipolar disorder." | 3.77 | Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine. ( De Dios, C; Fudio, S; Lorenzo, A, 2011) |
| "We present a patient who developed pancytopenia while taking valproic acid for bipolar illness." | 3.77 | Successful reintroduction of valproic acid after the occurrence of pancytopenia. ( Stewart, JT, 2011) |
| "Valproic acid, a conventional antiepileptic drug, is also used in the treatment of bipolar disorder, to provide rapid stabilization of the patient." | 3.77 | A rare occurrence of isolated neutropenia with valproic acid: a case report. ( Chakraborty, J; Chakraborty, S; Ghosal, MK; Mandal, S, 2011) |
| "Risperidone, as all atypical antipsychotics, can cause hyperprolactinemia which can in turn lead to galactorrhea." | 3.76 | Galactorrhea - side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder. ( Grahovac, T; Pavlović, E; Peitl, MV; Peitl, V, 2010) |
| "This 12-month, prospective, observational study investigated factors associated with symptomatic remission (total YMRS score < or =12) and full clinical recovery (sustained reduction in CGI-BP-S overall score) in bipolar disorder during treatment with atypical antipsychotics (predominantly olanzapine, risperidone and quetiapine; alone or in combination with a psychotropic such as lithium or valproate) in actual clinical practice." | 3.76 | Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics. ( Badr, MG; D'yachkova, Y; Dikeos, D; Fábián, Z; Harrison, G; Hudiţă, C; Okasha, T; Pesek, MB; Tapia-Paniagua, G; Treuer, T; Yang, F, 2010) |
| "This study investigated the effects of three AEDs (carbamazepine, oxcarbazepine, and valproic acid) on nicotine and nicotine metabolite levels in 149 smokers with schizophrenia and bipolar disorder who participated in an afternoon blood draw for nicotine, cotinine, and 3'-hydroxycotinine (3HC)." | 3.76 | Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness. ( Benowitz, NL; Gandhi, KK; Williams, JM, 2010) |
| "We report a case of severe restless legs syndrome (RLS) that occurred as a side effect of olanzapine therapy." | 3.75 | Refractory restless legs syndrome likely caused by olanzapine. ( Khalid, I; Khalid, TJ; Rana, L; Roehrs, T, 2009) |
| " We investigated the association of exon 26 C3435T genetic variants of MDR1 gene with susceptibility to bipolar disorder and serum valproic acid concentration." | 3.75 | Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid. ( Alatas, G; Herken, H; Kursunluoglu, R; Kurt, E; Oral, T; Sengul, C; Turgut, G; Turgut, S, 2009) |
| "To compare clinical responses of patients with pediatric bipolar disorder being treated with risperidone versus divalproex." | 3.74 | Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder. ( Gonzalez-Heydrich, JM; Korndörfer, SR; MacMillan, CM; Mrakotsky, C; Tilley, CA; Withney, JE, 2008) |
| "This study investigated the association between 2 mood stabilizers (carbamazepine and valproate) and other medications (including other anticonvulsants) and the risks of erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) among patients with bipolar disorder." | 3.74 | The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study. ( Chang, CJ; Chao, PF; Gau, CS; Gau, SS; Lin, YJ, 2008) |
| "To determine the incidence, characteristics, and predictors of clozapine-induced fever in a sample of patients in a local psychiatric unit." | 3.74 | The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong. ( Chan, WF; Chung, KF; Lai-wah Dunn, E; Pui-yin Chung, J; Shiu-yin Chong, C; Wai-nang Tang, O, 2008) |
| "This case report describes two children who developed hyperammonemia together with frank manic behavior during treatment with a combination of valproic acid and risperidone." | 3.74 | Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania. ( Caplan, R; Carlson, T; Reynolds, CA, 2007) |
| " In sight of the scarcity of studies with other neurotrophins, and the possible relevance of multiple neurotrophic signaling systems in bipolar disorder we investigated the effects of Li and VPT on NT-3 levels in rat serum and hippocampus, using an animal model of mania induced by amphetamine (AMPH)." | 3.74 | Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania. ( Andreazza, AC; Cacilhas, AA; Ceresér, KM; Frey, BN; Kapczinski, F; Quevedo, J; Valvassori, SS; Walz, JC, 2008) |
| "To analyze, from a payer perspective, the net pharmaceutical and medical costs of prescribing divalproex sodium extended-release (DVPX-ER) versus valproic acid (VPA) in patients with bipolar disorder." | 3.74 | Cost analysis of divalproex sodium extended-release compared to valproic acid in the treatment of bipolar disorder. ( Cramer, JA; Gupta, SR; Schumock, GT; Walton, SM, 2007) |
| " Lower doses of valproate and carbamazepine were required to prevent hyperactivity compared to doses required to block tonic-clonic seizures induced by pentylenetetrazole." | 3.73 | Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. ( Arban, R; Brackenborough, K; Gerrard, P; Large, C; Maraia, G; Wilson, A; Winyard, L, 2005) |
| "Inositol-1,4,5-trisphosphate (InsP3) depletion has been implicated in the therapeutic action of bipolar disorder drugs, including valproic acid (VPA)." | 3.73 | Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure. ( Adley, K; Chadborn, NH; Eickholt, BJ; Eikel, D; Harwood, AJ; Nau, H; Ryves, WJ; Towers, GJ; Williams, RS; Ylinen, LM, 2005) |
| "The mood stabilizing drugs commonly used to treat bipolar disorder--lithium, valproic acid (VPA), and carbamazepine (CBZ)--limit the frequency of swings to either manic or depressive states." | 3.73 | How can the mood stabilizer VPA limit both mania and depression? ( Cheng, L; Lumb, M; Mudge, AW; Polgár, L, 2005) |
| "Little is known about the effects of lithium on suicidal ideation or about the possible antisuicidal effects of divalproex, second-generation antipsychotics, or antidepressants among persons with bipolar disorder." | 3.73 | Suicidal ideation and pharmacotherapy among STEP-BD patients. ( Allen, MH; Bowden, CL; Calabrese, JR; Chessick, CA; Endick, CJ; Goldberg, JF; Miklowitz, DA; Miyahara, S; Sachs, GS; Sagduyu, K; Thase, ME; Wisniewski, SR, 2005) |
| "Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective phospholipase A(2)." | 3.73 | Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder. ( Bazinet, RP; Rapoport, SI; Rosenberger, TA; Weis, MT, 2006) |
| "A patient with a treatment-refractory bipolar disorder with ultradian cycling responded to adjunctive topiramate." | 3.73 | Adjunctive topiramate in ultradian cycling bipolar disorder: case report with 3-year follow-up. ( Karama, S; Lal, S, 2006) |
| "A 30-year-old man with bipolar disorder and HIV initiated treatment with lopinavir/ritonavir, zidovudine, and lamivudine." | 3.73 | Possible interaction between lopinavir/ritonavir and valproic Acid exacerbates bipolar disorder. ( Allan, J; Brouillette, MJ; Delisle, MS; Sheehan, NL, 2006) |
| " The present study aims to investigate the effects of the mood stabilizers lithium (Li) and valproate (VPT) in an animal model of bipolar disorder." | 3.73 | Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. ( Andreazza, AC; Ceresér, KM; Frey, BN; Kapczinski, F; Martins, MR; Quevedo, J; Réus, GZ; Valvassori, SS, 2006) |
| "Divalproex (DVP) and oxcarbazepine (OXC) are used to treat pediatric bipolar disorder (PBPD) with severe aggression but these agents have not been compared in head to head trials." | 3.73 | A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder. ( Fleisher, CA; Gonzalez-Heydrich, J; Korndörfer, SR; MacMillan, CM; Mezzacappa, E; Rao, S, 2006) |
| "To assess the efficacy of lamotrigine combined with either divalproex or lithium for the treatment of bipolar disorder." | 3.73 | Lamotrigine combined with divalproex or lithium for bipolar disorder: a case series. ( Bowden, CL; Jamison, KL; Redmond, JR, 2006) |
| "The purpose of the present paper was to remind physicians that hypothermia is a possible side-effect of combining zotepine, valproate,and benzodiazepine." | 3.72 | Two case studies of hypothermia induced by an increased dosage of zotepine in a combination therapy. ( Chen, KC; Chen, PS; Yang, MJ; Yang, YK; Yeh, TL, 2003) |
| "Levetiracetam (LEV) is a novel anticonvulsant that is currently investigated in bipolar disorder." | 3.72 | Levetiracetam in the treatment of rapid cycling bipolar disorder. ( Bräunig, P; Krüger, S, 2003) |
| "Population-based sample of 20 638 health plan members aged 14 years or older who had at least 1 outpatient diagnosis of bipolar disorder and at least 1 filled prescription for lithium, divalproex, or carbamazepine between January 1, 1994, and December 31, 2001." | 3.72 | Suicide risk in bipolar disorder during treatment with lithium and divalproex. ( Fireman, B; Goodwin, FK; Hunkeler, EM; Lee, J; Revicki, D; Simon, GE, 2003) |
| "A 47-year-old white man with a history of bipolar disorder was being maintained on citalopram 40 mg once daily and zolpidem 5 mg at bedtime." | 3.72 | Somnambulism due to probable interaction of valproic acid and zolpidem. ( Bhatia, SC; Petty, F; Ramaswamy, S; Sattar, SP, 2003) |
| "To evaluate whether valproic acid (VPA) can cause thrombocytopenia and impaired platelet function in young patients with new-onset bipolar disorder." | 3.72 | Thrombocytopenia during valproic acid treatment in young patients with new-onset bipolar disorder. ( Campanella, D; De Berardis, D; Ferro, FM; Gambi, F; Grimaldi, MR; La Rovere, R; Matera, V; Pacilli, AM; Salerno, RM; Sepede, G, 2003) |
| "This exploratory analysis was performed to compare the efficacy and tolerability of risperidone when added to two different mood stabilizers (lithium or valproate) for mania in bipolar disorder." | 3.72 | Risperidone plus lithium versus risperidone plus valproate in acute and continuation treatment of mania. ( Binder, C; Kusumakar, V; Riccardelli, R; Yatham, LN, 2004) |
| "Lithium is one of the most widely used mood-stabilizing agents for the treatment of bipolar disorder." | 3.72 | Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. ( Brune, K; Fox, N; Li, B; Liu, F; Ni, B; Paul, S; Ryder, J; Solenberg, P; Su, Y; Wu, X; Zhou, Y, 2004) |
| "Medical records were reviewed for 42 patients (ages 12-19 years) who were hospitalized for acute mania and discharged with a diagnosis of DSM-III-R or DSM-IV bipolar disorder on either lithium (N = 29) or divalproex sodium (N = 13) treatment." | 3.72 | Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania. ( Altshuler, LL; DeAntonio, M; Frye, MA; Hwang, S; Mintz, J; State, RC; Strober, M, 2004) |
| "This case suggests the potential utility of lamotrigine in treatment-resistant menstrually-related rapid cycling bipolar disorder, and raises the possibility that lamotrigine might be able to treat pathological entrainment of mood with the menstrual cycle." | 3.72 | Lamotrigine therapy in treatment-resistant menstrually-related rapid cycling bipolar disorder: a case report. ( Becker, OV; Glenn, T; Ketter, TA; Marsh, WK; Rasgon, NL, 2004) |
| "A nondiabetic young male patient in hypomanic phase of bipolar disorder on maintenance treatment with sodium valproate, developed transient episode of acute pancreatitis and diabetic ketoacidosis after addition of chlorpromazine and halopridol." | 3.72 | Acute pancreatitis and diabetic ketoacidosis in non-diabetic person while on treatment with sodium valproate, chlorpromazine and haloperidol. ( Gupta, SB; Laghate, VD, 2004) |
| " Average glia measures were not reduced in bipolar disorder cases; however, bipolar disorder cases not treated with lithium or valproate had significant glial reduction." | 3.71 | Low glial numbers in the amygdala in major depressive disorder. ( Bowley, MP; Drevets, WC; Ongür, D; Price, JL, 2002) |
| "To study the effectiveness of adding lamotrigine to the treatment of inpatient geriatric patients with bipolar disorder (BD) who were in the depressed phase and had been on lithium and valproate for at least 3 months." | 3.71 | Lamotrigine use in geriatric patients with bipolar depression. ( Conn, DK; Robillard, M, 2002) |
| "The pharmacokinetics of valproic acid (VPA) were studied in nine patients with bipolar disorder who were receiving VPA as prophylactic therapy, following the full daily dose (400-1500 mg), on which the patients had been maintained for at least the past 3 months." | 3.71 | Pharmacokinetics of valproic acid in patients with bipolar disorder. ( Das, S; Goswami, U; Tayal, G; Vasudev, K, 2001) |
| "A 47-year-old man suffering from a bipolar disorder and intermittent myoglobinuria presented with acute rhabdomyolysis with renal failure after starting therapy with valproic acid." | 3.71 | Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. ( Glocker, FX; Jaksch, M; Ketelsen, UP; Kottlors, M; Lücking, CH; Weiner, S, 2001) |
| "A potential model for bipolar disorder, quinpirole-induced biphasic locomotion, was used for a preliminary evaluation of behavioral effects of oral anticonvulsant treatment." | 3.71 | Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. ( Belmaker, RH; Einat, H; Shaldubina, A; Shimon, H; Szechtman, H, 2002) |
| "This report describes four geriatric patients, with rapid cycling bipolar disorder, who were treated successfully with divalproex sodium in combination with lithium carbonate, noting that both drugs were necessary for clinical remission of symptoms." | 3.70 | Divalproate augmentation in lithium-resistant rapid cycling mania in four geriatric patients. ( Schneider, AL; Wilcox, CS, 1998) |
| "Valproate may have greater acceptability than lithium among patients with bipolar disorder and substance use disorder." | 3.70 | Medication compliance among patients with bipolar disorder and substance use disorder. ( Greenfield, SF; Griffin, ML; Najavits, LM; Soto, JA; Tohen, M; Weiss, RD; Wyner, D, 1998) |
| " The authors present a bipolar disorder patient with dose-dependent valproic acid thrombocytopenia and suggest treatment strategies." | 3.70 | Dose-dependent valproic acid thrombocytopenia in bipolar disorder. ( Gerner, R; Kaufman, KR, 1998) |
| "Lithium, carbamazepine and sodium valproate are mood stabilizers used in the treatment of bipolar disorder, and although their mechanisms of action remain unknown, signal transduction systems and the associated modulation of gene expression may constitute significant actions." | 3.70 | Modulation of carbachol-stimulated AP-1 DNA binding activity by therapeutic agents for bipolar disorder in human neuroblastoma SH-SY5Y cells. ( Jope, RS; Pacheco, MA, 1999) |
| "Inositol uptake was measured at concentrations of 25, 40 and 50 microM in human astrocytoma cell cultures treated for 1-3 weeks with pharmacologically relevant concentrations of LiCl, valproic acid or carbamazepine as well as in control cultures that had not been treated with any drug." | 3.70 | Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. ( Belmaker, RH; Bersudsky, Y; Hertz, L; Simkin, M; Wolfson, M; Zinger, E, 2000) |
| "We report on three cases of acutely manic prepubertal children diagnosed with bipolar disorder who were treated with olanzapine in addition to their existing mood stabilizer regimens." | 3.70 | Mood stabilizer augmentation with olanzapine in acutely manic children. ( Chang, KD; Ketter, TA, 2000) |
| "A 28-year-old patient with a 5-year history of bipolar disorder developed signs of encephalopathy 2 weeks after the addition of valproic acid to his treatment regimen of doxepine, risperidone, and biperidene." | 3.70 | [Valproic acid in prophylaxis of bipolar disorder. A case of valproate-induced encephalopathy]. ( Rottach, KG; Schmauss, M; Weiss-Brummer, J; Wieland, U, 2000) |
| "Alterations in choline and myo-inositol metabolism have been noted in bipolar disorder, and the therapeutic efficacy of lithium in mania may be related to these effects." | 3.70 | Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex. ( Babb, SM; Breeze, JL; Cohen, BM; Frederick, BB; Gruber, SA; Hennen, J; Moore, CM; Renshaw, PF; Stoll, AL; Villafuerte, RA; Yurgelun-Todd, DA, 2000) |
| "We report two cases of severe bipolar disorder in which there was a dramatic response to the combination of lithium and sodium valproate." | 3.69 | Combining lithium and sodium valproate for bipolar disorder. ( Hickie, I; Jacobs, G; Mitchell, P; Withers, K, 1994) |
| "Lithium remains a first-line treatment for the acute and maintenance treatment of bipolar disorder." | 3.69 | Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series. ( Locke, CA; Mayer, PV; Stoll, AL; Vuckovic, A, 1996) |
| " The anticonvulsant drugs valproate and carbamazepine are emerging as efficacious alternative and adjunctive treatments for bipolar disorder." | 3.69 | Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? ( Lenox, RH; McNamara, RK; Watson, DG; Watterson, JM, 1996) |
| "To test the hypothesis that, although typical neuroleptics are commonly used in the treatment of bipolar disorder, newer atypical antipsychotic agents, like risperidone, may be more effective and better-tolerated." | 3.69 | Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. ( Baldassano, CF; Ghaemi, SN; Sachs, GS; Truman, CJ, 1997) |
| "Lithium remains the mainstay of pharmacologic therapy for the majority of patients with bipolar disorder; however, significant numbers of patients with both classical bipolar disorder and syndromal variants fail to respond to lithium therapy." | 3.68 | Algorithm for patient management of acute manic states: lithium, valproate, or carbamazepine? ( Gerner, RH; Stanton, A, 1992) |
| " An association between weight gain, obstructive sleep apnea, and lithium treatment is also illustrated." | 3.68 | Four cases of obstructive sleep apnea associated with treatment-resistant mania. ( Alpert, JE; Frankenburg, FR; Hudson, JI; Keck, PE; Strakowski, SM; Teschke, GC; Tohen, M; Wilson, DR, 1991) |
| "A case of rapid cycling bipolar disorder in a person with Down's syndrome, responsive to divalproex sodium, a valproic acid derivative, is presented." | 3.68 | Divalproex-responsive rapid cycling bipolar disorder in a patient with Down's syndrome: implications for the Down's syndrome-mania hypothesis. ( Sovner, R, 1991) |
| "Young Mania Rating Scale (YMRS), Clinical Global Impression Scale (CGI-S), and adverse effects of drugs were assessed at baseline and after 3 and 6 weeks." | 3.11 | Oxcarbazepine versus sodium valproate in treatment of acute mania: a double-blind randomized clinical trial. ( Afzaljavan, F; Akhondzadeh, S; Dastgheib, MS; Mokhber, N; Soltanifar, A; Talaei, A, 2022) |
| " VPM summary of product characteristics and pharmacokinetic studies revealed a lower bioavailability (80% vs." | 3.01 | Valproate, divalproex, valpromide: Are the differences in indications justified? ( Besson, VC; Blaise, N; Bloch, V; Chouchana, M; Delage, C; Etain, B; Hagenimana, M; Palayer, M; Smati, J, 2023) |
| "Because BD-II and alcohol dependence are neurodegenerative disorders, agents with anti-inflammatory and neurotrophic effects might provide effective therapy." | 2.87 | Add-On Memantine Treatment for Bipolar II Disorder Comorbid with Alcohol Dependence: A 12-Week Follow-Up Study. ( Chang, YH; Chen, KC; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, TY; Yang, YK, 2018) |
| "Memantine is an NMDA receptor antagonist with anti-inflammatory effects." | 2.84 | Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder. ( Chang, HH; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, SY; Lu, RB; Wang, TY; Yang, YK, 2017) |
| " To evaluate the recurrence prevention efficacy of lurasidone for the maintenance treatment of bipolar I disorder, patients received up to 20 weeks of open-label lurasidone (20-80mg/d) combined with lithium or valproate during an initial stabilization phase." | 2.84 | Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. ( Calabrese, JR; Cucchiaro, J; Loebel, A; Mao, Y; Pikalov, A; Streicher, C, 2017) |
| "In the treatment of major depressive disorder (MDD) with mixed features, the comparable efficacy of antidepressants versus other treatments, such as SGAs, remains unknown." | 2.84 | Treatment recommendations for DSM-5-defined mixed features. ( McIntyre, RS; Rosenblat, JD, 2017) |
| "This study reviewed all published valproic acid (VPA) population pharmacokinetic (PPK) models in adult patients and assessed them using external validation methods to determine predictive performance." | 2.82 | Published population pharmacokinetic models of valproic acid in adult patients: a systematic review and external validation in a Chinese sample of inpatients with bipolar disorder. ( de Leon, J; Dong, F; Guo, W; Li, AN; Ruan, CJ; Zang, YN, 2022) |
| "Characterization of dose-response relationships for psychotropic agents may be difficult to determine based on results of individual clinical studies, particularly those with a flexible dose design." | 2.82 | Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis. ( Chapel, S; Chiu, YY; Cucchiaro, J; Hsu, J; Loebel, A, 2016) |
| "The diagnoses were major depressive disorder (n = 15), bipolar I disorder (n = 6), and bipolar II disorder (n = 16)." | 2.82 | Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2. ( Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T, 2016) |
| "Celecoxib is an effective adjuvant therapy in the treatment of manic episodes (without psychotic features) of bipolar mood disorder." | 2.80 | Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. ( Akhondzadeh, S; Ameli, N; Arabzadeh, S; Farokhnia, M; Ghaleiha, A; Mohammadinejad, P; Rezaei, F; Zeinoddini, A, 2015) |
| "Memantine is a non-competitive N-methyl-d-asparate (NMDA) receptor antagonist with a mood-stabilizing effect." | 2.79 | Genotype variant associated with add-on memantine in bipolar II disorder. ( Chang, YH; Chen, SH; Chen, SL; Chu, CH; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, CL; Wang, LJ; Yang, YK; Yeh, TL, 2014) |
| "To determine the efficacy and safety of quetiapine combined with lithium or divalproex for preventing mood events in patients with bipolar I disorder." | 2.78 | Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials. ( Ekholm, B; Gustafsson, U; Suppes, T; Vieta, E, 2013) |
| "Inflammation is thought to be involved in the pathophysiology of bipolar disorder (BP) and metabolic syndrome." | 2.78 | Inflammation's Association with Metabolic Profiles before and after a Twelve-Week Clinical Trial in Drug-Naïve Patients with Bipolar II Disorder. ( Chang, YH; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, TY; Wang, YS; Yang, YK; Yeh, TL, 2013) |
| "Memantine is a noncompetitive NMDA receptor antagonist." | 2.78 | Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder. ( Chang, YH; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, YS; Yang, YK; Yeh, TL, 2013) |
| " Chronic administration of the mood stabilizers lithium and divalproex (valproate semisodium) reduces glucocorticoid signaling and function in the hippocampus." | 2.78 | Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression. ( Bain, EE; Carlson, PJ; Drevets, WC; Eckelman, W; Herscovitch, P; Manji, H; Nugent, AC; Zarate, CA, 2013) |
| "Risperidone was more efficacious than lithium or divalproex sodium for the initial treatment of childhood mania but had potentially serious metabolic effects." | 2.77 | A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. ( Axelson, DA; Birmaher, B; Bolhofner, K; Emslie, G; Geller, B; Joshi, P; Lavori, P; Luby, JL; Nusrat, N; Riddle, MA; Robb, A; Ryan, ND; Tillman, R; Vitiello, B; Wagner, KD; Walkup, JT; Wolf, DV, 2012) |
| "Dextromethorphan (DM) is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that may be neuroprotective for monoamine neurons." | 2.77 | The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder. ( Chang, YH; Chen, SH; Chen, SL; Chu, CH; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, CL; Yang, YK; Yeh, TL, 2012) |
| " Safety was assessed by treatment-emergent adverse events (TEAEs), vital signs, weight, and extrapyramidal symptoms (EPSs)." | 2.77 | Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder. ( Higuchi, T; Kanba, S; Katagiri, H; Takahashi, M; Takita, Y; Tohen, M, 2012) |
| "Risperidone was shown to have significant anti-manic effects which was observed as early as week 1, following start of treatment." | 2.77 | Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania. ( Hsu, MC; Kuo, CC; Ouyang, WC; Yeh, IN, 2012) |
| "Hazard ratios (HR) for time to recurrence were longer for quetiapine plus lithium/divalproex than placebo plus lithium/divalproex for mixed (HR=0." | 2.77 | Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. ( Ekholm, B; Gustafsson, U; Suppes, T; Udd, M; Vieta, E, 2012) |
| "Ziprasidone was well tolerated." | 2.77 | Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial. ( Bachinsky, M; Cavus, I; Karayal, ON; Kolluri, S; Sachs, GS; Vanderburg, DG, 2012) |
| "Co-morbid diagnoses, such as disruptive behavior disorders (DBDs) and high levels of aggression, are extremely common among youth with pediatric bipolar disorder (PBD) and may interfere with treatment response; however, they have rarely been examined as predictors of response to pharmacotherapy." | 2.76 | Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. ( Celio, CI; Henry, D; Pavuluri, MN; Weinstein, SM; West, AE, 2011) |
| "Ziprasidone is an effective, safe, and well-tolerated adjunctive treatment with a mood stabilizer for long-term maintenance treatment of bipolar mania." | 2.75 | Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. ( Bowden, CL; Ice, KS; Schwartz, JH; Versavel, M; Vieta, E; Wang, PP, 2010) |
| " The daily divalproex ER dosage was initiated at 20 mg/kg." | 2.75 | A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania. ( Bowden, CL; Collins, M; Hirschfeld, RM; Vigna, NV; Wozniak, P, 2010) |
| " Frequently reported adverse events (AEs) that occurred with ARI + LI vs." | 2.75 | Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. ( Baudelet, C; Marcus, RN; McQuade, RD; Owen, R; Sanchez, R; Vieta, E, 2010) |
| " Patients treated with lithium or divalproex (ongoing or assigned at screening) were randomized to receive quetiapine (dosed up to 400 mg/d over 7 days, followed by 300 to 800 mg/d flexible dosing until study end) or placebo." | 2.75 | A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. ( Brown, ES; Calabrese, JR; Kotz, M; Pettinati, HM; Raines, S; Stedman, M, 2010) |
| "Armodafinil was not associated with an increased incidence and/or severity of suicidality, depression, or mania or with changes in metabolic profile measurements." | 2.75 | Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. ( Calabrese, JR; Frye, MA; Ketter, TA; Tiller, JM; Yang, R; Youakim, JM, 2010) |
| "Ketamine was generally well tolerated; the most common adverse effect was dissociative symptoms, only at the 40-minute point." | 2.75 | A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. ( Brutsche, NE; Diazgranados, N; Ibrahim, L; Kammerer, WA; Khalife, S; Kronstein, P; Luckenbaugh, DA; Machado-Vieira, R; Manji, HK; Newberg, A; Quezado, Z; Salvadore, G; Zarate, CA, 2010) |
| " The most common adverse events were weight gain (16%), nausea (9%), and increased appetite (8%)." | 2.74 | Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder. ( Abi-Saab, W; DelBello, M; Greco, N; Kovacs, X; Malhotra, S; Redden, L; Saltarelli, M; Vigna, NV; Wagner, KD; Wilens, TE; Wozniak, P, 2009) |
| " After at least 12 weeks of clinical stability, 628 patients were randomly assigned to double-blind treatment with quetiapine or placebo, in combination with lithium or divalproex, for up to 104 weeks." | 2.74 | Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). ( Brecher, M; Liu, S; Paulsson, B; Suppes, T; Vieta, E, 2009) |
| " Adverse events were systematically recorded throughout the study." | 2.74 | Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study. ( Chopra, D; Gupta, NK; Kakkar, AK; Kataria, D; Rehan, HS; Unni, KE, 2009) |
| " During the randomization phase, the most common adverse events occurring in > or =5% in the quetiapine group were somnolence, nasopharyngitis, and headache." | 2.73 | Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). ( Brecher, M; Eggens, I; Paulsson, B; Persson, I; Suppes, T; Vieta, E, 2008) |
| "Olanzapine-treated patients had significantly greater increases in weight and in glucose, cholesterol, triglyceride, uric acid, and prolactin levels than divalproex-treated patients." | 2.73 | Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. ( Aaronson, ST; Amsterdam, JD; Banov, M; Bardenstein, L; Bowden, C; Goodwin, GM; Grecu-Gabos, I; Kryzhanovskaya, L; Oliff, HS; Prelipceanu, D; Shekhar, A; Sun, B; Tochilov, V; Tohen, M; Vieta, E, 2008) |
| "Unmedicated subjects with bipolar depression (UBD, n = 32), subjects with bipolar depression on therapeutic doses of lithium or valproic acid (MBD, n = 33), and healthy control subjects (HC, n = 52) performed neuropsychological tasks measuring affective processing, visual memory, and sustained attention." | 2.73 | A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression. ( Bain, EE; Cannon, DM; Drevets, WC; Erickson, K; Holmes, MK; Luckenbaugh, DA; Manji, HK; Sahakian, BJ; Snow, J; Zarate, CA, 2008) |
| "Lamotrigine was given for 12 weeks, with a target dosage of 200 mg/d." | 2.73 | Effect of open-label lamotrigine as monotherapy and adjunctive therapy on the self-assessed cognitive function scores of patients with bipolar I disorder. ( Graham, J; Kaye, NS; Nanry, K; Roberts, J; Thompson, T, 2007) |
| "To determine whether there is a pharmacokinetic drug interaction between quetiapine fumarate and divalproex sodium." | 2.73 | Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. ( Davis, PC; DeVane, CL; Ennis, DJ; Figueroa, C; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2007) |
| " Patients continued on ER + 500 for 4 additional weeks after the pharmacokinetic phase." | 2.73 | A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex. ( Bartolucci, AA; Davis, LL; Li, X; Lowe, JS; Williford, RB, 2007) |
| "Aripiprazole is an atypical antipsychotic compound that is approved by the U." | 2.73 | Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. ( Blow, FC; Cassidy, KA; Coconcea, N; Hays, RW; Ignacio, RV; Meyer, WJ; Sajatovic, M, 2008) |
| "Despite promising new therapies, bipolar depression remains difficult to treat." | 2.72 | Inositol augmentation of lithium or valproate for bipolar depression. ( Culhane, M; Demopulos, C; Eden Evins, A; Grandin, LD; Nierenberg, AA; Ogutha, J; Sachs, GS; Yovel, I, 2006) |
| "To identify symptoms associated with suicidality in bipolar I disorder patients, and to assess suicide risk during treatment with olan-zapine in combination with lithium or divalproex." | 2.72 | Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. ( Ahl, J; Baldessarini, RJ; Houston, JP; Kaiser, CJ; Meyers, AL; Tohen, M, 2006) |
| " Daily dosage was initiated at 25 mg/kg, increased 500 mg on day 3, and adjusted to serum valproate concentrations of 85 to 125 microg/mL." | 2.72 | A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. ( Abi-Saab, W; Bowden, CL; Calabrese, JR; Collins, MA; Rubenfaer, LM; Saltarelli, M; Swann, AC; Wozniak, PJ, 2006) |
| "Topiramate was titrated from 25 to 400 mg/day over 8 weeks and was continued for 4 additional weeks." | 2.72 | Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. ( Hulihan, JF; Rosenthal, NR; Roy Chengappa, KN; Schwarzman, LK; Xiang, J, 2006) |
| " However, the study suggests that chronic administration of sodium valproate to patients does not lead to similar changes in NAA concentrations." | 2.71 | Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. ( Asghar, SJ; Hanstock, CC; O'Donnell, T; Silverstone, PH; Ulrich, M; Wu, RH, 2003) |
| " A nonsignificant increase in the rate of adverse events was noted in the intravenous group." | 2.71 | Acute antimanic efficacy and safety of intravenous valproate loading therapy: an open-label study. ( Akhtar, S; Basu, S; Duggal, H; Gupta, S; Jagadheesan, K; Nizamie, SH; Ranjan, S; Sandil, R, 2003) |
| "Topiramate was generally well tolerated." | 2.71 | Adjunctive topiramate in bipolar II disorder. ( Benabarre, A; Colom, F; Comes, M; Corbella, B; Goikolea, JM; Martínez-Arán, A; Reinares, M; Sánchez-Moreno, J; Torrent, C; Vieta, E, 2003) |
| " QTP was rapidly dosed up to a maximum of 800 mg/day; Li was dosed to 0." | 2.71 | Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. ( Brecher, M; Chengappa, KN; Devine, NA; Mullen, JA; Sachs, G; Suppes, T; Sweitzer, DE, 2004) |
| " They could then enter a 10-week open-label study during which they received risperidone combined with a mood stabilizer." | 2.71 | Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. ( Bowden, CL; Grossman, F; Myers, JE; Xie, Y, 2004) |
| "Quetiapine (QTP) combined with lithium (Li) or divalproex (DVP) for the treatment of mania was evaluated in 2 double-blind, placebo-controlled studies." | 2.71 | Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. ( Mullen, J; Paulsson, B; Vågerö, AM; Yatham, LN, 2004) |
| "To evaluate the efficacy of olanzapine, in combination with lithium or valproate, for treating depressive symptoms associated with mania." | 2.71 | Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. ( Akiskal, HS; Baker, RW; Brown, E; Calabrese, JR; Ketter, TA; Schuh, LM; Tohen, M; Trzepacz, PT; Watkin, JG, 2004) |
| " The aim of this study was to compare the effectiveness and tolerability of topiramate and divalproex in combination with risperidone for treating acute mania patients in a naturalistic treatment setting." | 2.71 | Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. ( Bahk, WM; Choi, SK; Chung, SK; Jon, DI; Lee, JS; Pae, CU; Paik, IH; Shin, YC; Woo, JM; Yoon, BH, 2005) |
| "Additional marijuana abuse may impact on the clinical presentation of bipolar illness and may potentially act as mediator of treatment response in this population." | 2.71 | Patient characteristics and treatment implications of marijuana abuse among bipolar alcoholics: results from a double blind, placebo-controlled study. ( Cornelius, JR; Daley, DC; Douaihy, A; Kelly, TM; Kirisci, L; Salloum, IM, 2005) |
| "Mean weight gain was 10." | 2.70 | Quetiapine alone and added to a mood stabilizer for serious mood disorders. ( Bingham, CR; Brescan, DW; DiGiovanni, SK; Hattab, H; Perez, DE; Ray, JB; Sajatovic, M, 2001) |
| "The olanzapine treatment group had significantly greater mean improvement of mania ratings and a significantly greater proportion of patients achieving protocol-defined remission, compared with the divalproex treatment group." | 2.70 | Olanzapine versus divalproex in the treatment of acute mania. ( Altshuler, LL; Baker, RW; Breier, A; Gilmore, JA; Ketter, TA; Milton, DR; Risser, R; Suppes, T; Tohen, M; Tollefson, GA; Zarate, CA, 2002) |
| " Although patients who finished the algorithm were taking more medication, either dosage and/or drugs, somatic complaints did not increase." | 2.69 | Treatment algorithm use to optimize management of symptomatic patients with a history of mania. ( Kraemer, HC; Rush, AJ; Suppes, T; Webb, A, 1998) |
| "Past substance abuse was evident in 34% of the bipolar sample and comprised most often alcoholism (82%), followed by cocaine (30%), marijuana (29%), sedative-hypnotic or amphetamine (21%), and opiate (13%) abuse." | 2.69 | A history of substance abuse complicates remission from acute mania in bipolar disorder. ( Garno, JL; Goldberg, JF; Kocsis, JH; Leon, AC; Portera, L, 1999) |
| " It also appears that rapid dosage increases for antimanic treatment can cause potentially severe side effects." | 2.69 | Tiagabine appears not to be efficacious in the treatment of acute mania. ( Amann, B; Erfurth, A; Grunze, H; Marcuse, A; Normann, C; Walden, J, 1999) |
| " No patient was removed from the study because of an adverse event." | 2.69 | Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. ( Allen, MH; Hirschfeld, RM; Keck, PE; McEvoy, JP; Russell, JM, 1999) |
| " Further increment in dose was carried out at weekly intervals, guided by clinical improvement, serum levels and treatment emergent adverse events." | 2.69 | Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. ( Goswami, U; Kohli, K; Vasudev, K, 2000) |
| "Substance abuse is a common comorbid illness in patients with mood disorders." | 2.69 | Divalproex sodium in substance abusers with mood disorder. ( Albanese, MJ; Clodfelter, RC; Khantzian, EJ, 2000) |
| "Inositol is a constituent of the intracellular phosphatidyl inositol (PI) second messenger system, which is linked to various neurotransmitter receptors." | 2.69 | Inositol as an add-on treatment for bipolar depression. ( Buttenfield, J; Chengappa, KN; Gershon, S; Hardan, A; Kupfer, DJ; Levine, J; Luther, J; Mallinger, AG; Pollock, B; Vagnucci, A; Verfaille, S, 2000) |
| "Sixty-five hospitalized patients who met the Research Diagnostic Criteria for bipolar disorder with mania were treated with divalproex, 750 mg/day for 2 days and then 1,000 mg/day on days 3-5; the dosage was subsequently adjusted as clinically indicated for the remainder of the 21-day study." | 2.68 | Relation of serum valproate concentration to response in mania. ( Bowden, CL; Calabrese, JR; Davis, JM; Goodnick, P; Janicak, PG; Kimmel, SE; Morris, DD; Orsulak, P; Risch, SC; Rush, AJ; Small, JG; Swann, AC, 1996) |
| "Lamotrigine was used at a mean +/- SD dose of 185." | 2.68 | Lamotrigine in rapid-cycling bipolar disorder. ( Calabrese, JR; Fatemi, SH; Rapport, DJ; Thuras, P, 1997) |
| " Serum valproate concentrations were measured three times weekly; an unblinded investigator then adjusted dosage to produce serum concentrations between 50 and 100 mg/L." | 2.67 | Valproate in the treatment of acute mania. A placebo-controlled study. ( Hudson, JI; Keck, PE; McElroy, SL; Pope, HG, 1991) |
| "Although mania defines bipolar I disorder, depressive episodes and symptoms dominate the longitudinal course of, and disproportionately account for morbidity and mortality in, bipolar disorders." | 2.66 | Bipolar disorders. ( Berk, M; Brietzke, E; Goldstein, BI; Kessing, LV; López-Jaramillo, C; Majeed, A; Malhi, GS; Mansur, RB; McIntyre, RS; Nierenberg, AA; Rosenblat, JD; Vieta, E; Vinberg, M; Young, AH, 2020) |
| "Valproic acid (VPA) is a commonly used antiepileptic drug (AED)." | 2.61 | Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. ( Kashyap, A; Rashid, M; Undela, K, 2019) |
| "Subjects were diagnosed with either major depressive disorder (MDD) or bipolar depression." | 2.55 | Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. ( Luckenbaugh, DA; Niciu, MJ; Pennybaker, SJ; Zarate, CA, 2017) |
| " This systematic review aimed to assess the prevalence of their adverse effects (AEs) and to provide recommendations on their clinical management." | 2.52 | Management of adverse effects of mood stabilizers. ( Hidalgo, D; León-Caballero, J; Murru, A; Pacchiarotti, I; Popovic, D; Vieta, E, 2015) |
| "For patients with migraine, the pregnancy labeling of VPA will be changed from Category "D" to "X." | 2.50 | Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions. ( Gentile, S, 2014) |
| "Aripiprazole is an effective treatment for mania in a population that includes adults, children and adolescents, although its use leads to gastrointestinal disturbances and movement disorders." | 2.49 | Aripiprazole alone or in combination for acute mania. ( Brown, R; Geddes, J; Taylor, MJ, 2013) |
| "Their efficacy in bipolar depression has not always been confirmed in more recent and methodologically more reliable studies." | 2.47 | [Lithium and anticonvulsants in bipolar depression]. ( Llorca, PM; Nourry, A; Samalin, L, 2011) |
| "Pediatric epilepsy is a common, chronic, and challenging physical illness for children and their families." | 2.46 | Psychiatric concerns in pediatric epilepsy. ( Bujoreanu, IS; DeMaso, DR; Ibeziako, P, 2010) |
| "It has been used in other psychiatric disorders, including schizophrenia and borderline personality disorder, but data are insufficient to recommend this." | 2.45 | A review of valproate in psychiatric practice. ( Ashfaq, M; Das, A; Haddad, PM; Wieck, A, 2009) |
| " In the present paper, I review studies in unanaesthetized rats using a neuropharmacological approach, combined with kinetic, biochemical and molecular biology techniques, demonstrating that chronic administration of three commonly used mood stabilizers (lithium, valproic acid and carbamazepine), at therapeutically relevant doses, selectively target the brain arachidonic acid cascade." | 2.45 | Is the brain arachidonic acid cascade a common target of drugs used to manage bipolar disorder? ( Bazinet, RP, 2009) |
| "Women with untreated epilepsy are more likely to have irregular menstrual cycles than are nonepileptic controls, indicating that the disease itself plays a role in the etiology of these reproductive abnormalities." | 2.44 | Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: their treatment in adolescents. ( Hayes, FJ; Joffe, H, 2008) |
| "Bipolar disorder (BPD) is a severe and chronic illness, with a lifetime prevalence of approximately 1." | 2.44 | Anticonvulsant efficacy of valproate-like carboxylic acids: a potential target for anti-bipolar therapy. ( Azab, AN; Greenberg, ML, 2007) |
| "A major challenge in the treatment of bipolar depression is the tendency for antidepressant medications, particularly tricyclic antidepressants, to precipitate episodes of mania, or to increase cycle frequency or symptom intensity." | 2.44 | The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders. ( Bourin, M; Prica, C, 2007) |
| "Haloperidol was superior to quetiapine in efficacy at day 21 but similar at day 84." | 2.44 | Quetiapine for acute mania in bipolar disorder. ( Brahm, NC; Carnahan, RM; Gutierres, SL, 2007) |
| "Lamotrigine has obtained approval in several countries for the indication of preventing bipolar depressive episodes, which raises the question of differential efficacy of other antiepileptic drugs as mood stabilizers in the prevention of either depressive or hypo-/manic episodes." | 2.44 | Antiepileptic drugs and mood stability. ( Amann, B; Grunze, H; Trimble, M; Vieta, E, 2007) |
| " In this paper, we review studies using a neuropharmacological approach in unanesthetized rats, combined with kinetic, biochemical and molecular biology techniques, showing that chronic administration of three Food and Drug Administration-approved mood stabilizers (lithium, valproate and carbamazepine) at therapeutically relevant doses, selectively target the brain arachidonic acid (AA) cascade." | 2.44 | Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? ( Bazinet, RP; Lee, HJ; Rao, JS; Rapoport, SI, 2008) |
| "The mood disorders-primarily major depressive disorder and bipolar affective disorder-constitute one of the world's greatest public health problems and are associated with significant reductions in productivity, health, and longevity." | 2.44 | Pharmacotherapy of mood disorders. ( Denko, T; Thase, ME, 2008) |
| "Amphetamine salts have been helpful in treating bipolar children with comorbid ADHD, but no data are available on treating comorbid depression in bipolar children." | 2.43 | Recognizing and managing bipolar disorder in children. ( Wozniak, J, 2005) |
| " Also discussed are findings concerning the continuation of acute treatments, including antidepressants, into the maintenance phase; dosage adjustments for maintenance treatment; the rationale for combination treatments; and implications of comorbid substance abuse and strategies for its management." | 2.43 | Maintenance treatment of bipolar disorder: Applying research to clinical practice. ( Chou, JC; Fazzio, L, 2006) |
| "Agents introduced for the treatment of epilepsy have also been usedsimultaneously for psychiatric indications." | 2.43 | [Anticonvulsants treatment of psychiatric disorder in elderly patients]. ( Bidzan, L, 2006) |
| " Other agents frequently used as mood stabilizers in monotherapy and in combination with lithium are valproate and carbamazepine." | 2.42 | Drug interactions of lithium and other antimanic/mood-stabilizing medications. ( Dunner, DL, 2003) |
| "Lamotrigine has demonstrated efficacy in delaying time to depressive relapse." | 2.42 | Rethinking the treatment paradigm for bipolar depression: the importance of long-term management. ( Baldassano, CF; Ballas, CA; O'Reardon, JP, 2004) |
| "Lamotrigine has also demonstrated significant efficacy in recent studies and has been approved by the FDA." | 2.42 | Bipolar depression: an overview. ( Oral, ET; Vahip, S, 2004) |
| "Lamotrigine has emerged as a first line treatment for bipolar depression, which is an area of weakness for other mood stabilizers." | 2.42 | Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders. ( Goodwin, FK; Lieberman, DZ, 2004) |
| "As for the treatment of bipolar depression, consensus seems to be emerging that combined treatment with a mood stabilizer and SSRI or SNRI is the first choice because TCA with a mood stabilizer increases the risk of switch to mania." | 2.42 | [Treatment standard for bipolar disorders]. ( Higuchi, T, 2004) |
| "Lamotrigine has demonstrated efficacy in both acute bipolar depression and maintenance efficacy in rapid cycling bipolar patients, especially those patients with bipolar II disorder, which is principally manifested as depression." | 2.41 | Novel treatments for bipolar disorder. ( Bowden, CL, 2001) |
| " One general rule that may reduce the risks of toxic drug interactions is to add medication to the patient's current regimen in modest doses and increase the dose slowly." | 2.40 | Mood stabilizer combinations: a review of safety and efficacy. ( Freeman, MP; Stoll, AL, 1998) |
| " This review summarizes efficacy results of key studies in manic-depressive illness, the increasingly practical findings regarding predictors of response, and the implications of the increasingly better understood adverse effect profile of lithium." | 2.40 | Key treatment studies of lithium in manic-depressive illness: efficacy and side effects. ( Bowden, CL, 1998) |
| " A series of open studies indicates a reduction in frequency and intensity of manic and depressive episodes with the long-term administration of valproate suggesting efficaciousness in the prophylaxis of bipolar affective disorders." | 2.40 | [Therapy of bipolar affective illnesses with valproate. A review of the literature]. ( Emrich, HM; Retzow, A, 1998) |
| "Rapid cycling is a clinical subtype of bipolar mood disorder that has four or more episodes during the previous 12 months and has poor response to lithium (Li) prophylaxis treatment." | 2.40 | Algorithm for the treatment of rapid cycling. ( Yamada, K, 1999) |
| "The significant prevalence of substance use disorders among patients with psychiatric illnesses has attracted increasing interest." | 2.39 | The relationship between substance abuse and bipolar disorder. ( Brady, KT; Sonne, SC, 1995) |
| " For lithium, uncomplicated manic patients can be started at 15 mg/kg of body weight, with dosage increase every 3 to 4 days until response, complicating adverse effects, or a serum level of 1." | 2.39 | Dosing strategies and time course of response to antimanic drugs. ( Bowden, CL, 1996) |
| " Neuroleptic dosing of manic patients is probably too high and exposes patients to an unnecessary risk of side effects including tardive dyskinesia." | 2.38 | Treatment approaches for acute mania. ( Chou, JC; Sweeney, EA; Tuma, I, 1993) |
| " It is often necessary to have lithium combined with other psychopharmacological agents when efforts are aimed at either enhancing a less-than-optimal therapeutic effect or treating other symptoms as well." | 2.38 | [Drug combinations of lithium: reasons and limitations]. ( Lagomarsino, AJ, 1993) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| "Here we developed a novel mania mice model by combining a series of chronic unpredictable rhythm disturbances (CURD), which include disruption of circadian rhythm, sleep deprivation, exposure to cone light, with subsequent interference of followed spotlight, stroboscopic illumination, high-temperature stress, noise disturbance and foot shock." | 1.91 | A novel murine model of mania. ( Chen, B; Cui, L; Feng, Y; Gong, W; Ji, M; Li, B; Li, X; Verkhratsky, A; Wang, S; Wu, X; Xia, M; Zhang, D, 2023) |
| "Lithium carbonate was not associated with an increased risk of Parkinson-like events, but was related to these events in patients taking sodium valproate." | 1.72 | Relationship between lithium carbonate and the risk of Parkinson-like events in patients with bipolar disorders: A multivariate analysis using the Japanese adverse drug event report database. ( Nabekura, T; Uwai, Y, 2022) |
| "Prescribed drugs for the treatment of bipolar disorder, including mood stabilizers (i." | 1.72 | Prescribing changes for bipolar patients discharged from two public psychiatric hospitals in Taiwan, 2006-2019. ( Chan, HY; Chen, CC; Chou, FH; Lin, CH, 2022) |
| " The purpose of this study was to establish a model for predicting the blood concentration of Li carbonate through an artificial neural network (ANN), and to provide a basis for the clinical rapid and effective formulation of individualized dosing regimens." | 1.72 | The development and validation of a prediction model of lithium carbonate blood concentration by artificial neural network: a retrospective study. ( Feng, W; Hu, Z; Jing, Q; Li, J; Wang, Y; Zhang, J; Zhang, W, 2022) |
| "Lurasidone is used for treatment of bipolar depression in adults and adolescents." | 1.62 | Lurasidone-Induced Manic Switch in an Adolescent with Bipolar I Disorder: a Case Report. ( Chua, CJM; Nair, SS; Teo, DCL, 2021) |
| "VPA PopPK models developed using patients with epilepsy can also be used for individualized dosing of patients with mania, but before implementation, the accuracy of these models' predictions should be assessed in the target population." | 1.62 | Predictive ability of published population pharmacokinetic models of valproic acid in Thai manic patients. ( Leelakanok, N; Methaneethorn, J, 2021) |
| " This was achieved safely through a reduced dosing schedule of three times a week post dialysis, slow dose titration and blood level monitoring prior to each dialysis session." | 1.62 | Lithium use in a patient on haemodialysis with bipolar affective disorder and lithium-induced nephropathy. ( Salisbury, E; Topp, S, 2021) |
| "He was diagnosed with type 2 diabetes mellitus, started treatment with empagliflozin, and his body weight decreased gradually." | 1.56 | Valproate intoxication in a patient with bipolar I disorder due to SGLT2 inhibitor-induced weight reduction. ( Miyauchi, T, 2020) |
| "Finally, we made the diagnosis of eosinophilic pneumonia secondary to sodium divalproate." | 1.56 | [Eosinophilic pneumonia: A rare complication of sodium divalproate]. ( Chabot, F; Chaouat, A; Faure, M; Gomez, E; Petit, I; Petitpain, N; Ruuth-Praz, J, 2020) |
| "9% were treated with valproate with a mean daily dosage of 968 mg." | 1.56 | Evolution and characteristics of the use of valproate in women of childbearing age with bipolar disorder: Results from the FACE-BD cohort. ( Aouizerate, B; Aubin, V; Bellivier, F; Belzeaux, R; Bennabi, D; Bougerol, T; Courtet, P; Dubertret, C; Encely, L; Etain, B; Gard, S; Godin, O; Haffen, E; Henry, C; Leboyer, M; Llorca, PM; Loftus, J; Mazer, N; Olié, E; Passerieux, C; Pelletier, A; Poinso, F; Polosan, M; Roux, P; Samalin, L; Schwan, R; Schwitzer, T, 2020) |
| "In a woman with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) followed for 15 years, we observed magnetic resonance imaging white matter hyperintensities that vanished in the anterior temporal poles while the brain volume decreased unexpectedly." | 1.56 | Vanishing White Matter Hyperintensities in CADASIL: A Case Report with Insight into Disease Mechanisms. ( Alili, N; Chabriat, H; Hervé, D; Jouvent, E, 2020) |
| "Acute pancreatitis is considered as one of the idiosyncratic adverse reactions to antiepileptic drugs." | 1.51 | Sodium valproate induced acute pancreatitis in a bipolar disorder patient: a case report. ( Huang, W; Ren, X; Shen, F; Xing, B, 2019) |
| "Olanzapine is a second-generation antipsychotic." | 1.51 | Generalised tonic-clonic seizures on the subtherapeutic dose of olanzapine. ( Chachar, AS; Mansoor, M; Mesiya, MH, 2019) |
| " While women younger than 50 years of age were less likely to be prescribed valproate than men in the same age group, and at a lower dosage, it is unclear to what extent this reflects clinicians' concerns about teratogenicity or is driven by perceptions of the indication for valproate, and the dosage required, for the treatment of different phases of the disorder in men and women." | 1.48 | A UK clinical audit addressing the quality of prescribing of sodium valproate for bipolar disorder in women of childbearing age. ( Barnes, TRE; Bhatti, S; Cookson, J; Fagan, E; Ferrier, IN; Paton, C, 2018) |
| "Hypogonadotropic hypogonadism is a rare congenital disorder characterised by the deficiency and the absence of puberty and infertility." | 1.48 | Rare cause of manic period trigger in bipolar mood disorder: testosterone replacement. ( Elboga, G; Sayiner, ZA, 2018) |
| "Valproic acid was related to the highest risk." | 1.48 | Severe hair loss associated with psychotropic drugs in psychiatric inpatients-Data from an observational pharmacovigilance program in German-speaking countries. ( Bleich, S; Burda, K; Druschky, K; Frieling, H; Grohmann, R; Hillemacher, T; Neyazi, A; Stübner, S; Toto, S, 2018) |
| "Valproic acid data were adequately described by a 1-compartment model." | 1.46 | Population Pharmacokinetics of Valproic Acid in Patients with Mania: Implication for Individualized Dosing Regimens. ( Methaneethorn, J, 2017) |
| "Treatment with valproic acid for bipolar disorder resulted in complete resolution of symptoms." | 1.46 | A Case of Recurrent Hypersomnia With Autonomic Dysfunction. ( Friedman, D; Kothare, SV; Mahmoudi, M; Vendrame, M, 2017) |
| "Bipolar disorder (BD) spectrum and alcohol use disorders (AUDs) commonly occur together." | 1.46 | Pharmacological Treatment of Bipolar Disorder with Comorbid Alcohol Use Disorder. ( Adinoff, B; Brown, ES; Naglich, A, 2017) |
| "Hypothermia is a rare but serious condition that has been associated with various psychiatric medications." | 1.46 | Severe recurrent hypothermia in an elderly patient with refractory mania associated with atypical antipsychotic, valproic acid and oxcarbazepine therapy. ( Ajayi, OO; Holroyd, S, 2017) |
| " However, the oral dosage of valproate during the remission/recovery period (944." | 1.43 | Rate of Serum Valproate Concentration Monitoring in Patients with Bipolar Disorder Type I at Srinagarind Hospital Outpatient Clinic. ( Paholpak, P; Paholpak, S; Patanasethanant, D; Patjanasoontorn, N; Rangseekajee, P, 2016) |
| "Lamotrigine (LTG) was less successful in those with a parental history of mood disorders or in BP-I compared to BP-II disorder." | 1.43 | Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder. ( Altshuler, LL; Frye, MA; Grunze, H; Keck, PE; Kupka, R; Leverich, GS; McElroy, SL; Nolen, WA; Post, RM; Rowe, M; Suppes, T, 2016) |
| " Safety (primary outcome) was assessed by incidence of treatment emergent adverse events (AEs)." | 1.43 | Safety and effectiveness of divalproex sodium extended release containing regimen in Indian patients with bipolar I disorder in continuation phase: Results of EASED registry. ( Chaudhuri, U; Mohanasundaram, S; Reddy, MS; Shah, N; Vohra, S, 2016) |
| "The treatment with methylphenidate (10mg/kg, ip) increased locomotion in the open field test." | 1.43 | Lithium and valproate prevent methylphenidate-induced mania-like behaviors in the hole board test. ( Asth, L; Gavioli, EC; Lobão-Soares, B; Medeiros, IU; Santos, WB; Silva, EF; Soares-Rachetti, VP; Souza, LS, 2016) |
| " The objective of the study was to identify pharmacokinetic interactions of different mood stabilizers on the metabolism of risperidone (RIS) under natural conditions." | 1.43 | Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment. ( Gründer, G; Haen, E; Hiemke, C; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B, 2016) |
| "Alcohol withdrawal delirium is associated with significant morbidity and mortality." | 1.42 | Alcohol withdrawal delirium manifested by manic symptoms in an elderly patient. ( Chan, HY; Lee, KI, 2015) |
| " Chronic administration of lithium chloride or valproic acid, two clinically effective mood stabilizers, reverses the majority of these behavioral abnormalities." | 1.42 | Mice heterozygous for cathepsin D deficiency exhibit mania-related behavior and stress-induced depression. ( Duan, S; Han, Y; Li, X; Lou, H; Lu, Y; Zhen, X; Zhou, R; Zhu, L, 2015) |
| " In order to prove through face, construct, and predictive validities, we evaluated behavioral parameters (locomotor activity, stereotypy activity, and fecal boli amount) and brain energy metabolism (enzymes citrate synthase; malate dehydrogenase; succinate dehydrogenase; complexes I, II, II-III, and IV of the mitochondrial respiratory chain; and creatine kinase) in rats submitted to acute and chronic administration of fenproporex, treated with lithium (Li) and valproate (VPA)." | 1.40 | Fenproporex increases locomotor activity and alters energy metabolism, and mood stabilizers reverse these changes: a proposal for a new animal model of mania. ( Cardoso, MR; Ferreira, GK; Furlanetto, CB; Gonçalves, CL; Jeremias, IC; Quevedo, J; Resende, WR; Rezin, GT; Scaini, G; Streck, EL; Valvassori, SS; Varela, RB, 2014) |
| "Cases of acute pancreatitis caused by sodium valproate (VPA) have been reported by many authors thus far." | 1.40 | Development of acute pancreatitis caused by sodium valproate in a patient with bipolar disorder on hemodialysis for chronic renal failure: a case report. ( Okayasu, H; Osone, A; Ozeki, Y; Shimoda, K; Shinozaki, T, 2014) |
| "Co-morbid substance abuse was uncommon." | 1.39 | Prevalence and clinical presentation of HIV positive female psychiatric inpatients. ( Uys, H, 2013) |
| "Mutations in SHANK3 and large duplications of the region spanning SHANK3 both cause a spectrum of neuropsychiatric disorders, indicating that proper SHANK3 dosage is critical for normal brain function." | 1.39 | SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. ( Breman, AM; Chen, H; Cheung, SW; Han, K; Hao, S; Holder, JL; Kang, H; Lu, H; Lu, HC; Patel, A; Schaaf, CP; Sun, H; Tang, J; Wu, Z; Yu, P; Zoghbi, HY, 2013) |
| "Prevention of relapse or recurrence is a primary treatment objective in the management of the disorder." | 1.38 | Predictors of relapse or recurrence in bipolar I disorder. ( Degenhardt, EK; Gatz, JL; Jacob, J; Tohen, M, 2012) |
| "This audit was conducted on acute psychiatric in-patient wards with the aim of establishing if valproate prescribing in acute mania followed evidence-based guidelines with particular emphasis on formulations used and whether accelerated valproate dosing was employed." | 1.38 | Valproate in acute mania: is our practice evidence based? ( Macritchie, K; Mead, A; Vasudev, K; Young, AH, 2012) |
| "Ketamine has rapid antidepressant properties in major depressive disorder (MDD) as well as bipolar depression." | 1.38 | Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. ( Brutsche, N; Cassarly, C; Franco-Chaves, J; Ibrahim, L; Luckenbaugh, DA; Marquardt, CA; Mathews, D; Zarate, CA, 2012) |
| "Participants with bipolar I or schizoaffective disorder in this study were receiving complex medication treatments that were often discordant with recommendations made in contemporary major treatment guidelines." | 1.38 | Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice. ( Berk, L; Berk, M; Brnabic, AJ; de Castella, A; Dodd, S; Filia, K; Filia, S; Fitzgerald, PB; Kelin, K; Kulkarni, J; Lowry, AJ; Montgomery, W, 2012) |
| " Mean dosage was 687 (SD = 234) mg/day (min 400, max 1,500 mg/day)." | 1.36 | Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year "open" follow-up study. ( Akiskal, HS; Frare, F; Perugi, G; Toni, C; Tusini, G; Vannucchi, G, 2010) |
| "The effect of comorbid substance use on the likelihood of response differed significantly according to baseline BMI." | 1.36 | Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. ( Calabrese, JR; Chan, PK; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE, 2010) |
| "It shows the importance of recognising catatonia as a symptom of delirious mania." | 1.36 | What works for delirious catatonic mania? ( Grunze, H; Vasudev, K, 2010) |
| "Eating disorders are commonly associated with depressive symptoms." | 1.35 | Treatment emergent mania responding to valproate in a Chinese female adolescent population with eating disorders: a case series. ( Lee, EL; Tor, PC, 2008) |
| "A 23-year-old man had unilateral rubral tremors as a result of a midbrain lesion plus risperidone exposure for treatment of manic symptoms." | 1.35 | Unilateral rubral tremor following treatment with risperidone. ( Shen, YC, 2009) |
| " Frequent monitoring of serum levels to support dosing decisions is important to inform better clinical decision making, especially when a loading strategy is used." | 1.35 | Mood stabilizer loading versus titration in acute mania: audit of clinical practice. ( Fraser, A; Robinson, G; Wheeler, A, 2008) |
| " Significant reduction in lithium dosing was observed among individuals aged 50 and older and among individuals 60 and older for valproate." | 1.35 | Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a "recovered" status in the systematic treatment enhancement program for bipolar disorder. ( Al Jurdi, RK; Gyulai, L; Marangell, LB; Martinez, M; Petersen, NJ; Sajatovic, M, 2008) |
| "Rapid cycling with co-occurring substance use is not only associated with poor response to mood stabilizers, but is also a harbinger of serious medical problems." | 1.35 | Medical and substance use comorbidity in bipolar disorder. ( Bilali, S; Calabrese, JR; Caldes, E; Chan, PK; Conroy, C; Feldman, K; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE, 2009) |
| "Valproate-related peripheral oedema is usually regarded as a problem occurring after long-term administration of valproate." | 1.35 | Valproate-related peripheral oedema: a manageable but probably neglected condition. ( Chen, CS; Lin, ST; Tsei, JH; Wang, SY; Yen, CF, 2009) |
| "We describe a case of catatonia in a 51-year-old man in whom the catatonic symptoms could not be distinguished from symptoms of frontotemporal dementia (FTD) until they were resolved with electroconvulsive therapy (ECT)." | 1.35 | A case of catatonia resembling frontotemporal dementia and resolved with electroconvulsive therapy. ( Matsuoka, H; Suzuki, K; Takano, T, 2009) |
| " We found that chronic administration of the antimanic agents lithium and valproate (VPA) reduced synaptic AMPA receptor GluR1/2 in hippocampal neurons in vitro and in vivo." | 1.35 | The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. ( Blumenthal, R; Chen, G; Creson, TK; Du, J; Falke, C; Gray, NA; Machado-Vieira, R; Manji, HK; Ren, M; Wang, Y; Wei, Y; Wu, LJ; Yuan, P; Zhuo, M, 2008) |
| "In amphetamine-pretreated animals, valproate administration reversed citrate synthase activity inhibition induced by amphetamine." | 1.34 | Effects of lithium and valproate on hippocampus citrate synthase activity in an animal model of mania. ( Amboni, G; Assis, LC; Corrêa, C; Kapczinski, F; Martins, MR; Quevedo, J; Streck, EL, 2007) |
| "5 microg/mL) (Li/DVP) (for 3-6 weeks) in four double-blind, placebo-controlled studies according to a predetermined dosing schedule." | 1.34 | Quetiapine in the treatment of acute mania: target dose for efficacious treatment. ( Goldberg, JF; Mullen, J; Paulsson, B; Vågerö, M; Vieta, E, 2007) |
| " Adverse event reporting, Simpson Angus Scale (SAS), and Barnes Akathisia Rating Scale (BARS) scores were recorded." | 1.34 | Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder. ( Adler, CM; Brecher, M; Fleck, DE; Strakowski, SM, 2007) |
| "The aim of this analysis was to compare the rates of remission/euthymia in patients with bipolar mania receiving quetiapine in combination with lithium/divalproex (QTP+Li/DVP) versus placebo (PBO) in combination with Li/DVP (PBO+Li/DVP)." | 1.34 | Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania. ( Mullen, J; Paulsson, B; Sussman, N; Vågerö, M, 2007) |
| "Valproic acid-associated hyperammonemic encephalopathy (VHE) has been described in the neurology and emergency medicine literature, but the case reports identified therein are rarely derived from the psychiatric use of this medication." | 1.33 | Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting. ( Irwin, SA; Kimmel, RJ; Meyer, JM, 2005) |
| "Cotard's syndrome is another rare condition in which the patient has nihilistic delusions and ideation of immortality." | 1.33 | Co-existence of lycanthropy and Cotard's syndrome in a single case. ( Nejad, AG; Toofani, K, 2005) |
| "We accepted him as type 1 diabetes mellitus (DM type 1)." | 1.33 | Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus type 1 in a patient treated with valproate and lithium. ( Alpaslan, T; Bulent, C; Cengiz, T; Mithat, B, 2005) |
| "Olanzapine-treated, non-rapid cyclers experienced greater mania improvement than rapid cyclers." | 1.33 | Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data. ( Baker, RW; Brown, E; Schuh, LM; Suppes, T; Tohen, M, 2005) |
| "He presented coma requiring tracheal intubation and mechanical ventilation at 11 hours and central diabetes insipidus." | 1.33 | [Transient central diabetes insipidus during a valproic acid poisoning]. ( Corne, P; Jonquet, O; Lemaire, X, 2006) |
| " Therefore, the authors summarise adverse events of greatest prevalence and/or greatest severity based on data derived predominately from studies of geriatric patients with epilepsy and/or other non-psychiatric indications." | 1.33 | Safety and tolerability of mood-stabilising anticonvulsants in the elderly. ( Alldredge, B; Fenn, HH; Ketter, TA; Sommer, BR, 2006) |
| "A diagnosis of classic migraine with hypomanic aura was made." | 1.33 | Hypomania as an aura in migraine. ( Datta, SS; Kumar, S, 2006) |
| "Topiramate is an antiepileptic drug, recently also used in the treatment of psychiatric diseases." | 1.33 | Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. ( Gaudreau, PO; Gobbi, G; Leblanc, N, 2006) |
| "For the management of bipolar depression, new data support quetiapine monotherapy as a first-line option." | 1.33 | Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. ( Beaulieu, S; Kennedy, SH; MacQueen, G; McIntyre, RS; O'Donovan, C; Parikh, SV; Sharma, V; Yatham, LN, 2006) |
| "Gabapentin appears to be a safe and effective treatment in geriatric mania when combined with antipsychotic medications or valproate." | 1.32 | Gabapentin in geriatric mania. ( Devanand, DP; Mehta, R; Sethi, MA, 2003) |
| "Valproic acid was discontinued which resulted in rapid clinical recovery." | 1.32 | Ammonia induced encephalopathy from valproic acid in a bipolar patient: case report. ( Elgudin, L; Hall, Y; Schubert, D, 2003) |
| "Right hemispheric brain tumors involving the orbitofrontal or basotemporal cortex are a rare cause of secondary mania." | 1.32 | Exacerbation of mania secondary to right temporal lobe astrocytoma in a bipolar patient previously stabilized on valproate. ( Denson, TF; Sokolski, KN, 2003) |
| " Evidence shows that chronic administration of VPA or lithium can stimulate bcl-2 expression as well as inhibit GSK-3 beta activity, which renders a cell less susceptible to apoptosis." | 1.32 | Mood stabilizers: protecting the mood...protecting the brain. ( Brunello, N, 2004) |
| "Identifying genes for bipolar mood disorders through classic genetics has proven difficult." | 1.32 | Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. ( Geyer, MA; Kuczenski, R; Lohr, JB; Niculescu, AB; Ogden, CA; Paulus, MP; Rich, ME; Schork, NJ, 2004) |
| "One of the leading causes of hypersomnia is sleep apnea." | 1.31 | Influence of chronic barbiturate administration on sleep apnea after hypersomnia presentation: case study. ( Bishop, J; Takhar, J, 2000) |
| "This hypernatremia was due to renal diabetes insipidus stemming from the decades of lithium therapy, with accompanying polydipsia and polyuria, and also to the failure to give enough fluid to the somnolent patient." | 1.31 | [Hypernatremia as a rare complication in change from lithium to valproate]. ( Berendes, K; Glass, W; Warmke, C, 2001) |
| "Risks have been associated with the long-term use of antidepressant in the treatment of bipolar disorder." | 1.31 | Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use. ( Ghaemi, SN; Goodwin, FK, 2001) |
| "Carbamazepine is a second-line alternative." | 1.31 | Disodium valproate: new preparation. An alternative for acute mania after lithium failure or intolerance. ( , 2001) |
| "One patient had moderate confusion, and the other mild confusion and hypomania." | 1.30 | Combined valproate or carbamazepine and electroconvulsive therapy. ( Baraibar, G; Tohen, M; Zarate, CA, 1997) |
| " The mean +/- SD continuous neuroleptic dosage for these 33 outpatients was 416 +/- 527 mg/day chlorpromazine (CPZ) equivalents." | 1.30 | Chronic neuroleptic exposure in bipolar outpatients. ( Godleski, LS; Griffin, RA; Mazure, CM; Sernyak, MJ; Woods, SW, 1997) |
| "To conduct a pilot study on the safety and tolerability of a dosage strategy for divalproex sodium beginning with 30 mg/kg/day." | 1.30 | Tolerability of oral loading of divalproex sodium in the treatment of acute mania. ( Hirschfeld, RM; Martinez, JM; Russell, JM, 1998) |
| "The delirium was reversible when all drugs were stopped; however, dyskinesia was found to be persistent after a period of 6 months." | 1.30 | Delirium and persistent dyskinesia induced by a lithium-neuroleptic interaction. ( Berger, M; Brandt, C; Normann, C; Walden, J, 1998) |
| "Valproic acid (VPA) is a potent broad spectrum anticonvulsant with demonstrated efficacy in the treatment of Bipolar Affective Disorder, but the biochemical basis for VPA's antimanic or mood-stabilizing actions have not been fully elucidated." | 1.30 | Valproate robustly enhances AP-1 mediated gene expression. ( Chen, G; Huang, LD; Jiang, YM; Manji, HK; Yuan, PX, 1999) |
| " The objective of this study was to derive population pharmacokinetic (PK) parameters for valproate in healthy volunteers and to test the ability of these PK parameters to estimate concentrations in adult psychiatric patients using a Bayesian program." | 1.30 | Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters. ( Lum, BL; Puentes, E; Puzantian, T, 1999) |
| "Carbamazepine users who were male or in the 30-49-year age range were significantly less likely to be tested for serum drug level." | 1.30 | Therapeutic drug monitoring of mood stabilizers in Medicaid patients with bipolar disorder. ( Kupfer, DJ; Marcus, SC; Olfson, M; Pincus, HA; Zarin, DA, 1999) |
| "Valproic acid is an effective treatment for mania." | 1.30 | Sodium valproate increases pupillary responsiveness to a cholinergic agonist in responders with mania. ( DeMet, EM; Sokolski, KN, 1999) |
| "Pancreatitis is usually considered a rare side effect of valproate." | 1.29 | Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults. ( Buzan, RD; Dubovsky, SL; Firestone, D; Thomas, M, 1995) |
| " To provide further data on the safety and efficacy of valproate oral loading in the treatment of acute mania, we evaluated 13 consecutive patients with acute manic syndromes who received valproate initiated at a dosage of 20 mg/kg/day." | 1.29 | Valproate as a loading treatment in acute mania. ( Bennett, JA; Keck, PE; McElroy, SL; Tugrul, KC, 1993) |
| "Valproic acid has been proven to be efficient in the treatment of bipolar affective disorders as an adjunctive agent to lithium and carbamazepine." | 1.29 | Valproic acid in ultra-rapid cycling: a case report. ( Dannon, P; Iancu, I; Kotler, M; Lepkifker, E; Ziv, R, 1995) |
| "The case of an adolescent with severe mental retardation, blindness, and a complex of behavioral symptoms consistent with mania is reported." | 1.28 | Verapamil and valproic acid treatment of prolonged mania. ( Friedman, DL; Kastner, T, 1992) |
| " Dosage was adjusted up to a maximum of 1500 mg sodium valproate per day." | 1.27 | The role of sodium valproate as an anti-manic agent. ( Prasad, AJ, 1984) |
| " Safety is increased through temporary discontinuation or dosage reduction of lithium in special risk situations." | 1.27 | New developments in long-term preventive therapy. ( Schou, M, 1986) |
| "Dipropylacetamide (DEPAMIDE) was administered to 60 patients with bipolar manic-depressive psychoses." | 1.27 | [Preventive effect of dipropylacetamide in bipolar manic-depressive psychoses]. ( Kabes, J; Peterová, E; Vencovský, E, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (2.60) | 18.7374 |
| 1990's | 222 (16.52) | 18.2507 |
| 2000's | 574 (42.71) | 29.6817 |
| 2010's | 421 (31.32) | 24.3611 |
| 2020's | 92 (6.85) | 2.80 |
| Authors | Studies |
|---|---|
| Rodríguez-Ramírez, AM | 1 |
| Cedillo-Ríos, V | 1 |
| Becerra-Palars, C | 2 |
| Meza-Urzúa, F | 1 |
| Jiménez-Pavón, J | 1 |
| Morales-Cedillo, P | 1 |
| López-Titla, MM | 1 |
| Sánchez-Segura, CL | 1 |
| Martínez-Gudiño, ML | 1 |
| Ortega-Ortiz, H | 1 |
| Camarena-Medellin, B | 1 |
| Ho, AM | 2 |
| Weinshilboum, RM | 2 |
| Frye, MA | 15 |
| Biernacka, JM | 2 |
| Janiri, L | 2 |
| D'Ambrosio, F | 1 |
| Di Lorenzo, C | 1 |
| Nair, SS | 1 |
| Chua, CJM | 1 |
| Teo, DCL | 1 |
| Yatham, LN | 24 |
| Chakrabarty, T | 3 |
| Bond, DJ | 5 |
| Schaffer, A | 4 |
| Beaulieu, S | 4 |
| Parikh, SV | 3 |
| McIntyre, RS | 11 |
| Milev, RV | 2 |
| Alda, M | 10 |
| Vazquez, G | 2 |
| Ravindran, AV | 1 |
| Frey, BN | 7 |
| Sharma, V | 7 |
| Goldstein, BI | 3 |
| Rej, S | 5 |
| O'Donovan, C | 7 |
| Tourjman, V | 1 |
| Kozicky, JM | 3 |
| Kauer-Sant'Anna, M | 3 |
| Malhi, G | 2 |
| Suppes, T | 28 |
| Vieta, E | 33 |
| Kapczinski, F | 15 |
| Kanba, S | 4 |
| Lam, RW | 11 |
| Kennedy, SH | 7 |
| Calabrese, J | 6 |
| Berk, M | 6 |
| Post, R | 2 |
| Kishi, T | 1 |
| Ikuta, T | 1 |
| Matsuda, Y | 1 |
| Sakuma, K | 1 |
| Okuya, M | 1 |
| Nomura, I | 1 |
| Hatano, M | 1 |
| Iwata, N | 1 |
| Hsieh, TC | 2 |
| Lin, CC | 2 |
| Wu, LS | 2 |
| Marjani, M | 1 |
| Dolab, N | 1 |
| Kamkar, MZ | 1 |
| Amiriani, T | 1 |
| Yuzugulen, J | 1 |
| Marjani, A | 1 |
| Chang, CC | 2 |
| Chen, PS | 21 |
| Lin, JR | 1 |
| Chen, YA | 1 |
| Liu, CS | 1 |
| Lin, TT | 1 |
| Chang, HH | 8 |
| Gaudio, M | 1 |
| Konstantara, E | 1 |
| Joy, M | 1 |
| van Vlymen, J | 1 |
| de Lusignan, S | 1 |
| Talaei, A | 2 |
| Dastgheib, MS | 1 |
| Soltanifar, A | 1 |
| Mokhber, N | 1 |
| Akhondzadeh, S | 2 |
| Afzaljavan, F | 1 |
| Smith, EG | 2 |
| Austin, KL | 1 |
| Kim, HM | 2 |
| Miller, DR | 2 |
| Sauer, BC | 1 |
| Valenstein, M | 1 |
| Köhler-Forsberg, O | 3 |
| Sylvia, LG | 1 |
| Thase, M | 1 |
| Calabrese, JR | 68 |
| Tohen, M | 29 |
| Bowden, CL | 46 |
| McInnis, M | 1 |
| Iosifescu, DV | 1 |
| Kocsis, JH | 4 |
| Friedman, ES | 1 |
| Ketter, TA | 28 |
| McElroy, SL | 32 |
| Shelton, RC | 3 |
| Fung, V | 1 |
| Ostacher, MJ | 3 |
| Nierenberg, AA | 6 |
| Anyfandi, E | 1 |
| Owens, DA | 1 |
| Psarros, C | 1 |
| Ferentinos, P | 2 |
| Nikolakopoulou, M | 1 |
| Kalogerakou, S | 1 |
| Papakosta, VM | 1 |
| Tsaltas, E | 1 |
| De Picker, LJ | 1 |
| Leboyer, M | 5 |
| Geddes, JR | 11 |
| Morrens, M | 2 |
| Harrison, PJ | 1 |
| Taquet, M | 1 |
| Rohde, C | 2 |
| Østergaard, SD | 2 |
| Mahase, E | 1 |
| Kessing, LV | 3 |
| Ziersen, SC | 1 |
| Gerds, T | 1 |
| Budtz-Jørgensen, E | 1 |
| Zang, YN | 1 |
| Guo, W | 1 |
| Dong, F | 1 |
| Li, AN | 1 |
| de Leon, J | 4 |
| Ruan, CJ | 1 |
| Roosen, L | 1 |
| Sienaert, P | 1 |
| Uwai, Y | 1 |
| Nabekura, T | 1 |
| Holm, M | 1 |
| Tanskanen, A | 2 |
| Lähteenvuo, M | 1 |
| Tiihonen, J | 2 |
| Taipale, H | 1 |
| Moon, W | 1 |
| Ji, E | 3 |
| Shin, J | 1 |
| Kwon, JS | 1 |
| Kim, KW | 1 |
| Zhuo, C | 1 |
| Zhou, C | 1 |
| Tian, H | 1 |
| Li, Q | 1 |
| Chen, J | 2 |
| Yang, L | 1 |
| Zhang, Q | 1 |
| Li, R | 1 |
| Ma, X | 1 |
| Cai, Z | 2 |
| Chen, G | 11 |
| Xu, Y | 1 |
| Song, X | 1 |
| Lin, CH | 6 |
| Chan, HY | 3 |
| Chen, CC | 6 |
| Chou, FH | 1 |
| Samalin, L | 9 |
| Arnould, A | 1 |
| Boudieu, L | 1 |
| Henry, C | 6 |
| Haffen, E | 3 |
| Drapier, D | 1 |
| Anmella, G | 3 |
| Pacchiarotti, I | 7 |
| Belzeaux, R | 5 |
| Llorca, PM | 5 |
| Ricci, V | 2 |
| Martinotti, G | 3 |
| De Berardis, D | 3 |
| Maina, G | 5 |
| Delage, C | 2 |
| Palayer, M | 2 |
| Etain, B | 6 |
| Hagenimana, M | 2 |
| Blaise, N | 2 |
| Smati, J | 2 |
| Chouchana, M | 2 |
| Bloch, V | 2 |
| Besson, VC | 2 |
| Lin, HY | 1 |
| Zhang, J | 1 |
| Wang, Y | 2 |
| Zhang, W | 1 |
| Feng, W | 1 |
| Hu, Z | 1 |
| Jing, Q | 1 |
| Li, J | 2 |
| van Haaren, PCF | 1 |
| Bloemkolk, D | 1 |
| Rundervoort, RS | 1 |
| Gerritse, FL | 1 |
| Durgam, S | 1 |
| Kozauer, SG | 1 |
| Chen, R | 1 |
| Lakkis, HD | 1 |
| Davis, RE | 1 |
| Satlin, A | 1 |
| Vanover, KE | 1 |
| Mates, S | 1 |
| Carli, M | 2 |
| Weiss, F | 1 |
| Grenno, G | 1 |
| Ponzini, S | 1 |
| Kolachalam, S | 1 |
| Vaglini, F | 1 |
| Viaggi, C | 1 |
| Pardini, C | 1 |
| Tidona, S | 1 |
| Longoni, B | 1 |
| Maggio, R | 1 |
| Scarselli, M | 3 |
| Arora, S | 1 |
| Reddy, PV | 1 |
| Desai, G | 1 |
| Kesavan, M | 1 |
| Chandra, PS | 1 |
| Pahwa, M | 1 |
| Elsayed, OH | 1 |
| El-Mallakh, RS | 3 |
| Natale, G | 1 |
| Fini, E | 1 |
| Calabrò, PF | 1 |
| Bocci, G | 1 |
| Leopold, S | 1 |
| Quante, A | 1 |
| Li, X | 6 |
| Chen, B | 4 |
| Zhang, D | 1 |
| Wang, S | 3 |
| Feng, Y | 1 |
| Wu, X | 3 |
| Cui, L | 1 |
| Ji, M | 1 |
| Gong, W | 1 |
| Verkhratsky, A | 3 |
| Xia, M | 1 |
| Li, B | 5 |
| Goldspink, R | 2 |
| Pumipi, T | 2 |
| Menkes, DB | 2 |
| Martin, M | 1 |
| Braillon, A | 1 |
| Chen, Z | 2 |
| Huang, Y | 2 |
| Wang, B | 2 |
| Peng, H | 1 |
| Wang, X | 4 |
| Wu, H | 2 |
| Chen, W | 2 |
| Wang, M | 2 |
| Faridhosseini, F | 1 |
| Shahini, N | 1 |
| Salimi, Z | 1 |
| Eslamzadeh, M | 1 |
| Ahrari, S | 1 |
| Pourgholami, M | 1 |
| Khadem-Rezaiyan, M | 1 |
| Chen, CK | 1 |
| Yang, SY | 2 |
| Park, SC | 1 |
| Jang, OJ | 1 |
| Zhu, X | 1 |
| Xiang, YT | 1 |
| Ouyang, WC | 2 |
| Javed, A | 1 |
| Khan, MNS | 1 |
| Grover, S | 1 |
| Avasthi, A | 1 |
| Kallivayalil, RA | 1 |
| Chee, KY | 1 |
| Chemi, N | 1 |
| Kato, TA | 1 |
| Hayakawa, K | 1 |
| Pariwatcharakul, P | 1 |
| Maramis, M | 1 |
| Seneviratne, L | 1 |
| Sim, K | 1 |
| Tang, WK | 1 |
| Oo, T | 1 |
| Sartorius, N | 1 |
| Tan, CH | 1 |
| Chong, MY | 1 |
| Park, YC | 1 |
| Shinfuku, N | 1 |
| Lin, SK | 2 |
| Suzuki, E | 1 |
| Liu, J | 1 |
| Teng, Z | 1 |
| Xie, H | 1 |
| Yuan, H | 1 |
| Liu, M | 1 |
| Tang, H | 1 |
| Xiang, H | 1 |
| Huang, J | 2 |
| Dervic, K | 1 |
| Sher, L | 2 |
| Galfalvy, HC | 2 |
| Grunebaum, M | 1 |
| Burke, AK | 2 |
| Sullivan, G | 1 |
| Sublette, ME | 2 |
| Mann, JJ | 2 |
| Oquendo, MA | 2 |
| Case, KC | 1 |
| Beltman, RJ | 1 |
| Pflum, MKH | 1 |
| Greenberg, ML | 6 |
| Daniels, SD | 1 |
| Boison, D | 1 |
| Takım, U | 1 |
| Akgül Ceyhun, H | 1 |
| Ranjith, S | 1 |
| Abeysundera, H | 1 |
| Jeyaranjan, H | 1 |
| Pigoni, A | 1 |
| Mandolini, GM | 2 |
| Delvecchio, G | 2 |
| Bressi, C | 2 |
| Soares, JC | 6 |
| Brambilla, P | 4 |
| Charlton, R | 1 |
| Damase-Michel, C | 1 |
| Hurault-Delarue, C | 1 |
| Gini, R | 1 |
| Loane, M | 1 |
| Pierini, A | 1 |
| Puccini, A | 1 |
| Neville, A | 1 |
| Snowball, J | 1 |
| Morris, JK | 1 |
| Dal-Pont, GC | 4 |
| Jório, MTS | 1 |
| Resende, WR | 7 |
| Gava, FF | 2 |
| Aguiar-Geraldo, JM | 1 |
| Possamai-Della, T | 1 |
| Peper-Nascimento, J | 1 |
| Quevedo, J | 26 |
| Valvassori, SS | 21 |
| Fontana, E | 1 |
| Cubała, WJ | 1 |
| Dudek, D | 1 |
| Thomas, P | 1 |
| Missio, G | 1 |
| Moreno, DH | 2 |
| Demetrio, FN | 2 |
| Soeiro-de-Souza, MG | 1 |
| Dos Santos Fernandes, F | 1 |
| Barros, VB | 1 |
| Moreno, RA | 2 |
| Tran, HQ | 1 |
| Shin, EJ | 1 |
| Saito, K | 1 |
| Tran, TV | 1 |
| Phan, DH | 1 |
| Sharma, N | 1 |
| Kim, DW | 1 |
| Choi, SY | 1 |
| Jeong, JH | 2 |
| Jang, CG | 1 |
| Cheong, JH | 1 |
| Nabeshima, T | 1 |
| Kim, HC | 1 |
| Huang, W | 1 |
| Ren, X | 2 |
| Shen, F | 1 |
| Xing, B | 1 |
| Park, A | 1 |
| Shapiro, B | 1 |
| Hedayati, B | 1 |
| Faziola, L | 1 |
| Torres, IJ | 3 |
| Qian, H | 3 |
| Basivireddy, J | 1 |
| Wong, H | 3 |
| Kang, MG | 1 |
| Keramatian, K | 1 |
| Saraf, G | 1 |
| Mansoor, M | 1 |
| Mesiya, MH | 1 |
| Chachar, AS | 1 |
| Esposito, M | 1 |
| Giunta, A | 1 |
| Del Duca, E | 1 |
| Manfreda, V | 1 |
| Troisi, A | 1 |
| Bianchi, L | 1 |
| Fargnoli, MC | 1 |
| Woo, YS | 5 |
| Yoon, BH | 6 |
| Song, JH | 1 |
| Seo, JS | 2 |
| Nam, B | 1 |
| Lee, K | 1 |
| Lee, J | 2 |
| Jung, YE | 2 |
| Kim, MD | 3 |
| Lee, JG | 3 |
| Wang, SM | 1 |
| Kwon, YJ | 2 |
| Bahk, WM | 7 |
| Ali, Z | 1 |
| Tegin, C | 1 |
| Abulseoud, OA | 1 |
| Şenormancı, G | 1 |
| Şenormancı, Ö | 1 |
| Güçlü, O | 1 |
| Schleyer, B | 1 |
| Camsari, U | 1 |
| Flores-Ramos, M | 2 |
| Hernández González, C | 1 |
| Chavira, R | 1 |
| Bernal-Santamaría, N | 1 |
| Martínez Mota, L | 1 |
| Miyauchi, T | 1 |
| Lebedevs, T | 1 |
| Gan, M | 1 |
| Teoh, SWK | 1 |
| Brown, P | 1 |
| Varela, RB | 7 |
| Tye, SJ | 1 |
| Yokoyama, S | 1 |
| Yasui-Furukori, N | 1 |
| Nakagami, T | 1 |
| Miyazaki, K | 1 |
| Ishioka, M | 1 |
| Tarakita, N | 1 |
| Kubo, K | 1 |
| Sugawara, N | 1 |
| Shimoda, K | 2 |
| Gao, K | 13 |
| Arnold, JG | 1 |
| Prihoda, TJ | 1 |
| Quinones, M | 2 |
| Singh, V | 4 |
| Schinagle, M | 1 |
| Conroy, C | 6 |
| D'Arcangelo, N | 1 |
| Bai, Y | 2 |
| Dey, S | 1 |
| Asth, L | 3 |
| Tiago, PRF | 1 |
| Costa, LRF | 1 |
| Holanda, VAD | 1 |
| Pacifico, S | 1 |
| Zaveri, NT | 2 |
| Calo', G | 2 |
| Ruzza, C | 2 |
| Gavioli, EC | 3 |
| Coombes, BJ | 1 |
| Nguyen, TTL | 1 |
| Liu, D | 1 |
| Singh, B | 1 |
| Nassan, M | 1 |
| Colby, CL | 1 |
| Larrabee, BR | 1 |
| Andrade, G | 1 |
| Simões do Couto, F | 1 |
| Câmara-Pestana, L | 1 |
| Ruuth-Praz, J | 1 |
| Faure, M | 1 |
| Gomez, E | 1 |
| Petit, I | 1 |
| Petitpain, N | 1 |
| Chaouat, A | 1 |
| Chabot, F | 1 |
| Godin, O | 2 |
| Olié, E | 2 |
| Pelletier, A | 1 |
| Poinso, F | 1 |
| Encely, L | 1 |
| Mazer, N | 1 |
| Roux, P | 2 |
| Loftus, J | 1 |
| Gard, S | 2 |
| Bennabi, D | 1 |
| Polosan, M | 2 |
| Schwitzer, T | 1 |
| Aubin, V | 2 |
| Schwan, R | 2 |
| Passerieux, C | 1 |
| Bougerol, T | 2 |
| Dubertret, C | 2 |
| Aouizerate, B | 2 |
| Courtet, P | 3 |
| Bellivier, F | 4 |
| Sharpley, AL | 1 |
| Williams, C | 1 |
| Holder, AA | 1 |
| Godlewska, BR | 1 |
| Singh, N | 1 |
| Shanyinde, M | 1 |
| MacDonald, O | 1 |
| Cowen, PJ | 1 |
| Methaneethorn, J | 2 |
| Leelakanok, N | 1 |
| Lu, RB | 21 |
| Wang, TY | 12 |
| Lee, SY | 15 |
| Chang, YH | 13 |
| Chen, SL | 15 |
| Tsai, TY | 1 |
| Huang, SY | 18 |
| Tzeng, NS | 14 |
| Lee, IH | 13 |
| Chen, KC | 9 |
| Yang, YK | 22 |
| Hong, JS | 12 |
| Jouvent, E | 1 |
| Alili, N | 1 |
| Hervé, D | 1 |
| Chabriat, H | 1 |
| Brietzke, E | 1 |
| López-Jaramillo, C | 1 |
| Malhi, GS | 1 |
| Rosenblat, JD | 2 |
| Majeed, A | 1 |
| Vinberg, M | 1 |
| Young, AH | 9 |
| Mansur, RB | 1 |
| Kopel, J | 1 |
| Grooms, A | 1 |
| Ganapathy, V | 1 |
| Clothier, J | 2 |
| Verdolini, N | 2 |
| Hidalgo-Mazzei, D | 3 |
| Del Matto, L | 1 |
| Muscas, M | 1 |
| Murru, A | 6 |
| Aedo, A | 1 |
| Grunze, H | 20 |
| Carvalho, AF | 6 |
| Buoli, M | 2 |
| Gattoni, E | 1 |
| Collantoni, E | 1 |
| Monteleone, AM | 1 |
| Solmi, M | 1 |
| Longo, L | 1 |
| Ribolsi, M | 1 |
| Santambrogio, J | 1 |
| Bersani, FS | 1 |
| Aguglia, A | 2 |
| Serafini, G | 2 |
| Signorelli, MS | 1 |
| Dell'Osso, B | 3 |
| Luciano, M | 1 |
| Galderisi, S | 1 |
| Platzer, M | 1 |
| Fellendorf, FT | 1 |
| Bengesser, SA | 1 |
| Birner, A | 1 |
| Dalkner, N | 1 |
| Hamm, C | 1 |
| Lenger, M | 1 |
| Maget, A | 1 |
| Pilz, R | 1 |
| Queissner, R | 1 |
| Reininghaus, B | 1 |
| Reiter, A | 1 |
| Mangge, H | 1 |
| Zelzer, S | 1 |
| Kapfhammer, HP | 1 |
| Reininghaus, EZ | 1 |
| Hsueh, YS | 1 |
| Lin, CY | 2 |
| Chiu, NT | 1 |
| Bohlken, J | 1 |
| Riedel-Heller, S | 1 |
| Bauer, M | 5 |
| Kostev, K | 1 |
| Brodeur, S | 1 |
| Terrisse, H | 1 |
| Pouchon, A | 1 |
| Bosson, JL | 1 |
| Amerio, A | 3 |
| Russo, D | 1 |
| Miletto, N | 1 |
| Costanza, A | 1 |
| Benatti, B | 1 |
| Odone, A | 3 |
| Barroilhet, SA | 1 |
| Brakoulias, V | 1 |
| Amore, M | 1 |
| Ghaemi, SN | 14 |
| Arnold, I | 1 |
| Dehning, J | 1 |
| Grunze, A | 1 |
| Hausmann, A | 1 |
| Fico, G | 1 |
| Gomez-Ramiro, M | 1 |
| de Miquel, C | 1 |
| Manchia, M | 1 |
| Gonzalez-Pinto, A | 3 |
| Topp, S | 1 |
| Salisbury, E | 1 |
| Wingård, L | 1 |
| Bodén, R | 1 |
| Brandt, L | 1 |
| Kieler, H | 1 |
| Andersen, M | 1 |
| Reutfors, J | 1 |
| Kikkawa, A | 1 |
| Kitamura, Y | 1 |
| Aiba, T | 1 |
| Hiraki, K | 1 |
| Sendo, T | 1 |
| Holder, SD | 1 |
| Smits, JEMP | 1 |
| Wallenburg, E | 1 |
| van Spanje, A | 1 |
| van Luin, M | 1 |
| Marijnissen, RM | 1 |
| Ladwig, J | 1 |
| Andreae, D | 1 |
| Grohmann, R | 3 |
| Toto, S | 3 |
| Kropp, S | 1 |
| Bleich, S | 3 |
| Machado-Duque, ME | 1 |
| Alzate-Carvajal, C | 1 |
| Zapata-Castañeda, K | 1 |
| Machado-Alba, JE | 1 |
| Marino, P | 2 |
| Schulberg, HC | 2 |
| Gildengers, AG | 3 |
| Mulsant, BH | 3 |
| Sajatovic, M | 12 |
| Gyulai, L | 7 |
| Aljurdi, RK | 1 |
| Evans, LD | 1 |
| Banerjee, S | 2 |
| Gur, RC | 1 |
| Young, RC | 3 |
| Song, J | 1 |
| Sjölander, A | 1 |
| Joas, E | 1 |
| Bergen, SE | 1 |
| Runeson, B | 2 |
| Larsson, H | 1 |
| Landén, M | 3 |
| Lichtenstein, P | 2 |
| Ghossoub, E | 1 |
| Habli, M | 1 |
| Uthman, I | 1 |
| Maalouf, FT | 1 |
| Mahmoudi, M | 1 |
| Friedman, D | 1 |
| Vendrame, M | 1 |
| Kothare, SV | 1 |
| Torra, M | 1 |
| Callari, A | 1 |
| Romero, S | 1 |
| Gonzalez de la Presa, B | 1 |
| Varo, C | 1 |
| Goikolea, JM | 3 |
| Pérez-Sola, V | 1 |
| Colom, F | 3 |
| Naglich, A | 1 |
| Adinoff, B | 2 |
| Brown, ES | 2 |
| Pikalov, A | 6 |
| Streicher, C | 1 |
| Cucchiaro, J | 6 |
| Mao, Y | 1 |
| Loebel, A | 9 |
| Das, S | 2 |
| Palappallil, DS | 1 |
| B C, M | 1 |
| Chatterjee, SS | 1 |
| Casassus, B | 1 |
| de Queiroz, AIG | 1 |
| Chaves Filho, AJM | 1 |
| Araújo, TDS | 1 |
| Lima, CNC | 1 |
| Machado, MJS | 1 |
| Vasconcelos, SMM | 1 |
| de Lucena, DF | 2 |
| Macedo, D | 2 |
| Penchilaiya, V | 1 |
| Kuppili, PP | 1 |
| Preeti, K | 1 |
| Bharadwaj, B | 1 |
| Seredenina, T | 1 |
| Sorce, S | 1 |
| Herrmann, FR | 1 |
| Ma Mulone, XJ | 1 |
| Plastre, O | 1 |
| Aguzzi, A | 1 |
| Jaquet, V | 1 |
| Krause, KH | 1 |
| Aral, A | 1 |
| Usta, MB | 1 |
| Karabekiroglu, K | 1 |
| Akgün, S | 1 |
| Köken, T | 1 |
| Kahraman, A | 1 |
| Zhu, MM | 1 |
| Li, HL | 1 |
| Shi, LH | 1 |
| Chen, XP | 1 |
| Luo, J | 1 |
| Zhang, ZL | 1 |
| Zhu, S | 1 |
| Cordner, ZA | 1 |
| Xiong, J | 1 |
| Chiu, CT | 2 |
| Artola, A | 1 |
| Zuo, Y | 1 |
| Nelson, AD | 1 |
| Kim, TY | 1 |
| Zaika, N | 1 |
| Woolums, BM | 1 |
| Hess, EJ | 1 |
| Chuang, DM | 6 |
| Pletnikov, MM | 1 |
| Jenkins, PM | 1 |
| Tamashiro, KL | 1 |
| Ross, CA | 1 |
| Muñoz-Estrada, J | 1 |
| Lora-Castellanos, A | 1 |
| Meza, I | 1 |
| Alarcón Elizalde, S | 1 |
| Benítez-King, G | 1 |
| Cattaneo, CI | 1 |
| Ressico, F | 1 |
| Valsesia, R | 1 |
| D'Innella, P | 1 |
| Ballabio, M | 1 |
| Fornaro, M | 1 |
| Womersley, K | 1 |
| Chu, CS | 2 |
| Lan, TH | 2 |
| Chou, PH | 2 |
| Al Jurdi, RK | 2 |
| Beyer, J | 1 |
| Evans, J | 1 |
| Greenberg, R | 1 |
| Kunik, ME | 2 |
| Chen, P | 2 |
| Barrett, M | 1 |
| Bruce, ML | 2 |
| Reynolds, CF | 2 |
| Alexopoulos, GS | 1 |
| Forester, BP | 2 |
| Tsai, J | 2 |
| Ajayi, OO | 1 |
| Holroyd, S | 1 |
| Patel, N | 2 |
| Viguera, AC | 1 |
| Baldessarini, RJ | 6 |
| Graham, RK | 1 |
| Tavella, G | 1 |
| Parker, GB | 2 |
| Kwiatkowski, MA | 1 |
| Hellemann, G | 1 |
| Sugar, CA | 1 |
| Cope, ZA | 1 |
| Minassian, A | 1 |
| Perry, W | 1 |
| Geyer, MA | 3 |
| Young, JW | 2 |
| Pietruczuk, K | 1 |
| Lisowska, KA | 1 |
| Grabowski, K | 1 |
| Landowski, J | 1 |
| Witkowski, JM | 1 |
| Zubair, UB | 1 |
| Mumtaz, H | 1 |
| Mansoor, S | 1 |
| MacQueen, G | 3 |
| Ravindran, A | 4 |
| McIntosh, D | 1 |
| Kozicky, J | 1 |
| Lafer, B | 2 |
| Post, RM | 19 |
| Marazziti, D | 3 |
| Palego, L | 1 |
| Betti, L | 1 |
| Giannaccini, G | 1 |
| Massimetti, E | 1 |
| Baroni, S | 1 |
| Ciapparelli, A | 1 |
| Lucacchini, A | 1 |
| Mucci, F | 1 |
| DellʼOsso, L | 1 |
| Cheng, YW | 1 |
| Dautzenberg, G | 1 |
| Nederlof, M | 1 |
| Beekman, A | 1 |
| Egberts, T | 1 |
| Heerdink, ER | 2 |
| Paton, C | 1 |
| Cookson, J | 1 |
| Ferrier, IN | 2 |
| Bhatti, S | 1 |
| Fagan, E | 1 |
| Barnes, TRE | 1 |
| Bastos, JR | 1 |
| Perico, KM | 1 |
| Marciano Vieira, ÉL | 1 |
| Teixeira, AL | 4 |
| Machado, FS | 1 |
| de Miranda, AS | 1 |
| Moreira, FA | 1 |
| Wang, LJ | 10 |
| Ozerdem, A | 5 |
| Ceylan, D | 2 |
| Targıtay, B | 1 |
| Figueiredo, T | 1 |
| Dias da Costa, M | 1 |
| Segenreich, D | 1 |
| Pisanu, C | 2 |
| Heilbronner, U | 1 |
| Squassina, A | 3 |
| Macfarlane, A | 1 |
| Greenhalgh, T | 1 |
| Cazala, F | 1 |
| Suchting, R | 1 |
| Zeni, CP | 1 |
| Bauer, IE | 1 |
| Mwangi, B | 1 |
| Wu, MJ | 1 |
| Passos, IC | 1 |
| Spiker, DE | 1 |
| Zunta-Soares, GB | 1 |
| Li, L | 3 |
| Tang, F | 2 |
| Qiu, Y | 1 |
| Han, X | 2 |
| Zhang, S | 2 |
| Zhang, Z | 2 |
| Yang, H | 2 |
| Wentzell, N | 1 |
| Haug, U | 1 |
| Schink, T | 1 |
| Engel, S | 1 |
| Liebentraut, J | 1 |
| Linder, R | 1 |
| Onken, M | 1 |
| Schaefer, C | 1 |
| Dathe, K | 1 |
| Paholpak, P | 2 |
| Paholpak, S | 2 |
| Patanasethanant, D | 1 |
| Rangseekajee, P | 2 |
| Patjanasoontorn, N | 1 |
| Jia, S | 1 |
| Peng, L | 2 |
| Elboga, G | 1 |
| Sayiner, ZA | 1 |
| Maddaloni, G | 1 |
| Migliarini, S | 1 |
| Napolitano, F | 1 |
| Giorgi, A | 1 |
| Nazzi, S | 1 |
| Biasci, D | 1 |
| De Felice, A | 1 |
| Gritti, M | 1 |
| Cavaccini, A | 1 |
| Galbusera, A | 1 |
| Franceschi, S | 1 |
| Lessi, F | 1 |
| Ferla, M | 1 |
| Aretini, P | 1 |
| Mazzanti, CM | 1 |
| Tonini, R | 1 |
| Gozzi, A | 1 |
| Usiello, A | 1 |
| Pasqualetti, M | 1 |
| Aquadro, E | 1 |
| Youssef, NA | 1 |
| Kelly, E | 1 |
| Sharma, D | 1 |
| Wilkinson, CJ | 1 |
| Williams, RSB | 1 |
| Silva, EF | 2 |
| Silva, AI | 1 |
| Souza, LS | 2 |
| Guerrini, R | 1 |
| Peng, D | 1 |
| Fang, Y | 2 |
| Druschky, K | 1 |
| Burda, K | 1 |
| Frieling, H | 2 |
| Hillemacher, T | 1 |
| Neyazi, A | 1 |
| Stübner, S | 2 |
| Ruiter-Visser, R | 1 |
| Dols, A | 1 |
| Smulders, YM | 1 |
| Jacobs, GE | 1 |
| Nauta, KJ | 1 |
| Chen, PH | 2 |
| Tsai, SY | 1 |
| Pan, CH | 1 |
| Chang, CK | 1 |
| Su, SS | 1 |
| Kuo, CJ | 2 |
| Musetti, L | 4 |
| Tundo, A | 1 |
| Benedetti, A | 1 |
| Massimetti, G | 1 |
| Cambiali, E | 1 |
| Pergentini, I | 3 |
| Del Grande, C | 4 |
| Dell'Osso, L | 4 |
| Miguel, SRPS | 1 |
| Lima, AFBS | 1 |
| Cruz, LN | 1 |
| Cohen, M | 1 |
| Zimmermann, JJ | 1 |
| Ziegelmann, PK | 1 |
| Fleck, MPA | 1 |
| Herrmann, N | 3 |
| Gruneir, A | 2 |
| Jandoc, R | 1 |
| McArthur, E | 1 |
| Dixon, S | 1 |
| Garg, AX | 1 |
| Balasubramanian, D | 1 |
| Pearson, JF | 1 |
| Kennedy, MA | 1 |
| Shi, S | 1 |
| Song, L | 1 |
| Chen, TY | 1 |
| Kamali, M | 1 |
| Yeh, CB | 2 |
| Mao, WC | 1 |
| Lin, PY | 1 |
| Chen, YW | 1 |
| Tseng, PT | 1 |
| Hsu, CY | 1 |
| Alvarez, P | 1 |
| Papaseit, E | 1 |
| Pérez, V | 1 |
| Bulbena, A | 1 |
| Farré, M | 1 |
| Perera, C | 1 |
| Patterson, S | 1 |
| Bruxner, G | 1 |
| Valdes, M | 1 |
| Bertolin, S | 1 |
| Rashid, M | 1 |
| Kashyap, A | 1 |
| Undela, K | 1 |
| Tatay-Manteiga, A | 1 |
| Balanzá-Martínez, V | 1 |
| Bristot, G | 1 |
| Tabarés-Seisdedos, R | 1 |
| Cauli, O | 1 |
| Kim, HS | 1 |
| Youn, T | 1 |
| Kim, SH | 1 |
| Jeong, SH | 1 |
| Jung, HY | 1 |
| Jeong, SW | 1 |
| Kim, KK | 1 |
| Kim, YS | 1 |
| Chung, IW | 1 |
| Carmassi, C | 1 |
| Masci, I | 1 |
| Caruso, D | 1 |
| Fagiolini, A | 2 |
| Barbour, KK | 1 |
| Umfrid, CP | 1 |
| Brinton, BA | 1 |
| Avery, JD | 1 |
| Snow, CE | 1 |
| Corbett, N | 1 |
| Prieto, DI | 1 |
| Zehgeer, AA | 1 |
| Connor, DF | 1 |
| Coles, AS | 1 |
| Sasiadek, J | 1 |
| George, TP | 1 |
| McKnight, RF | 1 |
| de La Motte de Broöns de Vauvert, SJGN | 1 |
| Chesney, E | 1 |
| Amit, BH | 1 |
| Geddes, J | 9 |
| Cipriani, A | 6 |
| Zhang, H | 2 |
| Ouyang, K | 1 |
| Yan, C | 1 |
| Lai, J | 1 |
| Hu, S | 1 |
| Uys, H | 1 |
| Liao, YT | 1 |
| Liu, HC | 1 |
| Chen, WJ | 1 |
| Jomli, R | 1 |
| Nacef, F | 1 |
| Douki, S | 1 |
| Andrade, C | 2 |
| Machino, A | 1 |
| Jitsuiki, H | 1 |
| Okamoto, Y | 1 |
| Izumitani, S | 1 |
| Kimura, Y | 1 |
| Suzuki, K | 2 |
| Tanaka, T | 1 |
| Inoue, T | 1 |
| Koyama, T | 1 |
| Wada, K | 2 |
| Masaoka, Y | 1 |
| Sasaki, T | 1 |
| Yoshimura, R | 1 |
| Nakamura, J | 1 |
| Sumitan, S | 1 |
| Ohmori, T | 1 |
| Yamawaki, S | 1 |
| Adedinsewo, DA | 1 |
| Thurman, DJ | 1 |
| Luo, YH | 1 |
| Williamson, RS | 1 |
| Odewole, OA | 1 |
| Oakley, GP | 1 |
| Abe, Y | 1 |
| Yasugawa, S | 1 |
| Miyamoto, K | 1 |
| Terao, T | 3 |
| Gustafsson, U | 2 |
| Ekholm, B | 2 |
| Wang, YS | 3 |
| Yeh, TL | 6 |
| Kreys, TJ | 1 |
| Fabian, TJ | 1 |
| Saul, MI | 1 |
| Haskett, R | 1 |
| Coley, KC | 1 |
| Chen, D | 1 |
| Muti, M | 2 |
| Corsi, M | 2 |
| Turri, M | 2 |
| Umberto Corsini, G | 1 |
| Nugent, AC | 2 |
| Carlson, PJ | 1 |
| Bain, EE | 3 |
| Eckelman, W | 1 |
| Herscovitch, P | 1 |
| Manji, H | 1 |
| Zarate, CA | 19 |
| Drevets, WC | 6 |
| Halaby, A | 1 |
| Haddad, R | 1 |
| Naja, WJ | 1 |
| Lin, Y | 2 |
| Lao, G | 1 |
| Jiang, Z | 1 |
| Ye, B | 1 |
| Lin, W | 1 |
| Liu, Y | 1 |
| Cao, L | 1 |
| Baek, JH | 2 |
| Bernstein, EE | 1 |
| Lee, HB | 2 |
| Hranov, LG | 1 |
| Marinova, P | 1 |
| Stoyanova, M | 1 |
| Pandova, M | 1 |
| Hranov, G | 1 |
| Vishnu, VY | 1 |
| Kesav, P | 1 |
| Goyal, MK | 1 |
| Modi, M | 1 |
| Prabhakar, S | 1 |
| Chen, SH | 4 |
| Chu, CH | 4 |
| Wang, CL | 3 |
| Riesselman, A | 1 |
| Strobl, B | 1 |
| Cooley, AT | 1 |
| Rezin, GT | 5 |
| Furlanetto, CB | 1 |
| Scaini, G | 5 |
| Gonçalves, CL | 4 |
| Ferreira, GK | 2 |
| Jeremias, IC | 1 |
| Cardoso, MR | 2 |
| Streck, EL | 9 |
| Reid, K | 1 |
| Macritchie, K | 4 |
| Han, K | 1 |
| Holder, JL | 1 |
| Schaaf, CP | 1 |
| Lu, H | 1 |
| Chen, H | 1 |
| Kang, H | 1 |
| Tang, J | 1 |
| Wu, Z | 1 |
| Hao, S | 1 |
| Cheung, SW | 1 |
| Yu, P | 1 |
| Sun, H | 1 |
| Breman, AM | 1 |
| Patel, A | 1 |
| Lu, HC | 1 |
| Zoghbi, HY | 1 |
| Lin, XL | 1 |
| Tang, SY | 1 |
| Silva, R | 2 |
| Kroger, H | 4 |
| Sarma, K | 2 |
| Xu, J | 1 |
| Belmaker, RH | 7 |
| Reynolds-May, MF | 1 |
| Kenna, HA | 2 |
| Marsh, W | 1 |
| Stemmle, PG | 1 |
| Wang, P | 1 |
| Rasgon, NL | 7 |
| Brown, R | 2 |
| Taylor, MJ | 2 |
| Azorin, JM | 4 |
| Cermolacce, M | 1 |
| Kaladjian, A | 1 |
| Corréard, N | 1 |
| Dassa, D | 1 |
| Dubois, M | 1 |
| Maurel, M | 1 |
| Micoulaud Franchi, JA | 1 |
| Pringuey, D | 1 |
| Fakra, E | 1 |
| Geoffroy, PA | 2 |
| Vella, T | 1 |
| Mifsud, J | 1 |
| Felker, D | 1 |
| Lynn, A | 1 |
| Johnson, DE | 1 |
| Moss, MC | 1 |
| Kozlowski, T | 1 |
| Dupuis, R | 1 |
| Detwiler, R | 1 |
| Lee, RM | 1 |
| Deyo, JC | 1 |
| Won, SH | 1 |
| Lee, KH | 2 |
| Jon, DI | 3 |
| Min, KJ | 2 |
| Monji, A | 1 |
| Motomura, K | 1 |
| Mizoguchi, Y | 1 |
| Ohara, T | 1 |
| Baba, S | 1 |
| Yoshiura, T | 1 |
| Gentile, S | 1 |
| Pallanti, S | 1 |
| Grassi, G | 1 |
| Antonini, S | 1 |
| Quercioli, L | 1 |
| Salvadori, E | 1 |
| Hollander, E | 1 |
| Chauhan, S | 1 |
| Tripathi, P | 1 |
| Goyal, P | 1 |
| Kumar, D | 1 |
| Chou, YC | 1 |
| Chao, FH | 1 |
| Chou, YH | 1 |
| Selvi, Y | 1 |
| Annagur, BB | 1 |
| Sayin, AA | 1 |
| Akbaba, N | 1 |
| Okayasu, H | 1 |
| Shinozaki, T | 1 |
| Osone, A | 1 |
| Ozeki, Y | 1 |
| Villaseñor, A | 1 |
| Ramamoorthy, A | 1 |
| Silva dos Santos, M | 1 |
| Lorenzo, MP | 1 |
| Laje, G | 1 |
| Zarate, C | 1 |
| Barbas, C | 1 |
| Wainer, IW | 1 |
| Hou, YC | 1 |
| Lai, CH | 1 |
| Köksal, A | 1 |
| Dirican, AC | 1 |
| Altunkaynak, Y | 1 |
| Yildirim, EA | 1 |
| Alamo, C | 1 |
| López-Muñoz, F | 1 |
| García-García, P | 1 |
| Marusic, S | 1 |
| Obreli Neto, PR | 1 |
| Vuletic, V | 1 |
| Kirin, M | 1 |
| Dubovsky, SL | 2 |
| Daurignac, E | 1 |
| Leonard, KE | 1 |
| Vázquez, M | 2 |
| Fagiolino, P | 2 |
| Maldonado, C | 2 |
| Olmos, I | 1 |
| Ibarra, M | 1 |
| Alvariza, S | 1 |
| Guevara, N | 2 |
| Magallanes, L | 1 |
| Olano, I | 1 |
| Lee, YM | 1 |
| Mauer, S | 1 |
| Alahmari, R | 1 |
| Vöhringer, PA | 1 |
| Vergne, DE | 1 |
| Lövdahl, H | 1 |
| Correa, E | 1 |
| Patkar, A | 1 |
| Pae, C | 1 |
| Strejilevich, S | 1 |
| Dalley, S | 1 |
| Jaikasemwong, S | 1 |
| Roumcharoenkiat, A | 1 |
| Eryilmaz, G | 1 |
| Hizli Sayar, G | 1 |
| Özten, E | 1 |
| Gül, IG | 1 |
| Karamustafalioğlu, O | 1 |
| Yorbik, Ö | 1 |
| Silveira, LE | 2 |
| Tunca, Z | 4 |
| Yalçın, Y | 1 |
| Can, G | 1 |
| Resmi, H | 3 |
| Akan, P | 1 |
| Ergör, G | 1 |
| Aydemir, O | 1 |
| Cengisiz, C | 1 |
| Kerim, D | 1 |
| Kaminsky, Z | 1 |
| Jones, I | 1 |
| Verma, R | 1 |
| Saleh, L | 1 |
| Trivedi, H | 1 |
| Guintivano, J | 1 |
| Akman, R | 1 |
| Zandi, P | 1 |
| Lee, RS | 1 |
| Potash, JB | 1 |
| Wang, SC | 1 |
| Kao, YC | 2 |
| Liu, YP | 1 |
| Ghaleiha, A | 2 |
| Haghighi, M | 3 |
| Sharifmehr, M | 1 |
| Jahangard, L | 3 |
| Ahmadpanah, M | 1 |
| Bajoghli, H | 4 |
| Holsboer-Trachsler, E | 3 |
| Brand, S | 4 |
| Muralidharan, K | 1 |
| Bücker, J | 1 |
| Marchesi, C | 1 |
| Taylor, DM | 1 |
| Cornelius, V | 1 |
| Smith, L | 1 |
| Park, SW | 1 |
| Seo, MK | 1 |
| Cho, HY | 1 |
| Lee, CH | 1 |
| Lee, JH | 3 |
| Lee, BJ | 1 |
| Seol, W | 1 |
| Kim, YH | 1 |
| Moosavi, SM | 1 |
| Ahmadi, M | 1 |
| Monajemi, MB | 1 |
| Ionescu, DF | 2 |
| Luckenbaugh, DA | 9 |
| Niciu, MJ | 3 |
| Richards, EM | 2 |
| Citrome, L | 3 |
| Volkert, J | 1 |
| Zierhut, KC | 1 |
| Schiele, MA | 1 |
| Wenzel, M | 1 |
| Kopf, J | 1 |
| Kittel-Schneider, S | 1 |
| Reif, A | 1 |
| Lopes-Borges, J | 4 |
| Tonin, PT | 1 |
| Vieira, JS | 1 |
| Mariot, E | 2 |
| Amboni, RT | 1 |
| Bianchini, G | 1 |
| Lee, KI | 1 |
| Karanti, A | 2 |
| Bobeck, C | 1 |
| Osterman, M | 1 |
| Kardell, M | 2 |
| Tidemalm, D | 1 |
| Cirronis, M | 1 |
| Corsini, GU | 1 |
| Gélisse, P | 1 |
| Crespel, A | 1 |
| Sanford, M | 1 |
| Dhillon, S | 1 |
| Barnhorst, A | 1 |
| Xiong, GL | 1 |
| Martínez-Lazcano, MT | 1 |
| Esplá-González, S | 1 |
| Herraiz-Robles, P | 1 |
| Hernández-Pérez, P | 1 |
| Chillerón-Cuenca, R | 1 |
| Pol-Yanguas, E | 1 |
| Mohapatra, S | 1 |
| Deo, SJ | 1 |
| Rath, N | 1 |
| Molnar, GP | 1 |
| Stephens, KJ | 1 |
| George, LV | 1 |
| Stewart, JT | 3 |
| Jeremias, GC | 1 |
| Réus, GZ | 5 |
| Andersen, ML | 4 |
| Wilimowska, J | 1 |
| Kłys, M | 1 |
| Jawień, W | 1 |
| Inal-Emiroglu, FN | 2 |
| Karabay, N | 2 |
| Guleryuz, H | 2 |
| Baykara, B | 2 |
| Cevher, N | 1 |
| Akay, A | 2 |
| Alsen, S | 1 |
| Senturk-Pilan, B | 1 |
| Kose, S | 1 |
| Kowatch, RA | 8 |
| Scheffer, RE | 3 |
| Monroe, E | 1 |
| Delgado, S | 1 |
| Altaye, M | 1 |
| Lagory, D | 1 |
| Goodwin, GM | 6 |
| Bourin, M | 2 |
| de Bodinat, C | 1 |
| Laredo, J | 1 |
| Viswanath, B | 1 |
| Jose, SP | 1 |
| Thirthalli, J | 1 |
| Purushottam, M | 1 |
| Mukherjee, O | 1 |
| Vladimirov, V | 1 |
| Patrinos, GP | 1 |
| Del Zompo, M | 2 |
| Jain, S | 1 |
| de Souza, GC | 1 |
| Gomes, JA | 1 |
| de Góis Queiroz, AI | 1 |
| de Araújo, MM | 1 |
| Cavalcante, LM | 1 |
| Machado, Mde J | 1 |
| Monte, AS | 1 |
| Popovic, D | 1 |
| Hidalgo, D | 1 |
| León-Caballero, J | 1 |
| Zhou, R | 1 |
| Lu, Y | 1 |
| Han, Y | 1 |
| Lou, H | 1 |
| Zhu, L | 1 |
| Zhen, X | 1 |
| Duan, S | 1 |
| Laliberté, V | 1 |
| Yu, C | 1 |
| Xu, AJ | 1 |
| Lundin, NB | 1 |
| Vande Voort, JL | 1 |
| Ballard, ED | 1 |
| Brutsche, NE | 2 |
| Machado-Vieira, R | 3 |
| Cruceanu, C | 1 |
| Tan, PP | 1 |
| Rogic, S | 1 |
| Lopez, JP | 1 |
| Torres-Platas, SG | 1 |
| Gigek, CO | 1 |
| Rouleau, GA | 2 |
| Pavlidis, P | 1 |
| Turecki, G | 1 |
| Arabzadeh, S | 1 |
| Ameli, N | 1 |
| Zeinoddini, A | 1 |
| Rezaei, F | 1 |
| Farokhnia, M | 1 |
| Mohammadinejad, P | 1 |
| Peselow, ED | 1 |
| Clevenger, S | 1 |
| IsHak, WW | 1 |
| Glue, P | 2 |
| Herbison, P | 2 |
| Salpekar, JA | 2 |
| Joshi, PT | 2 |
| Axelson, DA | 6 |
| Reinblatt, SP | 1 |
| Yenokyan, G | 3 |
| Sanyal, A | 2 |
| Walkup, JT | 5 |
| Vitiello, B | 5 |
| Luby, JL | 3 |
| Wagner, KD | 8 |
| Nusrat, N | 2 |
| Riddle, MA | 5 |
| Miller, L | 2 |
| Robb, A | 4 |
| Wolf, D | 1 |
| Birmaher, B | 6 |
| Tonna, M | 1 |
| Stubbs, B | 1 |
| Kleimann, A | 1 |
| Schrader, V | 1 |
| Greil, W | 3 |
| Kahl, KG | 1 |
| Rajagopalan, K | 2 |
| Ng-Mak, D | 2 |
| Bacci, ED | 2 |
| Wyrwich, K | 2 |
| Chapel, S | 1 |
| Chiu, YY | 1 |
| Hsu, J | 1 |
| Khan, SJ | 1 |
| Fersh, ME | 1 |
| Ernst, C | 1 |
| Klipstein, K | 1 |
| Albertini, ES | 1 |
| Lusskin, SI | 1 |
| Nakamura, A | 1 |
| Mihara, K | 1 |
| Nagai, G | 1 |
| Kagawa, S | 1 |
| Suzuki, T | 1 |
| Nemoto, K | 1 |
| Kondo, T | 1 |
| Huang, CC | 1 |
| Lee, CC | 1 |
| Lundberg, U | 1 |
| Leff, P | 1 |
| Fernández-Guasti, A | 1 |
| Becerra Palars, C | 1 |
| Kasper, S | 4 |
| Tsai, CJ | 1 |
| Cheng, C | 1 |
| McInnis, MG | 2 |
| Chang, CL | 1 |
| Shansis, FM | 1 |
| Reche, M | 1 |
| Capp, E | 1 |
| Leverich, GS | 6 |
| Kupka, R | 2 |
| Keck, PE | 30 |
| Altshuler, LL | 12 |
| Rowe, M | 2 |
| Nolen, WA | 6 |
| Queijo, C | 1 |
| González, R | 1 |
| Shah, N | 1 |
| Reddy, MS | 1 |
| Vohra, S | 1 |
| Chaudhuri, U | 1 |
| Mohanasundaram, S | 1 |
| Dawson, LP | 1 |
| Lee, SJ | 1 |
| Hollander, YS | 1 |
| Aebischer, B | 1 |
| Elsig, S | 1 |
| Taeymans, J | 1 |
| Pomp, S | 1 |
| Kuhness, D | 1 |
| Barcaro, G | 1 |
| Sementa, L | 1 |
| Mankad, V | 1 |
| Fortunelli, A | 1 |
| Sterrer, M | 1 |
| Netzer, FP | 1 |
| Surnev, S | 1 |
| Schmieder, AH | 1 |
| Caruthers, SD | 1 |
| Keupp, J | 1 |
| Wickline, SA | 1 |
| Lanza, GM | 1 |
| Lowe, J | 1 |
| Wodarcyk, AJ | 1 |
| Floyd, KT | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Swager, SA | 1 |
| Chadwick, JA | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Janssen, PM | 1 |
| Rafael-Fortney, JA | 1 |
| Alcalay, RN | 1 |
| Levy, OA | 1 |
| Wolf, P | 1 |
| Oliva, P | 1 |
| Zhang, XK | 1 |
| Waters, CH | 1 |
| Fahn, S | 1 |
| Kang, U | 1 |
| Liong, C | 1 |
| Ford, B | 1 |
| Mazzoni, P | 1 |
| Kuo, S | 1 |
| Johnson, A | 1 |
| Xiong, L | 1 |
| Chung, W | 1 |
| Marder, KS | 1 |
| Gan-Or, Z | 1 |
| Kamei, K | 1 |
| Katayama, Y | 1 |
| Hatano, K | 1 |
| Kodama, K | 1 |
| Shirahama, M | 1 |
| Sakai, A | 1 |
| Hirakawa, H | 1 |
| Mizokami, Y | 1 |
| Shiotsuki, I | 1 |
| Ishii, N | 1 |
| Inoue, Y | 1 |
| Akboga, MK | 1 |
| Yayla, C | 1 |
| Balci, KG | 1 |
| Ozeke, O | 1 |
| Maden, O | 1 |
| Kisacik, H | 1 |
| Temizhan, A | 1 |
| Aydogdu, S | 1 |
| Zhu, J | 2 |
| Ying, SH | 1 |
| Feng, MG | 1 |
| Zhang, XG | 1 |
| Li, H | 2 |
| Wang, L | 1 |
| Hao, YY | 1 |
| Liang, GD | 1 |
| Ma, YH | 1 |
| Yang, GS | 1 |
| Hu, JH | 1 |
| Pfeifer, L | 1 |
| Goertz, RS | 1 |
| Neurath, MF | 1 |
| Strobel, D | 1 |
| Wildner, D | 1 |
| Lin, JT | 1 |
| Yang, XN | 1 |
| Zhong, WZ | 1 |
| Liao, RQ | 1 |
| Dong, S | 1 |
| Nie, Q | 1 |
| Weng, SX | 1 |
| Fang, XJ | 1 |
| Zheng, JY | 1 |
| Wu, YL | 1 |
| Řezanka, T | 1 |
| Kaineder, K | 1 |
| Mezricky, D | 1 |
| Řezanka, M | 1 |
| Bišová, K | 1 |
| Zachleder, V | 1 |
| Vítová, M | 1 |
| Rinker, JA | 1 |
| Marshall, SA | 1 |
| Mazzone, CM | 1 |
| Lowery-Gionta, EG | 1 |
| Gulati, V | 1 |
| Pleil, KE | 1 |
| Kash, TL | 1 |
| Navarro, M | 1 |
| Thiele, TE | 1 |
| Zhang, Y | 1 |
| Jin, Z | 1 |
| Xu, P | 1 |
| Huang, P | 1 |
| Liu, C | 1 |
| Fokdal, L | 1 |
| Sturdza, A | 1 |
| Mazeron, R | 1 |
| Haie-Meder, C | 1 |
| Tan, LT | 1 |
| Gillham, C | 1 |
| Šegedin, B | 1 |
| Jürgenliemk-Schultz, I | 1 |
| Kirisits, C | 1 |
| Hoskin, P | 1 |
| Pötter, R | 1 |
| Lindegaard, JC | 1 |
| Tanderup, K | 1 |
| Levin, DE | 1 |
| Schmitz, AJ | 1 |
| Hines, SM | 1 |
| Hines, KJ | 1 |
| Tucker, MJ | 1 |
| Brewer, SH | 1 |
| Fenlon, EE | 1 |
| Álvarez-Pérez, S | 1 |
| Blanco, JL | 1 |
| Peláez, T | 1 |
| Martínez-Nevado, E | 1 |
| García, ME | 1 |
| Puckerin, AA | 1 |
| Chang, DD | 1 |
| Subramanyam, P | 1 |
| Colecraft, HM | 1 |
| Dogan, H | 1 |
| Coteli, E | 1 |
| Karatas, F | 1 |
| Ceylan, O | 1 |
| Sahin, MD | 1 |
| Akdamar, G | 1 |
| Kryczyk, A | 1 |
| Żmudzki, P | 1 |
| Hubicka, U | 1 |
| Giovannelli, D | 1 |
| Chung, M | 1 |
| Staley, J | 1 |
| Starovoytov, V | 1 |
| Le Bris, N | 1 |
| Vetriani, C | 1 |
| Wu, L | 1 |
| Liu, X | 1 |
| Shen, Y | 1 |
| Liang, Y | 1 |
| Tan, H | 1 |
| Yang, Y | 1 |
| Liu, Q | 1 |
| Liu, L | 1 |
| Liu, B | 1 |
| Liu, GH | 1 |
| Zhu, YJ | 1 |
| Wang, JP | 1 |
| Che, JM | 1 |
| Chen, QQ | 1 |
| Maucksch, U | 1 |
| Runge, R | 1 |
| Wunderlich, G | 1 |
| Freudenberg, R | 1 |
| Naumann, A | 1 |
| Kotzerke, J | 1 |
| Balon, R | 1 |
| Riba, M | 1 |
| Oedegaard, KJ | 1 |
| Anand, A | 1 |
| Andreassen, OA | 1 |
| Balaraman, Y | 1 |
| Berrettini, WH | 1 |
| Bhattacharjee, A | 1 |
| Brennand, KJ | 1 |
| Burdick, KE | 2 |
| Calkin, CV | 1 |
| Claasen, A | 1 |
| Coryell, WH | 2 |
| Craig, D | 1 |
| DeModena, A | 1 |
| Frye, M | 3 |
| Gage, FH | 1 |
| Garnham, J | 2 |
| Gershon, E | 1 |
| Jakobsen, P | 1 |
| Leckband, SG | 1 |
| McCarthy, MJ | 1 |
| Maihofer, AX | 1 |
| Mertens, J | 1 |
| Morken, G | 1 |
| Nievergelt, CM | 1 |
| Nurnberger, J | 1 |
| Pham, S | 1 |
| Schoeyen, H | 1 |
| Shekhtman, T | 1 |
| Shilling, PD | 1 |
| Szelinger, S | 1 |
| Tarwater, B | 1 |
| Yao, J | 1 |
| Zandi, PP | 1 |
| Kelsoe, JR | 1 |
| Zhang, L | 2 |
| Li, S | 1 |
| Zou, X | 1 |
| Hayes, JF | 3 |
| Pitman, A | 1 |
| Marston, L | 2 |
| Walters, K | 3 |
| King, M | 3 |
| Osborn, DP | 2 |
| Kuo, YC | 1 |
| Lin, YC | 1 |
| Menon, V | 1 |
| Rajkumar, RP | 1 |
| Thamizh, JS | 1 |
| Selvakumar, N | 1 |
| Tsai, PS | 1 |
| Liu, IC | 1 |
| Chiu, CH | 1 |
| Huang, CJ | 1 |
| Wang, MY | 1 |
| Cancelier, K | 1 |
| Gomes, LM | 1 |
| Carvalho-Silva, M | 1 |
| Teixeira, LJ | 1 |
| Rebelo, J | 1 |
| Mota, IT | 1 |
| Arent, CO | 4 |
| Kist, LW | 1 |
| Bogo, MR | 1 |
| Li, CL | 2 |
| Chung, YL | 2 |
| Hsieh, TH | 2 |
| Uguz, F | 1 |
| Chang, TT | 1 |
| Papadima, EM | 1 |
| van den Ameele, S | 1 |
| van Diermen, L | 1 |
| Staels, W | 1 |
| Coppens, V | 1 |
| Dumont, G | 1 |
| Sabbe, B | 1 |
| Santos, WB | 1 |
| Lobão-Soares, B | 1 |
| Soares-Rachetti, VP | 1 |
| Medeiros, IU | 1 |
| Bauer, MS | 2 |
| Miller, CJ | 1 |
| Li, M | 1 |
| Bajor, LA | 1 |
| Lee, A | 2 |
| Lin, MW | 1 |
| Chang, C | 1 |
| Tai, YM | 1 |
| Chang, HA | 2 |
| Hassamal, S | 1 |
| Waller, S | 1 |
| Reese, K | 1 |
| Testa, C | 1 |
| Mnif, L | 1 |
| Sellami, R | 1 |
| Masmoudi, J | 1 |
| Tournikioti, K | 1 |
| Michopoulos, I | 1 |
| Alevizaki, M | 1 |
| Soldatos, CR | 1 |
| Dikeos, D | 2 |
| Douzenis, A | 1 |
| Jornada, LK | 3 |
| Peterle, BR | 1 |
| Machado, AG | 1 |
| Farias, HR | 1 |
| de Souza, CT | 1 |
| Schoretsanitis, G | 1 |
| Haen, E | 1 |
| Gründer, G | 1 |
| Stegmann, B | 1 |
| Schruers, KR | 1 |
| Hiemke, C | 1 |
| Lammertz, SE | 1 |
| Paulzen, M | 1 |
| Pennybaker, SJ | 1 |
| Masson, M | 1 |
| Huberfeld, G | 1 |
| Richa, S | 1 |
| Gaillard, R | 1 |
| Yang, YH | 1 |
| Chen, CS | 2 |
| Shulman, K | 1 |
| Fischer, HD | 1 |
| Fung, K | 1 |
| Hochman, E | 1 |
| Krivoy, A | 1 |
| Weizman, A | 1 |
| Valevski, A | 1 |
| Susser, LC | 1 |
| Hermann, AD | 1 |
| Jadhav, S | 1 |
| Russo, S | 1 |
| Cowart, LA | 1 |
| Azab, AN | 4 |
| Vainer, E | 1 |
| Agam, G | 4 |
| Bersudsky, Y | 3 |
| Rosso, G | 1 |
| Solia, F | 1 |
| Albert, U | 2 |
| Önen, Ö | 1 |
| Kutlu, A | 1 |
| Erkuran, HÖ | 1 |
| Landry, KB | 1 |
| Fargason, RE | 1 |
| Birur, B | 1 |
| Rogers, J | 2 |
| Kurt, E | 3 |
| Emul, M | 1 |
| Ozbulut, O | 1 |
| Guler, O | 1 |
| Erdur, F | 1 |
| Sağlam, H | 1 |
| Gecici, O | 1 |
| Oldham, J | 1 |
| MacMillan, CM | 2 |
| Withney, JE | 1 |
| Korndörfer, SR | 2 |
| Tilley, CA | 1 |
| Mrakotsky, C | 1 |
| Gonzalez-Heydrich, JM | 1 |
| Huang, CW | 1 |
| Hsu, YF | 1 |
| Chang, WH | 1 |
| Lane, HY | 1 |
| Tor, PC | 1 |
| Lee, EL | 1 |
| Joffe, H | 3 |
| Hayes, FJ | 1 |
| Eggens, I | 1 |
| Persson, I | 1 |
| Paulsson, B | 10 |
| Brecher, M | 6 |
| Pearlstein, T | 1 |
| Miklowitz, DJ | 1 |
| Chang, KD | 5 |
| Shen, YC | 1 |
| Shin, YC | 2 |
| Cho, HS | 1 |
| Lee, E | 1 |
| Ha, K | 2 |
| Kim, W | 1 |
| Chung, SK | 3 |
| Güntekin, B | 2 |
| Başar, E | 3 |
| Zajecka, JM | 4 |
| Gutierrez, SN | 1 |
| Kocaaslan, S | 1 |
| Whitehall, J | 1 |
| Smith, J | 1 |
| Kongsakon, R | 2 |
| Thomyangkoon, P | 1 |
| Kanchanatawan, B | 1 |
| Janenawasin, S | 1 |
| Bowden, C | 8 |
| Göğüş, A | 1 |
| Häggström, L | 1 |
| Rybakowski, J | 1 |
| Sümegi, A | 1 |
| Gau, SS | 1 |
| Chao, PF | 1 |
| Lin, YJ | 1 |
| Chang, CJ | 1 |
| Gau, CS | 1 |
| Langosch, JM | 1 |
| Drieling, T | 2 |
| Biedermann, NC | 1 |
| Born, C | 1 |
| Sasse, J | 1 |
| Bauer, H | 1 |
| Walden, J | 10 |
| Kemp, DE | 13 |
| Kim, JH | 1 |
| Choi, SW | 1 |
| Joe, SH | 1 |
| Ha, TH | 1 |
| Yoo, HJ | 1 |
| Choi, JE | 1 |
| Cha, B | 1 |
| Wheeler, A | 1 |
| Robinson, G | 1 |
| Fraser, A | 1 |
| Marangell, LB | 4 |
| Petersen, NJ | 1 |
| Martinez, M | 1 |
| Ding, D | 1 |
| Shi, Y | 1 |
| Shaltiel, G | 2 |
| Pullumbi, E | 1 |
| Campbell, A | 1 |
| Mehta, DV | 2 |
| DiazGranados, N | 2 |
| Andreazza, AC | 5 |
| Stertz, L | 1 |
| Zanotto, C | 1 |
| Ribeiro, L | 1 |
| Giasson, K | 1 |
| Salvador, M | 1 |
| Gonçalves, CA | 1 |
| Shafti, SS | 1 |
| Shahveisi, B | 1 |
| Bilo, L | 1 |
| Meo, R | 1 |
| Sun, B | 1 |
| Amsterdam, JD | 1 |
| Banov, M | 2 |
| Shekhar, A | 1 |
| Aaronson, ST | 1 |
| Bardenstein, L | 1 |
| Grecu-Gabos, I | 1 |
| Tochilov, V | 1 |
| Prelipceanu, D | 1 |
| Oliff, HS | 1 |
| Kryzhanovskaya, L | 1 |
| Chesebro, JE | 1 |
| Holmes, MK | 1 |
| Erickson, K | 1 |
| Cannon, DM | 2 |
| Snow, J | 1 |
| Sahakian, BJ | 1 |
| Manji, HK | 20 |
| Kummer, A | 1 |
| Teixeira, A | 1 |
| Elmslie, JL | 2 |
| Porter, RJ | 2 |
| Joyce, PR | 2 |
| Hunt, PJ | 2 |
| Shand, BI | 1 |
| Scott, RS | 1 |
| Pui-yin Chung, J | 1 |
| Shiu-yin Chong, C | 1 |
| Chung, KF | 1 |
| Lai-wah Dunn, E | 1 |
| Wai-nang Tang, O | 1 |
| Chan, WF | 1 |
| Ganocy, SJ | 10 |
| Caldes, E | 1 |
| Feldman, K | 1 |
| Chan, PK | 5 |
| Bilali, S | 3 |
| Findling, RL | 19 |
| Lingler, J | 1 |
| Rowles, BM | 1 |
| McNamara, NK | 6 |
| Kakiuchi, C | 2 |
| Ishigaki, S | 1 |
| Oslowski, CM | 1 |
| Fonseca, SG | 1 |
| Kato, T | 3 |
| Urano, F | 1 |
| Washizuka, S | 1 |
| Iwamoto, K | 1 |
| Bundo, M | 1 |
| Val, AC | 1 |
| Souza, A | 1 |
| Nicolato, R | 1 |
| Salgado, JV | 1 |
| Boarati, MA | 1 |
| Castillo, AR | 1 |
| Castillo, JC | 1 |
| Fu-I, L | 1 |
| Bisol, LW | 1 |
| Lara, DR | 1 |
| Rendell, JM | 3 |
| Praharaj, SK | 2 |
| Jana, AK | 1 |
| Sinha, VK | 5 |
| Gavin, DP | 1 |
| Kartan, S | 1 |
| Chase, K | 1 |
| Jayaraman, S | 1 |
| Sharma, RP | 1 |
| Elhaj, O | 4 |
| Bilali, SR | 2 |
| Chou, CH | 2 |
| Gean, PW | 4 |
| Huang, HC | 2 |
| Chang, K | 4 |
| Karchemskiy, A | 1 |
| Kelley, R | 1 |
| Howe, M | 2 |
| Garrett, A | 1 |
| Adleman, N | 2 |
| Reiss, A | 1 |
| Redden, L | 2 |
| DelBello, M | 1 |
| Wilens, TE | 3 |
| Malhotra, S | 1 |
| Wozniak, P | 6 |
| Vigna, NV | 3 |
| Greco, N | 1 |
| Kovacs, X | 1 |
| Abi-Saab, W | 3 |
| Saltarelli, M | 3 |
| Zugno, AI | 3 |
| Scherer, EB | 1 |
| Mattos, C | 1 |
| Matté, C | 1 |
| Ferreira, CL | 5 |
| Wyse, AT | 1 |
| Potter, M | 1 |
| Moses, A | 1 |
| Wozniak, J | 3 |
| Perlis, RH | 2 |
| Liu, S | 2 |
| Arora, M | 1 |
| Sarkar, S | 1 |
| Kelly, MP | 1 |
| Logue, SF | 1 |
| Dwyer, JM | 1 |
| Beyer, CE | 1 |
| Majchrowski, H | 1 |
| Liu, Z | 1 |
| Adedoyin, A | 1 |
| Rosenzweig-Lipson, S | 1 |
| Comery, TA | 1 |
| Khalid, I | 1 |
| Rana, L | 1 |
| Khalid, TJ | 1 |
| Roehrs, T | 1 |
| Kakkar, AK | 1 |
| Rehan, HS | 1 |
| Unni, KE | 1 |
| Gupta, NK | 1 |
| Chopra, D | 1 |
| Kataria, D | 1 |
| Segal, S | 1 |
| Jiang, B | 1 |
| Abreu, LN | 1 |
| Issler, C | 1 |
| Behzadi, AH | 1 |
| Omrani, Z | 1 |
| Chalian, M | 1 |
| Asadi, S | 1 |
| Ghadiri, M | 1 |
| Perova, T | 1 |
| Kwan, M | 1 |
| Li, PP | 1 |
| Warsh, JJ | 1 |
| Haddad, PM | 1 |
| Das, A | 1 |
| Ashfaq, M | 1 |
| Wieck, A | 1 |
| Lin, ST | 1 |
| Yen, CF | 1 |
| Tsei, JH | 1 |
| Wang, SY | 1 |
| Arvilommi, P | 1 |
| Suominen, K | 1 |
| Mantere, O | 1 |
| Leppämäki, S | 1 |
| Valtonen, HM | 1 |
| Isometsä, E | 1 |
| Bonnín, CM | 1 |
| Martínez-Arán, A | 3 |
| Torrent, C | 3 |
| Rosa, AR | 4 |
| Franco, C | 1 |
| Sanchez-Moreno, J | 3 |
| Kim, B | 2 |
| Kim, CY | 1 |
| Lee, MJ | 1 |
| Joo, YH | 2 |
| Novick, D | 1 |
| Haro, JM | 1 |
| Bertsch, J | 1 |
| Reed, C | 1 |
| Perrin, E | 1 |
| Muzina, DJ | 5 |
| Xia, G | 2 |
| Franco Hidalgo, S | 1 |
| Prieto de Paula, JM | 1 |
| Salado Valdivieso, I | 1 |
| Salvadore, G | 2 |
| Henter, ID | 1 |
| Chen, CY | 1 |
| Yeh, YW | 1 |
| Kuo, SC | 1 |
| Shiah, IS | 4 |
| Liu, PY | 1 |
| Chen, CL | 1 |
| Bellani, M | 1 |
| Yeh, PH | 1 |
| Patterson, JV | 1 |
| Sandman, CA | 1 |
| Ring, A | 1 |
| Jin, Y | 1 |
| Bunney, WE | 1 |
| Fajutrao, L | 1 |
| Locklear, J | 1 |
| Bazinet, RP | 3 |
| Teo, R | 1 |
| King, J | 1 |
| Dalton, E | 1 |
| Ryves, J | 1 |
| Williams, RS | 4 |
| Harwood, AJ | 4 |
| Kleineidam, A | 1 |
| Vavassori, S | 1 |
| Wang, K | 1 |
| Schweizer, LM | 1 |
| Griac, P | 1 |
| Schweizer, M | 1 |
| Terbach, N | 1 |
| Woodward, TC | 2 |
| Tafesse, E | 2 |
| Quon, P | 2 |
| Kim, J | 1 |
| Lazarus, A | 2 |
| Houston, JP | 3 |
| Degenhardt, EK | 3 |
| Jamal, HH | 2 |
| Liu, LL | 1 |
| Basu, D | 2 |
| Chakraborty, K | 1 |
| Rendell, J | 3 |
| Spina, E | 2 |
| D'Arrigo, C | 1 |
| Santoro, V | 1 |
| Muscatello, MR | 1 |
| Pandolfo, G | 1 |
| Zoccali, R | 1 |
| Diaz, FJ | 2 |
| Haymond, J | 1 |
| Ensom, MH | 1 |
| Kotbi, N | 1 |
| Mahgoub, N | 1 |
| Mokonogho, J | 1 |
| Young, R | 1 |
| Wang, PW | 2 |
| Nowakowska, C | 1 |
| Chandler, RA | 1 |
| Hill, SJ | 1 |
| Nam, JY | 1 |
| Culver, JL | 1 |
| Keller, KL | 1 |
| Smith, LA | 1 |
| Cornelius, VR | 1 |
| Perugi, G | 4 |
| Moretti, M | 3 |
| Padilha, PT | 1 |
| Fries, GR | 2 |
| Rubner, P | 1 |
| Koppi, S | 1 |
| Conca, A | 2 |
| Fountoulakis, K | 1 |
| Siamouli, M | 1 |
| Gonda, X | 1 |
| Goldberg, JF | 11 |
| Mosolov, SN | 1 |
| Kostiukova, EG | 1 |
| Kapiletti, SG | 1 |
| Belen'kaia, DV | 1 |
| Shafarenko, AA | 1 |
| Fedotov, DD | 1 |
| Sekhar, S | 1 |
| Kalra, B | 1 |
| Mendhekar, DN | 1 |
| Tekur, U | 2 |
| Licht, RW | 3 |
| Morriss, R | 1 |
| Alder, N | 1 |
| Juszczak, E | 1 |
| Mosolov, S | 1 |
| Hranov, L | 1 |
| Chen, E | 1 |
| Habil, H | 1 |
| Manfredi, R | 1 |
| Lin, HN | 1 |
| Ice, KS | 3 |
| Schwartz, JH | 3 |
| Wang, PP | 1 |
| Versavel, M | 1 |
| Möller, HJ | 9 |
| Chou, JC | 5 |
| Ozen, S | 1 |
| Bülbül, I | 1 |
| Soyuçok, E | 1 |
| Bève, E | 1 |
| Beck, E | 1 |
| Pinto, E | 1 |
| Ansseau, M | 1 |
| Frare, F | 1 |
| Toni, C | 1 |
| Tusini, G | 1 |
| Vannucchi, G | 1 |
| Akiskal, HS | 4 |
| Di Nicola, M | 1 |
| Mazza, M | 1 |
| Tedeschi, D | 1 |
| Pozzi, G | 1 |
| Peitl, MV | 1 |
| Peitl, V | 1 |
| Grahovac, T | 1 |
| Pavlović, E | 1 |
| Presecki, P | 1 |
| Grosić, V | 1 |
| Silić, A | 1 |
| Mihanović, M | 1 |
| Kennedy, R | 1 |
| McQueen, D | 1 |
| Badr, MG | 1 |
| Yang, F | 1 |
| Pesek, MB | 1 |
| Fábián, Z | 1 |
| Tapia-Paniagua, G | 1 |
| Hudiţă, C | 1 |
| Okasha, T | 1 |
| D'yachkova, Y | 1 |
| Harrison, G | 1 |
| Treuer, T | 1 |
| Lyoo, IK | 2 |
| Dager, SR | 2 |
| Kim, JE | 1 |
| Yoon, SJ | 1 |
| Friedman, SD | 2 |
| Dunner, DL | 5 |
| Renshaw, PF | 3 |
| Martens, BE | 1 |
| Creech, RS | 1 |
| Welge, JA | 5 |
| Jefferson, L | 1 |
| Guerdjikova, AI | 1 |
| Hirschfeld, RM | 9 |
| Collins, M | 1 |
| Atmaca, M | 3 |
| Silverstone, PH | 7 |
| McGrath, BM | 3 |
| Masi, G | 1 |
| Millepiedi, S | 1 |
| Mucci, M | 1 |
| Pfanner, C | 1 |
| Berloffa, S | 1 |
| Pari, C | 1 |
| Gagliano, A | 1 |
| D'Amico, F | 1 |
| Saatçi, E | 1 |
| Fountoulakis, KN | 2 |
| Owen, R | 1 |
| Baudelet, C | 1 |
| McQuade, RD | 1 |
| Sanchez, R | 2 |
| Marcus, RN | 1 |
| Vasudev, K | 6 |
| Mead, A | 2 |
| Bujoreanu, IS | 1 |
| Ibeziako, P | 1 |
| DeMaso, DR | 1 |
| Schmid, MM | 1 |
| Connemann, BJ | 1 |
| Wolf, RC | 1 |
| Flechtenmacher, C | 1 |
| Eisenbach, C | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Case, M | 1 |
| Campos, RN | 1 |
| Costa, LF | 1 |
| Bio, DS | 1 |
| Soeiro de Souza, MG | 1 |
| Garcia, CR | 1 |
| Wang, Z | 3 |
| Serrano, MB | 3 |
| Kálmán, J | 2 |
| Stedman, M | 1 |
| Pettinati, HM | 1 |
| Kotz, M | 1 |
| Raines, S | 1 |
| Steckert, AV | 3 |
| Mina, F | 1 |
| Dal-Pizzol, F | 4 |
| Applebaum, J | 2 |
| Gaiduk, Y | 1 |
| Sharony, L | 1 |
| Mishory, A | 1 |
| Podberezsky, A | 1 |
| Kumar, A | 1 |
| Gupta, M | 1 |
| Jiloha, RC | 1 |
| Youakim, JM | 1 |
| Tiller, JM | 1 |
| Yang, R | 1 |
| Ibrahim, L | 2 |
| Newberg, A | 1 |
| Kronstein, P | 1 |
| Khalife, S | 2 |
| Kammerer, WA | 1 |
| Quezado, Z | 1 |
| Williams, JM | 1 |
| Gandhi, KK | 1 |
| Benowitz, NL | 1 |
| Tsai, HC | 1 |
| Conroy, CM | 1 |
| West, AE | 2 |
| Celio, CI | 2 |
| Henry, DB | 4 |
| Pavuluri, MN | 11 |
| Parnes, S | 1 |
| Carbray, JA | 4 |
| Mohammed, T | 1 |
| Janicak, PG | 4 |
| Sweeney, JA | 5 |
| Pizzarello, S | 1 |
| Kupka, RW | 3 |
| Berwaerts, J | 1 |
| Lane, R | 1 |
| Nuamah, IF | 1 |
| Lim, P | 1 |
| Remmerie, B | 1 |
| Hough, DW | 1 |
| Young, L | 1 |
| Coffey, BJ | 1 |
| Ventriglio, A | 1 |
| Vincenti, A | 1 |
| Centorrino, F | 3 |
| Talamo, A | 1 |
| Fitzmaurice, G | 1 |
| Mesquita, J | 1 |
| Cepa, S | 1 |
| Silva, L | 1 |
| Machado, A | 1 |
| Stewart, JD | 1 |
| Horvath, R | 1 |
| Baruffini, E | 1 |
| Ferrero, I | 1 |
| Bulst, S | 1 |
| Watkins, PB | 1 |
| Fontana, RJ | 1 |
| Day, CP | 1 |
| Chinnery, PF | 1 |
| Savitz, JB | 1 |
| Bogers, W | 1 |
| Roiser, JP | 1 |
| Neumeister, A | 1 |
| Marrett, S | 1 |
| Henn, F | 1 |
| Charney, DS | 2 |
| Tarr, GP | 1 |
| Weiss, SR | 4 |
| Brandt, HM | 1 |
| Popish, SJ | 1 |
| Lott, RS | 1 |
| Shimshoni, JA | 1 |
| Basselin, M | 2 |
| Li, LO | 2 |
| Coleman, RA | 2 |
| Rapoport, SI | 5 |
| Modi, HR | 2 |
| Berle, JØ | 1 |
| Solberg, DK | 1 |
| Spigset, O | 1 |
| Wisner, KL | 6 |
| Leckman-Westin, E | 1 |
| Finnerty, M | 2 |
| Essock, SM | 1 |
| Trojak, B | 1 |
| de la Gastine, B | 1 |
| Dollfus, S | 2 |
| Al Jurdi, R | 1 |
| Gildengers, A | 1 |
| Greenberg, RL | 1 |
| Tenhave, T | 1 |
| Mulsant, B | 1 |
| Gupta, A | 1 |
| Schulze, TG | 2 |
| Nagarajan, V | 1 |
| Akula, N | 2 |
| Corona, W | 1 |
| Jiang, XY | 1 |
| Hunter, N | 1 |
| McMahon, FJ | 2 |
| Detera-Wadleigh, SD | 1 |
| Barbosa, FJ | 1 |
| Hesse, B | 1 |
| de Almeida, RB | 1 |
| Baretta, IP | 1 |
| Boerngen-Lacerda, R | 1 |
| Andreatini, R | 1 |
| Marcus, R | 1 |
| Khan, A | 1 |
| Rollin, L | 1 |
| Morris, B | 1 |
| Timko, K | 1 |
| Carson, W | 1 |
| Savoja, V | 1 |
| Sani, G | 1 |
| Kotzalidis, GD | 1 |
| De Rossi, P | 1 |
| Stefani, S | 1 |
| Pancheri, L | 1 |
| Santucci, C | 1 |
| Roma, P | 1 |
| Ferracuti, S | 1 |
| Simonetti, A | 1 |
| Ambrosi, E | 1 |
| Comparelli, A | 1 |
| Manfredi, G | 1 |
| Tatarelli, R | 1 |
| Angeletti, G | 1 |
| Girardi, P | 1 |
| Guillaume, S | 1 |
| Auclair, C | 1 |
| Li, SC | 1 |
| Aggarwal, SK | 1 |
| De Dios, C | 1 |
| Fudio, S | 1 |
| Lorenzo, A | 1 |
| Passarotti, AM | 4 |
| Lu, LH | 1 |
| Hellmund, G | 1 |
| Andersen, PK | 1 |
| Sachs, GS | 16 |
| Chappell, PB | 1 |
| Gurtovaya, O | 1 |
| Vanderburg, DG | 3 |
| Kasuba, B | 1 |
| Currier, D | 1 |
| Grunebaum, MF | 1 |
| Sullivan, GM | 1 |
| Harkavy-Friedman, J | 1 |
| Parsey, RV | 1 |
| Liu, HY | 1 |
| Potter, MP | 1 |
| Woodworth, KY | 1 |
| Yorks, DM | 1 |
| Petty, CR | 1 |
| Wozniak, JR | 1 |
| Faraone, SV | 2 |
| Biederman, J | 3 |
| Karayal, ON | 4 |
| Pappadopulos, E | 1 |
| Siu, CO | 1 |
| Meltzer, HY | 3 |
| Bonaccorso, S | 1 |
| Bobo, WV | 1 |
| Chen, Y | 1 |
| Jayathilake, K | 2 |
| Nadkarni, A | 1 |
| Oldham, M | 1 |
| Howard, M | 1 |
| Lazar, HL | 1 |
| Berenbaum, I | 1 |
| Schilbach, L | 1 |
| Weiss, PH | 1 |
| Kuhn, J | 1 |
| Timmermann, L | 1 |
| Klosterkötter, J | 1 |
| Huff, W | 1 |
| Osborn, D | 2 |
| Ellis, JA | 2 |
| Wegbreit, E | 3 |
| Stevens, MC | 2 |
| Gatz, JL | 1 |
| Jacob, J | 1 |
| Wang, ZF | 1 |
| Fessler, EB | 1 |
| Salsano, E | 1 |
| Gambini, O | 1 |
| Giovagnoli, AR | 1 |
| Farina, L | 1 |
| Uziel, G | 1 |
| Pareyson, D | 1 |
| Chung, MY | 1 |
| Kim, DH | 1 |
| Ahn, YM | 1 |
| Kim, JG | 1 |
| Paik, KC | 1 |
| Weinstein, SM | 1 |
| Henry, D | 1 |
| Vasudev, A | 1 |
| Watson, S | 1 |
| Hayes, J | 2 |
| Prah, P | 1 |
| Nazareth, I | 1 |
| Petersen, I | 1 |
| Chen, DT | 1 |
| Jiang, X | 1 |
| Shugart, YY | 1 |
| Wendland, JR | 1 |
| Steele, CJ | 1 |
| Kassem, L | 1 |
| Park, JH | 1 |
| Chatterjee, N | 1 |
| Jamain, S | 1 |
| Cheng, A | 1 |
| Muglia, P | 1 |
| Cichon, S | 1 |
| Nöthen, MM | 1 |
| Rietschel, M | 1 |
| Farmer, A | 1 |
| McGuffin, P | 1 |
| Craig, I | 1 |
| Lewis, C | 1 |
| Hosang, G | 1 |
| Cohen-Woods, S | 1 |
| Vincent, JB | 1 |
| Kennedy, JL | 1 |
| Strauss, J | 1 |
| Chakraborty, S | 1 |
| Chakraborty, J | 1 |
| Mandal, S | 1 |
| Ghosal, MK | 1 |
| Leon, AC | 3 |
| Solomon, DA | 4 |
| Li, C | 1 |
| Fiedorowicz, JG | 1 |
| Endicott, J | 1 |
| Keller, MB | 2 |
| Szegedi, A | 1 |
| Stet, L | 1 |
| Mackle, M | 1 |
| Zhao, J | 1 |
| Panagides, J | 1 |
| Nourry, A | 1 |
| Geller, B | 1 |
| Joshi, P | 3 |
| Emslie, G | 3 |
| Bolhofner, K | 1 |
| Wolf, DV | 1 |
| Ryan, ND | 3 |
| Tillman, R | 2 |
| Lavori, P | 2 |
| Lin, YH | 1 |
| Chien, YL | 1 |
| Bocchetta, A | 1 |
| Siddu, A | 1 |
| Sardu, C | 1 |
| Sarnicola, A | 1 |
| Martinelli, V | 1 |
| Pinheiro, RM | 1 |
| de Lima, MN | 1 |
| Garcia, VA | 1 |
| Presti-Torres, J | 1 |
| Hallmenschlager, LH | 1 |
| Alcalde, LA | 1 |
| Roesler, R | 1 |
| Schröder, N | 1 |
| Huang, TL | 1 |
| Hung, YY | 1 |
| Lee, CT | 1 |
| Chen, RF | 1 |
| Gould, TD | 4 |
| Can, A | 1 |
| Gottesman, II | 1 |
| Dickstein, DP | 1 |
| Fitzgerald, JM | 2 |
| Kuo, YL | 1 |
| Tsai, HF | 1 |
| Lai, MC | 1 |
| Katagiri, H | 1 |
| Takita, Y | 1 |
| Higuchi, T | 2 |
| Takahashi, M | 1 |
| Hsu, MC | 1 |
| Yeh, IN | 1 |
| Kuo, CC | 1 |
| da-Rosa, DD | 1 |
| Ornell, F | 1 |
| Nandam, A | 1 |
| Teng, PR | 1 |
| Shen, TY | 1 |
| Lai, TJ | 1 |
| Prohaska, ES | 1 |
| Muzyk, AJ | 1 |
| Rivelli, SK | 1 |
| Bhalerao, S | 1 |
| Seyfried, LS | 1 |
| Chiang, C | 1 |
| Kavanagh, J | 1 |
| Kales, HC | 1 |
| Blake, T | 1 |
| Bigdelou, G | 2 |
| Hung, WC | 1 |
| Hsieh, MH | 1 |
| Estabrook, KR | 1 |
| Pheister, M | 1 |
| Chen, CH | 1 |
| Adragna, MS | 1 |
| Strawn, JR | 1 |
| Patel, NC | 3 |
| Chu, WJ | 1 |
| Adler, CM | 4 |
| Kim, MJ | 1 |
| Bryan, HS | 1 |
| Alfieri, DC | 1 |
| Blom, TJ | 1 |
| Nandagopal, JJ | 1 |
| Strakowski, SM | 12 |
| DelBello, MP | 8 |
| Chung, AK | 1 |
| Weisler, R | 2 |
| Thompson, P | 1 |
| Chang, X | 1 |
| Mintz, J | 9 |
| Catanesi, R | 1 |
| Carabellese, F | 1 |
| La Tegola, D | 1 |
| Alfarano, E | 1 |
| Aldemir, E | 2 |
| Arici, Ş | 2 |
| Umul, M | 2 |
| Öztürk, U | 1 |
| Aydin, HH | 2 |
| Çelebisoy, M | 2 |
| Vahip, S | 5 |
| Ahearn, EP | 2 |
| Hertzberg, M | 1 |
| Cornette, M | 1 |
| Suvalsky, L | 1 |
| Cooley-Olson, D | 1 |
| Swanlund, J | 1 |
| Eickhoff, J | 1 |
| Becker, T | 1 |
| Krahn, D | 1 |
| Stringaris, A | 1 |
| Luby, J | 2 |
| Sheehan, DV | 1 |
| Harnett-Sheehan, K | 1 |
| Hidalgo, RB | 1 |
| Janavs, J | 1 |
| Amado, D | 1 |
| de Bartolomeis, A | 1 |
| Yazıcı, O | 1 |
| Cakır, S | 1 |
| Brutsche, N | 1 |
| Franco-Chaves, J | 1 |
| Mathews, D | 1 |
| Marquardt, CA | 1 |
| Cassarly, C | 1 |
| Ghedim, FV | 1 |
| Fraga, Dde B | 1 |
| Deroza, PF | 1 |
| Oliveira, MB | 1 |
| Budni, J | 1 |
| Gundapaneni, BK | 1 |
| O'Gorman, C | 2 |
| Feier, G | 1 |
| Bavaresco, DV | 1 |
| Morais, MO | 1 |
| Hung Chi, M | 1 |
| Hua Chang, H | 1 |
| Chou, KR | 1 |
| Chun Tsai, H | 1 |
| Kuang Yang, Y | 1 |
| See Chen, P | 1 |
| Pae, CU | 3 |
| Masand, PS | 1 |
| Mandel, FS | 1 |
| Tensho, M | 1 |
| Udd, M | 1 |
| Kamalinia, G | 1 |
| Ghaeli, P | 1 |
| Abedi, N | 1 |
| Sharifi, V | 1 |
| Zahiroddin, A | 1 |
| Amini, M | 1 |
| Rouini, MR | 1 |
| Mohammadpoor, AH | 1 |
| Fein, EB | 1 |
| Obral, S | 1 |
| van Enkhuizen, J | 1 |
| Kooistra, K | 1 |
| Kolluri, S | 2 |
| Bachinsky, M | 2 |
| Cavus, I | 2 |
| Edman, S | 1 |
| Akdeniz, F | 3 |
| Altay, AB | 1 |
| Kulkarni, J | 2 |
| Filia, S | 1 |
| Berk, L | 1 |
| Filia, K | 1 |
| Dodd, S | 3 |
| de Castella, A | 1 |
| Brnabic, AJ | 1 |
| Lowry, AJ | 1 |
| Kelin, K | 2 |
| Montgomery, W | 2 |
| Fitzgerald, PB | 2 |
| Fraga, DB | 1 |
| De Hert, M | 1 |
| Rahman, Z | 2 |
| Fyans, P | 2 |
| Eudicone, JM | 1 |
| Marler, SV | 2 |
| Baker, RA | 2 |
| Carlson, BX | 2 |
| Swartz, HA | 1 |
| Ammerman, D | 1 |
| Hunsberger, JG | 1 |
| Krępuła, K | 1 |
| Bidzińska-Speichert, B | 1 |
| Lenarcik, A | 1 |
| Tworowska-Bardzińska, U | 1 |
| Taha, AY | 1 |
| Bialer, M | 3 |
| Diler, RS | 1 |
| Ladouceur, CD | 1 |
| Segreti, A | 1 |
| Almeida, JR | 1 |
| Phillips, ML | 1 |
| Pan, LA | 1 |
| Blader, JC | 1 |
| Boudebesse, C | 1 |
| Labiner, DM | 1 |
| Goodwin, G | 3 |
| Hainsworth, J | 1 |
| Van der Gucht, E | 1 |
| Young, H | 1 |
| Jain, V | 1 |
| Swartz, CM | 2 |
| Bowley, MP | 1 |
| Ongür, D | 1 |
| Price, JL | 1 |
| Lalaguna, B | 1 |
| Pérez-Heredia, JL | 1 |
| Fernandez-Corres, B | 1 |
| Gutierrez, M | 1 |
| Micó, JA | 1 |
| Liddle, PF | 3 |
| Lane, C | 1 |
| Stoessl, AJ | 1 |
| Sossi, V | 2 |
| Ruth, TJ | 3 |
| Schwiers, ML | 1 |
| Rosenberg, HL | 1 |
| Weller, EB | 2 |
| Carlson, GA | 1 |
| Sachs, G | 4 |
| Frazier, JA | 1 |
| Tracy, K | 2 |
| Weller, RA | 1 |
| Cordeiro, Q | 1 |
| Vallada, H | 1 |
| Scott, J | 4 |
| Pope, M | 2 |
| Wu, RH | 2 |
| O'Donnell, T | 3 |
| Ulrich, M | 3 |
| Asghar, SJ | 4 |
| Hanstock, CC | 3 |
| Robillard, M | 1 |
| Conn, DK | 1 |
| Gurvich, N | 1 |
| Klein, PS | 1 |
| Baldwin, D | 1 |
| Licht, R | 1 |
| Oluboka, OJ | 2 |
| Bird, DC | 2 |
| Kutcher, S | 1 |
| Kusumakar, V | 6 |
| Shamir, A | 1 |
| Willmroth, F | 2 |
| Spleiss, O | 1 |
| Wiesmann, K | 1 |
| Moser, D | 1 |
| Atmanspacher, R | 1 |
| van Calker, D | 4 |
| Reischies, FM | 2 |
| Hartikainen, J | 2 |
| Berghöfer, AM | 1 |
| Swann, AC | 21 |
| Sommerville, KW | 3 |
| Haslam, D | 2 |
| de Lima, M | 1 |
| Taneli, F | 1 |
| Noyan, A | 1 |
| Yüncü, Z | 1 |
| Grossman, F | 3 |
| Augustyns, I | 1 |
| Berghöfer, A | 2 |
| Wiebe, EJ | 1 |
| Ernst, CL | 1 |
| Isoherranen, N | 1 |
| Yagen, B | 1 |
| Bown, CD | 3 |
| Wang, JF | 4 |
| Young, LT | 7 |
| Mancini, DA | 3 |
| McCann, S | 2 |
| Srinivasan, J | 3 |
| Makela, EH | 1 |
| Griffith, RK | 1 |
| Alderfer, BS | 1 |
| Allen, MH | 4 |
| Gitlin, MJ | 3 |
| Maguire, GA | 1 |
| Phillips, G | 1 |
| Jagadheesan, K | 3 |
| Duggal, H | 1 |
| Gupta, S | 1 |
| Basu, S | 1 |
| Ranjan, S | 2 |
| Sandil, R | 1 |
| Akhtar, S | 1 |
| Nizamie, SH | 2 |
| Revicki, DA | 2 |
| Paramore, LC | 1 |
| Shulman, KI | 3 |
| Rochon, P | 2 |
| Sykora, K | 2 |
| Anderson, G | 2 |
| Mamdani, M | 2 |
| Bronskill, S | 1 |
| Tran, CT | 1 |
| Gnanadesikan, M | 1 |
| Freeman, MP | 4 |
| Gelenberg, AJ | 1 |
| Ameen, S | 1 |
| Dutta, S | 2 |
| Petty, F | 9 |
| Wassef, A | 2 |
| Risch, CS | 1 |
| Nemeroff, CB | 5 |
| Evans, DL | 4 |
| Wozniak, PJ | 7 |
| Sethuraman, G | 2 |
| Hume, JH | 2 |
| Kromelis, M | 2 |
| Weinberg, WA | 2 |
| Sethi, MA | 1 |
| Mehta, R | 1 |
| Devanand, DP | 1 |
| Binder, C | 2 |
| Riccardelli, R | 2 |
| Leblanc, J | 2 |
| Connolly, M | 2 |
| Carandang, CG | 1 |
| Maxwell, DJ | 1 |
| Robbins, DR | 1 |
| Oesterheld, JR | 1 |
| Altshuler, L | 2 |
| Zajecka, J | 1 |
| Schuh, LM | 3 |
| Risser, RC | 3 |
| Brown, E | 3 |
| Baker, RW | 7 |
| Kelleher, JP | 1 |
| Berry, JM | 1 |
| Salvatore, P | 1 |
| Eakin, M | 1 |
| Fogarty, KV | 1 |
| Fellman, V | 1 |
| Yang, MJ | 1 |
| Bräunig, P | 4 |
| Krüger, S | 6 |
| Gracious, BL | 5 |
| Youngstrom, EA | 9 |
| Stansbrey, RJ | 3 |
| Reed, MD | 4 |
| Demeter, CA | 6 |
| Branicky, LA | 1 |
| Fisher, KE | 1 |
| Iwazaki, H | 1 |
| Nonomura, T | 1 |
| Iyo, M | 1 |
| Elgudin, L | 1 |
| Hall, Y | 1 |
| Schubert, D | 1 |
| Einat, H | 4 |
| Yuan, P | 3 |
| Du, J | 3 |
| Basile, VS | 1 |
| Sokolski, KN | 3 |
| Denson, TF | 2 |
| Dienes, K | 1 |
| Blasey, C | 1 |
| Ketter, T | 1 |
| Steiner, H | 3 |
| Baker, JD | 2 |
| Tavakoli, SA | 1 |
| Arguisola, MS | 1 |
| Davanzo, P | 1 |
| Gunderson, B | 1 |
| Belin, T | 1 |
| Pataki, C | 1 |
| Ott, D | 1 |
| Emley-Akanno, C | 1 |
| Montazeri, N | 1 |
| Oppenheimer, J | 1 |
| Strober, M | 2 |
| Goodwin, FK | 4 |
| Fireman, B | 1 |
| Simon, GE | 1 |
| Hunkeler, EM | 1 |
| Revicki, D | 1 |
| Sattar, SP | 1 |
| Ramaswamy, S | 1 |
| Bhatia, SC | 1 |
| Campanella, D | 1 |
| Matera, V | 1 |
| Gambi, F | 1 |
| La Rovere, R | 1 |
| Sepede, G | 1 |
| Grimaldi, MR | 1 |
| Pacilli, AM | 1 |
| Salerno, RM | 1 |
| Ferro, FM | 1 |
| Buka, R | 1 |
| Hille, R | 1 |
| McCormack, P | 1 |
| Gagliardi, JP | 1 |
| Krishnan, KR | 1 |
| Dittmann, S | 1 |
| Raja, M | 1 |
| Azzoni, A | 1 |
| Benabarre, A | 2 |
| Reinares, M | 1 |
| Comes, M | 2 |
| Corbella, B | 1 |
| Suzuki, H | 2 |
| Kimura, M | 2 |
| McElroy, S | 2 |
| Keck, P | 2 |
| Harris, M | 1 |
| Chandran, S | 1 |
| Chakraborty, N | 1 |
| Healy, D | 1 |
| Grof, P | 1 |
| Seman, C | 1 |
| Phrolov, K | 1 |
| Levine, J | 4 |
| Miodovnick, H | 1 |
| Aliev, NA | 1 |
| Berigan, T | 1 |
| Coffey, B | 1 |
| Henry, CA | 1 |
| Zamvil, LS | 1 |
| Lam, C | 1 |
| Rosenquist, KJ | 1 |
| Fawcett, J | 4 |
| Yerevanian, BI | 3 |
| Koek, RJ | 3 |
| Feusner, JD | 1 |
| Roepke, S | 1 |
| Treudler, R | 1 |
| Anghelescu, I | 1 |
| Orfanos, CE | 1 |
| Tebbe, B | 1 |
| Burt, VK | 2 |
| Rasgon, N | 1 |
| Yonkers, KA | 1 |
| Stowe, Z | 1 |
| Leibenluft, E | 2 |
| Cohen, L | 1 |
| Manber, R | 1 |
| Viguera, A | 1 |
| Chengappa, KN | 6 |
| Kupfer, DJ | 5 |
| Feldman, PD | 2 |
| Evans, AR | 1 |
| Mullen, JA | 1 |
| Devine, NA | 1 |
| Sweitzer, DE | 1 |
| Brunello, N | 1 |
| Bridle, C | 1 |
| Palmer, S | 2 |
| Bagnall, AM | 1 |
| Darba, J | 1 |
| Duffy, S | 2 |
| Sculpher, M | 1 |
| Riemsma, R | 1 |
| Mashiko, H | 1 |
| Kurita, M | 1 |
| Shirakawa, H | 1 |
| Ohtomo, K | 1 |
| Hashimoto, M | 1 |
| Miyashita, N | 1 |
| Niwa, S | 1 |
| Myers, JE | 1 |
| Xie, Y | 1 |
| Su, Y | 1 |
| Ryder, J | 1 |
| Fox, N | 1 |
| Solenberg, P | 1 |
| Brune, K | 1 |
| Paul, S | 1 |
| Zhou, Y | 1 |
| Liu, F | 1 |
| Ni, B | 1 |
| Kablinger, AS | 1 |
| Czerwinski, WP | 1 |
| Minagar, A | 1 |
| Green, B | 1 |
| Payne, JL | 1 |
| Singh, J | 3 |
| Quiroz, JA | 1 |
| Denicoff, KD | 4 |
| Lewis, FT | 1 |
| Kass, E | 1 |
| Klein, RM | 1 |
| Pardo, TB | 1 |
| Hsu, DJ | 1 |
| Stahl, SM | 1 |
| Daniel, DG | 1 |
| Kochan, LD | 1 |
| Silverstone, P | 2 |
| Lacroix, D | 1 |
| van Schaick, E | 1 |
| Vermeulen, A | 1 |
| Alexander, J | 1 |
| Ogden, CA | 1 |
| Rich, ME | 1 |
| Schork, NJ | 1 |
| Paulus, MP | 1 |
| Lohr, JB | 1 |
| Kuczenski, R | 1 |
| Niculescu, AB | 1 |
| Adler, C | 2 |
| State, RC | 1 |
| DeAntonio, M | 1 |
| Hwang, S | 1 |
| Salerian, AJ | 1 |
| Jurata, LW | 1 |
| Bukhman, YV | 1 |
| Charles, V | 1 |
| Capriglione, F | 1 |
| Bullard, J | 1 |
| Lemire, AL | 1 |
| Mohammed, A | 1 |
| Pham, Q | 1 |
| Laeng, P | 1 |
| Brockman, JA | 1 |
| Altar, CA | 1 |
| Parow, A | 1 |
| Hirashima, F | 1 |
| Demopulos, C | 3 |
| Stoll, AL | 6 |
| Namjoshi, MA | 1 |
| Risser, R | 2 |
| Shi, L | 2 |
| Breier, A | 3 |
| Baldassano, CF | 3 |
| Ballas, CA | 1 |
| O'Reardon, JP | 1 |
| Thakur, A | 2 |
| Jairam, R | 1 |
| Srinath, S | 1 |
| Girimaji, SC | 1 |
| Seshadri, SP | 1 |
| Becker, OV | 1 |
| Marsh, WK | 1 |
| Glenn, T | 1 |
| Oral, ET | 2 |
| Hanusa, BH | 1 |
| Peindl, KS | 2 |
| Perel, JM | 2 |
| Boufidou, F | 1 |
| Nikolaou, C | 1 |
| Alevizos, B | 1 |
| Liappas, IA | 1 |
| Christodoulou, GN | 1 |
| Jacquet, H | 1 |
| Demily, C | 1 |
| Houy, E | 1 |
| Hecketsweiler, B | 1 |
| Bou, J | 1 |
| Raux, G | 1 |
| Lerond, J | 1 |
| Allio, G | 1 |
| Haouzir, S | 1 |
| Tillaux, A | 1 |
| Bellegou, C | 1 |
| Fouldrin, G | 1 |
| Delamillieure, P | 1 |
| Ménard, JF | 1 |
| D'Amato, T | 1 |
| Petit, M | 1 |
| Thibaut, F | 1 |
| Frébourg, T | 1 |
| Campion, D | 1 |
| Prapotnik, M | 1 |
| Di Pauli, J | 1 |
| Vetter, Z | 1 |
| König, P | 1 |
| Waschgler, R | 1 |
| Sundararajan, V | 1 |
| Jainer, AK | 1 |
| Konarski, JZ | 2 |
| Mullen, J | 3 |
| Vågerö, AM | 1 |
| Meinhold, JM | 1 |
| Lieberman, DZ | 1 |
| Akimoto, T | 1 |
| Schatzberg, AF | 1 |
| Sampson, G | 1 |
| Naylor, MW | 2 |
| Niskala Apps, JA | 1 |
| Trzepacz, PT | 1 |
| Watkin, JG | 1 |
| Kimmel, RJ | 1 |
| Irwin, SA | 1 |
| Meyer, JM | 1 |
| Woo, JM | 1 |
| Lee, JS | 1 |
| Choi, SK | 1 |
| Paik, IH | 1 |
| Carmody, T | 1 |
| Rush, AJ | 6 |
| Salloum, IM | 3 |
| Cornelius, JR | 3 |
| Daley, DC | 2 |
| Kirisci, L | 3 |
| Himmelhoch, JM | 1 |
| Thase, ME | 4 |
| Laghate, VD | 1 |
| Gupta, SB | 1 |
| Kim, H | 2 |
| Arban, R | 1 |
| Maraia, G | 1 |
| Brackenborough, K | 1 |
| Winyard, L | 1 |
| Wilson, A | 1 |
| Gerrard, P | 1 |
| Large, C | 1 |
| Eickholt, BJ | 1 |
| Towers, GJ | 1 |
| Ryves, WJ | 1 |
| Eikel, D | 1 |
| Adley, K | 1 |
| Ylinen, LM | 1 |
| Chadborn, NH | 1 |
| Nau, H | 1 |
| Friedrich, MJ | 1 |
| Nejad, AG | 1 |
| Toofani, K | 1 |
| Hantouche, EG | 1 |
| Lancrenon, S | 1 |
| Chatenêt-Duchêne, L | 1 |
| Mithat, B | 1 |
| Alpaslan, T | 1 |
| Bulent, C | 1 |
| Cengiz, T | 1 |
| Curtis, V | 1 |
| Davis, LL | 4 |
| Bartolucci, A | 1 |
| Rapport, DJ | 8 |
| Jackson, K | 2 |
| Sheikh, R | 1 |
| Kang, J | 1 |
| Weller, R | 1 |
| Witschy, JK | 1 |
| Winter, AS | 1 |
| Gajwani, P | 4 |
| Stansbrey, R | 2 |
| Gill, SS | 1 |
| Marras, C | 1 |
| Wodchis, WP | 1 |
| Lee, PE | 1 |
| Rana, M | 1 |
| Khanzode, L | 1 |
| Karnik, N | 1 |
| Saxena, K | 2 |
| Williams, R | 2 |
| Cates, M | 1 |
| Curtis, D | 1 |
| Kerr, M | 1 |
| Rahman, M | 1 |
| Haider, N | 1 |
| Fairbanks, L | 1 |
| Elman, S | 2 |
| Bitran, J | 1 |
| Labarca, R | 1 |
| Saad, M | 2 |
| Leverich, G | 2 |
| Junig, JT | 1 |
| Lehrmann, JA | 1 |
| Zhu, B | 1 |
| Tunis, SL | 1 |
| Zhao, Z | 1 |
| Lage, MJ | 1 |
| Cheng, L | 2 |
| Lumb, M | 1 |
| Polgár, L | 1 |
| Mudge, AW | 2 |
| Weisler, RH | 3 |
| Palmer, C | 1 |
| Vajda, FJ | 1 |
| Solinas, C | 1 |
| Willson, MC | 2 |
| Bell, EC | 2 |
| Dave, S | 2 |
| Parikh, S | 2 |
| McIntyre, R | 1 |
| Baruch, P | 1 |
| Daigneault, A | 1 |
| Milev, R | 1 |
| Gorman, CP | 1 |
| Collins, MA | 3 |
| Forsthoff, A | 1 |
| Muzina, D | 1 |
| Amann, B | 5 |
| Chungh, DS | 1 |
| Kim, BN | 1 |
| Cho, SC | 1 |
| Howland, RH | 1 |
| Hahn, CG | 1 |
| Wang, HY | 1 |
| Koneru, R | 1 |
| Levinson, DF | 1 |
| Friedman, E | 1 |
| Andrews, G | 1 |
| Page, AC | 1 |
| Longo, LP | 1 |
| Douaihy, A | 2 |
| Kelly, TM | 2 |
| Wilman, AH | 1 |
| Kaur, S | 1 |
| Sassi, RB | 1 |
| Axelson, D | 1 |
| Nicoletti, M | 1 |
| Monkul, ES | 1 |
| Hatch, JP | 2 |
| Keshavan, MS | 1 |
| Ryan, N | 1 |
| Barzman, DH | 3 |
| McConville, BJ | 1 |
| Masterson, B | 1 |
| Moore, K | 1 |
| Kahwaty, AM | 1 |
| Nelson, D | 1 |
| Reynolds, MF | 2 |
| Semion, K | 1 |
| Dorsey, J | 1 |
| Bourgeois, J | 1 |
| Danielyan, A | 1 |
| Adam, MJ | 1 |
| Solomons, K | 1 |
| Chinnapalli, M | 1 |
| Dhondt, A | 1 |
| Verstraete, A | 1 |
| Vandewoude, K | 1 |
| Segers, H | 1 |
| Eloot, S | 1 |
| Decruyenaere, J | 1 |
| Vanholder, R | 1 |
| Shelton, MD | 3 |
| Kruszewski, SP | 1 |
| Paczynski, R | 1 |
| Chisholm, D | 2 |
| van Ommeren, M | 1 |
| Ayuso-Mateos, JL | 1 |
| Saxena, S | 1 |
| Miklowitz, DA | 1 |
| Endick, CJ | 1 |
| Chessick, CA | 1 |
| Wisniewski, SR | 1 |
| Miyahara, S | 1 |
| Sagduyu, K | 1 |
| Weis, MT | 1 |
| Rosenberger, TA | 1 |
| Karama, S | 1 |
| Lal, S | 1 |
| Sheehan, NL | 1 |
| Brouillette, MJ | 1 |
| Delisle, MS | 1 |
| Allan, J | 1 |
| Tsivkin, R | 1 |
| Saito, E | 1 |
| Kafantaris, V | 1 |
| Raskin, S | 1 |
| Teitelbaum, A | 1 |
| Zislin, J | 1 |
| Durst, R | 1 |
| Chiu, CC | 1 |
| Su, KP | 1 |
| Eden Evins, A | 2 |
| Nierenberg, A | 1 |
| Culhane, MA | 1 |
| Eisner, L | 1 |
| Lamla, U | 1 |
| Marcushen, M | 1 |
| Wark, HJ | 1 |
| Whipkey, RE | 1 |
| Phillips, RA | 1 |
| Nadel, ES | 1 |
| Brown, DF | 1 |
| Cohen, LS | 3 |
| McLaughlin, WL | 1 |
| Adams, JM | 2 |
| Hwang, CH | 2 |
| Hall, JE | 2 |
| Goldapple, K | 1 |
| Mayberg, HS | 1 |
| Schenkel, LS | 2 |
| Aryal, S | 1 |
| Harral, EM | 2 |
| Hill, SK | 1 |
| Herbener, ES | 2 |
| Ceresér, KM | 3 |
| Martins, MR | 4 |
| Antai-Otong, D | 1 |
| Klipstein, KG | 1 |
| Lemaire, X | 1 |
| Corne, P | 1 |
| Jonquet, O | 1 |
| Goodnick, PJ | 1 |
| Young, T | 1 |
| Tadke, RR | 1 |
| Suryavanshi, P | 1 |
| Stanford, KE | 2 |
| Nelson, E | 2 |
| Yovel, I | 1 |
| Culhane, M | 1 |
| Ogutha, J | 1 |
| Grandin, LD | 1 |
| McAllister-Williams, RH | 1 |
| Fenn, HH | 2 |
| Sommer, BR | 1 |
| Alldredge, B | 1 |
| Daban, C | 1 |
| Karren, NU | 1 |
| Hellings, JA | 1 |
| Bora, E | 1 |
| Ginsberg, LD | 1 |
| Simeonova, D | 1 |
| Nasrallah, HA | 4 |
| Kalali, AH | 2 |
| Datta, SS | 1 |
| Kumar, S | 1 |
| Saraga, M | 1 |
| Preisig, M | 1 |
| Zullino, DF | 1 |
| Rao, S | 1 |
| Fleisher, CA | 1 |
| Mezzacappa, E | 1 |
| Gonzalez-Heydrich, J | 1 |
| Molay, F | 1 |
| Ozdemir, H | 2 |
| Cetinkaya, S | 1 |
| Parmaksiz, S | 1 |
| Belli, H | 1 |
| Poyraz, AK | 1 |
| Tezcan, E | 2 |
| Ogur, E | 2 |
| Petronilho, FC | 1 |
| Bardini, K | 1 |
| Ahl, J | 1 |
| Meyers, AL | 1 |
| Kaiser, CJ | 1 |
| Peng, GS | 1 |
| Li, G | 1 |
| Yang, S | 1 |
| Wang, CC | 1 |
| Wilson, B | 1 |
| Yumru, M | 1 |
| Savas, HA | 1 |
| Kaya, MC | 1 |
| Selek, S | 1 |
| Savas, E | 1 |
| Atagun, I | 1 |
| Gobbi, G | 1 |
| Gaudreau, PO | 1 |
| Leblanc, N | 1 |
| Fazzio, L | 1 |
| Mah, L | 1 |
| Duan, YF | 1 |
| Schneck, CD | 1 |
| Mann, JI | 1 |
| Salvi, V | 1 |
| Mancini, M | 1 |
| Bogetto, F | 1 |
| Yildirim, H | 1 |
| Rubenfaer, LM | 1 |
| Redmond, JR | 1 |
| Jamison, KL | 1 |
| Roy Chengappa, KN | 1 |
| Schwarzman, LK | 1 |
| Hulihan, JF | 1 |
| Xiang, J | 1 |
| Rosenthal, NR | 1 |
| Bidzan, L | 1 |
| Chae, JH | 1 |
| Jun, TY | 1 |
| Butters, MA | 1 |
| Rogers, JC | 1 |
| Holm, MB | 1 |
| Bhalla, RK | 1 |
| Seligman, K | 1 |
| Dew, MA | 1 |
| Kilbourne, AM | 1 |
| Post, EP | 1 |
| Zeber, JE | 1 |
| Copeland, LA | 1 |
| Good, CB | 1 |
| Pincus, HA | 2 |
| Reeves, RR | 3 |
| Burke, RS | 1 |
| Parker, JD | 1 |
| Carlson, T | 1 |
| Reynolds, CA | 1 |
| Caplan, R | 1 |
| Roberts-Thomson, KC | 1 |
| Teo, KS | 1 |
| Young, GD | 1 |
| Colangelo, E | 1 |
| Manning, JS | 1 |
| Rademacher, J | 1 |
| Stanford, K | 1 |
| Corrêa, C | 1 |
| Amboni, G | 2 |
| Assis, LC | 1 |
| Buckley, PF | 1 |
| Vågerö, M | 3 |
| Fleck, DE | 1 |
| Sussman, N | 1 |
| Jones, M | 1 |
| Adli, M | 1 |
| Berger, M | 3 |
| Bergmann, A | 1 |
| Bschor, T | 1 |
| Falkai, P | 1 |
| Gastpar, M | 1 |
| Laux, G | 1 |
| Müller, WE | 1 |
| Naber, D | 1 |
| Kim, YK | 1 |
| Jung, HG | 1 |
| Myint, AM | 1 |
| Park, SH | 1 |
| Gazalle, FK | 1 |
| Hallal, PC | 1 |
| Tramontina, J | 1 |
| Zanatto, V | 1 |
| Santin, A | 1 |
| Munro, A | 1 |
| Slaney, C | 1 |
| Macdougall, M | 1 |
| Passmore, M | 1 |
| Duffy, A | 1 |
| Teehan, A | 1 |
| Patrick, DM | 1 |
| Prica, C | 1 |
| Kelly, DI | 1 |
| Hynan, LS | 1 |
| Snow, DE | 1 |
| Sureddi, S | 1 |
| Foster, B | 1 |
| Curley, E | 1 |
| Brahm, NC | 1 |
| Gutierres, SL | 1 |
| Carnahan, RM | 1 |
| Kim, SJ | 1 |
| Son, JI | 1 |
| Rowe, MK | 1 |
| Wiest, C | 1 |
| Frazier, TW | 1 |
| Walz, JC | 1 |
| Cacilhas, AA | 1 |
| Tahiroglu, AY | 1 |
| Avci, A | 1 |
| Rosenberg, G | 1 |
| Trimble, M | 1 |
| Senturk, V | 1 |
| Goker, C | 1 |
| Bilgic, A | 1 |
| Olmez, S | 1 |
| Tugcu, H | 1 |
| Oncu, B | 1 |
| Atbasoglu, EC | 1 |
| Drotar, D | 2 |
| Greenley, RN | 1 |
| Stange, J | 1 |
| Vijay, P | 1 |
| Carr, RB | 1 |
| Shrewsbury, K | 1 |
| Rodriguez, LJ | 1 |
| da Rocha, FF | 2 |
| Soares, FM | 1 |
| Correa, H | 2 |
| Schumock, GT | 1 |
| Walton, SM | 1 |
| Gupta, SR | 1 |
| Cramer, JA | 1 |
| Malatynska, E | 1 |
| Pinhasov, A | 1 |
| Crooke, JJ | 1 |
| Smith-Swintosky, VL | 1 |
| Brenneman, DE | 1 |
| Kaye, NS | 1 |
| Graham, J | 1 |
| Roberts, J | 1 |
| Thompson, T | 1 |
| Nanry, K | 1 |
| Feifel, D | 1 |
| Gardner-Schuster, EE | 1 |
| Fallu, A | 1 |
| Binder, CE | 1 |
| Madaan, V | 1 |
| Collins, JC | 1 |
| McFarland, BH | 2 |
| Thanacoody, HK | 1 |
| Prager, P | 1 |
| Winter, HR | 1 |
| DeVane, CL | 2 |
| Figueroa, C | 1 |
| Ennis, DJ | 1 |
| Hamer-Maansson, JE | 1 |
| Davis, PC | 1 |
| Smith, MA | 1 |
| Guelfi, JD | 1 |
| Perdrizet-Chevallier, C | 1 |
| Lorenz, RA | 1 |
| Weinstein, B | 1 |
| de Castella, AR | 1 |
| Brnabic, A | 1 |
| Granger, RE | 1 |
| Khan, AY | 1 |
| Ludvigson, LR | 1 |
| Stewart, M | 1 |
| Gorman, JM | 1 |
| Kamath, J | 1 |
| Temporini, HD | 1 |
| Quarti, S | 1 |
| Pagano, KL | 1 |
| Demartinis, N | 1 |
| Trestman, RL | 1 |
| Soares-Weiser, K | 1 |
| Bravo Vergel, Y | 1 |
| Beynon, S | 1 |
| Dunn, G | 1 |
| Barbieri, M | 1 |
| Gilbody, S | 1 |
| Woolacott, N | 1 |
| Bartolucci, AA | 1 |
| Williford, RB | 1 |
| Lowe, JS | 1 |
| Takano, T | 1 |
| Matsuoka, H | 1 |
| Habermeyer, B | 1 |
| Hess, M | 1 |
| Kozomara-Hocke, P | 1 |
| Mager, R | 1 |
| Kawohl, W | 1 |
| Gálvez-Andres, A | 1 |
| Blasco-Fontecilla, H | 1 |
| González-Parra, S | 1 |
| Molina, JD | 1 |
| Padín, JM | 1 |
| Rodriguez, RH | 1 |
| Iqbal, SU | 1 |
| Cunningham, F | 1 |
| Hamed, A | 1 |
| Kazis, L | 1 |
| Sisk, EC | 1 |
| Han, C | 1 |
| Marks, DM | 1 |
| Patkar, AA | 1 |
| Gilmer, WS | 1 |
| Zablotsky, B | 1 |
| Kelley, ME | 1 |
| Bauer, AD | 1 |
| Fleck, J | 1 |
| Filkowski, MM | 1 |
| Stan, VA | 1 |
| Dunn, RT | 1 |
| Turgut, G | 1 |
| Sengul, C | 1 |
| Alatas, G | 1 |
| Kursunluoglu, R | 1 |
| Oral, T | 1 |
| Turgut, S | 1 |
| Herken, H | 1 |
| Creson, TK | 1 |
| Wu, LJ | 1 |
| Ren, M | 1 |
| Gray, NA | 1 |
| Falke, C | 1 |
| Wei, Y | 1 |
| Blumenthal, R | 1 |
| Zhuo, M | 1 |
| Di-Pietro, PB | 1 |
| Luz, G | 1 |
| Ng, F | 1 |
| Wang, WV | 1 |
| Lubman, DI | 1 |
| Rao, P | 1 |
| Madhav Natu, S | 1 |
| Mati Goel, M | 1 |
| Ali, B | 1 |
| Coconcea, N | 1 |
| Ignacio, RV | 1 |
| Blow, FC | 1 |
| Hays, RW | 1 |
| Cassidy, KA | 1 |
| Meyer, WJ | 1 |
| Townsend, LD | 1 |
| Youngstrom, E | 1 |
| Altamura, AC | 2 |
| Mundo, E | 1 |
| Tacchini, G | 1 |
| Wilting, I | 1 |
| Souverein, PC | 1 |
| Egberts, AC | 1 |
| Rao, JS | 1 |
| Lee, HJ | 1 |
| Preskorn, SH | 1 |
| Hirschfeld, R | 1 |
| Cutler, AJ | 1 |
| Gazda, T | 1 |
| Sarkar, R | 1 |
| Pietsch, R | 1 |
| Hasenclever, D | 1 |
| Denko, T | 1 |
| Rocha, FF | 1 |
| Parsonage, B | 1 |
| Hinds, M | 1 |
| Khan, E | 1 |
| Huggan, P | 1 |
| Celi, L | 1 |
| MacGinley, R | 1 |
| Schollum, J | 1 |
| Walker, R | 1 |
| Banuelos-Arzac, C | 1 |
| Lan, MJ | 1 |
| Dervaux, A | 1 |
| Levasseur, M | 1 |
| Puzyński, S | 2 |
| Kłosiewicz, L | 2 |
| Meldrum, B | 1 |
| Emrich, HM | 8 |
| Günther, R | 1 |
| Dose, M | 2 |
| von Zerssen, D | 5 |
| Soucek, K | 1 |
| Vencovský, E | 2 |
| Zatecká, I | 1 |
| Altmann, H | 1 |
| Uhde, TW | 2 |
| Berrettini, W | 1 |
| Kellner, C | 1 |
| Prasad, AJ | 1 |
| Kissling, W | 3 |
| Windorfer, A | 1 |
| Swendsen, J | 1 |
| Heller, TL | 1 |
| Hammen, C | 2 |
| Buzan, RD | 1 |
| Firestone, D | 1 |
| Thomas, M | 1 |
| Blum, LD | 1 |
| Werder, SF | 1 |
| Papatheodorou, G | 2 |
| Kutcher, SP | 2 |
| Katic, M | 1 |
| Szalai, JP | 1 |
| Costello, LE | 1 |
| DasGupta, K | 1 |
| Jefferson, JW | 4 |
| Kolbrener, M | 1 |
| Mayer, PV | 2 |
| Castillo, J | 2 |
| Cohen, BM | 2 |
| Gross, R | 1 |
| Grunhaus, L | 1 |
| Brady, KT | 6 |
| Sonne, SC | 3 |
| Anton, R | 1 |
| Ballenger, JC | 1 |
| Woyshville, MJ | 5 |
| Byerly, MJ | 1 |
| Greer, RA | 1 |
| Tuma, I | 1 |
| Sweeney, EA | 1 |
| Wilcox, J | 1 |
| Mielke, DH | 1 |
| Fu, C | 1 |
| Katzman, M | 1 |
| Goldbloom, DS | 1 |
| Nurnberg, HG | 1 |
| Martin, GA | 1 |
| Karajgi, BM | 1 |
| Roskin, JK | 1 |
| Longshore, CT | 1 |
| Abbas, A | 1 |
| Styra, R | 1 |
| Mitchell, P | 1 |
| Withers, K | 1 |
| Jacobs, G | 1 |
| Hickie, I | 1 |
| Risinger, RC | 1 |
| Risby, ED | 2 |
| Risch, SC | 2 |
| Sen, D | 1 |
| Kravitz, HM | 1 |
| Joffe, RT | 2 |
| Cooper, SA | 1 |
| Collacott, RA | 1 |
| Pope, HG | 8 |
| Herbstein, J | 1 |
| Sonne, S | 1 |
| Lydiard, RB | 1 |
| Lagomarsino, AJ | 1 |
| Tugrul, KC | 3 |
| Bennett, JA | 6 |
| Deltito, JA | 1 |
| Schaff, MR | 1 |
| Trehan, R | 1 |
| Clark, CF | 1 |
| Jacobsen, FM | 1 |
| McCoy, L | 1 |
| Votolato, NA | 1 |
| Schwarzkopf, SB | 1 |
| Gnam, W | 1 |
| Flint, AJ | 1 |
| Glod, CA | 1 |
| Mathieu, J | 1 |
| Kimmel, SE | 7 |
| Dilsaver, SC | 6 |
| Shoaib, AM | 1 |
| Bowers, TC | 1 |
| Persad, E | 2 |
| Mazmanian, D | 1 |
| Karunaratne, K | 1 |
| Potter, WZ | 2 |
| Reece, B | 1 |
| Whittier, MC | 1 |
| West, SA | 1 |
| Galli, VB | 1 |
| Raute, NJ | 1 |
| Szuba, MP | 1 |
| Finch, NN | 1 |
| Levin, Z | 1 |
| Miller, LJ | 1 |
| Puryear, LJ | 1 |
| Workman, R | 1 |
| Maes, M | 2 |
| Goossens, F | 1 |
| Scharpé, S | 1 |
| Desnyder, R | 1 |
| Stanton, SP | 2 |
| Robinson, D | 1 |
| Luby, V | 1 |
| Dangel, C | 1 |
| Buxton, E | 1 |
| Beattie, M | 1 |
| Kraemer, H | 1 |
| Yesavage, JA | 1 |
| Worthington, JJ | 1 |
| Pollack, MH | 1 |
| Granneman, GR | 1 |
| Schneck, DW | 1 |
| Cavanaugh, JH | 1 |
| Witt, GF | 1 |
| Nabulsi, AA | 1 |
| Taylor, JL | 1 |
| Henke, CJ | 1 |
| Chmiel, JJ | 1 |
| Orsulak, P | 1 |
| Davis, JM | 4 |
| Goodnick, P | 2 |
| Small, JG | 2 |
| Morris, DD | 5 |
| Kramer, GL | 1 |
| Miller, MJ | 1 |
| Swann, AE | 1 |
| Orsulak, PJ | 1 |
| Blake, ME | 1 |
| Lepkifker, E | 1 |
| Iancu, I | 1 |
| Dannon, P | 1 |
| Ziv, R | 1 |
| Kotler, M | 1 |
| Hegarty, JI | 1 |
| Froeschl, M | 1 |
| Zarate, SB | 1 |
| Fatemi, SH | 2 |
| Kujawa, M | 2 |
| Pearlman, C | 1 |
| Obedian, E | 1 |
| Puzantian, T | 2 |
| Locke, CA | 1 |
| Vuckovic, A | 2 |
| Hammer, BA | 1 |
| Jenkins, JB | 1 |
| Schroeder, DH | 1 |
| Pazzaglia, PJ | 4 |
| George, MS | 3 |
| Callahan, AM | 2 |
| Hinton, ML | 1 |
| Chao, J | 1 |
| Prien, RF | 1 |
| McDonald, WM | 1 |
| Emilien, G | 1 |
| Maloteaux, JM | 1 |
| Seghers, A | 1 |
| Charles, G | 1 |
| Hesslinger, B | 1 |
| McKinney, PA | 1 |
| Finkenbine, RD | 1 |
| Garland, EJ | 1 |
| Behr, R | 1 |
| Denicoff, K | 3 |
| Lenox, RH | 3 |
| McNamara, RK | 1 |
| Watterson, JM | 1 |
| Watson, DG | 1 |
| Hsiao, JK | 1 |
| Masana, MI | 2 |
| Keitner, GI | 3 |
| Ryan, CE | 3 |
| Miller, IW | 3 |
| Morris, D | 4 |
| Small, J | 1 |
| Truman, CJ | 1 |
| Kmetz, GF | 1 |
| Collins, DJ | 1 |
| Wils, V | 1 |
| Golüke-Willemse, G | 1 |
| Shea, MT | 1 |
| Kazim, A | 1 |
| Fawcett, RG | 1 |
| Dixon, JF | 1 |
| Hokin, LE | 1 |
| Baraibar, G | 1 |
| Sernyak, MJ | 2 |
| Godleski, LS | 1 |
| Griffin, RA | 1 |
| Mazure, CM | 2 |
| Woods, SW | 4 |
| Crumley, FE | 1 |
| Townes, P | 1 |
| Longhurst, JG | 1 |
| Raby, WN | 1 |
| Prakash, R | 1 |
| Roback, HB | 1 |
| Gerhart, C | 1 |
| Semple, W | 1 |
| Steele, M | 1 |
| Fisman, S | 1 |
| Callahan, A | 1 |
| Smith-Jackson, EE | 1 |
| Bryan, AL | 2 |
| Ali, SO | 2 |
| Brazelton, T | 1 |
| Blanc, PD | 1 |
| Olson, KR | 1 |
| Davis, J | 1 |
| Swann, A | 1 |
| Lambert, M | 1 |
| Dardennes, RM | 1 |
| Even, C | 1 |
| Irwin, M | 1 |
| Masand, P | 1 |
| Thuras, P | 1 |
| Schneider, AL | 1 |
| Wilcox, CS | 1 |
| Baetz, M | 1 |
| Bowen, RC | 1 |
| Winsberg, ME | 2 |
| DeGolia, SG | 2 |
| Dunai, M | 1 |
| Tate, DL | 1 |
| Strong, CM | 2 |
| Kraemer, HC | 1 |
| Webb, A | 1 |
| Baker, CB | 2 |
| Damore, J | 1 |
| Stine, J | 1 |
| Brody, L | 1 |
| Garno, JL | 2 |
| Portera, L | 2 |
| Weiss, RD | 1 |
| Greenfield, SF | 1 |
| Najavits, LM | 1 |
| Soto, JA | 1 |
| Wyner, D | 1 |
| Griffin, ML | 1 |
| Schaller, JL | 1 |
| Behar, D | 1 |
| Martinez, JM | 1 |
| Russell, JM | 2 |
| Kaufman, KR | 1 |
| Gerner, R | 1 |
| Noaghiul, S | 1 |
| Narayan, M | 1 |
| Nelson, JC | 2 |
| Tueth, MJ | 1 |
| Murphy, TK | 1 |
| Alvarez, N | 1 |
| Boerlin, HL | 1 |
| Zoellner, LA | 1 |
| Hammen, CL | 1 |
| Sanderson, DR | 1 |
| Retzow, A | 2 |
| Xie, X | 1 |
| Hagan, RM | 1 |
| Erfurth, A | 4 |
| Normann, C | 2 |
| Brandt, C | 1 |
| Mick, E | 1 |
| Bostic, JQ | 1 |
| Prince, J | 1 |
| Daly, J | 1 |
| Spencer, T | 1 |
| Garcia-Jetton, J | 1 |
| Russell, R | 1 |
| Yuan, PX | 1 |
| Jiang, YM | 1 |
| Huang, LD | 2 |
| Niedermier, JA | 1 |
| Bebchuk, JM | 1 |
| Moore, GJ | 2 |
| Glitz, D | 1 |
| Hasanat, KA | 1 |
| Lapierre, O | 1 |
| Dubreucq, JL | 1 |
| Beauchemin, MA | 1 |
| Vinet, B | 1 |
| Grundy, S | 1 |
| Chen, ST | 1 |
| Melnyk, KA | 1 |
| Erhart, SM | 1 |
| Miller, E | 1 |
| Severus, WE | 1 |
| Rueter, S | 1 |
| Zboyan, HA | 1 |
| Diamond, E | 1 |
| Cress, KK | 1 |
| Kline, MD | 1 |
| Jaggers, ED | 1 |
| Lovell, RW | 1 |
| Puentes, E | 1 |
| Lum, BL | 1 |
| Mordecai, DJ | 1 |
| Sheikh, JI | 1 |
| Glick, ID | 1 |
| Marcus, SC | 1 |
| Olfson, M | 1 |
| Zarin, DA | 1 |
| Cott, AD | 1 |
| DeMet, EM | 1 |
| Conforti, D | 1 |
| Borgherini, G | 1 |
| Fiorellini Bernardis, LA | 1 |
| Magni, G | 1 |
| Giupponi, G | 1 |
| Kammerer, C | 1 |
| Schaffer, LC | 1 |
| Schaffer, CB | 1 |
| Caretto, J | 1 |
| Panikkar, GP | 1 |
| Gilman, SM | 1 |
| Goldstein, TR | 1 |
| Smith-Jackson, E | 1 |
| Pacheco, MA | 1 |
| Jope, RS | 1 |
| Vanstraelen, M | 1 |
| Tyrer, SP | 1 |
| Preda, A | 1 |
| Fazeli, A | 1 |
| McKay, BG | 1 |
| Bowers, MB | 1 |
| Maule, S | 1 |
| Giannella, R | 1 |
| Lanzio, M | 1 |
| Villari, V | 1 |
| Motohashi, N | 1 |
| Yamada, K | 1 |
| Marcuse, A | 1 |
| Broekmans, AW | 1 |
| Flekkerkerker, JF | 1 |
| Robb, JC | 1 |
| MacQueen, GM | 1 |
| Marriott, M | 1 |
| Patelis-Siotis, I | 1 |
| Mitchell, PB | 2 |
| Norton, JW | 1 |
| Quarles, E | 1 |
| Ryan, W | 2 |
| Wolfson, M | 1 |
| Zinger, E | 1 |
| Simkin, M | 1 |
| Hertz, L | 1 |
| McEvoy, JP | 1 |
| Davanzo, PA | 1 |
| McCracken, JT | 1 |
| Oostervink, F | 1 |
| Hoenderboom, AC | 1 |
| Chaudron, LH | 1 |
| Gardner, DM | 1 |
| Filteau, MJ | 1 |
| Lefrançoise, S | 1 |
| Demers, MF | 1 |
| Müller-Oerlinghausen, B | 2 |
| Henn, FA | 1 |
| Giedke, H | 1 |
| Perry, PJ | 1 |
| Bever-Stille, KA | 1 |
| Arndt, S | 1 |
| Gundersen, S | 1 |
| Rhodes, LJ | 1 |
| Tondo, L | 1 |
| Hertzman, M | 1 |
| Piontek, CM | 1 |
| Baab, S | 1 |
| Gudeman, D | 1 |
| Tanavoli, S | 1 |
| Hendrick, V | 1 |
| Korenman, S | 1 |
| Gershon, S | 3 |
| Sacks, MH | 1 |
| Herbert, PB | 1 |
| Lennkh, C | 1 |
| Simhandl, C | 1 |
| Carmody, TJ | 1 |
| Bucci, JP | 1 |
| Emslie, GJ | 1 |
| Rottach, KG | 1 |
| Weiss-Brummer, J | 1 |
| Wieland, U | 1 |
| Schmauss, M | 1 |
| Goswami, U | 2 |
| Kohli, K | 1 |
| Dalkilic, A | 1 |
| Diaz, E | 1 |
| Pearsall, HR | 1 |
| Juckel, G | 2 |
| Hegerl, U | 2 |
| Mavrogiorgou, P | 1 |
| Gallinat, J | 1 |
| Mager, T | 1 |
| Tigges, P | 2 |
| Dresel, S | 1 |
| Schröter, A | 2 |
| Stotz, G | 1 |
| Meller, I | 1 |
| Solhkhah, R | 1 |
| Finkel, J | 1 |
| Hird, S | 1 |
| Hilty, DM | 1 |
| Rodriguez, GD | 1 |
| Hales, RE | 1 |
| Griswold, KS | 1 |
| Pessar, LF | 1 |
| Takhar, J | 1 |
| Bishop, J | 1 |
| Guille, C | 1 |
| Lemoine, P | 1 |
| Fondarai, J | 1 |
| Faivre, T | 1 |
| Miller, PR | 1 |
| Schäfer, M | 1 |
| Sterr, A | 1 |
| Schaerer, L | 1 |
| Wild, E | 1 |
| Mustain, DW | 1 |
| Pendarvis, JE | 1 |
| Albanese, MJ | 1 |
| Clodfelter, RC | 1 |
| Khantzian, EJ | 1 |
| Alao, AO | 1 |
| Dewan, MJ | 1 |
| Bottlender, R | 1 |
| Rudolf, D | 1 |
| Strauss, A | 1 |
| Moore, CM | 1 |
| Breeze, JL | 1 |
| Gruber, SA | 1 |
| Babb, SM | 1 |
| Frederick, BB | 1 |
| Villafuerte, RA | 1 |
| Hennen, J | 1 |
| Yurgelun-Todd, DA | 1 |
| Pande, AC | 1 |
| Crockatt, JG | 1 |
| Janney, CA | 1 |
| Werth, JL | 1 |
| Tsaroucha, G | 1 |
| Mallinger, AG | 1 |
| Hardan, A | 1 |
| Vagnucci, A | 1 |
| Pollock, B | 1 |
| Luther, J | 1 |
| Buttenfield, J | 1 |
| Verfaille, S | 1 |
| Rathore, D | 1 |
| Atzert, R | 1 |
| Solai, L | 1 |
| Parepally, H | 1 |
| Levin, H | 1 |
| Moffa, N | 1 |
| Delaney, J | 1 |
| Brar, JS | 1 |
| Brusman, L | 1 |
| Holcomb, J | 1 |
| Soutullo, C | 1 |
| Beckman, D | 1 |
| Kuppili, N | 1 |
| Zeng, WZ | 1 |
| K Manji, H | 1 |
| Gergel, IP | 1 |
| Oakes, R | 1 |
| Pitts, CD | 1 |
| Maggi, JD | 1 |
| Halman, MH | 1 |
| Norton, J | 1 |
| Thiruvengadam, A | 1 |
| Hicks, LK | 1 |
| McFarlane, PA | 1 |
| Duggal, HS | 2 |
| Stoner, SC | 1 |
| Worrel, JA | 1 |
| Vlach, D | 1 |
| Jones, MT | 1 |
| Ramlatchman, LV | 1 |
| Shirley, ER | 1 |
| Caban, SJ | 1 |
| Berendes, K | 1 |
| Glass, W | 1 |
| Warmke, C | 1 |
| Regenold, WT | 1 |
| Prasad, M | 1 |
| Narendran, R | 1 |
| Young, CM | 1 |
| Valenti, AM | 1 |
| Pristach, CA | 1 |
| Pato, MT | 1 |
| Grace, JJ | 1 |
| Struve, FA | 1 |
| Patrick, G | 1 |
| Tayal, G | 1 |
| Kottlors, M | 1 |
| Jaksch, M | 1 |
| Ketelsen, UP | 1 |
| Weiner, S | 1 |
| Glocker, FX | 1 |
| Lücking, CH | 1 |
| Brescan, DW | 1 |
| Perez, DE | 1 |
| DiGiovanni, SK | 1 |
| Hattab, H | 1 |
| Ray, JB | 1 |
| Bingham, CR | 1 |
| Macritchie, KA | 1 |
| Haslam, DR | 1 |
| Lüttmann, RJ | 1 |
| Frese, A | 1 |
| Husstedt, IW | 1 |
| Evers, S | 1 |
| Sobhan, T | 1 |
| Munoz, C | 1 |
| Hardy-Baylé, MC | 1 |
| Keeter, EL | 1 |
| Tollefson, GD | 1 |
| Mota-Castillo, M | 1 |
| Torruella, A | 1 |
| Engels, B | 1 |
| Perez, J | 1 |
| Dedrick, C | 1 |
| Gluckman, M | 1 |
| Caban, S | 1 |
| Shaldubina, A | 1 |
| Szechtman, H | 1 |
| Shimon, H | 1 |
| Dinan, TG | 1 |
| Kim, E | 1 |
| Humaran, TJ | 1 |
| Ngan, E | 1 |
| Scarrow, G | 1 |
| Imperial, M | 1 |
| Stoessl, J | 1 |
| Graves, GR | 1 |
| Frankenburg, FR | 2 |
| Zanarini, MC | 1 |
| Milton, DR | 1 |
| Gilmore, JA | 1 |
| Tollefson, GA | 1 |
| Rzewuska, M | 1 |
| Bosetti, F | 1 |
| Okamoto, A | 1 |
| Pascalis, G | 1 |
| Chauvot, B | 1 |
| Maés, L | 1 |
| Guscott, R | 1 |
| Matthews-Ferrari, K | 1 |
| Karroum, N | 1 |
| Wolf, R | 1 |
| Friedman, LM | 1 |
| Freeman, T | 1 |
| Hudson, JI | 6 |
| Markovitz, PJ | 2 |
| Wagner, SC | 1 |
| Gerner, RH | 1 |
| Stanton, A | 1 |
| Kastner, T | 1 |
| Friedman, DL | 1 |
| Freeman, TW | 1 |
| Clothier, JL | 1 |
| Pazzaglia, P | 1 |
| Lesem, MD | 1 |
| Sovner, R | 4 |
| Keltner, NL | 1 |
| Folks, DG | 1 |
| Ellicott, A | 1 |
| Gitlin, M | 1 |
| Brown, G | 1 |
| Jamison, K | 1 |
| Miller, MR | 1 |
| Straumfjord, AA | 1 |
| Wilson, DR | 1 |
| Alpert, JE | 1 |
| Teschke, GC | 1 |
| Heller, VL | 1 |
| Ramoran, N | 1 |
| Hart, LL | 1 |
| Delucchi, GA | 2 |
| Shliselberg, N | 1 |
| Bosch, JR | 1 |
| Herrera, J | 1 |
| Mauri, MC | 1 |
| Percudani, M | 1 |
| Regazzetti, MG | 1 |
| Hayes, SG | 1 |
| Steingard, S | 1 |
| Onady, AA | 1 |
| Cookson, JC | 1 |
| Borsook, D | 1 |
| Richardson, GS | 1 |
| Moore-Ede, MC | 1 |
| Brennan, MJ | 1 |
| Lovett, L | 1 |
| Watkins, SE | 1 |
| Shaw, DM | 1 |
| Schou, M | 1 |
| Peterová, E | 1 |
| Kabes, J | 1 |
| Zapletálek, M | 1 |
| Hanus, H | 1 |
| Kindernayová, H | 1 |
| Williams, DP | 1 |
| Troost, BT | 1 |
| Schnetzler, JP | 1 |
| Préaubert, G | 1 |
| Schnetzler, F | 1 |
| Lerer, B | 1 |
| Herridge, PL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Tolerability of the Combination of LIthium and CArbamazepine Compared to Lithium and VALproic Acid in the Treatment of Young Bipolar Patients[NCT00976794] | Phase 4 | 40 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Randomised, Parallel Group, Double Blind, Placebo Controlled, Add on Clinical Trial to Investigate Whether the Lithium Mimetic, Ebselen, Can Reduce Symptoms of Hypomania and Mania in Bipolar Patients[NCT03013400] | Phase 2 | 60 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| Does the IMPase Inhibitor, Ebselen, Affect Emotional Processing and Brain Myo-inositol in Treatment-resistant Depression?[NCT05117710] | Phase 1 | 50 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| PSG in Valproate-induced Nocturnal Enuresis in Children[NCT04191863] | 260 participants (Actual) | Observational | 2018-09-01 | Completed | |||
| Acute Pharmacotherapy of Late-Life Mania (GERI-BD)[NCT00254488] | Phase 4 | 224 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A 24-Week, Flexible-Dose, Open-Label Extension Study of Lurasidone for the Treatment of Bipolar I Depression[NCT00868959] | Phase 3 | 817 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Study by 1H NMR of the Variations of the Metabolome During the Course of Electroconvulsive Therapy in Patients With Major Depressive Episode[NCT05973643] | 50 participants (Anticipated) | Interventional | 2023-10-15 | Not yet recruiting | |||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Clinical Evaluation of the Antidepressant Effect of the Use of Probiotics in Bipolar Disorder and Possible Mediating Effects of Systemic and Intestinal Inflammatory Markers in the Microbiota[NCT05762887] | 84 participants (Anticipated) | Interventional | 2023-01-09 | Recruiting | |||
| Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study[NCT04701866] | 32 participants (Actual) | Interventional | 2021-01-11 | Completed | |||
| A Collaborative Treatment Network for Youth With or at High Risk for Bipolar Disorder[NCT05427123] | 80 participants (Anticipated) | Observational | 2022-07-01 | Recruiting | |||
| PRIME Care (PRecision Medicine In MEntal Health Care)[NCT03170362] | 1,944 participants (Actual) | Interventional | 2017-06-15 | Completed | |||
| A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase 3 Comparison of the Efficacy & Safety of Quetiapine Fumarate to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Valproate) in the Maintenance Treatment of Bipolar I Disorder in Ad[NCT00107731] | Phase 3 | 710 participants | Interventional | 2004-04-30 | Completed | ||
| Multicenter, Randomized, Parallel-Group, Double-Blind, Phase 3 Comparison of the Efficacy & Safety of Quetiapine Fumarate to Placebo as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patient[NCT00081380] | Phase 3 | 710 participants | Interventional | 2004-03-31 | Completed | ||
| Series Studies of Bipolar Disorder-Valproate add-on Memantine Treatment[NCT01188148] | Phase 2/Phase 3 | 219 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Endophenotype Characterization of a Family Psychiatric Disorder of the Bipolar Spectrum, With an Autosomal Dominant Expression[NCT02843997] | 29 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | |||
| The Treatment of Sleep Bruxism With the Luco Hybrid OSA Appliance[NCT02882880] | 51 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| A Randomized, 6-Week, Double-Blind, Placebo- Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression[NCT00868452] | Phase 3 | 348 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
| Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders[NCT00221403] | Phase 3 | 46 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Placebo Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder[NCT02456454] | Phase 3 | 46 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Treatment of Early Age Mania (TEAM) Study[NCT00057681] | Phase 3 | 379 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression[NCT00868699] | Phase 3 | 505 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Diva[NCT01284517] | Phase 3 | 356 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)[NCT01272531] | 560 participants (Actual) | Observational | 2011-04-30 | Completed | |||
| Homeopathic Treatment in Pregnant Women With Overweight and Mental Disorder: a Double Blinded Controlled Clinical Trial[NCT00942097] | Phase 2/Phase 3 | 134 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Family-Focused Therapy as Early Treatment for Youth at Risk for Bipolar Disorder[NCT00943085] | 52 participants (Anticipated) | Interventional | 2007-04-30 | Completed | |||
| Early Intervention for Youth at Risk for Bipolar Disorder[NCT01483391] | 150 participants (Anticipated) | Interventional | 2011-10-06 | Completed | |||
| Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder[NCT00094549] | Phase 4 | 500 participants | Interventional | 2004-10-31 | Completed | ||
| Investigation of the Effects of in Vivo Lithium Treatment on Gene Expression Levels Using Lymphoblastoid Cell Lines From Human Healthy Subjects[NCT01565759] | Phase 1 | 20 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | ||
| A Randomized, Double Blind Comparison of Lithium Monotherapy Versus Lithium Plus Divalproex for the Outpatient Management of Hypomania/Mania in Patients With Rapid Cycling Bipolar Disorder Comorbid With Substance Abuse/Dependence[NCT00194129] | Phase 3 | 31 participants (Actual) | Interventional | 1997-11-30 | Completed | ||
| Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder[NCT02456896] | Phase 4 | 50 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Depakote ER for the Treatment of Bipolar Disorder in Children and Adolescents[NCT00067262] | Phase 3 | 150 participants | Interventional | 2003-03-31 | Completed | ||
| An Open-Label Long-Term Study to Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents[NCT00195767] | Phase 3 | 150 participants | Interventional | 2004-07-31 | Completed | ||
| A Double-Blind Placebo Controlled Trial of Divalproex and Olanzapine in Bipolar I Disorder, Mixed Episode[NCT00402324] | Phase 4 | 202 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Depakote ER in Bipolar Depression[NCT00186186] | Phase 4 | 28 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Targeted Alterations in n-3 and n-6 Fatty Acids for the Management of Mood Variability in the Maintenance Phase of Bipolar Disorder[NCT02272010] | 83 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| A Phase 3, Randomized, 6-Month, Double-Blind Trial in Subjects With Bipolar I Disorder to Evaluate the Continued Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer (vs Placebo Plus a Mood Stabilizer) Following a Minimum of 2 Months of [NCT00280566] | Phase 3 | 584 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| "A Randomized, Double-Blind, Placebo-Controlled Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to- Severe Hypomania or Mild Mania"[NCT00278772] | Phase 3 | 62 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder[NCT00060905] | Phase 3 | 370 participants | Interventional | 2003-01-31 | Completed | ||
| Efficacy of Aripiprazole in Combination With Valproate or Lithium in the Treatment of Mania in Patients With Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium Monotherapy[NCT00257972] | Phase 3 | 400 participants | Interventional | 2004-10-31 | Completed | ||
| An 8 Week Double Blind, Placebo-Controlled, Parallel Group, Fixed Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder[NCT00481195] | Phase 2 | 257 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Prospective Randomized Double Blinded Control Trial Using Ketamine or Propofol Anesthesia for Electroconvulsive Therapy: Improving Treatment-Resistant Depression[NCT01935115] | Phase 4 | 27 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Clinical Trial of the Use of Ketamine in Treatment Resistant Depression[NCT02610712] | Phase 4 | 20 participants (Anticipated) | Interventional | 2014-05-31 | Recruiting | ||
| Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557] | Phase 3 | 30 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| A Study of Ketamine as an Antidepressant[NCT01441505] | Phase 2 | 42 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| A Safe Ketamine-Based Therapy for Treatment Resistant Depression[NCT01179009] | 20 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| Nicotine Intake in Smokers With Schizophrenia[NCT00382915] | 276 participants (Actual) | Observational | 2006-10-31 | Completed | |||
| Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression[NCT00194116] | Phase 3 | 54 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone as Adjunctive Therapy to Mood Stabilizers in the Treatment of Acute Manic and Mixed Episo[NCT00309686] | Phase 3 | 300 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase[NCT01893229] | Phase 4 | 120 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | ||
| Efficacy of Aripiprazole in Combination With Lithium or Valproate in the Long-Term Maintenance Treatment of Bipolar I Disorder in Outpatients Partially Nonresponsive to Lithium or Valproate Monotherapy[NCT00261443] | Phase 4 | 1,270 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Six-Week, Double-Blind, Multicenter, Placebo Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral Ziprasidone As Add-On, Adjunctive Therapy With Lithium, Valproate Or Lamotrigine In Bipolar I Depression[NCT00483548] | Phase 3 | 298 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Effects of Risperidone and Olanzapine on Weight Gain, Physical Health, and Outcome in a Community Sample of Severity and Persistently Ill Patients[NCT00179062] | 300 participants (Actual) | Interventional | 2000-02-29 | Completed | |||
| A Phase 3, Placebo-Controlled, Double-Blinded Continuation Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Completing a 12-week Lead-in Trial and Continuing Lithium or Valproic Acid/Divalproex Sodium for the Treatment of an Acute Manic o[NCT00145509] | Phase 3 | 77 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Continuing Lithium or Valproic Acid/Divalproex Sodium for the Treatment of an Acute Manic or Mixed Episode[NCT00145470] | Phase 3 | 326 participants (Actual) | Interventional | 2005-06-02 | Completed | ||
| Controlled Trial of Risperidone and Divalproex Sodium With MRI Assessment of Affected Circuitry in Pre and Post Treatment in Pediatric Bipolar[NCT00176202] | Phase 3 | 65 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Eight-Month Maintenance Treatment of Bipolar Depression With Lamotrigine or Lamotrigine Plus Divalproex Combination[NCT00183469] | Phase 4 | 86 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Three-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Add-On Oral Ziprasidone in Subjects With Acute Mania Treated With Lithium or Divalproex[NCT00312494] | Phase 3 | 680 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder[NCT00250367] | Phase 3 | 151 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial[NCT02155972] | Phase 2 | 16 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to The trial was terminated because of inability to recruit the needed number of participants) | ||
| Low-Dose Adjunctive Brexpiprazole in the Treatment of Bipolar I Depression: An Open-Label Study[NCT04569448] | Phase 3 | 58 participants (Anticipated) | Interventional | 2021-05-10 | Recruiting | ||
| A Randomised Double-Blinded Placebo-Controlled Trial to Assess the Efficacy and Safety of Scopolamine Compared to Placebo in Individuals With Bipolar Disorder Who Are Experiencing a Depressive Episode[NCT04211961] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| A Prophylactic Trial of Omega-3 Polyunsaturated Fatty Acids in Bipolar Disorder[NCT04210804] | Phase 2 | 80 participants (Actual) | Interventional | 2014-04-01 | Completed | ||
| A Comparison of Omega-3 Fatty Acids vs. Placebo in Children and Adolescents With Bipolar Disorder[NCT00252486] | 65 participants (Actual) | Interventional | 2001-11-30 | Completed | |||
| Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Cross-Over Placebo Controlled Trial[NCT00305370] | Phase 4 | 20 participants (Anticipated) | Interventional | 2005-08-31 | Completed | ||
| Efficacy of Valproate Maintenance in Bipolar Alcoholics[NCT00000439] | Phase 2 | 72 participants (Actual) | Interventional | 2000-10-31 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder[NCT02811133] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2023-08-31 | Withdrawn (stopped due to Funding terminated) | ||
| Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions[NCT02292056] | 50 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | |||
| Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study[NCT00837707] | Phase 4 | 25 participants (Anticipated) | Interventional | 2008-06-30 | Recruiting | ||
| Treatment of Psychosis and Agitation in Alzheimer's Disease[NCT02129348] | Phase 2 | 77 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study[NCT00400088] | Phase 3 | 2 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Recruitment difficulties) | ||
| Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression: Double-Blind, Placebo-Controlled Study to Establish Efficacy and Safety[NCT00590265] | 50 participants (Anticipated) | Interventional | 2008-01-31 | Active, not recruiting | |||
| Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)[NCT00012558] | 5,000 participants | Interventional | 1998-09-30 | Completed | |||
| Valproate Efficacy in Cocaine-Bipolar Comorbidity[NCT00240110] | Phase 1/Phase 2 | 152 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Phase 4 Study: Double-blind Placebo-controlled Trial of Depakote-ER for Depressive and Anxiety Symptoms in Non-refractory Bipolar Depression[NCT00226343] | Phase 4 | 25 participants | Interventional | 2003-08-31 | Completed | ||
| Aripiprazole in Late Life Bipolar Disorder[NCT00194038] | Phase 4 | 20 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Prophylactic Use of Immediate Postpartum Sertraline to Prevent Postpartum Depression: A Double Blind Randomized Placebo Controlled Trial[NCT02235064] | 2 participants (Actual) | Interventional | 2014-07-31 | Terminated (stopped due to Low recruitment, completion of funding cycle) | |||
| A Randomised Trial on the Usefulness of Supportive Text Messages in the Treatment of Depressed Patients With Co-morbid Alcohol Dependency Syndrome[NCT01037868] | 56 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study in Adolescents With Bipolar Disorder[NCT00391001] | Phase 1 | 4 participants (Actual) | Interventional | 2006-02-28 | Terminated | ||
| Omega-3 Fatty Acids in Bipolar Disorder Prophylaxis[NCT00010868] | Phase 2 | 0 participants | Interventional | 2000-07-31 | Completed | ||
| A Combination of Cytidine and Omega-3 Fatty Acids in Bipolar Disorder: Are There Additive or Synergistic Mood Stabilizing Effects?[NCT00854737] | Phase 2 | 90 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Supplementation of Antidepressants With Fatty Acid Therapy[NCT00963196] | 78 participants (Anticipated) | Interventional | 2009-09-30 | Withdrawn (stopped due to End of allotted time for subject recruiting.) | |||
| Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms[NCT00202514] | Phase 2/Phase 3 | 40 participants | Interventional | 2004-09-30 | Completed | ||
| A Preliminary Study of the Efficacy and Safety of Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency[NCT01379469] | Phase 2 | 20 participants (Actual) | Interventional | 2012-01-31 | Terminated | ||
| The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo Versus Haloperidol As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder[NCT00253149] | Phase 3 | 158 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Sedation Item score of the UKU (Norwegian for Committee of Clinical Investigations) Side Effect Rating Scale. A higher value indicates greater severity. Range is 0-3 (not present, mild, moderate, or severe). (NCT00254488)
Timeframe: Day 4, Day 9, Day 15, and then Weekly from Week 3 to Week 9
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 4 | Day 9 | Day 15 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | |
| Divalproex (DV) | 0.5 | 0.6 | 0.5 | 0.6 | 0.5 | 0.4 | 0.5 | 0.4 | 0.3 | 0.4 |
| Lithium (LI) | 0.5 | 0.6 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.4 |
The Young Mania Rating Scale is an eleven item interviewer-rated instrument. Four items are scored 0-8, the others 0-4. The total score therefore ranges from 0-60, with higher values reflecting greater severity. (NCT00254488)
Timeframe: Day 4, Day 9, Day 15, and then Weekly from Week 3 to Week 9
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 4 | Day 9 | Day 15 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | |
| Divalproex (DV) | 19.7 | 16.3 | 15.2 | 13.1 | 9.9 | 9.8 | 8.2 | 7.0 | 6.7 | 6.8 |
| Lithium (LI) | 21.4 | 19.0 | 14.3 | 12.1 | 9.4 | 7.6 | 7.2 | 6.0 | 6.0 | 6.3 |
"This CGI-BP-S is a clinician-rated assessment of the subjects current severity of depression and ranges from 1=Normal, not ill to 7=Very severly ill. Higher scores are associated with greater severity." (NCT00868959)
Timeframe: 24 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lurasidone | -0.58 |
"The MADRS is a clinician-rated assessment of the subject's level of depression. Ten items are rated on a Likert scale, from 0=Normal to 6=Most Severe. The MADRS total score is calculated as the sum of ten items: reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity." (NCT00868959)
Timeframe: 24 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lurasidone | -4.4 |
Rate of treatment-emergent adverse events in subjects who have completed (ie, reached 6-week endpoint) of Study D1050235 (NCT00868452), Study D1050236 (NCT00868699) or Study D1050292 (NCT01284517) (NCT00868959)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| Lurasidone | 529 |
MADRS total score ranges from a minimum of 0 to a maximum of 60. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening. (NCT00868452)
Timeframe: Baseline, Week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Lurasidone | -17.1 |
| Placebo | -13.5 |
CGI-EP-S depression score ranges from a minimum of 0 to a maximum of 7. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening. (NCT00868452)
Timeframe: Baseline Week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Lurasidone | -1.96 |
| Placebo | -1.51 |
STS total score ranges from a minimum of 0 to a maximum of 30. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening. (NCT00868452)
Timeframe: Baselin Week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Lurasidone | -9.5 |
| Placebo | -7.0 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 1.17 |
| Placebo - Healthy Volunteers | 1.48 |
| Ketamine - MDD Patients | 33.83 |
| Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 2.45 |
| Placebo - Healthy Volunteers | 0.67 |
| Ketamine - MDD Patients | 23.73 |
| Placebo - MDD Patients | 30.68 |
Young Mania Rating Scale (YMRS) total scores change from baseline by treatment group. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. (NCT00221403)
Timeframe: 6 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Valproate (VPA) | 10 |
| Risperidone | 18.82 |
| Placebo | 4.29 |
The Clinical Global Impressions-Bipolar (CGI-BP) assessment instrument measured improvement in mania, depression, and overall bipolar illness. The primary outcome measure was mania improvement, which measured the change in mania from baseline. Scores were 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Medication - Lithium | 2.49 |
| Randomized Medication - Divalproex Sodium | 2.73 |
| Randomized Medication - Risperidone | 1.70 |
The K-SADS Mania Rating Scale (KMRS) is comprised of 15 items modified from WASH-U-KSADS items. The individual items are scored on a 1-6 severity scale and then these item scores are summed to create an overall KMRS score. Guidelines for interpretation are as follows: 0-11 = no or minimal mania, 12-17 = mild mania, 18-25 = moderate mania, 26+ = marked or worse mania. The maximum possible score is 64. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Medication - Lithium | 24.06 |
| Randomized Medication - Divalproex Sodium | 26.31 |
| Randomized Medication - Risperidone | 14.58 |
The Modified Side Effects Form for Children and Adolescents includes 62 potential side effects, with measures of frequency and severity for each item. Frequencies are 0=not present, 1=1-2 days, 2=3-4 days, 3=5-7 days. Severity scores are 0=not present, 1=mild (does not interfere with functioning), 2=moderate (some interference with functioning), 3=severe (functioning is significantly impaired because of side effects). Items for cardiovascular, gastrointestinal, central nervous system, ocular, mouth and nose, genito urinary, dermatology, musculo-skeletal, and other side effects are included. For analyses, side effects that were reported at any frequency and a severity of 2 or greater were considered present. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | side effects at week 8 (Mean) |
|---|---|
| Randomized Medication - Lithium | 5.11 |
| Randomized Medication - Divalproex Sodium | 4.95 |
| Randomized Medication - Risperidone | 3.70 |
"Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression.~The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.~The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items." (NCT00868699)
Timeframe: Baseline to Week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -10.7 |
| Lurasidone High Arm | -15.4 |
| Lurasidone Low Arm | -15.4 |
"Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression.~The CGI depression score ranges from a minimum of 0 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome." (NCT00868699)
Timeframe: Baseline to Week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.14 |
| Lurasidone High Arm | -1.71 |
| Lurasidone Low Arm | -1.83 |
"Sheehan Disability Scale (SDS) total score is a subject-rated assessment of a subject's level of depression.~The SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.~The SDS contains three (3) items. The total score is computed as the sum of the scores for the 3 items." (NCT00868699)
Timeframe: Baseline to Week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -6.3 |
| Lurasidone High Arm | -9.8 |
| Lurasidone Low Arm | -9.5 |
MADRS total score ranges from a minimum of 0 to a maximum of 60. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening. (NCT01284517)
Timeframe: Baseline to week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Lurasidone 20-120 mg Flexible Dose+Li/VPA | -11.8 |
| Placebo + Li/VPA | -10.4 |
CGI-EP-S depression score ranges from a minimum of 0 to a maximum of 7. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening. (NCT01284517)
Timeframe: Baseline to week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Lurasidone 20-120 mg Flexible Dose+Li/VPA | -1.36 |
| Placebo + Li/VPA | -1.13 |
SDS total score ranges from a minimum of 0 to a maximum of 30. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening. (NCT01284517)
Timeframe: Baseline to week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Lurasidone 20-120 mg Flexible Dose+Li/VPA | -5.4 |
| Placebo + Li/VPA | -5.4 |
Number of subjects who no longer met criteria for active abuse or had entered into early full remission after receiving up to 6 months of open-label treatment with lithium and divalproex (NCT00194129)
Timeframe: Baseline to Month 6
| Intervention | Participants (Count of Participants) |
|---|---|
| Completers | 11 |
Number of subjects who no longer met criteria for active cannabis abuse or had entered into early full remission after receiving up to 6 months of open-label treatment with lithium and divalproex (NCT00194129)
Timeframe: Baseline to Month 6
| Intervention | Participants (Count of Participants) |
|---|---|
| Completers | 8 |
Number of subjects who no longer met criteria for active cocaine abuse or had entered into early full remission after receiving up to 6 months of open-label treatment with lithium and divalproex (NCT00194129)
Timeframe: Baseline to Month 6
| Intervention | Participants (Count of Participants) |
|---|---|
| Completers | 7 |
A relapse is a return to either a depressive, manic, hypomanic or mixed episode after a period of not have any symptoms. (NCT00194129)
Timeframe: Up to 6 months
| Intervention | weeks (Median) |
|---|---|
| Lithium Plus Divalproex | 17.8 |
| Lithium Plus Placebo | 15.9 |
Serum BDNF was estimated by ELISA using human BDNF ELISA kit from Boster Biological Technology Co. Ltd., Pleasanton, CA. (NCT02456896)
Timeframe: Baseline and 4 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Healthy Control | 23.1 |
| Oxcarbazepine | 90.7 |
"The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania.~Spearman's rank correlation coefficient (Spearman's ρ) was calculated for measuring correlation between YMRS score and serum BDNF." (NCT02456896)
Timeframe: At baseline
| Intervention | Spearman's ρ (Number) |
|---|---|
| Healthy Control | -0.59 |
| Oxcarbazepine | -0.59 |
Change from baseline to endpoint in body mass index (an estimate of body fat derived by dividing body weight by height squared): Value of body mass index measure at endpoint minus value at baseline. (NCT00402324)
Timeframe: Baseline to endpoint (6 weeks)
| Intervention | kilograms per square meters (Least Squares Mean) |
|---|---|
| Olanzapine | 1.18 |
| Placebo | 0.26 |
Percentages of participants in each group who experienced an increase in weight of at least 7% from baseline to endpoint. (NCT00402324)
Timeframe: Baseline to endpoint (6 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Olanzapine | 22 |
| Placebo | 3 |
Change from baseline to endpoint: Value of weight measure at endpoint minus value at baseline. (NCT00402324)
Timeframe: Baseline to endpoint (6 weeks)
| Intervention | kilograms (Least Squares Mean) |
|---|---|
| Olanzapine | 3.34 |
| Placebo | 0.70 |
CGI-BP Severity is used by the clinician to record the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). (NCT00402324)
Timeframe: Baseline to endpoint (6 weeks)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Olanzapine | -1.34 |
| Placebo | -1.06 |
The 21-item HAMD measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 60. (NCT00402324)
Timeframe: Baseline to endpoint (6 weeks)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Olanzapine | -9.37 |
| Placebo | -7.69 |
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. (NCT00402324)
Timeframe: Baseline to endpoint (6 weeks)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Olanzapine | -10.15 |
| Placebo | -7.68 |
The original outcome measure was Time to Mixed Onset of Action (at least a 25% reduction on HAMD and YMRS total scores from baseline); however since upper limit of measure of dispersion could not be computed by observed data, which is not allowed on this system, number of patients with event are presented instead. (NCT00402324)
Timeframe: Baseline to endpoint (6 weeks)
| Intervention | participants (Number) |
|---|---|
| Olanzapine | 81 |
| Placebo | 71 |
The original outcome measure was Time to Mixed Response(at least a 50% reduction on HAMD and YMRS total scores from baseline); however since upper limit of measure of dispersion could not be computed by observed data, which is not allowed on this system, number of patients with event are presented instead. (NCT00402324)
Timeframe: baseline to endpoint (6 weeks)
| Intervention | participants (Number) |
|---|---|
| Olanzapine | 54 |
| Placebo | 40 |
Number of participants hospitalized as a result of relapse of mania or depression. (NCT00402324)
Timeframe: Baseline to endpoint (6 weeks)
| Intervention | participants (Number) |
|---|---|
| Olanzapine | 1 |
| Placebo | 0 |
Change from baseline to endpoint in bilirubin total: Value of bilirubin total measure at endpoint minus value at baseline. (NCT00402324)
Timeframe: Baseline to endpoint (6 weeks)
| Intervention | micromoles per Liter (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 6.50 | -1.56 |
| Placebo | 6.65 | -0.74 |
Change from baseline to endpoint in fasting blood glucose: Value of fasting blood glucose measure at endpoint minus value at baseline. (NCT00402324)
Timeframe: Baseline to endpoint (6 weeks)
| Intervention | milligrams per deciliter (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 91.81 | 6.93 |
| Placebo | 91.90 | -0.55 |
Change from Baseline to endpoint in cholesterol: value of cholesterol measure at endpoint minus the value at baseline. (NCT00402324)
Timeframe: Baseline to endpoint (6 weeks)
| Intervention | milligrams per deciliter (Mean) | |||||
|---|---|---|---|---|---|---|
| Total Cholesterol Baseline | Total Cholesterol Change from Baseline | Low Density Lipoprotein Baseline (N=62,N=64) | Low Density Lipoprotein Change (N=62,N=64) | High Density Lipoprotein Baseline | High Density Lipoprotein Change from Baseline | |
| Olanzapine | 191.37 | -7.80 | 115.32 | -9.22 | 53.76 | -3.24 |
| Placebo | 192.25 | -8.72 | 111.01 | -9.77 | 51.48 | -1.22 |
Change from baseline to endpoint in triglycerides: Value of triglyceride measure at endpoint minus value at baseline. (NCT00402324)
Timeframe: Baseline to endpoint (6 weeks)
| Intervention | milligrams per deciliter (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 111.46 | 22.91 |
| Placebo | 139.75 | 16.80 |
"The Montgomery-Åsberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders.~Higher MADRS score indicates more severe depression the overall score ranges from 0 to 60.~Usual cutoff points are:~0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression." (NCT00186186)
Timeframe: Baseline, 7 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Depakote ER | 14.9 |
A reduction greater than or equal to 50% in MADRS total score from baseline to the endpoint. (NCT00186186)
Timeframe: 7 weeks
| Intervention | participants (Number) |
|---|---|
| Depakote ER | 11 |
Time to intervention for a mood episode or time to discontinuation for treatment related adverse events, or death due to drug, or death due to disease. Mood episode considered to have occurred and subject discontinued if one or more of the following: Investigator (INV) decides discontinuation is in best interest of subject; loss of effect and/or change to treatment regimen (INV judgment); subject hospitalized for disease under study; Mania Rating Scale (MRS) and/or Montgomery-Asberg Rating Scale (MADRS) rating is ≥18 for 2 consecutive visits scheduled no more than 10 days apart. (NCT00280566)
Timeframe: Period 2: Week 24 or time of early termination
| Intervention | Days (Mean) |
|---|---|
| Ziprasidone | 168.145 |
| Placebo | 140.325 |
Key Secondary endpoint is time to discontinuation for any reason. Profile of patients remaining in the trial over time. (NCT00280566)
Timeframe: Period 2: 24 weeks or time of early termination
| Intervention | days (Mean) |
|---|---|
| Ziprasidone | 153.526 |
| Placebo | 123.313 |
Time to Intervention for Mood Episode (TIME) while on randomized drug after at least 8 weeks of symptom reduction on open-label ziprasidone plus mood stabilizer. Mood episode considered to have occurred and subject discontinued if one or more of the following: Investigator (INV) decides discontinuation is in best interest of subject; loss of effect and/or change to treatment regimen (INV judgment); subject hospitalized for disease under study; Mania Rating Scale (MRS) and/or Montgomery-Asberg Rating Scale (MADRS) rating is ≥18 for 2 consecutive visits scheduled no more than 10 days apart. (NCT00280566)
Timeframe: Period 2: 24 weeks or time of early termination
| Intervention | Days (Mean) |
|---|---|
| Ziprasidone | 172.159 |
| Placebo | 143.133 |
Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. Clinical Global Impression Severity Score is 7-item scale rates severity of illness from 0=not assessed, 1= normal to 7=most extremely ill. (NCT00280566)
Timeframe: Period 2: Weeks 1 - 24 or time of early termination
| Intervention | scores on scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 1 (n=122, 106) | Week 2 (n=117, 95) | Week 4 (n=117, 95) | Week 8 (n=107, 79) | Week 12 (n=98, 70) | Week 16 (n=94, 65) | Week 20 (n=83, 58) | Week 24 (n=85, 53) | |
| Placebo | 0.3 | 0.2 | 0.1 | -0.1 | 0.0 | 0.0 | -0.2 | -0.2 |
| Ziprasidone | 0.1 | 0.2 | -0.0 | -0.0 | -0.1 | -0.1 | -0.1 | -0.2 |
Period 2 Baseline = last observation in Period 1 to the start of Period 2. MRS is 11-item scale to measure mania; derived from Schedule for Affective Disorders and Schizophrenia-Change Behavior (SADS-CB). Subscales: Manic Syndrome (elevated mood, less need for sleep, excessive energy and activity, grandiosity), Behavior and Ideation (irritability, motor hyperactivity, accelerated speech, racing thoughts, poor judgment), and Impaired Insight. Racing thoughts range=0 to 2 (highest level of abnormal=2); all other items 0 to 5 (highest level of abnormal=5). Higher score = greater abnormality. (NCT00280566)
Timeframe: Period 2: Weeks 1 - 24 or time of early termination
| Intervention | scores on scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 1 (n=121, 106) | Week 2 (n=116, 95) | Week 4 (n=117,95) | Week 8 (n=107, 79) | Week 12 (n=98, 70) | Week 16 (n=94,65) | Week 20 (n=84, 58) | Week 24 (n=85,53) | |
| Placebo | 0.8 | -0.1 | 0.2 | 0.8 | 1.2 | 1.2 | 0.2 | 0.3 |
| Ziprasidone | -0.2 | -0.4 | -0.6 | -0.3 | -1.0 | -1.4 | -1.1 | -1.1 |
Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. MADRS is 10-item instrument measuring depression: scales from 0=Normal to 6 = most abnormal. (NCT00280566)
Timeframe: Period 2: Weeks 1 - 24 or time of early termination
| Intervention | scores on scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 1 (n=121, 106) | Week 2 (n=117, 95) | Week 4 (n=117, 95) | Week 8 (n=107, 79) | Week 12 (n=98, 70) | Week 16 (n=94,65) | Week 20 (n=84, 58) | Week 24 (n=85, 53) | |
| Placebo | 2.7 | 2.7 | 1.6 | 0.4 | 0.6 | 0.4 | -0.2 | 1.0 |
| Ziprasidone | -0.2 | 1.1 | -0.3 | 0.4 | 1.1 | 1.2 | 0.5 | 0.4 |
Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. Negative Scale is 7 items derived from PANSS; scale is 1 (absent) to 7 (extreme). (NCT00280566)
Timeframe: Period 2: Weeks 4 - 24 or time of early termination
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4 (n=123, 98) | Week 8 (n=107, 79) | Week 12 (n=98, 70) | Week 16 (n=94, 65) | Week 20 (n=84, 58) | Week 24 (n=85, 53) | |
| Placebo | 0.4 | -0.1 | 0.1 | 0.4 | -0.4 | -0.1 |
| Ziprasidone | 0.2 | 0.2 | 0.1 | 0.3 | -0.0 | -0.1 |
Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. Positive Scale is 7-items derived from PANSS; 1 (absent), 2 (minimal) to 7 (extreme). (NCT00280566)
Timeframe: Period 2: Weeks 4 - 24 or time of early termination
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4 (n=123, 98) | Week 8 (n=107, 79) | Week 12 (n=98, 70) | Week 16 (n=94, 65) | Week 20 (n=84, 58) | Week 24 (n=85, 53) | |
| Placebo | 0.1 | -0.2 | 0.3 | 0.0 | -0.1 | -0.1 |
| Ziprasidone | 0.0 | -0.2 | -0.3 | -0.4 | -0.2 | -0.2 |
Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. Positive and Negative Syndrome Scale Total Score is 30-item scale measuring severity of psychopathology (16 items), positive symptoms (7 items) and negative symptoms (7 items); scale from 1 (absent) to 7 (extreme) (NCT00280566)
Timeframe: Period 2: Weeks 4 - 24 or time of early termination
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4 (n=123, 98) | Week 8 (n=107, 79) | Week 12 (n=98, 70) | Week 16 (n=94, 65) | Week 20 (n=84, 58) | Week 24 (n=85, 53) | |
| Placebo | 1.5 | -0.8 | 0.3 | 0.7 | -1.0 | -0.9 |
| Ziprasidone | 0.4 | -0.1 | -0.1 | -0.0 | -0.2 | -0.6 |
Clinical Global Impression measures 7 items in Global assessment of improvement in patient's condition; 0=not assessed, 1= very much improved to 7= very much worse. (NCT00280566)
Timeframe: Period 2: Weeks 1 - 24 or time of early termination
| Intervention | scores on scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 1 (n=122, 106) | Week 2 (n=117, 95) | Week 4 (n=117, 95 | Week 8 (n=107, 79) | Week 12 (n=98, 70) | Week 16 (n=94, 65) | Week 20 (n=83, 58) | Week 24 (n=85, 53) | |
| Placebo | 2.8 | 2.6 | 2.5 | 2.2 | 2.2 | 2.5 | 2.1 | 2.2 |
| Ziprasidone | 2.3 | 2.4 | 2.3 | 2.3 | 2.2 | 2.3 | 2.1 | 2.2 |
The HAM-A is a clinician-rated 14 item scale that provides an overall measure of global anxiety, including psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety) symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0 - 56, where less than 17 indicates mild anxiety, 18 - 24 mild to moderate anxiety and 25-30 moderate to severe. The data presented here summarizes the change in HAM-A score from Baseline to 4 Weeks (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -3.6 |
| Placebo | -3.5 |
The HAM-A is a clinician-rated 14 item scale that provides an overall measure of global anxiety, including psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety) symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0 - 56, where less than 17 indicates mild anxiety, 18 - 24 mild to moderate anxiety and 25-30 moderate to severe. The data presented here summarizes the change in HAM-A score from Baseline to 8 Weeks (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -4.7 |
| Placebo | -4.4 |
The HAM-A is a clinician-rated 14 item scale that provides an overall measure of global anxiety, including psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety) symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0 - 56, where less than 17 indicates mild anxiety, 18 - 24 mild to moderate anxiety, 25-30 moderate to severe, >30 very severe. The data presented here summarizes the change in HAM-A score from Baseline to Endpoint (8 weeks or last observation after baseline). (NCT00481195)
Timeframe: baseline and 8 weeks (or last observation after baseline)
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -4.1 |
| Placebo | -3.9 |
The MADRS is a 10-item scale to evaluate the overall severity of a patient's depressive symptoms, that is completed by the physician. The rating scale makes use of both observational clues as to the subject's level of depression (eg. apparent sadness) and verbal indicators of depression expressed by the patient. Each of the 10 items is graded on a 6-point scale with anchors at 2 point intervals. Total scores range from 0 to 60, with the higher number indicating more severe symptoms of depression. Here we present data summarizing the change in MADRS from Baseline to Endpoint. (NCT00481195)
Timeframe: Baseline and Endpoint (8 weeks following the start of study drug administration or last observation after baseline)
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -12.3 |
| Placebo | -10.2 |
The Q-LES-Q-SF is an instrument designed to measure general activities of daily living. It is a patient-rated quality of life questionnaire and consists of 16 items, but only the first 14 are included in the total score. Each item is rated by the patient on a scale from 1 - 5 (1=very poor, 2=poor, 3=fair, 4=good, and 5=very good). The minimum score is 14 and the maximum score is 70, with lower scores indicating poorer quality of life. The data presented here summarizes the change in score from baseline to endpoint (8 weeks or last observation after baseline). (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | 8.2 |
| Placebo | 7.4 |
The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Endpoint (Week 8 or last observation after baseline). (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -7.0 |
| Placebo | -6.5 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Item 4 assesses hypersomnia on a scale from 0 (sleeps no longer than 7-8 hours a night) to 3 (sleeps longer than 12 hours in 24 hour period). The data presented here summarizes the change from baseline to Endpoint in the score of Item 4 assessing hypersomnia. (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -0.4 |
| Placebo | -0.2 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Items 1 - 3 assess sleep onset insomnia, mid-nocturnal insomnia, and early morning insomnia respectively each on a 0 - 3 scale. The data presented here summarizes the change from baseline to Endpoint in the combined score of these three items assessing insomnia. (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -1.6 |
| Placebo | -1.2 |
The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 1 (NCT00481195)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -3.5 |
| Placebo | -3.7 |
The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 2 (NCT00481195)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -5.0 |
| Placebo | -4.1 |
The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 3. (NCT00481195)
Timeframe: Baseline and 3 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -5.8 |
| Placebo | -5.0 |
The MADRS is a 10-item scale to evaluate the overall severity of a patient's depressive symptoms, that is completed by the physician. The rating scale makes use of both observational clues as to the subject's level of depression (eg. apparent sadness) and verbal indicators of depression expressed by the patient. Each of the 10 items is graded on a 6-point scale with anchors at 2 point intervals. Total scores range from 0 to 60, with the higher number indicating more severe symptoms of depression. Here we present data summarizing the difference in MADRS score from Baseline to Week 4. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -9.6 |
| Placebo | -8.9 |
The Q-LES-Q-SF is an instrument designed to measure general activities of daily living. It is a patient-rated quality of life questionnaire and consists of 16 items, but only the first 14 are included in the total score. Each item is rated by the patient on a scale from 1 - 5 (1=very poor, 2=poor, 3=fair, 4=good, and 5=very good). The minimum score is 14 and the maximum score is 70, with lower scores indicating poorer quality of life. The data presented here summarizes the change in score from baseline to 4 weeks. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | 5.9 |
| Placebo | 4.6 |
The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 4. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -6.4 |
| Placebo | -5.6 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Item 4 assesses hypersomnia on a scale from 0 (sleeps no longer than 7-8 hours a night) to 3 (sleeps longer than 12 hours in 24 hour period). The data presented here summarizes the change from baseline to week 4 in the score of Item 4 assessing hypersomnia. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -0.2 |
| Placebo | -0.2 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Items 1 - 3 assess sleep onset insomnia, mid-nocturnal insomnia, and early morning insomnia respectively each on a 0 - 3 scale. The data presented here summarizes the change from baseline to week 4 in the combined score of these three items assessing insomnia. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -1.2 |
| Placebo | -1.1 |
The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 6. (NCT00481195)
Timeframe: Baseline and 6 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -7.8 |
| Placebo | -6.7 |
The MADRS is a 10-item scale to evaluate the overall severity of a patient's depressive symptoms, that is completed by the physician. The rating scale makes use of both observational clues as to the subject's level of depression (eg. apparent sadness) and verbal indicators of depression expressed by the patient. Each of the 10 items is graded on a 6-point scale with anchors at 2 point intervals. Total scores range from 0 to 60, with the higher number indicating more severe symptoms of depression. Here we present data summarizing the difference in MADRS score from Baseline to Week 8. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -13.4 |
| Placebo | -11.0 |
The Q-LES-Q-SF is an instrument designed to measure general activities of daily living. It is a patient-rated quality of life questionnaire and consists of 16 items, but only the first 14 are included in the total score. Each item is rated by the patient on a scale from 1 - 5 (1=very poor, 2=poor, 3=fair, 4=good, and 5=very good). The minimum score is 14 and the maximum score is 70, with lower scores indicating poorer quality of life. The data presented here summarizes the change in score from baseline to 8 weeks. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | 10.1 |
| Placebo | 8.5 |
The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 8. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -8.2 |
| Placebo | -7.6 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Item 4 assesses hypersomnia on a scale from 0 (sleeps no longer than 7-8 hours a night) to 3 (sleeps longer than 12 hours in 24 hour period). The data presented here summarizes the change from baseline to week 8 in the score of Item 4 assessing hypersomnia. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -0.3 |
| Placebo | -0.2 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Items 1 - 3 assess sleep onset insomnia, mid-nocturnal insomnia, and early morning insomnia respectively each on a 0 - 3 scale. The data presented here summarizes the change from baseline to week 8 in the combined score of these three items assessing insomnia. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -2.0 |
| Placebo | -1.6 |
The IDS C30 is a standardized 30 item, clinician rated scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Endpoint (either week 8 or the last observation after baseline) in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 8 weeks from start of study drug administration (or last observation after baseline)
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -15.6 |
| Placebo | -12.5 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 1 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -6.5 |
| Placebo | -4.8 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 2 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -10.0 |
| Placebo | -7.3 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 3 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 3 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -13.1 |
| Placebo | -10.7 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 4 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -13.7 |
| Placebo | -12.1 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 6 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 6 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -16.7 |
| Placebo | -13.7 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 8 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Armodafinil 150 mg/Day | -17.8 |
| Placebo | -14.8 |
"The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data here summarizes the number of subjects in each treatment group who achieved a response (> 50% decrease from baseline in total score)." (NCT00481195)
Timeframe: Baseline, 4 and 8 weeks following start of study drug administration (or last observation after baseline)
| Intervention | Participants (Number) | |
|---|---|---|
| Response | No Response | |
| Armodafinil 150 mg/Day | 46 | 78 |
| Placebo | 47 | 76 |
"The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data here summarizes the number of subjects in each treatment group who achieved a sustained remission (total score <= 11 that persists over the four week period from Week 4 to Week 8)." (NCT00481195)
Timeframe: Baseline, 4 and 8 weeks following start of study drug administration (or last observation after baseline)
| Intervention | Participants (Number) | |
|---|---|---|
| Sustained Remission | No Sustained Remission | |
| Armodafinil 150 mg/Day | 13 | 111 |
| Placebo | 8 | 115 |
"The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data here summarizes the number of subjects in each treatment group who achieved a sustained response (> 50% decrease from baseline in total score that persisted over the four week period between Week 4 and Week 8)." (NCT00481195)
Timeframe: Baseline, 4 and 8 weeks following start of study drug administration (or last observation after baseline)
| Intervention | Participants (Number) | |
|---|---|---|
| Sustained Response | No Sustained Response | |
| Armodafinil 150 mg/Day | 23 | 101 |
| Placebo | 17 | 106 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data here summarizes the number of subjects in each treatment group who achieved a remission (total score <=11). (NCT00481195)
Timeframe: Baseline, 4 and 8 weeks following start of study drug administration (or last observation after baseline)
| Intervention | Participants (Number) | |
|---|---|---|
| Remission | No Remission | |
| Armodafinil 150 mg/Day | 30 | 94 |
| Placebo | 22 | 101 |
"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Endpoint are presented." (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)
| Intervention | Participants (Number) | |
|---|---|---|
| Responder | Non Responder | |
| Armodafinil 150 mg/Day | 64 | 60 |
| Placebo | 60 | 62 |
"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 1 are presented." (NCT00481195)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Participants (Number) | |
|---|---|---|
| Responder | Non Responder | |
| Armodafinil 150 mg/Day | 12 | 107 |
| Placebo | 12 | 105 |
"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 2 are presented." (NCT00481195)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Participants (Number) | |
|---|---|---|
| Responder | Non Responder | |
| Armodafinil 150 mg/Day | 25 | 83 |
| Placebo | 26 | 84 |
"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 3 are presented." (NCT00481195)
Timeframe: Baseline and 3 weeks following the start of study drug administration
| Intervention | Participants (Number) | |
|---|---|---|
| Responder | Non Responder | |
| Armodafinil 150 mg/Day | 38 | 64 |
| Placebo | 32 | 68 |
"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 4 are presented." (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Participants (Number) | |
|---|---|---|
| Responder | Non Responder | |
| Armodafinil 150 mg/Day | 46 | 53 |
| Placebo | 42 | 55 |
"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 6 are presented." (NCT00481195)
Timeframe: Baseline and 6 weeks following the start of study drug administration
| Intervention | Participants (Number) | |
|---|---|---|
| Responder | Non Responder | |
| Armodafinil 150 mg/Day | 47 | 45 |
| Placebo | 43 | 49 |
"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 8 are presented." (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
| Intervention | Participants (Number) | |
|---|---|---|
| Responder | Non Responder | |
| Armodafinil 150 mg/Day | 52 | 37 |
| Placebo | 47 | 41 |
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item scale that measures the severity of depression, with a higher score indicating a higher level of depression. The range of scores is 0 to 60. (NCT01179009)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Ketamine 100-hour Infusion | -9.0 |
| Ketamine 40-minute Infusion | -6.4 |
GBI Depression Scale Scores range from 46-184, where higher scores are indicative of more depression. (NCT00194116)
Timeframe: Acute phase (week0-week6)
| Intervention | units on a scale (Mean) |
|---|---|
| Divalproex Sodium ER | -11.56 |
| Placebo | 0.9 |
GBI Hypomanic/Biphasic Scale scores range from 28-112, where higher scores are indicative of more hypomanic/manic symptoms. (NCT00194116)
Timeframe: Acute phase (week0-week6)
| Intervention | units on a scale (Mean) |
|---|---|
| Divalproex Sodium ER | -7.2 |
| Placebo | -6.8 |
HAMA Scores range from 0 to 56 where higher scores are indicative of more anxiety. (NCT00194116)
Timeframe: Acute phase (week0-week6)
| Intervention | units on a scale (Mean) |
|---|---|
| Divalproex Sodium ER | -4.6 |
| Placebo | -3.5 |
MADRS total scores range from 0-60, where higher scores are indicative of more depression. (NCT00194116)
Timeframe: Acute phase (week0-week6)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Divalproex Sodium ER | -9.64 |
| Placebo | -5.32 |
SF-36 Mental Component Summary scores range from 0-100, with a higher score indicating better mental health. (NCT00194116)
Timeframe: Acute phase (week0-week6)
| Intervention | units on a scale (Mean) |
|---|---|
| Divalproex Sodium ER | 17.9 |
| Placebo | 13.5 |
SF-36 Physical Component Summary scores range from 0-100, with a higher score indicating better physical health. (NCT00194116)
Timeframe: Acute phase (week0-week6)
| Intervention | units on a scale (Mean) |
|---|---|
| Divalproex Sodium ER | -3.4 |
| Placebo | -4.2 |
YMRS Scores range from 0 to 60 where higher scores are indicative of more mania. (NCT00194116)
Timeframe: Acute phase (week0-week6)
| Intervention | units on a scale (Mean) |
|---|---|
| Divalproex Sodium ER | -0.54 |
| Placebo | -0.46 |
The AIMS is an assessment of movement dysfunctions. It is a 12-item instrument assessing abnormal involuntary movements associated with antipsychotic drugs and 'spontaneous' motor disturbance related to the illness itself. Scoring the AIMS consists of rating the severity of movement in 3 main anatomic areas (facial/oral, extremities, and trunk), based on a five-point scale (0=none, 4=severe). The AIMS Total Score has a possible range from 0 to 28. Negative change scores indicate improvement in movement dysfunction. (NCT00261443)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Lithium | 0.10 |
| Valproate | 0.08 |
The Barnes Akathisia Rating Scale is a 4-item scale to assess presence and severity of drug-induced akathisia, including both objective items and subjective items, together with a global clinical assessment of akathisia. Global assessment is made on a scale of 0 to 5 with comprehensive definitions provided for each anchor point on scale: 0=absent; 1=questionable; 2=mild akathisia; 3=moderate akathisia; 4=marked akathisia; 5=severe akathisia. Score has a possible range from 0 (absent) to 5 (severe akathisia). Negative change scores indicate improvement in akathisia. (NCT00261443)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Lithium | 0.09 |
| Valproate | 0.14 |
The SAS is a 10-item instrument used to evaluate the presence and severity of parkinsonian symptomatology. It is the most commonly used rating scale for Parkinsonism in clinical trials over the past 25 years. The ten items focus on rigidity rather than bradykinesia, and do not assess subjective rigidity or slowness. Items are rated for severity on a 0-4 scale, with definitions given for each anchor point. The total SAS Score has a possible range from 10 to 50.(lower score=less severe). Negative change scores indicate improvement. (NCT00261443)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Lithium | 10.28 |
| Valproate | 10.30 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change in patients with bipolar disorder. Patients are rated on Change from Preceding Phase (mania, depression and overall bipolar illness) items (also a 7-point scale [1 to 7], with 1 being normal and 7 being very severely ill). A negative change score signifies improvement. (NCT00261443)
Timeframe: Baseline, Extension Phase Endpoint. LTE Phase (A 72-week Extension Phase [until study unblinding] following Phase 3 [52 weeks], Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.05 |
| Aripiprazole | -0.35 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change in patients with bipolar disorder. Patients are rated on Change from Preceding Phase (mania, depression and overall bipolar illness) items (also a 7-point scale [1 to 7], with 1 being normal and 7 being very severely ill). A negative change score signifies improvement. (NCT00261443)
Timeframe: Baseline, Extension Phase Endpoint. LTE Phase (A 72-week Extension Phase [until study unblinding] following Phase 3 [52 weeks], Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.16 |
| Aripiprazole | 0.00 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change in patients with bipolar disorder. Patients are rated on Change from Preceding Phase (mania, depression and overall bipolar illness) items (also a 7-point scale [1 to 7], with 1 being normal and 7 being very severely ill). A negative change score signifies improvement. (NCT00261443)
Timeframe: Baseline, Extension Phase Endpoint. LTE Phase (A 72-week Extension Phase [until study unblinding] following Phase 3 [52 weeks], Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.11 |
| Aripiprazole | -0.35 |
(NCT00261443)
Timeframe: Baseline
| Intervention | percentage of total blood volume (Median) |
|---|---|
| Lithium | 41.30 |
| Valproate | 41.10 |
(NCT00261443)
Timeframe: Baseline
| Intervention | g/dL (Median) |
|---|---|
| Lithium | 13.75 |
| Valproate | 13.80 |
HOMA stands for homeostasis model assessment of insulin resistance and beta-cell function. These are model-based calculations that use fasting insulin and glucose concentrations in order to assess pancreatic beta-cell function and insulin resistance. The HOMA2 model assesses beta-cell function (HOMA2-%β) relative to expected normal function (indexed to 100% for normal function) and is based on predictions from experimental human data on the relationship between insulin and glucose in a fasted state. HOMA2-%Beta is a percentage of 'normal function.' (NCT00261443)
Timeframe: Baseline
| Intervention | percentage of 'normal function' (Median) |
|---|---|
| Lithium | 99.95 |
| Valproate | 118.70 |
HOMA stands for homeostasis model assessment of insulin resistance and beta-cell function. These are model-based calculations that use fasting insulin and glucose concentrations in order to assess pancreatic beta-cell function and insulin resistance. The HOMA2 model assesses insulin resistance (HOMA2-IR) relative to expected normal function (indexed to 1.0 for normal function) and is based on predictions from experimental human data on the relationship between insulin and glucose in a fasted state. HOMA2-IR is a proportion of 'normal function.' (NCT00261443)
Timeframe: Baseline
| Intervention | proportion of 'normal function' (Median) |
|---|---|
| Lithium | 1.14 |
| Valproate | 1.42 |
(NCT00261443)
Timeframe: Baseline
| Intervention | x10^3 c/L (Median) |
|---|---|
| Lithium | 8.350 |
| Valproate | 6.800 |
(NCT00261443)
Timeframe: Baseline
| Intervention | x10^9 c/L (Median) |
|---|---|
| Lithium | 297.0 |
| Valproate | 226.0 |
(NCT00261443)
Timeframe: Baseline
| Intervention | ng/dL (Median) |
|---|---|
| Lithium | 10.0 |
| Valproate | 9.5 |
(NCT00261443)
Timeframe: Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | percentage of total blood volume (Median) |
|---|---|
| Lithium | 0.30 |
| Valproate | 0.20 |
(NCT00261443)
Timeframe: Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | g/dL (Median) |
|---|---|
| Lithium | 0.05 |
| Valproate | 0.10 |
HOMA stands for homeostasis model assessment of insulin resistance and beta-cell function. These are model-based calculations that use fasting insulin and glucose concentrations in order to assess pancreatic beta-cell function and insulin resistance. The HOMA2 model assesses insulin resistance (HOMA2-IR) relative to expected normal function (indexed to 1.0 for normal function) and is based on predictions from experimental human data on the relationship between insulin and glucose in a fasted state. HOMA2-IR is a proportion of 'normal function.' (NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 Endpoint (endpoint of a 13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout and Confirmation of Partial Nonresponse Phase)
| Intervention | proportion of 'normal function' (Median) |
|---|---|
| Lithium | 0.09 |
| Valproate | 0.15 |
HOMA stands for homeostasis model assessment of insulin resistance and beta-cell function. These are model-based calculations that use fasting insulin and glucose concentrations in order to assess pancreatic beta-cell function and insulin resistance. The HOMA2 model assesses beta-cell function (HOMA2-%β) relative to expected normal function (indexed to 100% for normal function) and is based on predictions from experimental human data on the relationship between insulin and glucose in a fasted state. HOMA2-%Beta is a percentage of 'normal function.' (NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 Endpoint (endpoint of a 13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout and Confirmation of Partial Nonresponse Phase)
| Intervention | percentage of 'normal function' (Median) |
|---|---|
| Lithium | 7.70 |
| Valproate | 17.05 |
(NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | x10^3 c/L (Median) |
|---|---|
| Lithium | -0.100 |
| Valproate | -0.200 |
(NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | x10^9 c/L (Median) |
|---|---|
| Lithium | -4.0 |
| Valproate | -2.0 |
(NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | ng/dL (Median) |
|---|---|
| Lithium | -2.5 |
| Valproate | -3.0 |
(NCT00261443)
Timeframe: Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | Proportion of Participants (Number) |
|---|---|
| Placebo | 0.473 |
| Aripiprazole | 0.387 |
The AIMS is an assessment of movement dysfunctions. It is a 12-item instrument assessing abnormal involuntary movements associated with antipsychotic drugs and 'spontaneous' motor disturbance related to the illness itself. Scoring the AIMS consists of rating the severity of movement in 3 main anatomic areas (facial/oral, extremities, and trunk), based on a five-point scale (0=none, 4=severe). The AIMS Total Score has a possible range from 0 to 28. Negative change scores indicate improvement in movement dysfunction. (NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | units on a scale (Mean) |
|---|---|
| Lithium | 0.05 |
| Valproate | 0.04 |
The Barnes Akathisia Rating Scale is a 4-item scale to assess presence and severity of drug-induced akathisia, including both objective items and subjective items, together with a global clinical assessment of akathisia. Global assessment is made on a scale of 0 to 5 with comprehensive definitions provided for each anchor point on scale: 0=absent; 1=questionable; 2=mild akathisia; 3=moderate akathisia; 4=marked akathisia; 5=severe akathisia. Score has a possible range from 0 (absent) to 5 (severe akathisia). Negative change scores indicate improvement in akathisia. (NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | units on a scale (Mean) |
|---|---|
| Lithium | 0.14 |
| Valproate | 0.07 |
The SAS is a 10-item instrument used to evaluate the presence and severity of parkinsonian symptomatology. It is the most commonly used rating scale for Parkinsonism in clinical trials over the past 25 years. The ten items focus on rigidity rather than bradykinesia, and do not assess subjective rigidity or slowness. Items are rated for severity on a 0-4 scale, with definitions given for each anchor point. The total SAS Score has a possible range from 10 to 50(lower score=less severe). Negative change scores indicate improvement. (NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | units on a scale (Mean) |
|---|---|
| Lithium | 0.44 |
| Valproate | 0.15 |
The AIMS is an assessment of movement dysfunctions. It is a 12-item instrument assessing abnormal involuntary movements associated with antipsychotic drugs and 'spontaneous' motor disturbance related to the illness itself. Scoring the AIMS consists of rating the severity of movement in 3 main anatomic areas (facial/oral, extremities, and trunk), based on a five-point scale (0=none, 4=severe). AIMS Item 10 Score range from 0 to 4. A negative score signifies improvement. (NCT00261443)
Timeframe: Baseline, Weeks 4, 8, 12, 24, 36, 52, throughout Phase 3 (for Highest Value of Change)
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=164, 162) | Change at Week 4 (n=160, 162) | Change at Week 8 (n=151, 145) | Change at Week 12 (n=144, 136) | Change at Week 24 (n=113, 120) | Change at Week 36 (n=97, 105) | Change at Week 52 (n=85, 96) | Change at Week 52 LOCF (n=164, 162) | Highest Value in Change During Phase 3 (n=164,162) | |
| Aripiprazole | 0.04 | 0.03 | 0.01 | 0.00 | -0.01 | -0.02 | -0.03 | -0.01 | 0.06 |
| Placebo | 0.02 | -0.00 | 0.02 | 0.02 | 0.05 | 0.02 | 0.01 | 0.00 | 0.04 |
The AIMS is an assessment of movement dysfunctions. It is a 12-item instrument assessing abnormal involuntary movements associated with antipsychotic drugs and 'spontaneous' motor disturbance related to the illness itself. Scoring the AIMS consists of rating the severity of movement in 3 main anatomic areas (facial/oral, extremities, and trunk), based on a five-point scale (0=none, 4=severe). AIMS Item 8 Score range from 0 to 4. A negative score signifies improvement. (NCT00261443)
Timeframe: Baseline, Weeks 4, 8, 12, 24, 36, 52, throughout Phase 3 (for Highest Value of Change)
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=164, 162) | Change at Week 4 (n=160, 162) | Change at Week 8 (n=151, 145) | Change at Week 12 (n=144, 136) | Change at Week 24 (n=113, 120) | Change at Week 36 (n=97, 105) | Change at Week 52 (n=85, 96) | Change at Week 52 LOCF (n=164, 162) | Highest Value in Change During Phase 3 (n=164,162) | |
| Aripiprazole | 0.03 | 0.03 | 0.02 | 0.01 | 0.00 | -0.00 | -0.01 | 0.01 | 0.07 |
| Placebo | 0.04 | -0.01 | 0.01 | 0.02 | 0.02 | 0.01 | -0.00 | 0.01 | 0.03 |
The AIMS is an assessment of movement dysfunctions. It is a 12-item instrument assessing abnormal involuntary movements associated with antipsychotic drugs and 'spontaneous' motor disturbance related to the illness itself. Scoring the AIMS consists of rating the severity of movement in 3 main anatomic areas (facial/oral, extremities, and trunk), based on a five-point scale (0=none, 4=severe). AIMS Item 9 Score range from 0 to 4. A negative score signifies improvement. (NCT00261443)
Timeframe: Baseline, Weeks 4, 8, 12, 24, 36, 52, throughout Phase 3 (for Highest Value of Change)
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=164, 162) | Change at Week 4 (n=160, 162) | Change at Week 8 (n=151, 145) | Change at Week 12 (n=144, 136) | Change at Week 24 (n=113, 120) | Change at Week 36 (n=97, 105) | Change at Week 52 (n=85, 96) | Change at Week 52 LOCF (n=164, 162) | Highest Value in Change During Phase 3 (n=164,162) | |
| Aripiprazole | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | -0.00 | -0.00 | 0.01 | 0.05 |
| Placebo | 0.01 | -0.01 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | 0.04 |
The AIMS is an assessment of movement dysfunctions. It is a 12-item instrument assessing abnormal involuntary movements associated with antipsychotic drugs and 'spontaneous' motor disturbance related to the illness itself. Scoring the AIMS consists of rating the severity of movement in 3 main anatomic areas (facial/oral, extremities, and trunk), based on a five-point scale (0=none, 4=severe). The AIMS Total Score has a possible range from 0 to 28. Negative change scores indicate improvement in movement dysfunction. (NCT00261443)
Timeframe: Baseline, Weeks 4, 8, 12, 24, 36, 52, throughout Phase 3 (for Highest Value of Change)
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=164, 162) | Change at Week 4 (n=160, 162) | Change at Week 8 (n=151, 145) | Change at Week 12 (n=144, 136) | Change at Week 24 (n=113, 120) | Change at Week 36 (n=97, 105) | Change at Week 52 (n=85, 96) | Change at Week 52 LOCF (n=164, 162) | Highest Value in Change During Phase 3 (n=164,162) | |
| Aripiprazole | 0.14 | 0.05 | 0.11 | -0.01 | -0.03 | -0.07 | -0.02 | 0.06 | 0.28 |
| Placebo | 0.11 | -0.01 | 0.11 | 0.10 | 0.13 | 0.08 | 0.06 | 0.01 | 0.16 |
The Barnes Akathisia Rating Scale is a 4-item scale to assess presence and severity of drug-induced akathisia, including both objective items and subjective items, together with a global clinical assessment of akathisia. Global assessment is made on a scale of 0 to 5 with comprehensive definitions provided for each anchor point on scale: 0=absent; 1=questionable; 2=mild akathisia; 3=moderate akathisia; 4=marked akathisia; 5=severe akathisia. Score has a possible range from 0 (absent) to 5 (severe akathisia). Negative change scores indicate improvement in akathisia. (NCT00261443)
Timeframe: Baseline, Weeks 4, 8, 12, 24, 36, 52, throughout Phase 3 (for Highest Value of Change)
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=164, 162) | Change at Week 4 (n=160, 162) | Change at Week 8 (n=151, 144) | Change at Week 12 (n=144, 136) | Change at Week 24 (n=113, 120) | Change at Week 36 (n=97, 104) | Change at Week 52 (n=85, 96) | Change at Week 52 LOCF (n=164, 162) | Highest Value in Change During Phase 3 (n=164,162) | |
| Aripiprazole | 0.16 | 0.01 | -0.04 | -0.03 | -0.04 | -0.05 | -0.07 | -0.05 | 0.11 |
| Placebo | 0.10 | -0.01 | -0.06 | -0.07 | -0.06 | -0.09 | -0.10 | -0.06 | 0.07 |
The SAS is a 10-item instrument used to evaluate the presence and severity of parkinsonian symptomatology. It is the most commonly used rating scale for Parkinsonism in clinical trials over the past 25 years. The ten items focus on rigidity rather than bradykinesia, and do not assess subjective rigidity or slowness. Items are rated for severity on a 0-4 scale, with definitions given for each anchor point. The total SAS Score has a possible range from 10 to 50(lower scores=less severe). Negative change scores indicate improvement. (NCT00261443)
Timeframe: Baseline, Weeks 4,8, 12, 24, 36, 52, throughout Phase 3 (for Highest Value of Change)
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=164, 162) | Change at Week 4 (n=160, 161) | Change at Week 8 (n=151, 145) | Change at Week 12 (n=144, 136) | Change at Week 24 (n=113, 120) | Change at Week 36 (n=97, 104) | Change at Week 52 (n=85, 95) | Change at Week 52 LOCF (n=164, 162) | Highest Value in Change During Phase 3 (n=164,162) | |
| Aripiprazole | 10.50 | 0.04 | -0.03 | -0.10 | -0.02 | 0.01 | -0.07 | -0.10 | 0.53 |
| Placebo | 10.48 | -0.02 | -0.13 | -0.20 | -0.24 | -0.26 | -0.24 | -0.20 | 0.17 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change from baseline (in this case, preceding phase) in patients with bipolar disorder. Patients are rated on mania, depression and overall bipolar illness items on a 7-point scale [1 to 7], with 1 being very much improved and 7 being very much worse). (NCT00261443)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52. Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | units on a scale (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean Change at Week 4 (n=160, 162) | Mean Change at Week 8 | Mean Change at Week 12 | Mean Change at Week 16 | Mean Change at Week 20 | Mean Change at Week 24 | Mean Change at Week 28 | Mean Change at Week 32 | Mean Change at Week 36 | Mean Change at Week 40 | Mean Change at Week 44 | Mean Change at Week 48 | Mean Change at Week 52 | |
| Aripiprazole | 3.56 | 3.52 | 3.45 | 3.45 | 3.53 | 3.54 | 3.52 | 3.49 | 3.52 | 3.47 | 3.49 | 3.44 | 3.44 |
| Placebo | 3.46 | 3.55 | 3.51 | 3.52 | 3.58 | 3.63 | 3.65 | 3.69 | 3.62 | 3.55 | 3.52 | 3.58 | 3.56 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change from baseline in patients with bipolar disorder. Patients are rated on mania, depression and overall bipolar illness items on a 7-point scale [1 to 7], with 1 being normal and 7 being very severely ill). A negative change score signifies improvement. (NCT00261443)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52. Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | units on a scale (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean Change at Week 4 (n=160, 162) | Mean Change at Week 8 | Mean Change at Week 12 | Mean Change at Week 16 | Mean Change at Week 20 | Mean Change at Week 24 | Mean Change at Week 28 | Mean Change at Week 32 | Mean Change at Week 36 | Mean Change at Week 40 | Mean Change at Week 44 | Mean Change at Week 48 | Mean Change at Week 52 | |
| Aripiprazole | 3.00 | 2.98 | 3.03 | 2.98 | 3.03 | 2.96 | 3.01 | 3.00 | 2.94 | 2.94 | 2.96 | 2.96 | 2.89 |
| Placebo | 2.96 | 3.17 | 3.14 | 3.27 | 3.29 | 3.26 | 3.37 | 3.31 | 3.37 | 3.32 | 3.33 | 3.35 | 3.29 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change from baseline (in this case, preceding phase) in patients with bipolar disorder. Patients are rated on mania, depression and overall bipolar illness items on a 7-point scale [1 to 7], with 1 being very much improved and 7 being very much worse). (NCT00261443)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52. Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | units on a scale (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean Change at Week 4 (n=160, 162) | Mean Change at Week 8 | Mean Change at Week 12 | Mean Change at Week 16 | Mean Change at Week 20 | Mean Change at Week 24 | Mean Change at Week 28 | Mean Change at Week 32 | Mean Change at Week 36 | Mean Change at Week 40 | Mean Change at Week 44 | Mean Change at Week 48 | Mean Change at Week 52 | |
| Aripiprazole | 3.27 | 3.22 | 3.27 | 3.22 | 3.31 | 3.31 | 3.31 | 3.29 | 3.28 | 3.24 | 3.28 | 3.26 | 3.25 |
| Placebo | 3.17 | 3.36 | 3.34 | 3.45 | 3.53 | 3.60 | 3.65 | 3.63 | 3.61 | 3.54 | 3.57 | 3.63 | 3.58 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change from baseline in patients with bipolar disorder. Patients are rated on mania, depression and overall bipolar illness items on a 7-point scale [1 to 7], with 1 being normal and 7 being very severely ill). A negative change score signifies improvement. (NCT00261443)
Timeframe: Baseline (end of Ph 2), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52. Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Mean | Mean Change from Baseline at Week 4 (n=160, 162) | Mean Change from Baseline at Week 8 | Mean Change from Baseline at Week 12 | Mean Change from Baseline at Week 16 | Mean Change from Baseline at Week 20 | Mean Change from Baseline at Week 24 | Mean Change from Baseline at Week 28 | Mean Change from Baseline at Week 32 | Mean Change from Baseline at Week 36 | Mean Change from Baseline at Week 40 | Mean Change from Baseline at Week 44 | Mean Change from Baseline at Week 48 | Mean Change from Baseline at Week 52 | |
| Aripiprazole | 1.47 | 0.29 | 0.24 | 0.23 | 0.24 | 0.28 | 0.27 | 0.28 | 0.27 | 0.32 | 0.28 | 0.28 | 0.27 | 0.30 |
| Placebo | 1.43 | 0.30 | 0.35 | 0.37 | 0.35 | 0.41 | 0.44 | 0.50 | 0.53 | 0.49 | 0.47 | 0.46 | 0.50 | 0.51 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change from baseline in patients with bipolar disorder. Patients are rated on mania, depression and overall bipolar illness items on a 7-point scale [1 to 7], with 1 being normal and 7 being very severely ill). A negative change score signifies improvement. (NCT00261443)
Timeframe: Baseline (end of Phase 2), 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean Baseline (n=164, 162) | Mean Change from Baseline to Week 4 (n=160, 162) | Mean Change from Baseline to Week 8 (n=164, 162) | Mean Change from Baseline to Week 12 (n=164, 162) | Mean Change from Baseline to Week 16 (n=164, 162) | Mean Change from Baseline to Week 20 (n=164, 162) | Mean Change from Baseline to Week 24 (n=164, 162) | Mean Change from Baseline to Week 28 (n=164, 162) | Mean Change from Baseline to Week 32 (n=164, 162) | Mean Change from Baseline to Week 36 (n=164, 162) | Mean Change from Baseline to Week 40 (n=164, 162) | Mean Change from Baseline to Week 44 (n=164, 162) | Mean Change from Baseline to Week 48 (n=164, 162) | Mean Change from Baseline to Week 52 (n=164, 162) | |
| Aripiprazole | 1.54 | 0.05 | 0.01 | 0.07 | 0.07 | 0.07 | 0.05 | 0.10 | 0.08 | 0.05 | 0.05 | 0.06 | 0.05 | 0.04 |
| Placebo | 1.54 | 0.01 | 0.05 | 0.12 | 0.19 | 0.23 | 0.25 | 0.31 | 0.27 | 0.30 | 0.27 | 0.33 | 0.33 | 0.32 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change from baseline in patients with bipolar disorder. Patients are rated on mania, depression and overall bipolar illness items on a 7-point scale [1 to 7], with 1 being normal and 7 being very severely ill). A negative change score signifies improvement. (NCT00261443)
Timeframe: Baseline (end of Ph 2), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52. Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean Baseline | Mean Change from Baseline At Week 4 (n=160, 162) | Mean Change from Baseline At Week 8 | Mean Change from Baseline At Week 12 | Mean Change from Baseline At Week 16 | Mean Change from Baseline At Week 20 | Mean Change from Baseline At Week 24 | Mean Change from Baseline At Week 28 | Mean Change from Baseline At Week 32 | Mean Change from Baseline At Week 36 | Mean Change from Baseline At Week 40 | Mean Change from Baseline At Week 44 | Mean Change from Baseline At Week 48 | Mean Change from Baseline At Week 52 | |
| Aripiprazole | 1.70 | 0.27 | 0.21 | 0.26 | 0.26 | 0.29 | 0.25 | 0.32 | 0.30 | 0.33 | 0.28 | 0.30 | 0.28 | 0.31 |
| Placebo | 1.65 | 0.25 | 0.32 | 0.40 | 0.44 | 0.51 | 0.56 | 0.62 | 0.61 | 0.62 | 0.57 | 0.64 | 0.68 | 0.66 |
(NCT00261443)
Timeframe: Baseline, Weeks 12, 24, 36, 52, During Phase 3 (for highest value)
| Intervention | kg (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline (n=161, 160) | Change at Week 12 (n=129, 121) | Change at Week 24 (n=111, 118) | Change at Week 36 (n=89, 98) | Change at Week 52 (n=85, 95) | Change at Week 52 (LOCF) (n=161, 160) | Highest Change Value (n=161, 160) | |
| Aripiprazole | 80.22 | 0.28 | 0.13 | 0.59 | 1.61 | 1.07 | 2.35 |
| Placebo | 81.33 | -1.00 | 0.35 | 0.64 | 1.66 | 0.60 | 2.39 |
Participants with Adverse Events (AEs), Deaths, Serious AEs (SAEs), and AEs leading to study discontinuation. AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a cancer, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event. (NCT00261443)
Timeframe: During Phase 2 (a 13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout and Confirmation of Partial Nonresponse Phase)
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Deaths | SAEs | Discontinuations due to AEs | Any AE | Treatment-related AEs in >=2% of Participants | Any Extrapyramidal Syndrome-Related AE | |
| Lithium | 0 | 5 | 38 | 226 | 188 | 108 |
| Valproate | 0 | 10 | 50 | 287 | 233 | 113 |
Participants with Adverse Events (AEs), Deaths, Serious AEs (SAEs), and AEs leading to study discontinuation. AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a cancer, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event. (NCT00261443)
Timeframe: Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Deaths | Treatment-Emergent SAEs | Treatment-Emergent AEs | Treatment-Emergent AEs in >=2% of Participants | Treatment-Emergent AEs Leading to Discontinuation | |
| Aripiprazole | 1 | 11 | 105 | 62 | 19 |
| Placebo | 1 | 8 | 105 | 49 | 15 |
AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. By Common Terminology Criteria Version 3.0 (CTC v3) Grade (Gr): Gr 1 (mild); Gr 2 (moderate); Gr 3 (severe); Gr 4 (life-threatening); Gr 5 (death). (NCT00261443)
Timeframe: From first day until 30 days after the last dose of double-blind dosing in the Extension Phase (A 72-week Extension Phase [until study unblinding] following Phase 3 [52 weeks], Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Mild / Grade 1 | Moderate / Grade 2 | Severe / Grade 3 | Very Severe / Grade 4 | |
| Aripiprazole | 7 | 2 | 0 | 0 |
| Placebo | 4 | 1 | 0 | 0 |
Participants with Adverse Events (AEs), Deaths, Serious AEs (SAEs), and AEs leading to study discontinuation. AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a cancer, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event. (NCT00261443)
Timeframe: From first day until 30 days after the last dose of double-blind dosing in the Extension Phase (A 72-week Extension Phase [until study unblinding] following Phase 3 [52 weeks], Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Deaths | SAEs | AEs | Discontinuations due to AEs | Treatment-related AEs | |
| Aripiprazole | 0 | 0 | 8 | 0 | 1 |
| Placebo | 0 | 0 | 5 | 1 | 2 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change in patients with bipolar disorder. Patients are rated on Change from Preceding Phase (mania, depression and overall bipolar illness) items (also a 7-point scale [1 to 7], with 1 being normal and 7 being very severely ill). A negative change score signifies improvement. (NCT00261443)
Timeframe: Baseline, Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72 of LTE Phase. LTE Phase (A 72-week Extension Phase [until study unblinding] following Phase 3 [52 weeks], Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean Baseline (N=19, 23) | Mean Change at Week 8 (n=19, 23) | Mean Change at Week 16 (n=18, 23) | Mean Change at Week 24 (n=17, 20) | Mean Change at Week 32 (n=15, 15) | Mean Change at Week 40 (n=9, 12) | Mean Change at Week 48 (n=9, 9) | Mean Change at Week 56 (n=5, 9) | Mean Change at Week 64 (n=5, 4) | Mean Change at Week 72 (n=1, 2) | |
| Aripiprazole | 1.35 | -0.30 | -0.30 | -0.40 | -0.33 | -0.33 | -0.22 | -0.22 | 0.00 | -0.50 |
| Placebo | 1.26 | -0.26 | -0.28 | -0.29 | 0.00 | -0.11 | -0.11 | 0.00 | 0.00 | 0.00 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change in patients with bipolar disorder. Patients are rated on Change from Preceding Phase (mania, depression and overall bipolar illness) items (also a 7-point scale [1 to 7], with 1 being normal and 7 being very severely ill). A negative change score signifies improvement. (NCT00261443)
Timeframe: Baseline, Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72. LTE Phase (A 72-week Extension Phase [until study unblinding] following Phase 3 [52 weeks], Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean Baseline (N=19, 23) | Mean Change at Week 8 (n=19, 23) | Mean Change at Week 16 (n=18, 23) | Mean Change at Week 24 (n=17, 20) | Mean Change at Week 32 (n=15, 15) | Mean Change at Week 40 (n=9, 12) | Mean Change at Week 48 (n=9, 9) | Mean Change at Week 56 (n=5, 9) | Mean Change at Week 64 (n=5, 4) | Mean Change at Week 72 (n=1, 2) | |
| Aripiprazole | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Placebo | 1.21 | -0.11 | -0.11 | -0.12 | -0.20 | -0.11 | -0.11 | -0.20 | -0.20 | 0.00 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change in patients with bipolar disorder. Patients are rated on Change from Preceding Phase (mania, depression and overall bipolar illness) items (also a 7-point scale [1 to 7], with 1 being normal and 7 being very severely ill). A negative change score signifies improvement. (NCT00261443)
Timeframe: Baseline, Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72. LTE Phase (A 72-week Extension Phase [until study unblinding] following Phase 3 [52 weeks], Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean Baseline (N=19, 23) | Mean Change at Week 8 (n=19, 23) | Mean Change at Week 16 (n=18, 23) | Mean Change at Week 24 (n=17, 20) | Mean Change at Week 32 (n=15, 15) | Mean Change at Week 40 (n=9, 12) | Mean Change at Week 48 (n=9, 9) | Mean Change at Week 56 (n=5, 9) | Mean Change at Week 64 (n=5, 4) | Mean Change at Week 72 (n=1, 2) | |
| Aripiprazole | 1.35 | -0.30 | -0.30 | -0.40 | -0.33 | -0.33 | -0.22 | -0.22 | 0.00 | -0.50 |
| Placebo | 1.37 | -0.26 | -0.28 | -0.29 | -0.07 | -0.22 | -0.22 | -0.20 | -0.20 | 0.00 |
ECG abnormalities considered by the investigator as clinically relevant.Left Bundle Branch Block: Not present at Baseline--> present post-baseline. (NCT00261443)
Timeframe: From first day until 30 days after the last dose of double-blind dosing in the Extension Phase (A 72-week Extension Phase [until study unblinding] following Phase 3 [52 weeks], Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Left Bundle Branch Block (see description) | QTcB > 450 msec | QTcF > 450 msec | QTcB Change from Baseline > 30 msec | QTcF Change from Baseline > 30 msec | QTcB Change from Baseline > 60 msec | QTcF Change from Baseline > 60 msec | |
| Aripiprazole | 1 | 3 | 1 | 5 | 3 | 0 | 0 |
| Placebo | 4 | 1 | 1 | 3 | 4 | 1 | 1 |
Chemistry, hematology, and urinalysis abnormalities considered by the investigator as clinically relevant. Hematocrit: ≤37%(M)/≤32%(F)+3 percentage pts↓from baseline. (NCT00261443)
Timeframe: From first day until 30 days after the last dose of double-blind dosing in the Extension Phase (A 72-week Extension Phase [until study unblinding] following Phase 3 [52 weeks], Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Creatine Kinase >= 3 x ULN | Hematocrit (see description) | Hemoglobin ≤11.5 g/dL(M)/≤9.5 g/dL(F) | Eosinophils relative (calculated) ≥10% | Urine Glucose (any glucose in the urine) | |
| Aripiprazole | 0 | 0 | 0 | 2 | 2 |
| Placebo | 1 | 2 | 2 | 2 | 0 |
Metabolic abnormalities considered by the investigator as clinically relevant. (Need normal values for each.) (NCT00261443)
Timeframe: From first day until 30 days after the last dose of double-blind dosing in the Extension Phase (A 72-week Extension Phase [until study unblinding] following Phase 3 [52 weeks], Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | Participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose, non-fasting (n=3,1) | Glucose, fasting (n=17, 22) | HDL Cholesterol, combined (n=18, 22) | HDL Cholesterol, fasting (n=17, 22) | HDL Cholesterol, non-fasting (n=2, 1) | Total Cholesterol, combined (n=18, 22) | Total Cholesterol, fasting (n=17, 22) | Total Cholesterol, non-fasting (n=2, 1) | LDL Cholesterol, combined (n=18, 22) | LDL Cholesterol, fasting (n=17, 22) | LDL Cholesterol, non-fasting (n=2, 1) | Triglycerides, combined (n=18, 22) | Triglycerides, fasting (n=17, 22) | Triglycerides, non-fasting (n=2, 1) | |
| Aripiprazole | 0 | 3 | 11 | 11 | 0 | 1 | 1 | 0 | 3 | 3 | 0 | 0 | 0 | 0 |
| Placebo | 0 | 2 | 12 | 12 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 4 | 4 | 0 |
Vital sign abnormalities considered by the investigator as clinically relevant. (NCT00261443)
Timeframe: From first day until 30 days after the last dose of double-blind dosing in the Extension Phase (A 72-week Extension Phase [until study unblinding] following Phase 3 [52 weeks], Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Systolic Blood Pressure Increase | Systolic Blood Pressure Decrease | Diastolic Blood Pressure Increase | Diastolic Blood Pressure Decrease | Heart Rate Increase | Heart Rate Decrease | Weight Increase | Weight Decrease | |
| Aripiprazole | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 1 |
| Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. MADRS total score, a 10-item, ordinal rating scale (0=no symptoms; 60=most severe symptoms). Change from baseline=postbaseline score - baseline score. A negative change score indicates improvement. (NCT00261443)
Timeframe: Baseline (end of Ph 2), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52. Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean Baseline (n=164, 162) | Mean Change from Baseline at Week 4 (n=160, 162) | Mean Change from Baseline at Week 8 (n=164, 162) | Mean Change from Baseline at Week 12 (n=164, 162) | Mean Change from Baseline at Week 16 (n=164, 162) | Mean Change from Baseline at Week 20 (n=164, 162) | Mean Change from Baseline at Week 24 (n=164, 162) | Mean Change from Baseline at Week 28 (n=164, 162) | Mean Change from Baseline at Week 32 (n=164, 162) | Mean Change from Baseline at Week 36 (n=164, 162) | Mean Change from Baseline at Week 40 (n=164, 162) | Mean Change from Baseline at Week 44 (n=164, 162) | Mean Change from Baseline at Week 48 (n=164, 162) | Mean Change from Baseline at Week 52 (n=164, 162) | |
| Aripiprazole | 4.62 | 1.42 | 1.23 | 1.42 | 1.27 | 1.47 | 1.49 | 1.64 | 1.70 | 1.89 | 1.65 | 1.53 | 1.48 | 1.46 |
| Placebo | 4.41 | 1.92 | 2.27 | 2.42 | 2.12 | 2.61 | 2.92 | 3.14 | 3.32 | 3.03 | 3.18 | 3.10 | 3.57 | 3.47 |
"The Y-MRS consists of 11 items: 1) Elevated Mood, 2) Increased Motor Activity -Energy, 3) Sexual Interest, 4) Sleep, 5) Irritability, 6) Speech (Rate and Amount), 7) Language -Thought Disorder, 8) Content, 9) Disruptive-Aggressive Behavior, 10) Appearance, 11) Insight. 7 items are rated on a 0 to 4 scale, while 4 items (items 5, 6, 8 and 9) are rated on a 0 to 8 scale (twice the weight of the other items.) For all items, 0 is the best rating and 4 or 8 is the worst rating. Total Score is the sum of the ratings for all 11 items. The possible Total Scores are from 0 (best) to 60 (worst)." (NCT00261443)
Timeframe: Baseline (end of Ph 2), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 of Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=164, 162) | Change at Week 4 (n=160, 162) | Change at Week 8 (n=164, 162) | Change at Week 12 (n=164, 162) | Change at Week 16 (n=164, 162) | Change at Week 20 (n=164, 162) | Change at Week 24 (n=164, 162) | Change at Week 28 (n=164, 162) | Change at Week 32 (n=164, 162) | Change at Week 36 (n=164, 162) | Change at Week 40 (n=164, 162) | Change at Week 44 (n=164, 162) | Change at Week 48 (n=164, 162) | Change at Week 52 (n=164, 162) | |
| Aripiprazole | 4.06 | 0.53 | 0.23 | 0.43 | 0.35 | 0.38 | 0.24 | 0.40 | 0.39 | 0.26 | 0.11 | 0.27 | 0.07 | -0.11 |
| Placebo | 4.03 | 0.47 | 0.91 | 1.53 | 1.74 | 2.29 | 2.42 | 3.02 | 2.72 | 3.04 | 2.82 | 3.19 | 3.15 | 2.93 |
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. MADRS total score, a 10-item, ordinal rating scale (0=no symptoms; 60=most severe symptoms). Change from baseline=postbaseline score - baseline score. A negative change score indicates improvement. (NCT00261443)
Timeframe: Baseline (end of Ph 1), Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, and Phase 2 (Ph2) Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | units on a scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean Baseline (n=289, 383) | Change from Baseline at Week 1 (n=277, 371) | Change from Baseline at Week 2 (n=267, 355) | Change from Baseline at Week 4 (n=245, 326) | Change from Baseline at Week 6 (n=221, 305) | Change from Baseline at Week 8 (n=201, 287) | Change from Baseline at Week 12 (n=179, 253) | Change from Baseline at Week 16 (n=138, 193) | Change from Baseline at Week 20 (n=59, 99) | Change from Baseline at Week 24 (n=22, 39) | Change from Baseline at Ph2 Endpoint (n=289, 383) | |
| Lithium | 10.97 | -1.48 | -2.23 | -2.94 | -2.92 | -3.07 | -2.82 | -2.88 | -4.68 | -3.77 | -2.13 |
| Valproate | 11.56 | -1.51 | -2.70 | -3.16 | -3.69 | -3.64 | -3.91 | -4.28 | -4.49 | -5.15 | -2.54 |
"The Y-MRS consists of 11 items: 1) Elevated Mood, 2) Increased Motor Activity -Energy, 3) Sexual Interest, 4) Sleep, 5) Irritability, 6) Speech (Rate and Amount), 7) Language -Thought Disorder, 8) Content, 9) Disruptive-Aggressive Behavior, 10) Appearance, 11) Insight. Seven items are rated on a 0 to 4 scale, while 4 items (items 5, 6, 8 and 9) are rated on a 0 to 8 scale (twice the weight of the other items.) For all items, 0 is the best rating and 4 or 8 is the worst rating. Total Score is the sum of the ratings for all 11 items. The possible Total Scores are from 0 (best) to 60 (worst)." (NCT00261443)
Timeframe: Baseline (end of ph 1), Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, and Phase 2 (Ph2) Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, + Confirmation of Partial Nonresponse Phase)
| Intervention | units on a scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=289, 383) | Change from Baseline at Week 1 (n=277, 371) | Change from Baseline at Week 2 (n=266, 355) | Change from Baseline at Week 4 (n=245, 326) | Change from Baseline at Week 6 (n=221, 305) | Change from Baseline at Week 8 (n=201, 287) | Change from Baseline at Week 12 (n=179, 253) | Change from Baseline at Week 16 (n=138, 193) | Change from Baseline at Week 20 (n=59, 99) | Change from Baseline at Week 24 (n=22, 39) | Change from Baseline at Ph2 endpoint (n=289, 383) | |
| Lithium | 23.15 | -4.50 | -7.90 | -12.11 | -13.92 | -16.18 | -17.74 | -18.88 | -20.37 | -20.82 | -14.78 |
| Valproate | 22.32 | -4.86 | -7.82 | -10.75 | -13.28 | -14.84 | -16.28 | -17.55 | -17.64 | -19.77 | -14.32 |
(NCT00261443)
Timeframe: Baseline
| Intervention | U/L (Median) | ||||
|---|---|---|---|---|---|
| ALP (n=265, 347) | ALT (n=266, 346) | AST (n=266, 346) | CK (n=266, 347) | LD (n=262, 342) | |
| Lithium | 72.0 | 20.0 | 19.0 | 79.0 | 168.0 |
| Valproate | 64.0 | 17.0 | 20.0 | 91.0 | 173.0 |
(NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 (a 13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout and Confirmation of Partial Nonresponse Phase)
| Intervention | mmHg (Median) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supine Systolic BP (SBP) at Baseline (n=286, 372) | Supine SBP Change at Phase 2 Endpoint (n=286, 372) | Supine Diastolic BP (DBP) at Baseline(n=286, 372) | Supine DBP Change at Phase 2 Endpoint (n=286, 372) | Sitting SBP at Baseline (n=51, 67) | Sitting SBP Change at Phase 2 Endpoint (n=51, 67) | Sitting DBP at Baseline (n=51, 67) | Sitting DBP Change at Phase 2 Endpoint (n=51, 67) | Standing SBP at Baseline (n=260, 333) | Standing SBP Change at Phase 2 Endpoint(n=260,333) | Standing DBP at Baseline (n=260, 333) | Standing DBP Change at Phase 2 Endpoint(n=260,333) | |
| Lithium | 120.0 | 0.0 | 76.0 | 0.0 | 120.0 | 0.0 | 78.0 | 0.0 | 120.0 | 0.0 | 78.5 | 0.0 |
| Valproate | 120.0 | 0.0 | 77.5 | 0.0 | 120.0 | 0.0 | 80.0 | 0.0 | 120.0 | 0.0 | 78.0 | 0.0 |
(NCT00261443)
Timeframe: Baseline, Week 12, Week 24, Week 36, Week 52, Week 52 (LOCF), During Phase 3 (for lowest/highest values)
| Intervention | kg/m^2 (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (n=161, 160) | Change at Week 12 (n=129, 121) | Change at Week 24 (n=111, 118) | Change at Week 36 (n=89, 98) | Change at Week 52 (n=85, 95) | Change at Week 52 (LOCF) (n=161, 160) | Highest Value During Phase 3 (n=161, 160) | Lowest Value During Phase 3 (n=161, 160) | |
| Aripiprazole | 27.9 | 0.2 | 0.2 | 0.4 | 0.7 | 0.5 | 0.7 | -0.1 |
| Placebo | 27.0 | 0.0 | 0.1 | 0.1 | 0.5 | 0.2 | 0.4 | -0.4 |
(NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | kg/m^2 (Median) | |
|---|---|---|
| BMI at Baseline | BMI Change at Phase 2 Endpoint | |
| Lithium | 26.9 | 0.3 |
| Valproate | 27.2 | 0.5 |
(NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 (a 13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout and Confirmation of Partial Nonresponse Phase)
| Intervention | msecs (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| QTcBazett (QTcB) at Baseline (n=223, 285) | QTcB Change at Phase 2 Endpoint (n=223, 285) | QTcB (0.33) at Baseline (n=223, 284) | QTcB(0.33) Change at Phase 2 Endpoint (n=223, 284) | PR at Baseline (n=222, 284) | PR Change at Phase 2 Endpoint (n=222, 284) | RR at Baseline (n=223, 284) | RR Change at Phase 2 Endpoint (n=223, 284) | QRS at Baseline (n=223, 284) | QRS Change at Phase 2 Endpoint (n=223, 284) | |
| Lithium | 415.0 | 4.0 | 403.0 | 4.0 | 154.0 | 2.0 | 845.0 | 0.0 | 90.0 | 0.0 |
| Valproate | 412.0 | -8.0 | 400.0 | -6.0 | 150.0 | -2.0 | 870.0 | 0.0 | 90.0 | -1.0 |
(NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 (a 13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout and Confirmation of Partial Nonresponse Phase)
| Intervention | msecs (Median) | |
|---|---|---|
| Heart Rate at Baseline (n=223, 284) | Heart Rate Change at Phase 2 Endpoint (n=223, 284) | |
| Lithium | 71.0 | 0.0 |
| Valproate | 69.0 | 0 |
(NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 (a 13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout and Confirmation of Partial Nonresponse Phase)
| Intervention | beats per minute (Median) | |||||
|---|---|---|---|---|---|---|
| Supine Heart Rate (HR) at Baseline (n=286, 372) | Supine HR Change at Phase 2 Endpoint (n=286, 372) | Sitting Heart Rate (HR) at Baseline (n=51, 67) | Sitting HR Change at Phase 2 Endpoint (n=51, 67) | Standing HR at Baseline (n=260, 333) | Standing HR Change at Phase 2 Endpoint(n=260, 333) | |
| Lithium | 76.0 | 0.0 | 78.0 | 2.0 | 78.0 | 0.0 |
| Valproate | 74.0 | 0.0 | 82.0 | -2.0 | 78.0 | 0.0 |
(NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 Endpoint. Phase 2 (a 13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout and Confirmation of Partial Nonresponse Phase)
| Intervention | kg (Median) | |
|---|---|---|
| Weight at Baseline | Weight Change at Phase 2 Endpoint | |
| Lithium | 76.2 | 0.9 |
| Valproate | 76.4 | 1.5 |
(NCT00261443)
Timeframe: Baseline
| Intervention | U/L (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| BUN (n=223, 302) | TC (n=245, 318) | Creatine (n=263, 343) | Glucose (n=242, 312) | HDL-C (n=245, 318) | LDL-C (n=245, 318) | Bilirubin (n=265, 347) | Triglycerides (n=245, 318) | Uric Acid (n=266, 347) | |
| Lithium | 11.0 | 182.0 | 0.900 | 92.0 | 47.0 | 105.0 | 0.40 | 112.0 | 5.55 |
| Valproate | 13.0 | 174.0 | 0.900 | 89.0 | 45.0 | 101.0 | 0.40 | 114.0 | 5.10 |
(NCT00261443)
Timeframe: Baseline
| Intervention | percent of total white blood cell count (Median) | |
|---|---|---|
| Eosinophils, relative (n=266, 347) | Neutrophils, relative (n=266, 346) | |
| Lithium | 2.50 | 67.60 |
| Valproate | 2.20 | 58.10 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest/lowest value)
| Intervention | x 10^3 c/uL (Median) | |||
|---|---|---|---|---|
| Baseline | Change from Baseline at Week 52 LOCF | Highest Value of Change During Phase 3 | Lowest Value of Change During Phase 3 | |
| Aripiprazole | 7.650 | -0.100 | 1.100 | -1.000 |
| Placebo | 6.900 | 0.150 | 1.100 | -0.900 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest/lowest value)
| Intervention | x10^9 c/L (Median) | |||
|---|---|---|---|---|
| Baseline | Change from Baseline at Week 52 LOCF | Highest Value of Change During Phase 3 | Lowest Value of Change During Phase 3 | |
| Aripiprazole | 254.0 | -3.5 | 17.5 | -22.0 |
| Placebo | 252.0 | -1.0 | 26.0 | -27.0 |
(NCT00261443)
Timeframe: Baseline, During Phase 3 (for highest/lowest values), Week 52
| Intervention | mm Hg (Median) | |||
|---|---|---|---|---|
| Baseline | Change from Baseline at Week 52 (LOCF) | Highest Change Value During Phase 3 | Lowest Change Value During Phase 3 | |
| Aripiprazole | 80.0 | -2.0 | 0.0 | -4.0 |
| Placebo | 80.0 | 0.0 | 4.0 | -4.0 |
(NCT00261443)
Timeframe: Baseline, During Phase 3 (for highest/lowest values), Week 52
| Intervention | beats per minute ? (Median) | |||
|---|---|---|---|---|
| Baseline | Change from Baseline at Week 52 (LOCF) | Highest Change Value During Phase 3 | Lowest Change Value During Phase 3 | |
| Aripiprazole | 76.0 | -2.0 | 4.0 | -2.0 |
| Placebo | 78.0 | -4.0 | 3.0 | -4.0 |
(NCT00261443)
Timeframe: Baseline, During Phase 3 (for highest/lowest values), Week 52
| Intervention | mm Hg (Median) | |||
|---|---|---|---|---|
| Baseline | Change from Baseline at Week 52 (LOCF) | Highest Change Value During Phase 3 | Lowest Change Value During Phase 3 | |
| Aripiprazole | 120.0 | 0.0 | 4.0 | -6.0 |
| Placebo | 120.0 | 2.0 | 8.0 | -3.0 |
(NCT00261443)
Timeframe: Baseline, During Phase 3 (for highest/lowest values), Week 52
| Intervention | mm Hg (Median) | |||
|---|---|---|---|---|
| Baseline | Change from Baseline at Week 52 (LOCF) | Highest Change Value During Phase 3 | Lowest Change Value During Phase 3 | |
| Aripiprazole | 78.0 | 0.0 | 6.0 | -6.0 |
| Placebo | 78.0 | 0.0 | 6.0 | -6.0 |
(NCT00261443)
Timeframe: Baseline, During Phase 3 (for highest/lowest values), Week 52
| Intervention | beats per minute (Median) | |||
|---|---|---|---|---|
| Baseline | Change from Baseline at Week 52 (LOCF) | Highest Change Value During Phase 3 | Lowest Change Value During Phase 3 | |
| Aripiprazole | 78.0 | 1.0 | 7.0 | -6.0 |
| Placebo | 78.0 | 0.0 | 6.0 | -7.0 |
(NCT00261443)
Timeframe: Baseline, During Phase 3 (for highest/lowest values), Week 52
| Intervention | mm Hg (Median) | |||
|---|---|---|---|---|
| Baseline | Change from Baseline at Week 52 (LOCF) | Highest Change Value During Phase 3 | Lowest Change Value During Phase 3 | |
| Aripiprazole | 120.0 | 0.0 | 6.0 | -8.0 |
| Placebo | 120.0 | 0.0 | 8.0 | -7.0 |
(NCT00261443)
Timeframe: Baseline, During Phase 3 (for highest/lowest values), Week 52
| Intervention | mm Hg (Median) | |||
|---|---|---|---|---|
| Baseline | Change from Baseline at Week 52 (LOCF) | Highest Change Value During Phase 3 | Lowest Change Value During Phase 3 | |
| Aripiprazole | 79.0 | 0.0 | 6.0 | -6.0 |
| Placebo | 78.0 | 0.0 | 5.5 | -6.0 |
(NCT00261443)
Timeframe: Baseline, During Phase 3 (for highest/lowest values), Week 52
| Intervention | beats per minute (bpm) (Median) | |||
|---|---|---|---|---|
| Baseline | Change from Baseline at Week 52 (LOCF) | Highest Change Value During Phase 3 | Lowest Change Value During Phase 3 | |
| Aripiprazole | 74.0 | 1.0 | 8.0 | -5.0 |
| Placebo | 74.0 | 0.0 | 7.5 | -5.5 |
(NCT00261443)
Timeframe: Baseline, During Phase 3 (for highest/lowest values), Week 52
| Intervention | mm Hg (Median) | |||
|---|---|---|---|---|
| Baseline | Change from Baseline at Week 52 (LOCF) | Highest Change Value During Phase 3 | Lowest Change Value During Phase 3 | |
| Aripiprazole | 120.0 | 0.0 | 6.0 | -8.0 |
| Placebo | 120.0 | 0.0 | 8.0 | -6.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | mg/dL (Median) | ||
|---|---|---|---|
| Baseline | Change from Baseline in Week 52 LOCF | Highest Value of Change During Phase 3 | |
| Aripiprazole | 100.0 | 0.0 | 16.5 |
| Placebo | 104.5 | 3.5 | 16.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | U/L (Median) | ||
|---|---|---|---|
| Baseline | Change at Week 52 LOCF | Highest Value of Change in Phase 3 | |
| Aripiprazole | 62.5 | 0.0 | 7.0 |
| Placebo | 60.5 | 1.0 | 8.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | U/L (Median) | ||
|---|---|---|---|
| Baseline | Change at Week 52 LOCF | Highest Value of Change in Phase 3 | |
| Aripiprazole | 20.0 | 0.0 | 5.0 |
| Placebo | 19.5 | -1.0 | 6.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | U/L (Median) | ||
|---|---|---|---|
| Baseline | Change at Week 52 LOCF | Highest Value of Change in Phase 3 | |
| Aripiprazole | 22.0 | -1.0 | 6.0 |
| Placebo | 20.0 | 1.0 | 5.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | mg/dL (Median) | ||
|---|---|---|---|
| Baseline | Change at Week 52 LOCF | Highest Value of Change in Phase 3 | |
| Aripiprazole | 12.0 | 0.0 | 2.0 |
| Placebo | 11.0 | 0.0 | 3.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | U/L (Median) | ||
|---|---|---|---|
| Baseline | Change at Week 52 LOCF | Highest Value of Change in Phase 3 | |
| Aripiprazole | 91.5 | -2.0 | 28.0 |
| Placebo | 82.0 | 5.0 | 33.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | mg/dL (Median) | ||
|---|---|---|---|
| Baseline | Change at Week 52 LOCF | Highest Value of Change in Phase 3 | |
| Aripiprazole | 0.900 | 0.000 | 0.100 |
| Placebo | 0.900 | 0.000 | 0.100 |
The change values reported are the median of (post baseline percentage (of white blood cell count) minus baseline percentage (of white blood cell count). (NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | percent of total white blood cell count (Median) | ||
|---|---|---|---|
| Baseline | Change at Week 52 LOCF | Highest Value of Change in Phase 3 | |
| Aripiprazole | 2.20 | -0.10 | 0.90 |
| Placebo | 2.30 | 0.00 | 0.80 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | mg/dL (Median) | ||
|---|---|---|---|
| Baseline | Change at Week 52 LOCF | Highest Value of Change in Phase 3 | |
| Aripiprazole | 90.0 | 0.0 | 7.0 |
| Placebo | 90.0 | 0.0 | 6.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | bpm (Median) | |||
|---|---|---|---|---|
| Baseline | Change from Baseline at Week 52 LOCF | Highest Value of Change in Heart Rate | Lowest Value of Change in Heart Rate | |
| Aripiprazole | 69.0 | 0.0 | 3.0 | -2.0 |
| Placebo | 70.0 | 0.0 | 1.0 | -3.0 |
HOMA stands for homeostasis model assessment of insulin resistance and beta-cell function. These are model-based calculations that use fasting insulin and glucose concentrations in order to assess pancreatic beta-cell function and insulin resistance. The HOMA2 model assesses insulin resistance (HOMA2-IR) relative to expected normal function (indexed to 1.0 for normal function) and is based on predictions from experimental human data on the relationship between insulin and glucose in a fasted state. HOMA2-IR is a proportion of 'normal function.' (NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value
| Intervention | proportion of 'normal function' (Median) | ||
|---|---|---|---|
| Baseline | Change from Baseline at Week 52 LOCF | Highest Value of Change During Phase 3 | |
| Aripiprazole | 1.06 | -0.13 | 0.37 |
| Placebo | 1.24 | -0.13 | 0.20 |
HOMA stands for homeostasis model assessment of insulin resistance and beta-cell function. These are model-based calculations that use fasting insulin and glucose concentrations in order to assess pancreatic beta-cell function and insulin resistance. The HOMA2 model assesses beta-cell function (HOMA2-%β) relative to expected normal function (indexed to 100% for normal function) and is based on predictions from experimental human data on the relationship between insulin and glucose in a fasted state. HOMA2-%Beta is a percentage of 'normal function.' (NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value
| Intervention | percentage of 'normal function' (Median) | ||
|---|---|---|---|
| Baseline | Change at Week 52 LOCF | Highest Value of Change in Phase 3 | |
| Aripiprazole | 106.90 | 8.50 | 5.30 |
| Placebo | 120.0 | -6.35 | -10.85 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | U/L (Median) | ||
|---|---|---|---|
| Baseline | Change at Week 52 LOCF | Highest Value of Change During Phase 3 | |
| Aripiprazole | 171.0 | 0.0 | 19.0 |
| Placebo | 161.0 | 4.0 | 25.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | percent of total white blood cell count (Median) | ||
|---|---|---|---|
| Baseline | Change from Week 52 LOCF | Highest Value of Change During Phase 3 | |
| Aripiprazole | 62.60 | -0.55 | -6.20 |
| Placebo | 61.55 | -1.30 | -6.45 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | msecs (Median) | ||
|---|---|---|---|
| Baseline | Change from Baseline at Week 52 LOCF | Highest Value of Change in PR | |
| Aripiprazole | 150.0 | 0.0 | 4.0 |
| Placebo | 155.0 | -2.0 | 2.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | ng/mL (Median) | ||
|---|---|---|---|
| Baseline | Change from Baseline in Week 52 LOCF | Highest Value of Change During Phase 3 | |
| Aripiprazole | 6.0 | 0.0 | 1.0 |
| Placebo | 7.0 | 2.0 | 3.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | msecs (Median) | ||
|---|---|---|---|
| Baseline | Change from Baseline at Week 52 LOCF | Highest Value of Change in QRS | |
| Aripiprazole | 90.0 | 0.0 | 2.0 |
| Placebo | 89.0 | 0.0 | 2.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | msecs (Median) | ||
|---|---|---|---|
| Baseline | Change from Baseline at Week 52 LOCF | Highest Value of Change in QTc Bazett | |
| Aripiprazole | 410.0 | 3.0 | 12.0 |
| Placebo | 415.0 | 3.0 | 6.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | msecs (Median) | ||
|---|---|---|---|
| Baseline | Change from Baseline at Week 52 LOCF | Highest Value of Change in QTc (0.33) | |
| Aripiprazole | 400.0 | 2.0 | 10.0 |
| Placebo | 404.0 | 1.0 | 3.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | msecs (Median) | |||
|---|---|---|---|---|
| Baseline | Change from Baseline at Week 52 LOCF | Highest Value of Change in RR | Lowest Value of Change in RR | |
| Aripiprazole | 870.0 | -4.0 | 20.0 | -42.0 |
| Placebo | 857.0 | 3.0 | 38.0 | -15.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | mg/dL (Median) | ||
|---|---|---|---|
| Baseline | Change from Baseline at Week 52 LOCF | Highest Value of Change in Phase 3 | |
| Aripiprazole | 0.40 | 0.00 | 0.10 |
| Placebo | 0.40 | 0.00 | 0.10 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | mg/dL (Median) | ||
|---|---|---|---|
| Baseline | Change at Week 52 LOCF | Highest Value of Change in Phase 3 | |
| Aripiprazole | 181.0 | -0.5 | 20.5 |
| Placebo | 180.0 | 5.0 | 18.5 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | mg/dL (Median) | ||
|---|---|---|---|
| Baseline | Change from Baseline at Week 52 LOCF | Highest Value of Change During Phase 3 | |
| Aripiprazole | 134.5 | 0.0 | 42.0 |
| Placebo | 130.0 | 4.0 | 37.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for highest value)
| Intervention | mg/dL (Median) | ||
|---|---|---|---|
| Baseline | Change from Baseline at Week 52 LOCF | Highest Value of Change in Uric Acid | |
| Aripiprazole | 5.75 | 0.00 | 0.50 |
| Placebo | 5.50 | -0.10 | 0.65 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for lowest value
| Intervention | mg/dL (Median) | ||
|---|---|---|---|
| Baseline | Change at Week 52 LOCF | Lowest Value of Change in Phase 3 | |
| Aripiprazole | 45.0 | -1.0 | -5.0 |
| Placebo | 46.0 | -1.0 | -5.0 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for lowest value)
| Intervention | percentage of total blood volume (Median) | ||
|---|---|---|---|
| Baseline | Change at Week 52 LOCF | Lowest Value of Change in Phase 3 | |
| Aripiprazole | 42.15 | -0.30 | -1.90 |
| Placebo | 41.40 | -0.40 | -1.60 |
(NCT00261443)
Timeframe: Baseline, Week 52 (LOCF), Throughout Phase 3 (for lowest value)
| Intervention | g/dL (Median) | ||
|---|---|---|---|
| Baseline | Change at Week 52 LOCF | Lowest Value of Change in Phase 3 | |
| Aripiprazole | 14.00 | -0.10 | -0.60 |
| Placebo | 13.80 | -0.10 | -0.50 |
(NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | U/L (Median) | ||||
|---|---|---|---|---|---|
| ALP (n=265, 347) | ALT (n=266, 346) | AST (n=266, 346) | CK (n=266, 347) | LD (n=262, 342) | |
| Lithium | -2.0 | 0.0 | 0.0 | -1.0 | -3.0 |
| Valproate | -2.0 | 2.0 | 1.0 | -2.0 | -1.0 |
(NCT00261443)
Timeframe: Baseline (end of Ph 1), Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | U/L (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| BUN (n=223, 302) | TC (n=245, 318) | Creatine (n=263, 343) | Glucose (n=242, 312) | HDL-C (n=245, 318) | LDL-C (n=245, 318) | Bilirubin (n=265, 347) | Triglycerides (n=245, 318) | Uric Acid (n=266, 347) | |
| Lithium | 0.0 | -1.0 | 0.0 | 2.0 | -1.0 | -4.0 | 0.0 | 2.0 | -0.10 |
| Valproate | 0.0 | 4.5 | 0.0 | 1.0 | 1.0 | 2.0 | 0.0 | 3.0 | 0.10 |
(NCT00261443)
Timeframe: Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | percent of total white blood cell count (Median) | |
|---|---|---|
| Eosinophils, relative (n=266, 347) | Neutrophils, relative (n=266, 346) | |
| Lithium | -0.40 | 0.25 |
| Valproate | -0.20 | 0.60 |
Remission is defined as Y-MRS Total Score <=12 and MADRS Total Score <=12. (NCT00261443)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52. Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 (n=160, 162) | Week 8 (n=152, 145) | Week 12 (n=144, 136) | Week 16 (n=138, 131) | Week 20 (n=131, 127) | Week 24 (n=115, 122) | Week 28 (n=114, 122) | Week 32 (n=104, 119) | Week 36 (n=99, 108) | Week 40 (n=100, 110) | Week 44 (n=91, 109) | Week 48 (n=92, 102) | Week 52 (n=89, 97) | |
| Aripiprazole | 142 | 136 | 126 | 126 | 117 | 119 | 115 | 112 | 104 | 109 | 102 | 101 | 95 |
| Placebo | 142 | 138 | 133 | 122 | 115 | 107 | 100 | 99 | 91 | 93 | 81 | 85 | 82 |
Relevant weight gain: >=7% increase from baseline (NCT00261443)
Timeframe: Weeks 12, 24, 36, 52, 52 (LOCF), and throughout Phase 3 (for 'at any time' assessment)
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Weight Gain at Week 12 (n=129, 121) | Weight Gain at Week 24 (n=111, 118) | Weight Gain at Week 36 (n=89, 98) | Weight Gain at Week 52 (n=85, 95) | Weight Gain at Week 52 (LOCF) (n=161, 160) | Weight Gain at Any Time (n=163, 164) | |
| Aripiprazole | 6 | 11 | 12 | 18 | 22 | 29 |
| Placebo | 3 | 6 | 16 | 16 | 19 | 23 |
Relevant weight loss: >=7% decrease from baseline (NCT00261443)
Timeframe: Weeks 12, 24, 36, 52, 52 (LOCF), and throughout Phase 3 (for 'at any time' assessment)
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Weight Gain at Week 12 (n=129, 121) | Weight Gain at Week 24 (n=111, 118) | Weight Gain at Week 36 (n=89, 98) | Weight Gain at Week 52 (n=85, 95) | Weight Gain at Week 52 (LOCF) (n=161, 160) | Weight Gain at Any Time (n=163, 164) | |
| Aripiprazole | 6 | 8 | 8 | 5 | 10 | 18 |
| Placebo | 5 | 7 | 7 | 7 | 13 | 18 |
(NCT00261443)
Timeframe: Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Any EPS Medications | Cardiovascular System-Propanolol | Nervous System-Benztropine | Nervous System-Biperiden | Nervous System-Trihexyphenidyl | |
| Aripiprazole | 40 | 21 | 19 | 2 | 10 |
| Placebo | 36 | 18 | 10 | 4 | 11 |
Sinus Tachycardia: ≥120bpm+↑≥15bpm+no current diagnosis of supraventricular (SV) or ventricular tachycardia or atrial fibrillation (AF) or flutter or other rhythm abnormality (RA). Sinus Bradycardia:≥50bpm+↓≥15bpm+no current diagnosis of AF or flutter or other RA. AF:not present→present or present at rate <100bpm pretreatment to present with rate ≥100bpm+increase of ≥15bpm. AV=atrioventricular; PR=PR interval. Other Intraventricular Block: QRS wave ≥0.12 sec+↑≥0.02 sec+no current diagnosis of left or right bundle branch block. Old Infarction not present→present at ≥12 weeks post study entry. (NCT00261443)
Timeframe: Phase 2 (a 13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout and Confirmation of Partial Nonresponse Phase)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tachycardia ≥ 120 bpm and ↑ ≥ 15 bpm | Bradycardia ≤ 50 bpm and ↓ 15 bpm | Sinus Tachycardia (see description) | Sinus Bradycardia (see description) | SV Premature Beat - not present → present | Ventricular Premature Beat - not present → present | SV Tachycardia not present → present | Ventricular Tachycardia not present → present | Atrial Fibrillation (see description) | Atrial Flutter not present → present | 1st Degree AV Block PR ≥0.20 sec and ↑ ≥0.05 sec | 2nd Degree AV Block not present → present | 3rd Degree AV Block not present → present | Left Bundle Branch Block not present → present | Right Bundle Branch Block not present → present | Pre-excitation Syndrome not present → present | Other Intraventricular Block (see description) | Acute Infarction not present → present | Subacute (Recent) Infarction not present → present | Old Infarction not present → present at >=12 weeks | Myocardial Ischemia not present → present | Symmetrical T-Wave Inversion not present → present | QTc Bazett (QTcB) > 450 msec | QTc Frederica (QTcF) > 450 msec | QTcB > 500 msec | QTcF > 500 msec | QTcB Change from Baseline > 30 msec | QTcF Change from Baseline > 30 msec | QTcB Change from Baseline > 60 msec | QTcF Change from Baseline > 60 msec | |
| Lithium | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 5 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 15 | 5 | 2 | 0 | 28 | 21 | 2 | 1 |
| Valproate | 2 | 4 | 2 | 4 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 8 | 2 | 0 | 0 | 17 | 11 | 4 | 0 |
Sinus Tachycardia: ≥120bpm+↑≥15bpm+no current diagnosis of supraventricular (SV) or ventricular tachycardia or atrial fibrillation (AF) or flutter or other rhythm abnormality (RA). Sinus Bradycardia:≥50bpm+↓≥15bpm+no current diagnosis of AF or flutter or other RA. AF:not present→present or present at rate <100bpm pretreatment to present with rate ≥100bpm+increase of ≥15bpm. AV=atrioventricular; PR=PR interval. Other Intraventricular Block: QRS wave ≥0.12 sec+↑≥0.02 sec+no current diagnosis of left or right bundle branch block. Old Infarction not present→present at ≥12 weeks post study entry. (NCT00261443)
Timeframe: Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tachycardia ≥ 120 bpm and ↑ ≥ 15 bpm | Bradycardia ≤ 50 bpm and ↓ 15 bpm | Sinus Tachycardia (see description) | Sinus Bradycardia (see description) | SV Premature Beat - not present → present | Ventricular Premature Beat - not present → present | SV Tachycardia not present → present | Ventricular Tachycardia not present → present | Atrial Fibrillation (see description) | Atrial Flutter not present → present | 1st Degree AV Block PR ≥0.20 sec and ↑ ≥0.05 sec | 2nd Degree AV Block not present → present | 3rd Degree AV Block not present → present | Left Bundle Branch Block not present → present | Right Bundle Branch Block not present → present | Pre-excitation Syndrome not present → present | Other Intraventricular Block (see description) | Acute Infarction not present → present | Subacute (Recent) Infarction not present → present | Old Infarction (see description) | Myocardial Ischemia not present → present | Symmetrical T-Wave Inversion not present → present | QTc Bazett (QTcB) > 450 msec | QTc Frederica (QTcF) > 450 msec | QTcB > 500 msec | QTcF > 500 msec | QTcB Change from Baseline > 30 msec | QTcF Change from Baseline > 30 msec | QTcB Change from Baseline > 60 msec | QTcF Change from Baseline > 60 msec | |
| Lithium | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 6 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 12 | 5 | 0 | 0 | 20 | 10 | 3 | 2 |
| Valproate | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 3 | 0 | 0 | 0 | 2 | 0 | 2 | 1 | 15 | 4 | 1 | 1 | 25 | 20 | 4 | 3 |
ULN=upper limit of normal; HDL=high density lipoprotein; LDL=low density lipoprotein. Values for ULN are provided by the lab in the database and could be different for each individual patient based on characteristics such as age, gender, or other patient attributes. (NCT00261443)
Timeframe: Phase 2 (a 13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout and Confirmation of Partial Nonresponse Phase)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline Phosphatase ≥ 3 x ULN (n=272, 360) | Alanine Aminotransferase ≥ 3 x ULN (n=273, 359) | Aspartate Aminotransferase ≥ 3 x ULN (n=273, 359) | Blood Urea Nitrogen ≥ 30 mg/dL (n=225, 312) | Creatine Kinase >= 3 x ULN (n=273, 360) | Creatinine ≥ 2.0 mg/dL (n=271, 359) | Lactate Dehydrogenase >= 3 x ULN (n=270, 358) | Prolactin > ULN (n=231, 306) | Bilirubin Total ≥ 2.0 mg/dL (n=n=272, 360) | Uric Acid ≥10.5mg/dL(M)/≥8.5mg/dL(F) (n=273, 360) | Total Calcium ≤8.2 mg/dL or ≥12 mg/dL (n=273, 360) | Chloride Serum ≤90 mEq/L or ≥118 mEq/L(n=273, 360) | Potassium Serum ≤2.5 mEq/L/≥6.5 mEq/L(n=271, 358) | Sodium Serum ≤126 mEq/L/≥156 mEq/L (n=273, 360) | Hematocrit ≤37(M)/≤32(F)+3 pts↓from BL(n=272, 358) | Hemoglobin ≤11.5 g/dL(M)/≤9.5 g/dL(F) (n=272, 359) | Leukocytes <=2800 mm^3 or >=16000 mm^3(n=272, 358) | Eosinophils Relative (Calculated) ≥10%(n=272, 358) | Neutrophils Relative (Calculated) ≤15%(n=272, 358) | Platelets ≤75,000 mm^3/≥700,000 mm^3 (n=268, 357) | Urine Glucose-any glucose in the urine(n=269,357) | Urine Protein Increase of ≥ 2 units (n=269, 357) | Glucose (Non-fasting) ≥200 mg/dL (n=78, 89) | Glucose (Fasting) ≥ 126 mg/dL (n=251, 332) | HDL Cholesterol (combined) <40 mg/dL (n=273, 360) | HDL Cholesterol (Fasting) <40 mg/dL (n=252, 332) | HDL Cholesterol (Non-fasting) <40 mg/dL (n=79, 91) | Total Cholesterol (Combined) ≥240 mg/dL(n=273,360) | Total Cholesterol (Fasting) ≥240 mg/dL (n=252,332) | Total Cholesterol (Non-fasting) ≥240mg/dL(n=79,92) | LDL Cholesterol (Combined) ≥160 mg/dL (n=273, 360) | LDL Cholesterol (Fasting) ≥160 mg/dL (n=252, 332) | LDL Cholesterol (Non-fasting) ≥160 mg/dL (n=79,91) | Triglycerides (Combined) ≥ 200 mg/dL (n=273, 360) | Triglycerides (Non-Fasting) ≥ 200 mg/dL (n=79, 93) | Triglycerides (Fasting) ≥ 200 mg/dL (n=252, 332) | |
| Lithium | 0 | 3 | 0 | 0 | 6 | 1 | 0 | 10 | 2 | 10 | 2 | 1 | 0 | 0 | 5 | 8 | 9 | 9 | 0 | 1 | 7 | 10 | 2 | 42 | 94 | 85 | 20 | 37 | 32 | 7 | 30 | 28 | 4 | 88 | 25 | 73 |
| Valproate | 0 | 6 | 3 | 7 | 20 | 1 | 0 | 9 | 1 | 7 | 13 | 4 | 1 | 2 | 4 | 3 | 2 | 12 | 1 | 0 | 13 | 6 | 3 | 28 | 131 | 117 | 31 | 53 | 49 | 11 | 47 | 44 | 8 | 108 | 33 | 85 |
ULN=upper limit of normal; Hb=hemoglobin (NCT00261443)
Timeframe: Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline Phosphatase ≥ 3 x ULN (n=166,165) | Alanine Aminotransferase ≥ 3 x ULN (n=166,165) | Aspartate Aminotransferase ≥ 3 x ULN (n=166,165) | Blood Urea Nitrogen ≥ 30 mg/dL (n=139, 138) | Creatine Kinase (n=166,165) | Creatinine ≥ 2.0 mg/dL (n=166,164) | Lactate Dehydrogenase (n=166,164) | Prolactin > ULN (n=163, 158) | Bilirubin Total ≥ 2.0 mg/dL (n=166, 165) | Uric Acid≥10.5 mg/dL(M)/≥ 8.5 mg/dL(F)(n=166, 165) | Total Calcium ≤8.2 mg/dL or ≥12 mg/dL (n=166, 165) | Chloride Serum ≤90 mEq/L or ≥118 mEq/L(n=166, 165) | Potassium Serum ≤2.5 or ≥6.5 mEq/L (n=166, 164) | Sodium Serum ≤126 or ≥156 mEq/L (n=166, 165) | Hematocrit ≤37(M) or ≤32(F)3 poi (n=166, 164) | Hb ≤11.5 g/dl (M) / ≤9.5 g/dL (F) (n=166, 164) | Leukocytes (n=166, 164) | Eosinophils Relative (Calculated) ≥10 (n=166, 164) | Neutrophils Relative (Calculated) ≤15 (n=166, 164) | Platelet Count (n=165, 162) | Urine Glucose (n=166, 165) | Urine Protein (n=166, 165) | Glucose (non-fasting) (n=38, 28) | Glucose (fasting) (n=159, 158) | HDL Cholesterol (combined) (n=166, 165) | HDL Cholesterol (fasting) (n=160, 159) | HDL Cholesterol (non-fasting) (n=38, 27) | Total Cholesterol (combined) (n=166, 165) | Total Cholesterol (fasting) (n=160, 159) | Total Cholesterol (non-fasting) (n=38, 27) | LDL Cholesterol (combined) (n=166, 165) | LDL Cholesterol (fasting) (n=160, 159) | LDL Cholesterol (non-fasting) (n=38, 27) | Triglycerides (combined) (n=166, 165) | Triglycerides (non-fasting) (n=38, 28) | Triglycerides (fasting) (n=160,159) | |
| Aripiprazole | 0 | 3 | 0 | 1 | 6 | 1 | 0 | 14 | 3 | 7 | 7 | 1 | 3 | 1 | 8 | 4 | 3 | 11 | 0 | 0 | 8 | 4 | 0 | 27 | 91 | 88 | 11 | 38 | 35 | 7 | 23 | 22 | 3 | 67 | 15 | 63 |
| Placebo | 2 | 3 | 0 | 3 | 8 | 0 | 0 | 14 | 2 | 4 | 4 | 1 | 0 | 1 | 7 | 2 | 5 | 6 | 0 | 0 | 8 | 5 | 1 | 26 | 81 | 76 | 20 | 28 | 27 | 3 | 24 | 24 | 1 | 59 | 16 | 48 |
Heart Rate: increase, ≥120 beats per minute (bpm) and ≥15 relative to baseline (RBL); decrease, ≤50 bpm and ≥15 RBL. Systolic BP: increase, ≥180 mmHg and ≥20 RBL; decrease, ≤90 mmHg and ≥20 RBL. Diastolic BP: increase, ≥105 mmHg and ≥15 RBL; decrease, ≤50 mmHg and ≥15 RBL. For patients missing a baseline value, an on-treatment value was considered potentially clinically relevant if the value meets the criterion value. (NCT00261443)
Timeframe: Phase 2 (a 13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout and Confirmation of Partial Nonresponse Phase)
| Intervention | Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic Blood Pressure (SBP) - Standing Increase | SBP - Standing Decrease | SBP - Supine Increase | SBP - Supine Decrease | SBP - Sitting Increase | SBP - Sitting Decrease | Diastolic Blood Pressure (DBP) - Standing Increase | DBP - Standing Decrease | DBP - Supine Increase | DBP - Supine Decrease | DBP - Sitting Increase | DBP - Sitting Decrease | Heart Rate - Standing Increase | Heart Rate - Standing Decrease | Heart Rate - Supine Increase | Heart Rate - Supine Decrease | Heart Rate - Sitting Increase | Heart Rate - Sitting Decrease | Weight - Increase | Weight - Decrease | |
| Lithium | 2 | 0 | 1 | 2 | 0 | 1 | 4 | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 26 | 15 |
| Valproate | 4 | 4 | 6 | 4 | 0 | 0 | 7 | 3 | 5 | 3 | 3 | 0 | 2 | 0 | 1 | 1 | 1 | 0 | 46 | 6 |
Heart Rate: increase, ≥120 beats per minute (bpm) and ≥15 relative to baseline (RBL); decrease, ≤50 bpm and ≥15 RBL. Systolic BP: increase, ≥180 mmHg and ≥20 RBL; decrease, ≤90 mmHg and ≥20 RBL. Diastolic BP: increase, ≥105 mmHg and ≥15 RBL; decrease, ≤50 mmHg and ≥15 RBL. For patients missing a baseline value, an on-treatment value was considered potentially clinically relevant if the value meets the criterion value. (NCT00261443)
Timeframe: Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | Participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP- Standing Increase (n=145, 147) | SBP- Standing Decrease (n=145, 147) | SBP- Supine Increase (n=165, 164) | SBP- Supine Decrease (n=165, 164) | SBP- Sitting Increase (n=41, 47) | SBP- Sitting Decrease (n=41, 47) | DBP- Standing Increase (n=145, 147) | DBP- Standing Decrease (n=145, 147) | DBP- Supine Increase (n=165, 164) | DBP- Supine Decrease (n=165, 164) | DBP- Sitting Increase (n=41, 47) | DBP- Sitting Decrease (n=41, 47) | HR- Standing Increase (n=145, 147) | HR- Standing Decrease (n=145, 147) | HR- Supine Increase (n=165, 164) | HR- Supine Decrease (n=165, 164) | HR- Sitting Increase (n=41, 47) | HR- Sitting Decrease (n=41, 47) | |
| Aripiprazole | 0 | 1 | 0 | 2 | 0 | 1 | 1 | 2 | 3 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
| Placebo | 0 | 2 | 0 | 2 | 0 | 0 | 5 | 0 | 4 | 1 | 1 | 0 | 1 | 2 | 0 | 1 | 0 | 0 |
Kaplan Meier estimated survival rate. Relapse is defined as any of the following events accompanied by a YMRS > 16 and/or a MADRS > 16; serious adverse event of worsening disease, or discontinuation by the investigator for lack of efficacy. A hospitalization for a manic, mixed, or depressive episode does meet the criteria for relapse, however does not require an accompanying Y-MRS and/or MADRS score > 16. (NCT00261443)
Timeframe: Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 of phase 3
| Intervention | proportion of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proportion at Week 0 (n=169, 168) | Proportion at Week 4 (n=153, 148) | Proportion at Week 8 (n=148, 139) | Proportion at Week 12 (n=142, 133) | Proportion at Week 16 (n=132, 130) | Proportion at Week 20 (n=123, 128) | Proportion at Week 24 (n=115, 125) | Proportion at Week 28 (n=107, 121) | Proportion at Week 32 (n=104, 114) | Proportion at Week 36 (n=101, 111) | Proportion at Week 40 (n=98, 110) | Proportion at Week 44 (n=94, 107) | Proportion at Week 48 (n=91, 98) | Proportion at Week 52 (n=6, 8) | |
| Aripiprazole | 1.00 | 0.98 | 0.97 | 0.97 | 0.96 | 0.96 | 0.95 | 0.95 | 0.91 | 0.91 | 0.91 | 0.91 | 0.90 | 0.90 |
| Placebo | 1.00 | 0.96 | 0.94 | 0.94 | 0.93 | 0.92 | 0.92 | 0.89 | 0.89 | 0.89 | 0.88 | 0.88 | 0.87 | 0.87 |
Kaplan-Meier estimated survival rate. Criteria for relapse include one or more of the following: relapse is defined as any of the following events accompanied by a Young-Mania Rating Scale (Y-MRS) >16 and/or a Montgomery Åsberg Depression Rating Scale (MADRS) >16; serious adverse event of worsening disease, or discontinuation by the investigator for lack of efficacy. A hospitalization for a manic, mixed, or depressive episode does meet the criteria for relapse, however does not require an accompanying Y-MRS and/or MADRS score >16. (NCT00261443)
Timeframe: Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 of phase 3
| Intervention | proportion of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proportion at Week 0 (n=169,168) | Proportion at Week 4 (n=153,148) | Proportion at Week 8 (n=148,139) | Proportion at Week 12 (n=142,133) | Proportion at Week 16 (n=132,130) | Proportion at Week 20 (n=122,128) | Proportion at Week 24 (n=113,125) | Proportion at Week 28 (n=105,121) | Proportion at Week 32 (n=102,115) | Proportion at Week 36 (n=99, 111) | Proportion at Week 40 (n=95,110) | Proportion at Week 44 (n=91,107) | Proportion at Week 48 (n=88, 98) | Proportion at Week 52 (n=5, 8) | |
| Aripiprazole | 1.00 | 0.99 | 0.98 | 0.97 | 0.97 | 0.97 | 0.97 | 0.97 | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 |
| Placebo | 1.00 | 0.99 | 0.99 | 0.97 | 0.95 | 0.93 | 0.91 | 0.90 | 0.89 | 0.88 | 0.87 | 0.86 | 0.85 | 0.85 |
Kaplan-Meier estimated survival rate. Criteria for relapse include one or more of the following: hospitalization for a manic, mixed or depressive episode; serious adverse event of worsening disease under study accompanied by a Y-MRS > 16 and/or a MADRS > 16; discontinuation due to lack of efficacy as determined by the investigator accompanied by a Y-MRS > 16 and/or a MADRS > 16. (NCT00261443)
Timeframe: Week 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 of Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | proportion of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proportion at Week 0 (n=169, 168) | Proportion at Week 4 (n=153, 148) | Proportion at Week 8 (n=148, 139) | Proportion at Week 12 (n=142, 133) | Proportion at Week 16 (n=131, 130) | Proportion at Week 20 (n=122, 128) | Proportion at Week 24 (n=113, 125) | Proportion at Week 28 (n=105, 121) | Proportion at Week 32 (n=102, 114) | Proportion at Week 36 (n=99, 111) | Proportion at Week 40 (n=95, 110) | Proportion at Week 44 (n=91,107) | Proportion at Week 48 (n=88, 98) | Proportion at Week 52 (n=5, 8) | |
| Aripiprazole | 1.00 | 0.96 | 0.94 | 0.93 | 0.92 | 0.91 | 0.89 | 0.89 | 0.84 | 0.84 | 0.84 | 0.84 | 0.83 | 0.83 |
| Placebo | 1.00 | 0.95 | 0.93 | 0.90 | 0.87 | 0.83 | 0.81 | 0.77 | 0.76 | 0.75 | 0.73 | 0.73 | 0.71 | 0.71 |
AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. By Common Terminology Criteria Version 3.0 (CTC v3) Grade (Gr): Gr 1 (mild); Gr 2 (moderate); Gr 3 (severe); Gr 4 (life-threatening); Gr 5 (death). (NCT00261443)
Timeframe: During Phase 2. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Any Adverse Event | Mild/Grade 1 | Moderate/Grade 2 | Severe/Grade 3 | Very Severe/Grade 4 | |
| Lithium | 226 | 172 | 109 | 20 | 2 |
| Valproate | 287 | 219 | 165 | 31 | 1 |
AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. By Common Terminology Criteria Version 3.0 (CTC v3) Grade (Gr): Gr 1 (mild); Gr 2 (moderate); Gr 3 (severe); Gr 4 (life-threatening); Gr 5 (death). (NCT00261443)
Timeframe: Phase 3 (A 52-Week Assessment of Relapse Phase following Phase 2 [13 to 24 weeks] and Phase 1 [2 to 8 weeks])
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Participants <= 50 Years (n=132, 131) | Participants >50 Years (n=34, 36) | Male Participants (n=70, 81) | Female Participants (n=96, 86) | White Participants (n=63, 74) | Non-White Participants (n=42, 31) | Participants with Mild/Grade 1 AE | Participants with Moderate/Grade 2 AE | Participants with Severe/Grade 3 AE | Participants with Very Severe/Grade 4 AE | |
| Aripiprazole | 84 | 21 | 47 | 58 | 74 | 31 | 75 | 55 | 9 | 2 |
| Placebo | 81 | 24 | 45 | 60 | 63 | 42 | 75 | 53 | 11 | 1 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change in patients with bipolar disorder. Patients are rated on Change from baseline (mania, depression and overall bipolar illness) items (also a 7-point scale [1 to 7], with 1 being normal and 7 being very severely ill). A negative change score signifies improvement. (NCT00261443)
Timeframe: Baseline (end of Ph 1), Weeks 1, 2, 4,6, 8, 12, 16, 20, 24, and Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | units on a scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean Baseline (BL) (n=289, 383) | Mean Change from BL to Week 1 (n=275, 370) | Mean Change from BL to Week 2 (n=267, 354) | Mean Change from BL to Week 4 (n=245, 326) | Mean Change from BL to Week 6 (n=219, 305) | Mean Change from BL to Week 8 (n=200, 287) | Mean Change from BL to Week 12 (n=179, 252) | Mean Change from BL to Week 16 (n=138, 193) | Mean Change from BL to Week 20 (n=59, 99) | Mean Change from BL to Week 24 (n=22, 39) | Mean Change from BL to Phase 2 Endpoint(n=289,383) | |
| Lithium | 4.22 | -0.58 | -1.15 | -1.73 | -2.04 | -2.40 | -2.60 | -2.83 | -2.93 | -2.91 | -2.21 |
| Valproate | 4.06 | -0.58 | -1.06 | -1.45 | -1.82 | -2.06 | -2.27 | -2.40 | -2.32 | -2.56 | -2.01 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change in patients with bipolar disorder. Patients are rated on Change from baseline (mania, depression and overall bipolar illness) items (also a 7-point scale [1 to 7], with 1 being normal and 7 being very severely ill). A negative change score signifies improvement. (NCT00261443)
Timeframe: Baseline (end of Ph 1), Weeks 1, 2, 4,6, 8, 12, 16, 20, 24, and Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | units on a scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean Baseline (BL) (n=289, 383) | Mean Change from BL to Week 1 (n=275, 370) | Mean Change from BL to Week 2 (n=267, 354) | Mean Change from BL to Week 4 (n=245, 326) | Mean Change from BL to Week 6 (n=219, 305) | Mean Change from BL to Week 8 (n=200, 287) | Mean Change from BL to Week 12 (n=179, 252) | Mean Change from BL to Week 16 (n=138, 193) | Mean Change from BL to Week 20 (n=59, 99) | Mean Change from BL to Week 24 (n=22, 39) | Mean Change from BL to Phase 2 Endpoint(n=289,383) | |
| Lithium | 2.16 | -0.16 | -0.22 | -0.29 | -0.31 | -0.30 | -0.17 | -0.21 | -0.27 | -0.23 | -0.16 |
| Valproate | 2.33 | -0.19 | -0.33 | -0.39 | -0.43 | -0.37 | -0.35 | -0.36 | -0.37 | -0.46 | -0.26 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change from baseline in patients with bipolar disorder. Patients are rated on mania, depression and overall bipolar illness items on a 7-point scale [1 to 7], with 1 being normal and 7 being very severely ill). A negative change score signifies improvement. (NCT00261443)
Timeframe: Baseline (end of Ph 1), Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, and Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | units on a scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean Baseline (BL) (n=289, 383) | Mean Change from BL to Week 1 (n=275, 370) | Mean Change from BL to Week 2 (n=267, 354) | Mean Change from BL to Week 4 (n=245, 326) | Mean Change from BL to Week 6 (n=219, 305) | Mean Change from BL to Week 8 (n=200, 287) | Mean Change from BL to Week 12 (n=179, 252) | Mean Change from BL to Week 16 (n=138, 193) | Mean Change from BL to Week 20 (n=59, 99) | Mean Change from BL to Week 24 (n=22, 39) | Mean Change from BL to Phase 2 Endpoint(n=289,383) | |
| Lithium | 4.25 | -0.52 | -1.05 | -1.56 | -1.86 | -2.17 | -2.31 | -2.57 | -2.71 | -2.73 | -1.90 |
| Valproate | 4.08 | -0.53 | -0.97 | -1.31 | -1.62 | -1.80 | -1.99 | -2.17 | -2.14 | -2.38 | -1.66 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change in patients with bipolar disorder. Patients are rated on Change from Preceding Phase (mania, depression and overall bipolar illness) items (also a 7-point scale [1 to 7], with 1 being very much improved and 7 being very much worse). (NCT00261443)
Timeframe: Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, and Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean Change from BL to Week 1 (n=274, 368) | Mean Change from BL to Week 2 (n=265, 353) | Mean Change from BL to Week 4 (n=245, 325) | Mean Change from BL to Week 6 (n=219, 305) | Mean Change from BL to Week 8 (n=200, 287) | Mean Change from BL to Week 12 (n=179, 250) | Mean Change from BL to Week 16 (n=138, 193) | Mean Change from BL to Week 20 (n=59, 99) | Mean Change from BL to Week 24 (n=22, 39) | Mean Change from BL to Phase 2 Endpoint(n=289,382) | |
| Lithium | 3.56 | 3.42 | 3.35 | 3.22 | 3.13 | 3.28 | 3.30 | 3.24 | 2.91 | 3.30 |
| Valproate | 3.40 | 3.25 | 3.19 | 3.13 | 3.11 | 3.06 | 2.99 | 3.18 | 3.15 | 3.26 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change from baseline in patients with bipolar disorder. Patients are rated on mania, depression and overall change from preceding phase items on a 7-point scale [1 to 7], with 1 being very much improved and 7 being very much worse). (NCT00261443)
Timeframe: Weeks 1, 2, 4,6, 8, 12, 16, 20, 24, and Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean Change from BL to Week 1 (n=274, 369) | Mean Change from BL to Week 2 (n=265, 353) | Mean Change from BL to Week 4 (n=245, 325) | Mean Change from BL to Week 6 (n=219, 305) | Mean Change from BL to Week 8 (n=200, 287) | Mean Change from BL to Week 12 (n=179, 252) | Mean Change from BL to Week 16 (n=138, 193) | Mean Change from BL to Week 20 (n=59, 99) | Mean Change from BL to Week 24 (n=22, 39) | Mean Change from BL to Phase 2 Endpoint(n=289,382) | |
| Lithium | 3.15 | 2.61 | 2.14 | 1.95 | 1.73 | 1.66 | 1.54 | 1.69 | 1.64 | 1.95 |
| Valproate | 3.09 | 2.58 | 2.24 | 1.97 | 1.80 | 1.65 | 1.61 | 1.68 | 1.67 | 1.94 |
Clinical Global Impression-Bipolar (CGI-BP) assesses global illness severity and change from baseline (in this case, preceding phase) in patients with bipolar disorder. Patients are rated on mania, depression and overall bipolar illness items on a 7-point scale [1 to 7], with 1 being very much improved and 7 being very much worse). (NCT00261443)
Timeframe: Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, and Phase 2 Endpoint. Phase 2 (13- to 24-week Stability and Maintenance of Stability Phase, which followed a 2- to 8-week Screening, Washout, and Confirmation of Partial Nonresponse Phase)
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean Change from BL to Week 1 (n=274, 369) | Mean Change from BL to Week 2 (n=265, 353) | Mean Change from BL to Week 4 (n=245, 325) | Mean Change from BL to Week 6 (n=219, 305) | Mean Change from BL to Week 8 (n=200, 287) | Mean Change from BL to Week 12 (n=179, 252) | Mean Change from BL to Week 16 (n=138, 193) | Mean Change from BL to Week 20 (n=59, 99) | Mean Change from BL to Week 24 (n=22, 39) | Mean Change from BL to Phase 2 Endpoint(n=289,382) | |
| Lithium | 3.20 | 2.70 | 2.27 | 2.11 | 1.94 | 1.87 | 1.74 | 1.81 | 1.68 | 2.26 |
| Valproate | 3.13 | 2.69 | 2.40 | 2.19 | 2.08 | 1.94 | 1.80 | 1.90 | 1.82 | 2.37 |
CGI-S is a single-item clinician rated scale used to assess global severity of bipolar illness based on an overall evaluation of symptoms of bipolar mania, associated behavioral symptoms, and condition of the subject. Scored from 1 (normal, not at all ill) to 7 (among the most severely ill subjects). Higher score = more affected. Change calculated as a difference between post-baseline observation and baseline CGI-S score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) |
|---|---|
| Ziprasidone | -1.5 |
| Placebo | -1.5 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Change calculated as a difference between post-baseline observation and baseline MADRS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) |
|---|---|
| Ziprasidone | -14.7 |
| Placebo | -13.2 |
Number of subjects with improvement defined as CGI-I response of 1 (very much improved) or 2 (much improved). CGI-I is a single-item clinician rated scale used to assess global improvement in the subject's clinical state (bipolar mania) in response to study treatment and as compared to their status at pre-treatment baseline. Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse). Higher score = more affected. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 66 |
| Placebo | 69 |
Number of subjects with MADRS total score ≤ 12 (indicates remission). MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). (NCT00483548)
Timeframe: Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 48 |
| Placebo | 54 |
Number of subjects with reduction of ≥50 percent (%) in MADRS total score (indicates response). MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Reduction calculated as ([A-B]/B*100): A=value at observation; B=baseline value. (NCT00483548)
Timeframe: Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 62 |
| Placebo | 65 |
CGI-I is a single-item clinician rated scale used to assess global improvement in the subject's clinical state (bipolar mania) in response to study treatment and as compared to their status at pre-treatment baseline. Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse). Higher score = more affected. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=120, 138) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | Week 6 (n=92, 108) | |
| Placebo | 3.4 | 3.1 | 2.9 | 2.8 | 2.6 | 2.4 |
| Ziprasidone | 3.2 | 2.9 | 2.7 | 2.6 | 2.5 | 2.4 |
AIMS is a clinician rated 12-item scale to rate 7 body areas and global judgments on the severity of abnormal movements, incapacitation and subject's awareness of abnormal movements. Items 1 to 10 scored 0 (none) to 4 (severe); items 11 to 14 are No or Yes response to dental status and sleep movements and are assessed separately. AIMS total score is sum of first 7 items. Change calculated as a difference between post-baseline observation and baseline AIMS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total score: Week 2 (n=136, 142) | Total score: Week 4 (n=111, 127) | Total score: Week 6 (n=100, 111) | Global severity score: Week 2 (n=136, 142) | Global severity score: Week 4 (n=111, 127) | Global severity score: Week 6 (n=100, 111) | Incapacitation score: Week 2 (n=136, 142) | Incapacitation score: Week 4 (n=111, 127) | Incapacitation score: Week 6 (n=100, 111) | |
| Placebo | -0.1 | -0.0 | -0.0 | -0.0 | 0.0 | 0.0 | -0.0 | -0.0 | 0.0 |
| Ziprasidone | 0.1 | -0.0 | -0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
BARS is a clinician rated scale to evaluate akathisia associated with use of antipsychotic medications: objective motor restlessness, range 0 to 3; subjective complaints of restlessness and associated distress, range 0 to 3; global clinical assessment of akathisia, range 0 to 5. Higher scores indicate more affected. Change calculated as a difference between post-baseline observation and baseline BARS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=135, 139) | Week 4 (n=111, 125) | Week 6 (n=100, 110) | |
| Placebo | -0.0 | 0.0 | -0.0 |
| Ziprasidone | 0.1 | 0.0 | 0.0 |
CGI-S is a single-item clinician rated scale used to assess global severity of bipolar illness based on an overall evaluation of symptoms of bipolar mania, associated behavioral symptoms, and condition of the subject. Scores range from 1 (normal, not at all ill) to 7 (among the most severely ill subjects). Higher score = more affected. Change calculated as a difference between post-baseline observation and baseline CGI-S score values. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5
| Intervention | scores on scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=120, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | |
| Placebo | -0.4 | -0.7 | -0.9 | -1.1 | -1.3 |
| Ziprasidone | -0.5 | -0.9 | -0.9 | -1.1 | -1.3 |
GAF is a clinician rated scale to measure the severity of illness-related impairment in psychological, social, and occupational functioning using a 100-point scale (single score of 1 to 100) with 100 indicating a superior level of function. Change calculated as a difference between post-baseline observation and baseline GAF score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |
|---|---|---|
| Week 6 (n=100, 110) | ET (n=34, 27) | |
| Placebo | 11.2 | 2.8 |
| Ziprasidone | 14.7 | 0.0 |
HAM-A is a clinician rated 14-item scale that rates the intensity of psychic anxiety (items 1 to 6 and item 14) and somatic anxiety (items 7 to 13) on a 5-point severity scale; scores range from 0 (not present) to 4 (very severe); lower score indicates less affected. Change calculated as a difference between post-baseline observation and baseline HAM-A score values. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=136, 141) | Week 4 (n=111, 127) | Week 6 (n=100, 111) | |
| Placebo | -5.9 | -7.4 | -8.6 |
| Ziprasidone | -5.6 | -7.1 | -8.5 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Change calculated as a difference between post-baseline observation and baseline MADRS score values. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5
| Intervention | scores on scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=121, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | |
| Placebo | -6.1 | -9.0 | -11.0 | -11.8 | -13.3 |
| Ziprasidone | -8.1 | -11.7 | -13.0 | -14.1 | -14.9 |
Q-LES-Q is a 16-item subject rated scale to measure satisfaction with areas of daily functioning (physical health, social relationships, medication, and overall life satisfaction); rated on a 5-point Likert scale: higher scores indicate greater enjoyment and satisfaction with general life activities. Scores for items 1 to 14 are summed for a total score and converted to 0 to 100 range. Items 15 and 16 measure satisfaction with medication and overall satisfaction and are analyzed separately. Change calculated as a difference between post-baseline observation and baseline Q-LES-Q score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Total Q-LES-Q: Week 6 (n=82, 94) | Total Q-LES-Q: ET (n=27, 17) | Medications: Week 6 (n=91, 93) | Medications: ET (n=27, 20) | Overall life satisfaction: Week 6 (n=94, 103) | Overall life satisfaction: ET (n=31, 23) | |
| Placebo | 11.6 | 1.6 | 0.3 | -0.4 | 0.5 | 0.0 |
| Ziprasidone | 15.2 | -0.1 | 0.4 | -0.3 | 0.8 | 0.1 |
SDS is a 5-item subject rated scale to measure the extent to which work and or school, social life and or leisure activities, and home life and or family responsibilities were impaired by psychiatric illness. Items 1 to 3 rated on 11-point scale ranging 0 (not at all) to 10 (extremely affected). Total score 0 to 30; higher score indicates greater impairment; items 4 and 5 report number of days in the last month (0 to 31) subject missed work or school or was unproductive and are rated separately. Change calculated as a difference between post-baseline observation and baseline SDS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total SDS: Week 6 (n=58, 63) | Total SDS: ET (n=19, 14) | Work/School: Week 6 (n=58, 64) | Work/School: ET (n=19, 14) | Social life: Week 6 (n=94, 102) | Social life: ET (n=31, 23) | Family/Home: Week 6 (n=94, 102) | Family/Home: ET (n=31, 23) | |
| Placebo | -3.7 | -1.4 | -1.6 | -0.1 | -1.7 | 0.1 | -1.7 | -0.6 |
| Ziprasidone | -8.5 | 0.2 | -2.1 | 0.4 | -2.5 | -0.5 | -2.6 | 0.2 |
SDS is a 5-item subject rated scale to measure the extent to which work and or school, social life and or leisure activities, and home life and or family responsibilities were impaired by psychiatric illness. Items 1 to 3 rated on 11-point scale ranging 0 (not at all) to 10 (extremely affected). Total score 0 to 30; higher score indicates greater impairment; items 4 and 5 report number of days in the last month (0 to 31) subject missed work or school or was unproductive and are rated separately. Change calculated as a difference between post-baseline observation and baseline SDS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | days (Mean) | |||
|---|---|---|---|---|
| Days lost: Week 6 (n=85, 93) | Days lost: ET (n=29, 21) | Days unproductive: Week 6 (n=87, 89) | Days unproductive: ET (n=29, 21) | |
| Placebo | -0.7 | 0.0 | -1.3 | -0.1 |
| Ziprasidone | -1.2 | 0.5 | -1.6 | -0.2 |
SAS is a clinician rated 10-item scale to measure extrapyramidal side effects (Parkinsonism or Parkinsonian side effects induced with antipsychotics); rated on a 5-point scale with range 0 (absence of condition) to 4 (presence of condition in extreme form). Global score is sum of all scores divided by the total number of items. Change calculated as a difference between post-baseline observation and baseline SAS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=136, 141) | Week 4 (n=111, 126) | Week 6 (n=100, 110) | |
| Placebo | -0.1 | 0.0 | -0.1 |
| Ziprasidone | 0.1 | 0.0 | 0.0 |
YMRS is clinician rated 11-item scale (elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, speech [rate and amount], language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight) used to assess the severity of manic symptoms and effect of treatment on mania severity. Seven items ranked on scale from 0 to 4; 4 items ranked 0 to 8. Higher scores indicate greater severity. Change calculated as a difference between post-baseline observation and baseline YMRS score values. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=121, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | Week 6 (n=92, 108) | |
| Placebo | -0.2 | -0.2 | -0.2 | -1.1 | -1.3 | -0.9 |
| Ziprasidone | 0.7 | 0.5 | -0.0 | -0.9 | -0.9 | -1.0 |
The MADRS is a 10-item clinician-rated scale for assessing the severity of symptoms of depression. MADRS total score range = 0-60; higher scores indicate greater severity of symptoms. (NCT00145509)
Timeframe: Baseline and 52 Weeks
| Intervention | Score on a scale (Mean) |
|---|---|
| Asenapine | -3.3 |
| Placebo | -3.9 |
The Y-MRS is an 11-item, clinician-rated instrument used for assessing the symptoms of mania. Y-MRS total score range = 0-60; higher scores indicate greater severity of symptoms. (NCT00145509)
Timeframe: Baseline and 52 Weeks
| Intervention | Score on a Scale (Mean) |
|---|---|
| Asenapine | -17.2 |
| Placebo | -19.7 |
Participants who discontinued study medication due to adverse events. (NCT00145509)
Timeframe: 40 weeks
| Intervention | participants (Number) |
|---|---|
| Asenapine | 10 |
| Placebo | 3 |
Participants who experienced treatment-emergent adverse events, defined as adverse events reported on or after the first dose of study medication in the 12-week lead-in study through the last dose of study drug + 7 days (or + 30 days for serious adverse events). (NCT00145509)
Timeframe: up to 52 weeks
| Intervention | Participants (Number) |
|---|---|
| Asenapine | 32 |
| Placebo | 25 |
The number of participants discontinuing study treatment due to an AE was assessed. An AE is any untoward or unfavorable medical occurrence in a participant, including any abnormal sign, symptom, or disease, temporally associated with the use of the investigational product, whether or not considered related to the investigational product. (NCT00145470)
Timeframe: Up to Day 84
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 18 |
| Asenapine | 25 |
The number of participants experiencing an AE was assessed. An AE is any untoward or unfavorable medical occurrence in a participant, including any abnormal sign, symptom, or disease, temporally associated with the use of the investigational product, whether or not considered related to the investigational product. (NCT00145470)
Timeframe: Up to Day 114
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 114 |
| Asenapine | 116 |
"The percentage of participants determined to be ready to discharge at day 84 was estimated (Kaplan-Meier), using the readiness to discharge questionnaire (RDQ). The RDQ is clinician-rated scale to assess readiness for discharge, composed of 7 items. Of the 7 items, only the first 5 items were utilized:~Not actively suicidal/homicidal;~Adequate control over aggression and impulsivity;~Able to carry out basic activities of daily life;~Able to take medicine independently; and~Delusions and hallucinations do not significantly interfere with functioning.~For the 5 items, the clinician provided a response (Strongly Disagree; Disagree; Agree; or Strongly Agree) at each pre-specified visit. The first visit at which the responses to the first 5 items on the RDQ are Strongly Agree or Agree, was defined as the point a participant was ready to discharge." (NCT00145470)
Timeframe: Day 84
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 74.1 |
| Asenapine | 89.7 |
Least squares mean change from baseline at day 21 in quality of life was assessed, as determined by SF-36v2. The SF-36v2 is a self-administered questionnaire, measuring 8 domains: Physical Functioning (PF); Role-Physical (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role-Emotional (RE); and Mental Health (MH). These 8 concepts are further organized into a Physical Component Summary (PCS; composite of PF, RP, BP, and GH) and a Mental Component Summary (MCS; composite of VT, SF, RE, and MH). The SF-36v2 domains and composite summaries were scored using a norm-based scoring approach, yielding a mean of 50 and standard deviation of 10 based on the norms from the 1998 SF-36 United States general population norms. For the PCS and MCS, scores range from 0 to 100, with higher scores indicating better quality of life. Further, decreases in quality of life (by PCS and MCS) are reflected by a negative change from baseline. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |||
|---|---|---|---|---|
| PCS - Baseline | PCS - Change from Baseline at Day 21 | MCS - Baseline | MCS - Change from Baseline at Day 21 | |
| Asenapine | 51.64 | -2.47 | 39.03 | 5.93 |
| Placebo | 50.49 | -0.72 | 40.83 | 2.29 |
Least squares mean change from baseline at day 84 in quality of life was assessed, as determined by SF-36v2. The SF-36v2 is a self-administered questionnaire, measuring 8 domains: Physical Functioning (PF); Role-Physical (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role-Emotional (RE); and Mental Health (MH). These 8 concepts are further organized into a Physical Component Summary (PCS; composite of PF, RP, BP, and GH) and a Mental Component Summary (MCS; composite of VT, SF, RE, and MH). The SF-36v2 domains and composite summaries were scored using a norm-based scoring approach, yielding a mean of 50 and standard deviation of 10 based on the norms from the 1998 SF-36 United States general population norms. For the PCS and MCS, scores range from 0 to 100, with higher scores indicating better quality of life. Further, decreases in quality of life (by PCS and MCS) are reflected by a negative change from baseline. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |||
|---|---|---|---|---|
| PCS - Baseline | PCS - Change from Baseline at Day 84 | MCS - Baseline | MCS - Change from Baseline at Day 84 | |
| Asenapine | 51.64 | -0.95 | 39.03 | 2.49 |
| Placebo | 50.49 | 1.37 | 40.83 | -1.05 |
The least squares mean change from baseline in CGI-BP severity of depression score at day 21 was assessed. The CGI-BP severity of depression scale is a clinician-rated scale for assessing the severity of depressive symptoms of bipolar disorder, with scores ranging from 1 (normal) to 7 (very severely ill). Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 2.3 | -0.2 |
| Placebo | 2.3 | -0.1 |
The least squares mean change from baseline in CGI-BP severity of depression score at day 84 was assessed. The CGI-BP severity of depression scale is a clinician-rated scale for assessing the severity of depressive symptoms of bipolar disorder, with scores ranging from 1 (normal) to 7 (very severely ill). Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 2.3 | -0.1 |
| Placebo | 2.3 | -0.1 |
The least squares mean change from baseline in CGI-BP severity of mania score at day 21 was assessed. The CGI-BP severity of mania scale is a clinician-rated scale for assessing the severity of manic symptoms of bipolar disorder, with scores ranging from 1 (normal) to 7 (very severely ill). Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 4.5 | -1.1 |
| Placebo | 4.5 | -0.8 |
The least squares mean change from baseline in CGI-BP severity of mania score at day 84 was assessed. The CGI-BP severity of mania scale is a clinician-rated scale for assessing the severity of manic symptoms of bipolar disorder, with scores ranging from 1 (normal) to 7 (very severely ill). Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 4.5 | -1.5 |
| Placebo | 4.5 | -1.0 |
The least squares mean change from baseline in CGI-BP severity of severity of overall bipolar illness score at day 21 was assessed. The CGI-BP severity of overall bipolar illness scale is a clinician-rated scale for assessing the severity of overall symptoms of bipolar disorder, with scores ranging from 1 (normal) to 7 (very severely ill). Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 4.6 | -1.0 |
| Placebo | 4.6 | -0.7 |
The least squares mean change from baseline in CGI-BP severity of severity of overall bipolar illness score at day 84 was assessed. The CGI-BP severity of overall bipolar illness scale is a clinician-rated scale for assessing the severity of overall symptoms of bipolar disorder, with scores ranging from 1 (normal) to 7 (very severely ill). Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 4.6 | -1.2 |
| Placebo | 4.6 | -0.8 |
The least squares mean change from baseline in HAM-A score at day 21 was assessed. The HAM-A is a clinician-rated instrument for assessing anxiety symptoms, composed of 14 items. For the 14 items, scores range from 0 (not present) to 4 (severe). Scores for individual items add to a total score (range: 0-56), with higher scores indicating greater severity of anxiety. Further, decreases in anxiety severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 8.8 | -2.4 |
| Placebo | 9.3 | -2.1 |
The least squares mean change from baseline in HAM-A score at day 84 was assessed. The HAM-A is a clinician-rated instrument for assessing anxiety symptoms, composed of 14 items. For the 14 items, scores range from 0 (not present) to 4 (severe). Scores for individual items add to a total score (range: 0-56), with higher scores indicating greater severity of anxiety. Further, decreases in anxiety severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 8.8 | -2.1 |
| Placebo | 9.3 | -2.1 |
The least squares mean change from baseline in ISST-Modified score at day 21 was assessed. The ISST-Modified is a clinician-rated scale for rating suicidality, composed of 12 items (score range: 0-2). Scores for the 12 items add to a total ISST-Modified score (range: 0-24), with higher scores indicating increased severity of suicidal thinking. Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 0.4 | 0.0 |
| Placebo | 0.6 | -0.0 |
The least squares mean change from baseline in ISST-Modified score at day 84 was assessed. The ISST-Modified is a clinician-rated scale for rating suicidality, composed of 12 items (score range: 0-2). Scores for the 12 items add to a total ISST-Modified score (range: 0-24), with higher scores indicating increased severity of suicidal thinking. Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 0.4 | 0.3 |
| Placebo | 0.6 | -0.0 |
The least squares mean change from baseline in MADRS score at day 21 was assessed. The MARDS is a clinician-rated scale for assessing the severity of symptoms of depression, composed of 10 items. For the 10 items, scores range from 0 (symptoms absent) to 6 (severe). Scores for individual items add to a total score (range: 0-60), with higher scores indicating greater severity of depression. Further, decreases in depression severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 11.3 | -2.9 |
| Placebo | 11.4 | -2.2 |
The least squares mean change from baseline in MADRS score at day 84 was assessed. The MARDS is a clinician-rated scale for assessing the severity of symptoms of depression, composed of 10 items. For the 10 items, scores range from 0 (symptoms absent) to 6 (severe). Scores for individual items add to a total score (range: 0-60), with higher scores indicating greater severity of depression. Further, decreases in depression severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 11.3 | -1.6 |
| Placebo | 11.4 | -1.7 |
The least squares mean change from baseline in PANSS score at day 21 was assessed. The PANSS assesses the severity of schizophrenia symptoms through a clinician-rated inventory of 30 items organized in 3 subscales: 1) positive subscale (7 items); 2) negative subscale (7 items); and 3) general psychopathology subscale (16 items). For each item, symptoms are scored from 1 (absent) to 7 (extreme) and add to a total PANSS score (range: 30-210). Higher scores reflect more severe symptoms of schizophrenia. Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 65.1 | -7.2 |
| Placebo | 67.1 | -5.4 |
The least squares mean change from baseline in PANSS score at day 84 was assessed. The PANSS assesses the severity of schizophrenia symptoms through a clinician-rated inventory of 30 items organized in 3 subscales: 1) positive subscale (7 items); 2) negative subscale (7 items); and 3) general psychopathology subscale (16 items). For each item, symptoms are scored from 1 (absent) to 7 (extreme) and add to a total PANSS score (range: 30-210). Higher scores reflect more severe symptoms of schizophrenia. Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 65.1 | -7.4 |
| Placebo | 67.1 | -6.0 |
The least squares mean change from baseline in Q-LES-Q score at day 21 was assessed. The Q-LES-Q is a participant-completed questionnaire to assess general satisfaction with activities such as physical health, mood, work, household tasks, social and family relationships, leisure activities, and overall satisfaction, composed of 16 items. For each of the 16 items, scores range from 0 (very poor) to 5 (very good), with scores for all items adding to a total score (range: 0-80); higher scores indicate better quality of life. Further, decreases in quality of life are reflected by a negative change from baseline. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 61.3 | 4.6 |
| Placebo | 61.0 | 3.9 |
The least squares mean change from baseline in Q-LES-Q score at day 84 was assessed. The Q-LES-Q is a participant-completed questionnaire to assess general satisfaction with activities such as physical health, mood, work, household tasks, social and family relationships, leisure activities, and overall satisfaction, composed of 16 items. For each of the 16 items, scores range from 0 (very poor) to 5 (very good), with scores for all items adding to a total score (range: 0-80); higher scores indicate better quality of life. Further, decreases in quality of life are reflected by a negative change from baseline. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 61.3 | -1.1 |
| Placebo | 61.0 | -3.7 |
The least squares mean change from baseline in Y-MRS score at day 21 was assessed. The Y-MRS is a clinician-rated instrument used for assessing the symptoms of mania, composed of 11 items. For the 11 items, scores range from 0 (symptoms absent) to, depending on the item, either 4 (7 items) or 8 (4 items). Scores for individual items add to a total score (range: 0-60), with higher scores indicating greater symptom severity. Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a last observation carried forward (LOCF) analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 27.9 | -10.3 |
| Placebo | 28.2 | -7.9 |
The least squares mean change from baseline in Y-MRS score at day 42 was assessed. The Y-MRS is a clinician-rated instrument used for assessing the symptoms of mania, composed of 11 items. For the 11 items, scores range from 0 (symptoms absent) to, depending on the item, either 4 (7 items) or 8 (4 items). Scores for individual items add to a total score (range: 0-60), with higher scores indicating greater symptom severity. Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 42
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 42 | |
| Asenapine | 27.9 | -11.4 |
| Placebo | 28.2 | -8.7 |
The least squares mean change from baseline in Y-MRS score at day 84 was assessed. The Y-MRS is a clinician-rated instrument used for assessing the symptoms of mania, composed of 11 items. For the 11 items, scores range from 0 (symptoms absent) to, depending on the item, either 4 (7 items) or 8 (4 items). Scores for individual items add to a total score (range: 0-60), with higher scores indicating greater symptom severity. Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 27.9 | -12.7 |
| Placebo | 28.2 | -9.3 |
"Nine neurocognitive tests with higher scores indicating better performance:~Verbal Memory test: recognize/remember/retrieve words (range 0-60)~Visual Memory test: recognize/remember/retrieve geometric figures (range 0-60)~Speed of Processing: recognize/process information. No min./max. score. Normative average (NA); correct answers: 65.1, avg. errors: 1.37~Social Acuity/Perception of Emotions test: perceive/respond to emotional cues. Min. score: -64/Max. score: 16~Reasoning: reason/respond to non-verbal, visual-abstract stimuli; scores range: -15 to 15~Executive Function: recognize rules/categories/decision making. No min./max. score. NA correct answers: 55.01/avg. errors: 5.28~Working Memory/Continuous Performance Task (CPT): perceive/attend to symbols. Min. score: -45/Max. score: 15~Sustained Attention: direct/focus on specific stimuli: Max. score (raw score); 45; Min. score: -170~Composite Memory: working+verbal+visual memory, Range 0-135." (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verbal Memory - Baseline | Visual Memory - Baseline | Processing Speed - Baseline | Social Acuity - Baseline | Reasoning - Baseline | Executive Functioning - Baseline | Working Memory - Baseline | Sustained Attention - Baseline | Composite Memory - Baseline | Verbal Memory - CFB at Day 21 | Visual Memory - CFB at Day 21 | Processing Speed - CFB at Day 21 | Social Acuity - CFB at Day 21 | Reasoning - CFB at Day 21 | Executive Functioning - CFB at Day 21 | Working Memory - CFB at Day 21 | Sustained Attention - CFB at Day 21 | Composite Memory - CFB at Day 21 | |
| Asenapine | 44.6 | 38.2 | 39.5 | 2.7 | 1.3 | 16.9 | 2.9 | 13.5 | 82.8 | 0.8 | -0.4 | 4.2 | 0.3 | 0.7 | 10.1 | -0.4 | -0.8 | 0.5 |
| Placebo | 43.6 | 38.0 | 34.3 | 2.8 | 2.1 | 17.6 | 2.9 | 14.0 | 81.6 | -0.8 | -0.3 | 3.8 | 1.0 | 0.3 | 4.4 | 0.2 | 0.3 | -1.1 |
"Nine neurocognitive tests with higher scores indicating better performance:~Verbal Memory test: recognize/remember/retrieve words (range 0-60)~Visual Memory test: recognize/remember/retrieve geometric figures (range 0-60)~Speed of Processing: recognize/process information. No min./max. score. Normative average (NA); correct answers: 65.1, avg. errors: 1.37~Social Acuity/Perception of Emotions test: perceive/respond to emotional cues. Min. score: -64/Max. score: 16~Reasoning: reason/respond to non-verbal, visual-abstract stimuli; scores range: -15 to 15~Executive Function: recognize rules/categories/decision making. No min./max. score. NA correct answers: 55.01/avg. errors: 5.28~Working Memory/Continuous Performance Task (CPT): perceive/attend to symbols. Min. score: -45/Max. score: 15~Sustained Attention: direct/focus on specific stimuli: Max. score (raw score); 45; Min. score: -170~Composite Memory: working+verbal+visual memory, Range 0-135." (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verbal Memory - Baseline | Visual Memory - Baseline | Processing Speed - Baseline | Social Acuity - Baseline | Reasoning - Baseline | Executive Functioning - Baseline | Working Memory - Baseline | Sustained Attention - Baseline | Composite Memory - Baseline | Verbal Memory - CFB at Day 84 | Visual Memory - CFB at Day 84 | Processing Speed - CFB at Day 84 | Social Acuity - CFB at Day 84 | Reasoning - CFB at Day 84 | Executive Functioning - CFB at Day 84 | Working Memory - CFB at Day 84 | Sustained Attention - CFB at Day 84 | Composite Memory - CFB at Day 84 | |
| Asenapine | 44.6 | 38.2 | 39.5 | 2.7 | 1.3 | 16.9 | 2.9 | 13.5 | 82.8 | -0.3 | -0.5 | -1.4 | 0.9 | 1.0 | 10.2 | -0.4 | 0.5 | -0.7 |
| Placebo | 43.6 | 38.0 | 34.3 | 2.8 | 2.1 | 17.6 | 2.9 | 14.0 | 81.6 | -0.0 | 0.0 | 3.6 | 0.7 | -0.1 | 3.9 | -0.2 | -0.5 | -0.0 |
The Y-MRS is a clinician-rated instrument used for assessing the symptoms of mania, composed of 11 items. For the 11 items, scores range from 0 (symptoms absent) to, depending on the item, either 4 (7 items) or 8 (4 items). Scores for individual items add to a total score (range: 0-60), with higher scores indicating greater symptom severity. At pre-specified time points, the number of participants achieving Y-MRS remitter status was assessed, defined as the number of participants with a Y-MRS total score of 12 or lower. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Up to Day 84
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Day 3 | Day 7 | Day 14 | Day 21 | Day 42 | Day 63 | Day 84 | |
| Asenapine | 11 | 19 | 42 | 52 | 64 | 63 | 67 |
| Placebo | 8 | 21 | 32 | 35 | 46 | 46 | 49 |
The Y-MRS is a clinician-rated instrument used for assessing the symptoms of mania, composed of 11 items. For the 11 items, scores range from 0 (symptoms absent) to, depending on the item, either 4 (7 items) or 8 (4 items). Scores for individual items add to a total score (range: 0-60), with higher scores indicating greater symptom severity. At pre-specified time points, the number of participants achieving Y-MRS responder status was assessed, defined as the number of participants with a 50% decrease from baseline in Y-MRS total score. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Up to Day 84
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Day 3 | Day 7 | Day 14 | Day 21 | Day 42 | Day 63 | Day 84 | |
| Asenapine | 13 | 22 | 46 | 53 | 67 | 66 | 74 |
| Placebo | 10 | 25 | 34 | 44 | 52 | 52 | 56 |
Response for depressive symptoms was defined as a score less than 40 on the CDRS-R. Range is 18 to 120. Score 18 is normal and higher score signifies depression. The Children's Depression Rating Scale (CDRS) is a 16-item measure used to determine the severity of depression in children 6-18 years of age. Items are measured on 3-, 4-, 5-, and 6-point scales. The mean and standard deviation are measured in this study to illustrate outcome at baseline and when the subject ended the study. (NCT00176202)
Timeframe: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last Observation Carried Forward (p<.01) | |
| Divalproex | 40.76 | 35.76 |
| Risperidone | 41.72 | 25.88 |
Child Mania rating scale is a parent rated measure to screen for symptoms of mania. It includes 21 items reflecting the DSM-IV criteria for a manic episode. Each item is answered on a four-point Likert type scale anchored by 0 (Never/Rare), 1 (Sometimes), 2 (Often), and 3 (Very Often). Maximum score possible is 63. Score higher than 20 is considered clinically significant, and this is a dimensional score of manic severity. (NCT00176202)
Timeframe: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).
| Intervention | units on scale (Mean) | |
|---|---|---|
| Baseline | LOCF | |
| Divalproex Sodium | 28.0 | 19.20 |
| Risperidone | 30.84 | 16.35 |
Severity of Illness and Global Improvement are rated on a 7-point scale by the clinician. In addition to rating the overall illness with the CGI-BP, severity and improvement are considered on various other dimensions such as mania, depression, attention deficit/hyperactivity, psychosis, aggression and sleep difficulties. Score of 1, 2 and 3 would mean there is clinically observed symptom improvement where 1 is the best outcome than 2 or 3. The point 4 is the point where the subject presents at baseline of that specific individual. If they become worse on clinical symptoms, they are rated as 5, 6 or 7 where 7 is worse than 5. (NCT00176202)
Timeframe: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | LOCF | |
| Divalproex Sodium | 4.37 | 2.97 |
| Risperidone | 4.80 | 2.77 |
This measure has 11 items. The purpose of each item is to rate the severity of that abnormality in the patient. A severity rating is assigned to each of the eleven items, based on the patient's subjective report of his or her condition over the previous forty-eight hours and the clinician's behavioral observations during the interview, with the emphasis on the latter. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. Total score of zero to 60 is possible, zero being normal and 60 being severe, 12 serving as a cut off point for illness if equal or above. There are several ways to show change in outcome. We show the mean and standard deviation at week 0 and 6. (NCT00176202)
Timeframe: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last observation carried forward (LOCF) | |
| Divalproex | 25.09 | 15.24 |
| Risperidone | 30.59 | 10.22 |
Severity of the illness and psychopathological features will be measured by the increase in the SADS Mania Rating Scale, with higher scores representing worse mania. The range of this scale is 0-75. (NCT00183469)
Timeframe: up to 8 months
| Intervention | units on a scale (Mean) |
|---|---|
| Double-Blind Lamotrigine and Divalproex ER | 4.54 |
| Double-Blind Lamotrigine and Placebo Divalproex ER | 5.57 |
GAF measures the severity of illness-related impairment in psychological, social, and occupational functioning; rated on a 100-point scale (single score of 1 to 100) with 100 indicating superior functioning. Change calculated as mean of (value of GAF score at observation minus baseline value). (NCT00312494)
Timeframe: Baseline, Week 3
| Intervention | scores on scale (Least Squares Mean) |
|---|---|
| Ziprasidone (Higher Dose) | 8.79 |
| Ziprasidone (Lower Dose) | 9.62 |
| Placebo | 7.79 |
LIFE-RIFT measures severity of illness-related impairment in 4 domains: work, interpersonal relations, recreation, and global satisfaction; has a total score and individual domain scores. Domain scores range from 1 to 5 (scores ≥ 2 reflect impaired functioning). Total score is sum of the 4 domains with range of 4 (very good) to 20 (very poor): higher scores indicate greater impairment. Change calculated as mean of (value of LIFE-RIFT score at observation minus baseline value). (NCT00312494)
Timeframe: Baseline, Week 3
| Intervention | scores on scale (Least Squares Mean) |
|---|---|
| Ziprasidone (Higher Dose) | -1.68 |
| Ziprasidone (Lower Dose) | -1.58 |
| Placebo | -1.27 |
YMRS is an 11-item scale (elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, speech [rate and amount], language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight) used to assess the severity of manic symptoms and effect of treatment on mania severity. Seven items ranked on scale from 0 to 4; 4 items ranked 0 to 8. Total possible score 0 to 60: higher scores indicate greater severity. Change calculated as mean of (value of YMRS score at observation minus baseline value). (NCT00312494)
Timeframe: Baseline, Week 3
| Intervention | scores on scale (Least Squares Mean) |
|---|---|
| Ziprasidone (Higher Dose) | -10.19 |
| Ziprasidone (Lower Dose) | -10.95 |
| Placebo | -9.47 |
CGI-S is a single-item clinician rated scale used to assess global severity of bipolar illness based on an overall evaluation of symptoms of bipolar mania, associated behavioral symptoms, and condition of the subject. Rating ranges from 1 (normal, not at all ill) to 7 (among the most severely ill subjects); higher score = more affected. Change calculated as mean of (value of CGI-S score at observation minus baseline value). (NCT00312494)
Timeframe: Baseline, Week 1, Week 2, Week 3
| Intervention | scores on scale (Least Squares Mean) | ||
|---|---|---|---|
| Week 1 (n=202, 206, 200) | Week 2 (n=178, 188, 186) | Week 3 (n=163, 172, 171) | |
| Placebo | -0.39 | -0.73 | -1.00 |
| Ziprasidone (Higher Dose) | -0.35 | -0.70 | -0.94 |
| Ziprasidone (Lower Dose) | -0.43 | -0.74 | -1.13 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal) with anchors at 2-point intervals; total score 0 to 44 (higher score indicates greater severity of symptoms). Change calculated as mean of (value of MADRS score at observation minus baseline value). (NCT00312494)
Timeframe: Baseline, Week 1, Week 2, Week 3
| Intervention | scores on scale (Least Squares Mean) | ||
|---|---|---|---|
| Week 1 (n=202, 205, 200) | Week 2 (n=178, 188, 186) | Week 3 (n=163, 172, 170) | |
| Placebo | -1.11 | -1.71 | -2.90 |
| Ziprasidone (Higher Dose) | -2.16 | -3.27 | -4.20 |
| Ziprasidone (Lower Dose) | -2.47 | -3.24 | -3.79 |
PANSS is a 30-item scale to measure severity of psychopathology (16 items); positive scale (7 items); negative scale (7 items); summarized as positive score, negative score, and total score. Scores rated 1 (absent symptoms) to 7 (extreme); total score range 30 to 210: higher score indicates greater severity. Change calculated as mean of (value of PANSS score at observation minus baseline value). (NCT00312494)
Timeframe: Baseline, Week 3
| Intervention | scores on scale (Least Squares Mean) | ||
|---|---|---|---|
| Week 3 total score (n=198, 199, 189) | Week 3 positive score (n=198, 199, 189) | Week 3 negative score (n=198, 199, 189) | |
| Placebo | -3.44 | -1.56 | -0.20 |
| Ziprasidone (Higher Dose) | -4.87 | -1.94 | -0.58 |
| Ziprasidone (Lower Dose) | -5.34 | -2.26 | -0.43 |
YMRS is an 11-item scale (elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, speech [rate and amount], language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight) used to assess the severity of manic symptoms and effect of treatment on mania severity. Seven items ranked on scale from 0 to 4; 4 items ranked 0 to 8. Total possible score 0 to 60: higher scores indicate greater severity. Change calculated as mean of (value of YMRS score at observation minus baseline value). (NCT00312494)
Timeframe: Baseline, Week 1, Week 2
| Intervention | scores on scale (Least Squares Mean) | |
|---|---|---|
| Week 1 (n=202, 205, 200) | Week 2 (n=178, 188, 186) | |
| Placebo | -5.10 | -8.24 |
| Ziprasidone (Higher Dose) | -4.38 | -7.10 |
| Ziprasidone (Lower Dose) | -4.56 | -7.56 |
CGI-I is a single-item clinician rated scale used to assess global improvement in the subject's clinical state (bipolar mania) in response to study treatment and as compared to their status at pre-treatment baseline. Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse); higher score = more affected. (NCT00312494)
Timeframe: Week 1, Week 2, Week 3
| Intervention | scores on scale (Least Squares Mean) | ||
|---|---|---|---|
| Week 1 (n=202, 206, 200) | Week 2 (n=178, 188, 186) | Week 3 (n=163, 172, 171) | |
| Placebo | 3.38 | 2.98 | 2.72 |
| Ziprasidone (Higher Dose) | 3.34 | 3.02 | 2.65 |
| Ziprasidone (Lower Dose) | 3.34 | 2.91 | 2.57 |
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 | -15.5 |
| Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
| Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
| Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
Basic Activities of Daily Living with items for 6 functions: bathing, dressing, toileting, transferring, continence, and feeding. Each item is scored as unimpaired=1, impaired=0. Total score is the measure used, range 0-6; higher scores indicate better functioning. (NCT02129348)
Timeframe: Assessed at Week 0, Week2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.3 |
| Placebo Group | 0.1 |
Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain is the measure used that combines symptoms of agitation and aggression. Frequency X Severity rating score, range 0-12. Higher score indicates more agitation and aggressive behavior. (NCT02129348)
Timeframe: Assessed at screening, Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.2 |
| Placebo Group | 2.5 |
Clinical Global Impression (CGI) Behavior Change score is the measure used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Scores ranging from 1-3 indicate improvement. Only patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 8 |
The patient is classified as a responder (score=1) if both criteria are met or as a non-responder (score=0) if both criteria are not met. The first criterion to determine responder status, NPI core score, has a scoring range 0-36; each of the three component scores for symptoms of agitation/aggression, delusions and hallucinations has a scoring range 0-12. For each symptom and the total score, higher score indicates more symptoms. The second criterion to determine responder status, Clinical Global Impression (CGI), is used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Only patients who met both criteria, assessed as change compared to baseline, were counted as responders; all other patients were non-responders. Patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 7 |
30 item questionnaire used to assess degree of cognitive impairment. Orientation, registration, attention/calculation, recall, language, repetitions and commands are assessed. Total score is the measure used; range 0-30, higher scores indicate better global cognitive function. (NCT02129348)
Timeframe: Assessed at Screening, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.9 |
| Placebo Group | 0.9 |
Neuropsychological test used to assess a patient's cognitive ability. The patient is asked to complete small tasks such as drawing shapes and printing their name. They are also asked to remember certain names and objects, such as a cup and a spoon, and the evaluator's first name. Total score is the measure used; range 0-100, higher scores indicate better cognition. (NCT02129348)
Timeframe: Assessed at Week 0, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.1 |
| Placebo Group | -0.0 |
Simpson Angus Scale for Extrapyramidal Sign requires in-person examination to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. Total score is the measure used, range 0-40; higher scores indicate increased severity of signs. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | -0.0 |
| Placebo Group | 0.0 |
Treatment Emergent Symptom Scale that covers 26 somatic symptoms, each rated as present (score=1) or absent (score=0). Total score is the measure used with scoring range 0-26; higher scores indicate more somatic symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.6 |
| Placebo Group | 0.7 |
Young Mania Rating Scale total score is the measure used to assess symptoms that occur in mania; each item is a symptom that is rated for severity. Scoring range 0-60; higher scores indicate more severe symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.1 |
| Placebo Group | 1.1 |
Zarit Caregiver Burden Interview with the caregiver asked to rank 22 items on a scale with responses for each item from 'never' (score 0) to 'nearly always' (score 4). Total score is the measure used; range 0-88 with higher scores indicating greater caregiver burden. (NCT02129348)
Timeframe: Assessed at Week 0, Week 4, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.8 |
| Placebo Group | -0.4 |
Change from baseline in percentage of self-report cocaine-abstinent (non-use) days (difference in base percent values) (NCT00240110)
Timeframe: Week 12
| Intervention | percentage of days cocaine abstinent (Mean) |
|---|---|
| Lithium Carbonate Add on Placebo | 16.4 |
| Lithium Carbonate Add on Valproate | 14.5 |
Change from baseline in percentage of the amount of money spent on cocaine (NCT00240110)
Timeframe: week 12
| Intervention | Percentage of Money Spent on Cocaine (Mean) |
|---|---|
| Lithium Carbonate Add on Placebo | -43.6 |
| Lithium Carbonate Add on Valproate | -34.9 |
The Antidepressant Side-Effect Checklist (ASEC) was employed to detect any adverse reaction to treatment regimens (NCT02235064)
Timeframe: Discharge from hospital to 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 1 |
"Patients met with single psychiatrist (co-investigator), blinded to group assignment, who evaluated the patient using Edinburgh Postpartum Depression Screen, Hamilton Depression Rating Scale, Global Assessment of Functioning Scale, and clinical assessment~0 = No postpartum depression up to 12 weeks following discharge from hospital~1 = Postpartum depression up to 12 weeks following discharge from hospital" (NCT02235064)
Timeframe: Discharge from hospital to 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 5301 |
| Placebo | 4734 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 3033 |
| Placebo | 2750 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 5301 |
| Placebo | 3685 |
304 reviews available for valproic acid and Bipolar Disorder
| Article | Year |
|---|---|
Genetics and antiepileptic mood stabilizer treatment response in bipolar disorder: what do we know?
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Humans; La | 2021 |
Combined treatment of myo-inositol and d-chiro-inositol (80:1) as a therapeutic approach to restore inositol eumetabolism in patients with bipolar disorder taking lithium and valproic acid.
Topics: Antimanic Agents; Bipolar Disorder; Dietary Supplements; Humans; Inositol; Lithium Compounds; Medica | 2021 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations.
Topics: Antipsychotic Agents; Anxiety; Aripiprazole; Bipolar Disorder; Canada; Humans; Olanzapine; Valproic | 2021 |
Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Female; | 2022 |
Published population pharmacokinetic models of valproic acid in adult patients: a systematic review and external validation in a Chinese sample of inpatients with bipolar disorder.
Topics: Adult; Anticonvulsants; Bayes Theorem; Bipolar Disorder; Child; China; Epilepsy; Humans; Inpatients; | 2022 |
Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review.
Topics: Anticonvulsants; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Lamotrigine; Olanzapi | 2022 |
Valproate, divalproex, valpromide: Are the differences in indications justified?
Topics: Bipolar Disorder; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; Valproic Acid | 2023 |
Valproate, divalproex, valpromide: Are the differences in indications justified?
Topics: Bipolar Disorder; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; Valproic Acid | 2023 |
Valproate, divalproex, valpromide: Are the differences in indications justified?
Topics: Bipolar Disorder; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; Valproic Acid | 2023 |
Valproate, divalproex, valpromide: Are the differences in indications justified?
Topics: Bipolar Disorder; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; Valproic Acid | 2023 |
Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors?
Topics: Antimanic Agents; Bipolar Disorder; Brain Neoplasms; Glioblastoma; Humans; Lithium; Lithium Carbonat | 2023 |
[Effects of lithium, valproic acid, carbamazepine and antipsychotic agents on cognition in bipolar disorders-A systematic review].
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamazepine; Cognition; | 2023 |
T cells: an emerging cast of roles in bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Lithium; T-Lymphocytes; Valproic Acid | 2023 |
Bipolar mania and epilepsy pathophysiology and treatment may converge in purine metabolism: A new perspective on available evidence.
Topics: Adenosine; Adenosine Triphosphate; Antimanic Agents; Bipolar Disorder; Epilepsy; Humans; Hydrocortis | 2023 |
A focus on valproate and cognitive deficits in Bipolar Disorders: A mini-review: Special Section on "Translational and Neuroscience Studies in Affective Disorders" Section Editor, Maria Nobile MD, PhD.
Topics: Adult; Affect; Antimanic Agents; Bipolar Disorder; Cognitive Dysfunction; Cross-Sectional Studies; F | 2020 |
Intravenous valproate in the treatment of acute manic episode in bipolar disorder: A review.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Euphoria; Female; Humans; Male; Valproic Acid | 2020 |
Expert advice on the management of valproate in women with bipolar disorder at childbearing age.
Topics: Age Factors; Bipolar Disorder; Female; Guidelines as Topic; Humans; Pregnancy; Valproic Acid | 2019 |
Evaluating lurasidone as a treatment option for bipolar disorder.
Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Lurasidone Hydrochloride; Randomized Controlled Tria | 2020 |
[Recommendations about the Use of Psychotropic Medications during the COVID-19 Pandemic].
Topics: Antiviral Agents; Benzodiazepines; Betacoronavirus; Bipolar Disorder; Body Temperature Regulation; B | 2020 |
Bipolar disorders.
Topics: Adolescent; Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; B | 2020 |
Long-term treatment of bipolar disorder type I: A systematic and critical review of clinical guidelines with derived practice algorithms.
Topics: Algorithms; Antipsychotic Agents; Bipolar Disorder; Humans; Quetiapine Fumarate; Valproic Acid | 2021 |
Polypharmacy as maintenance treatment in bipolar illness: A systematic review.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Lithium Compounds; Polypharmacy; Valproic Acid | 2021 |
Old Age Bipolar Disorder-Epidemiology, Aetiology and Treatment.
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Humans; Lithium; Valproic Acid | 2021 |
Psychotic and Bipolar Disorders: Bipolar Disorder.
Topics: Antimanic Agents; Bipolar Disorder; Cardiovascular Diseases; Chronic Pain; Comorbidity; Family Pract | 2017 |
The pharmacogenomics of valproic acid.
Topics: Anticonvulsants; Bipolar Disorder; Cytochrome P-450 Enzyme System; Drug Delivery Systems; Epilepsy; | 2017 |
Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Carnitine; Humans; Hyperammonemia; Male; Substance-Relate | 2017 |
Is there consensus across international evidence-based guidelines for the psychotropic drug management of bipolar disorder during the perinatal period?
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Bre | 2018 |
Dopamine transporter knockdown mice in the behavioral pattern monitor: A robust, reproducible model for mania-relevant behaviors.
Topics: alpha-Methyltyrosine; Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Cohort Studies; | 2019 |
The Relationship Between Lithium and Cancer Proliferation: A Case-Based Review of the Literature.
Topics: Angiomyolipoma; Antimanic Agents; Apoptosis; Bipolar Disorder; Carcinoma, Renal Cell; Cell Prolifera | 2018 |
Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depre | 2018 |
The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.
Topics: Antidepressive Agents; Bipolar Disorder; Carbamazepine; Humans; Lithium Compounds; Narration; Pharma | 2018 |
Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Decision Making; E | 2018 |
Divalproex and its effect on suicide risk in bipolar disorder: A systematic review and meta-analysis of multinational observational studies.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Internationality; Observational Studies as Topic; Suicid | 2019 |
'Conceivably Neglected' - Are prescribers sufficiently aware of the risks of prescribing sodium valproate to women with mental illness?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Epilepsy; Female; | 2019 |
Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Epilepsy; Hum | 2019 |
Lithium and valproate serum level fluctuations within the menstrual cycle: a systematic review.
Topics: Affect; Bipolar Disorder; Female; Humans; Lithium; Male; Menstrual Cycle; Mood Disorders; Valproic A | 2019 |
Pharmacotherapies for co-occurring substance use and bipolar disorders: A systematic review.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Humans; Lamo | 2019 |
Lithium for acute mania.
Topics: Acute Disease; Antipsychotic Agents; Bipolar Disorder; Humans; Lithium Compounds; Randomized Control | 2019 |
Antidepressant action of atypical antipsychotics: focus on ziprasidone monotherapy, with a few twists in the tale.
Topics: Adult; Affect; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Huma | 2013 |
Evidence for seasonal mania: a review.
Topics: Antimanic Agents; Bipolar Disorder; Circadian Rhythm; Humans; Light; Lithium Compounds; Melatonin; S | 2013 |
One-carbon metabolism and bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Brain; Folic Acid; Humans; Lamotrigine; M | 2013 |
The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Substitution; Drug Therapy, Com | 2013 |
Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.
Topics: Antimanic Agents; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithium Comp | 2013 |
Aripiprazole alone or in combination for acute mania.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Dr | 2013 |
[Recommendations for the treatment of mixed episodes in current guidelines].
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Comorbidity; Consensus; Depressive Disord | 2013 |
Can the response to mood stabilizers be predicted in bipolar disorder?
Topics: Antimanic Agents; Bipolar Disorder; Circadian Rhythm Signaling Peptides and Proteins; Genetic Associ | 2014 |
Interactions between valproic acid and quetiapine/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring.
Topics: Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug I | 2014 |
Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity.
Topics: Animals; Anticonvulsants; Bipolar Disorder; Carnitine; Chemical and Drug Induced Liver Injury; Child | 2014 |
Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Bipolar Di | 2014 |
The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Isoindoles; Lithium; Lurasido | 2014 |
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; | 2014 |
Treatment of bipolar depression: making sensible decisions.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; De | 2014 |
Lurasidone: a review of its use in adult patients with bipolar I depression.
Topics: Adult; Bipolar Disorder; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Lithium Compou | 2015 |
Cellular models to study bipolar disorder: A systematic review.
Topics: Animals; Antipsychotic Agents; Apoptosis; Bipolar Disorder; Brain; Calcium; Humans; Ion Channels; Li | 2015 |
Management of adverse effects of mood stabilizers.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Disease Ma | 2015 |
Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: Network meta-analysis.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Double-Blind | 2015 |
Bipolar Disorder in Pregnancy and Postpartum: Principles of Management.
Topics: Antipsychotic Agents; Bipolar Disorder; Electroconvulsive Therapy; Female; Humans; Lactation; Lamotr | 2016 |
Is it important to consider the sex of the patient when using lithium or valproate to treat the bipolar disorder?
Topics: Antipsychotic Agents; Bipolar Disorder; Epigenesis, Genetic; Female; Humans; Hypothalamo-Hypophyseal | 2017 |
Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; A | 2016 |
Reproductive and metabolic abnormalities in women taking valproate for bipolar disorder: a meta-analysis.
Topics: Bipolar Disorder; Female; Humans; Hyperandrogenism; Menstruation Disturbances; Metabolic Diseases; P | 2016 |
Mood stabilizers during breastfeeding: a systematic review of the recent literature.
Topics: Bipolar Disorder; Breast Feeding; Female; Humans; Infant; Infant Welfare; Lithium; Milk, Human; Post | 2016 |
Understanding the molecular mechanisms underlying mood stabilizer treatments in bipolar disorder: Potential involvement of epigenetics.
Topics: Antimanic Agents; Bipolar Disorder; Carbamazepine; Epigenesis, Genetic; Epigenomics; Humans; Lithium | 2018 |
The effect of mood-stabilizing drugs on cytokine levels in bipolar disorder: A systematic review.
Topics: Affect; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cytokines; Female; Humans; Lamotri | 2016 |
Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
Topics: Adult; Alcohol-Related Disorders; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Majo | 2017 |
Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: their treatment in adolescents.
Topics: Adolescent; Amenorrhea; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Bone and Bones; Epi | 2008 |
Perinatal depression: treatment options and dilemmas.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Case-Control Studies; Cyclohexan | 2008 |
Prevention of bipolar disorder in at-risk children: theoretical assumptions and empirical foundations.
Topics: Adolescent; Adult; Affect; Amygdala; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; | 2008 |
Prevention of bipolar disorder in at-risk children: theoretical assumptions and empirical foundations.
Topics: Adolescent; Adult; Affect; Amygdala; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; | 2008 |
Prevention of bipolar disorder in at-risk children: theoretical assumptions and empirical foundations.
Topics: Adolescent; Adult; Affect; Amygdala; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; | 2008 |
Prevention of bipolar disorder in at-risk children: theoretical assumptions and empirical foundations.
Topics: Adolescent; Adult; Affect; Amygdala; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; | 2008 |
[Mood stabilizers--past, present and future].
Topics: Affect; Antimanic Agents; Bipolar Disorder; Calcium; Carbamazepine; Depressive Disorder; gamma-Amino | 2008 |
A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder.
Topics: Adult; Animals; Antimanic Agents; Bipolar Disorder; Brain; Controlled Clinical Trials as Topic; Dise | 2008 |
Polycystic ovary syndrome in women using valproate: a review.
Topics: Antimanic Agents; Bipolar Disorder; Epilepsy; Female; Humans; Polycystic Ovary Syndrome; Prevalence; | 2008 |
Olanzapine in long-term treatment for bipolar disorder.
Topics: Antimanic Agents; Benzodiazepines; Bipolar Disorder; Humans; Lithium Compounds; Olanzapine; Randomiz | 2009 |
Alternative treatments in pediatric bipolar disorder.
Topics: Acupuncture; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Child; Humans; Hypericum; Inos | 2009 |
Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder.
Topics: Acute Disease; Affect; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agent | 2008 |
Clinical decision making in the treatment of mania.
Topics: Adverse Drug Reaction Reporting Systems; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; D | 2008 |
Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment.
Topics: Bipolar Disorder; Dyslipidemias; Endocrine System Diseases; Female; Humans; Hypogonadism; Hypothalam | 2009 |
A review of valproate in psychiatric practice.
Topics: Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug | 2009 |
Early intervention in bipolar disorder, part II: therapeutics.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Brain; Early Diagnosis; Humans; Lamotrigin | 2008 |
Myelination in bipolar patients and the effects of mood stabilizers on brain anatomy.
Topics: Animals; Bipolar Disorder; Brain; Diffusion Magnetic Resonance Imaging; Humans; Lithium Compounds; M | 2009 |
Is the brain arachidonic acid cascade a common target of drugs used to manage bipolar disorder?
Topics: Animals; Anticonvulsants; Antidepressive Agents; Arachidonic Acid; Bipolar Disorder; Brain; Carbamaz | 2009 |
Structure-function studies for the panacea, valproic acid.
Topics: Animals; Anticonvulsants; Bipolar Disorder; Epilepsy; gamma-Aminobutyric Acid; Glycogen Synthase Kin | 2009 |
Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combination | 2010 |
Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder?
Topics: Algorithms; Animals; Antimanic Agents; Bipolar Disorder; Drug Monitoring; Humans; Valproic Acid | 2010 |
Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis.
Topics: Acute Disease; Affect; Anticonvulsants; Bipolar Disorder; Humans; Randomized Controlled Trials as To | 2010 |
Frequency of and rationales for the combined use of electroconvulsive therapy and antiepileptic drugs in Austria and the literature.
Topics: Anticonvulsants; Austria; Bipolar Disorder; Carbamazepine; Combined Modality Therapy; Electroconvuls | 2009 |
Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials.
Topics: Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Cy | 2011 |
Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis.
Topics: Acute Disease; Anticonvulsants; Bipolar Disorder; Humans; Randomized Controlled Trials as Topic; Tre | 2010 |
Mixed episodes with psychotic features.
Topics: Acute Disease; Adult; Affect; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; | 2009 |
Valproate and neuroprotective effects for bipolar disorder.
Topics: Animals; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brain; Gene Expression; Humans; Lithiu | 2009 |
Lithium and valproate and their possible effects on themyo-inositol second messenger system in healthy volunteers and bipolar patients.
Topics: Affect; Animals; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brain; Humans; Inositol; Lithi | 2009 |
Psychiatric concerns in pediatric epilepsy.
Topics: Adolescent; Amines; Anxiety Disorders; Bipolar Disorder; Child; Child, Preschool; Cyclohexanecarboxy | 2010 |
[Sense and sensibility: bipolar affective disorder as a battlefield of cognitions and emotions--lamotrigine therapy as a peacekeeper].
Topics: Adolescent; Adult; Affect; Aged; Antimanic Agents; Bipolar Disorder; Cerebral Cortex; Child; Clinica | 2010 |
Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania--a systematic review and meta-analysis.
Topics: Affect; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Diso | 2011 |
Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders.
Topics: Amygdala; Animals; Anticonvulsants; Bipolar Disorder; Carbamazepine; Drug Resistance; Drug Tolerance | 2011 |
[Treatment of bipolar disorder during pregnancy and in the postpartum period].
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Contraindications; Female; Humans; Lactati | 2011 |
Pharmacologic treatments for pediatric bipolar disorder: a review and meta-analysis.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivi | 2011 |
Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Disease Models, Animal; Humans; Lamotrigine; Lithiu | 2011 |
[Therapeutic evidence for manic episode].
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Therapy, Combination; | 2011 |
Oxcarbazepine for acute affective episodes in bipolar disorder.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Child; Humans; | 2011 |
[Lithium and anticonvulsants in bipolar depression].
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; | 2011 |
[Mood stabilizers].
Topics: Antimanic Agents; Bipolar Disorder; Carbamazepine; Humans; Lamotrigine; Lithium; Triazines; Valproic | 2012 |
[Methodological approach to inter "guideline" variability in the management of bipolar disorders].
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Consensus; Drug Therapy, Combination; Evid | 2012 |
Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance.
Topics: Affect; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Therapy, Combin | 2012 |
[Mood stabilizer].
Topics: Antimanic Agents; Bipolar Disorder; Carbamazepine; Humans; Lamotrigine; Lithium Compounds; Triazines | 2012 |
Combination therapy for manic phases: a critical review of a common practice.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithium | 2012 |
Cardiovascular disease and bipolar disorder: risk and clinical implications.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Cardiovascular Diseases; | 2012 |
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Central Nervous System Diseases; Humans; Lithium Compou | 2013 |
Psychiatric disorders related to polycystic ovary syndrome.
Topics: Antimanic Agents; Bipolar Disorder; Depression; Feeding and Eating Disorders; Female; Hirsutism; Hor | 2012 |
[Emotional hyper-reactivity and sleep disturbances in remitted patients with bipolar disorders].
Topics: Affect; Amygdala; Anticonvulsants; Antimanic Agents; Arousal; Bipolar Disorder; Combined Modality Th | 2012 |
DP-VPA D-Pharm.
Topics: Animals; Bipolar Disorder; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Epileps | 2002 |
The Wnt signaling pathway in bipolar disorder.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Circadian Rhythm; Glycogen Synthase Kinase 3; Glycogen | 2002 |
Carbamazepine and valproate in the maintenance treatment of bipolar disorder.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Administration Schedule; | 2002 |
Lithium and valproic acid: parallels and contrasts in diverse signaling contexts.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Gene Expression; Glycogen Synthase Kinase 3; Histone De | 2002 |
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression.
Topics: Antidepressive Agents; Antimanic Agents; Biological Psychiatry; Bipolar Disorder; Carbamazepine; Ele | 2002 |
Myo-inositol-1-phosphate (MIP) synthase: a possible new target for antibipolar drugs.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Blood Cells; Enzyme Inhibitors; Eukaryotic Cells; H | 2002 |
Valproate for acute mood episodes in bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Mood Disorders; Randomized Controlled Trials as Topic; V | 2003 |
New approaches in managing bipolar depression.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Clini | 2003 |
Antidepressant properties of anticonvulsant drugs for bipolar disorder.
Topics: Acetates; Affect; Amines; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Carbamazepine; C | 2003 |
New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?
Topics: Amides; Anticonvulsants; Bipolar Disorder; Epilepsy; Humans; Migraine Disorders; Valproic Acid | 2003 |
Treatment of agitation in bipolar disorder across the life cycle.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Age of Onset; Anticonvulsants; Antipsychotic Agents; | 2003 |
Treating acute mania.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Li | 2003 |
Treating bipolar depression.
Topics: Acetates; Affect; Amines; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; | 2003 |
Long-term therapy of bipolar illness.
Topics: Affect; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamazepine; Co | 2003 |
Optimal dosing of medications (in bipolar disorder).
Topics: Acute Disease; Affect; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Ch | 2003 |
Drug interactions of lithium and other antimanic/mood-stabilizing medications.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug Interactions; Humans; Lithi | 2003 |
Valproate.
Topics: Antimanic Agents; Bipolar Disorder; Drug Interactions; Humans; Lamotrigine; Lithium Compounds; Progn | 2003 |
Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar | 2003 |
[Manic phase (manic episode)].
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diagnostic and Statistical Manual of Mental | 2003 |
[Antidepressant induced rapid cycling].
Topics: Antidepressive Agents, Tricyclic; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Hum | 2003 |
The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dia | 2003 |
[Treatment of acute bipolar disorder. Intriguing balancing act between mania and depression].
Topics: Acute Disease; Algorithms; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiaze | 2003 |
[Organic manic disorder].
Topics: Bipolar Disorder; Brain Diseases; Carbamazepine; Clonazepam; Diagnostic and Statistical Manual of Me | 2003 |
[Organic bipolar disorder].
Topics: Bipolar Disorder; Brain Diseases; Carbamazepine; Humans; International Classification of Diseases; L | 2003 |
A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network.
Topics: Adult; Affect; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Dr | 2003 |
Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice.
Topics: Animals; Behavior, Animal; Bipolar Disorder; Humans; Lithium; Mice; Mice, Mutant Strains; Mitogen-Ac | 2003 |
Special considerations in treating bipolar disorder in women.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Breast Feeding; Contraceptives, Oral; Drug Inte | 2004 |
Divalproex in the treatment of bipolar disorder.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Humans; Valproic Acid | 2003 |
Lithium and valproate protect against dextro-amphetamine induced brain choline concentration changes in bipolar disorder patients.
Topics: Antipsychotic Agents; Bipolar Disorder; Brain; Choline; Creatine; Dextroamphetamine; Female; Humans; | 2004 |
Management of bipolar disorder during pregnancy and the postpartum period.
Topics: Adolescent; Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbam | 2004 |
A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cost-Benefit Analysis; Di | 2004 |
An overview of primary care assessment and management of bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diagnostic Errors; Humans | 2004 |
Strategies for preventing the recurrence of bipolar disorder.
Topics: Anticonvulsants; Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Cognitive Behavioral Ther | 2004 |
Bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Fema | 2004 |
Bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Fema | 2004 |
Bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Fema | 2004 |
Bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Fema | 2004 |
Rethinking the treatment paradigm for bipolar depression: the importance of long-term management.
Topics: Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Ch | 2004 |
Bipolar depression: an overview.
Topics: Acute Disease; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Chemoprev | 2004 |
Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders.
Topics: Acute Disease; Administration, Oral; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; | 2004 |
[Treatment standard for bipolar disorders].
Topics: Algorithms; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bipolar Disorder; Carbamazepine | 2004 |
Employing pharmacologic treatment of bipolar disorder to greatest effect.
Topics: Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; | 2004 |
Bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Chlorpromazine; Humans; Lithium; Psychoth | 2003 |
Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Brain; Humans; Inositol; Lithium Compounds; Signal Tran | 2005 |
Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia; Bipolar Disorder; Frontal Lobe; | 2005 |
Recognizing and managing bipolar disorder in children.
Topics: Adolescent; Age Factors; Amphetamine; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disor | 2005 |
Latest therapies for bipolar disorder. Looking beyond lithium.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Thera | 2005 |
Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder.
Topics: Acute Disease; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; De | 2005 |
Women are not the same as men: specific clinical issues for female patients with bipolar disorder.
Topics: Anticonvulsants; Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Counseling; Dibenzothiaze | 2005 |
[Mood disorders and XBP1].
Topics: Bipolar Disorder; Chromosomes, Human, Pair 22; DNA-Binding Proteins; Endoplasmic Reticulum; Endoplas | 2004 |
Update on the treatment of bipolar disorder in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Child; Humans; Lithium Carbonat | 2005 |
New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Humans; Lamotrigine; Lithium Carbonate; Pe | 2005 |
Treatment of mania in children and adolescents.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Child; Humans; | 2005 |
Valproate in bipolar disorder: 2000 onwards.
Topics: Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Glycogen Synthase Kinase 3; Hu | 2005 |
Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder.
Topics: Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cyclohexa | 2005 |
Divalproex sodium in the treatment of pediatric psychiatric disorders.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Autistic Diso | 2005 |
Divalproex sodium in the treatment of adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Diagnosis, Dual (Psychiatry); Humans; Valproic Acid | 2004 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Antiepileptic drugs in mood-disordered patients.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Depressive Disorder; Humans; Lamotrigine; Treatmen | 2005 |
Anticonvulsant drug therapies.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Depressive Di | 2005 |
Bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Chlorpromazine; Cognitiv | 2005 |
Management options for bipolar disorder in children and adolescents.
Topics: Adolescent; Benzodiazepines; Bipolar Disorder; Carbamazepine; Child; Clozapine; Dibenzothiazepines; | 2005 |
Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania.
Topics: Acute Disease; Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Dose-Response Relati | 2006 |
Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder.
Topics: Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Disease Models, Animal; Extracellular | 2006 |
Treatment considerations for patients experiencing rapid-cycling bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Diagnosis, Differential; Drug Administrat | 2006 |
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Glycogen Synthase Kinase 3; Histone Deacetylases; Humans; Lithiu | 2006 |
Anticonvulsants in the treatment of bipolar mania.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Humans; Oxcarbazepine; Randomize | 2006 |
[Pharmacotherapy of manic-depressive mixed States].
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Controll | 2006 |
Relapse prevention in bipolar disorder: a critical review of current guidelines.
Topics: Algorithms; Antimanic Agents; Bipolar Disorder; Humans; Lithium Carbonate; Long-Term Care; Practice | 2006 |
Anticonvulsants in bipolar disorder.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Humans; Lamotrigine; Triazines; Valproic Acid | 2006 |
New antiepileptic drugs that are second generation to existing antiepileptic drugs.
Topics: Amines; Animals; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Drug | 2006 |
Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Humans; Valproic Acid | 2006 |
Haloperidol alone or in combination for acute mania.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; D | 2006 |
Maintenance treatment of bipolar disorder: Applying research to clinical practice.
Topics: Anticonvulsants; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepin | 2006 |
Treatment of rapid-cycling bipolar disorder.
Topics: Age of Onset; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Combin | 2006 |
Bipolar depression: diagnostic and treatment considerations.
Topics: Age of Onset; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Child; Depressive Disor | 2006 |
Acute treatment of mania: an update on new medications.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Approval; Drug Therapy | 2006 |
Spectrum of effectiveness of valproate in neuropsychiatry.
Topics: Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug | 2007 |
[Anticonvulsants treatment of psychiatric disorder in elderly patients].
Topics: Aged; Anticonvulsants; Anxiety Disorders; Bipolar Disorder; Carbamazepine; Epilepsy; Humans; Mental | 2006 |
Differentiating bipolar disorder from depression in primary care.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Diagnosis, Differential; Humans; Lamotrigi | 2007 |
[Clinical standing of valproate treatment of bipolar disorders].
Topics: Acute Disease; Antimanic Agents; Bipolar Disorder; Depression; Drug Therapy, Combination; Humans; Lo | 2007 |
Anticonvulsant efficacy of valproate-like carboxylic acids: a potential target for anti-bipolar therapy.
Topics: Anticonvulsants; Bipolar Disorder; Carboxylic Acids; Chronic Disease; Humans; Valproic Acid | 2007 |
The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders.
Topics: Affective Symptoms; Animals; Antimanic Agents; Bipolar Disorder; Carbamazepine; Depressive Disorder; | 2007 |
Quetiapine for acute mania in bipolar disorder.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Drug In | 2007 |
GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder.
Topics: Affective Symptoms; Animals; Bipolar Disorder; Disease Models, Animal; Enzyme Inhibitors; Female; Gl | 2007 |
The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?
Topics: Animals; Anticonvulsants; beta Catenin; Bipolar Disorder; Brain; Enzyme Inhibitors; Epilepsy; Extrac | 2007 |
Antiepileptic drugs and mood stability.
Topics: Affect; Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Humans; Lamotrig | 2007 |
Hyperammonemia due to valproic acid in the psychiatric setting.
Topics: Adult; Aged; Bipolar Disorder; Carnitine; Child; Female; Humans; Hyperammonemia; Liver; Middle Aged; | 2007 |
[Anticonvulsants in the treatment of bipolar disorder].
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Drug T | 2007 |
Adjunctive treatment of acute mania: a clinical overview.
Topics: Acute Disease; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Thera | 2007 |
Pharmacotherapeutic strategies for pediatric bipolar disorder.
Topics: Adolescent; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine | 2007 |
[Bipolar disorders: the disease of extreme emotions].
Topics: Adolescent; Adult; Age Factors; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Antimanic Age | 2007 |
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disor | 2007 |
Valproate use in children and adolescents with bipolar disorder.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Child, Preschool; Humans; Pediatrics; Valproi | 2007 |
Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Contraceptives, Oral; Epilepsy; Female; Hormone | 2007 |
Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Comorbidity; Double-Blind Method; Fe | 2008 |
Mode of action of mood stabilizers: is the arachidonic acid cascade a common target?
Topics: Antimanic Agents; Arachidonic Acid; Bipolar Disorder; Brain; Carbamazepine; Humans; Lithium; Valproi | 2008 |
Pharmacotherapy of mood disorders.
Topics: Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder, Major; Diagnosti | 2008 |
ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Bipolar Disorder; Breast Feed | 2008 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
Current perspectives in the pharmacopsychiatry of depression and mania.
Topics: Affective Disorders, Psychotic; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Endorp | 1983 |
Treatment of mood disorders with antiepileptic medications: clinical and theoretical implications.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Clonazepam; Depressive D | 1983 |
An update on the diagnosis and treatment of mania in bipolar disorder.
Topics: Bipolar Disorder; Carbamazepine; Diagnosis, Differential; Humans; Lithium; Psychotherapy; Valproic A | 1995 |
Treatment of mania in the medically ill.
Topics: Bipolar Disorder; Carbamazepine; Comorbidity; Humans; Lithium; Metabolic Clearance Rate; Neurocognit | 1994 |
A medication algorithm for treatment of bipolar rapid cycling?
Topics: Algorithms; Bipolar Disorder; Carbamazepine; Clozapine; Controlled Clinical Trials as Topic; Drug Ad | 1995 |
The relationship between substance abuse and bipolar disorder.
Topics: Alcoholism; Bipolar Disorder; Carbamazepine; Comorbidity; Diagnosis, Dual (Psychiatry); Hospitalizat | 1995 |
Predictors of response to divalproex and lithium.
Topics: Bipolar Disorder; Carbamazepine; Comorbidity; Drug Administration Schedule; Drug Therapy, Combinatio | 1995 |
Secondary mania: diagnosis and treatment.
Topics: Age of Onset; Bipolar Disorder; Diagnosis, Differential; Humans; Lithium; Treatment Outcome; Valproi | 1995 |
Mixed or dysphoric manic states: psychopathology and treatment.
Topics: Bipolar Disorder; Diagnosis, Differential; Electroconvulsive Therapy; Humans; Lithium; Psychiatric S | 1995 |
Treatment approaches for acute mania.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamazepine; Dyskinesia, Drug-Induced; Fe | 1993 |
Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; C | 1994 |
Valproate in bipolar disorder: the Canadian perspective.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithium; | 1993 |
Mania and Down's syndrome.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Down Syndrome; Humans; Lithium; Male; Middle Aged; Va | 1993 |
[Drug combinations of lithium: reasons and limitations].
Topics: Antidepressive Agents; Bipolar Disorder; Carbamazepine; Drug Therapy, Combination; Female; Humans; L | 1993 |
The manic syndrome: factors which may predict a patient's response to lithium, carbamazepine and valproate.
Topics: Bipolar Disorder; Carbamazepine; Humans; Lithium Carbonate; Prognosis; Valproic Acid | 1993 |
Pharmacological issues in the treatment of bipolar disorder: focus on mood-stabilizing compounds.
Topics: Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Carbamazepine; Drug Interactions; Female; | 1993 |
Rapid cycling bipolar disorder and its treatment with valproate.
Topics: Adult; Bipolar Disorder; Female; Humans; Lithium; Male; Psychiatric Status Rating Scales; Valproic A | 1993 |
Treatment guidelines for valproate in bipolar and schizoaffective disorders.
Topics: Bipolar Disorder; Depressive Disorder; Drug Monitoring; Humans; Metabolic Clearance Rate; Psychotic | 1993 |
Lithium therapy: limitations and alternatives in the treatment of bipolar disorders.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Humans; Lithium; Patient Compliance; Tranquilizing | 1995 |
Outcome in the pharmacologic treatment of bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Follow-Up Studies; Huma | 1996 |
Predictors of response to mood stabilizers.
Topics: Antimanic Agents; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Comorbidity; Humans; Li | 1996 |
Bipolar mood disorder: practical strategies for acute and maintenance phase treatment.
Topics: Acute Disease; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Clinical T | 1996 |
Role of newer medications for bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; | 1996 |
Criteria for use of valproate in adult psychiatric inpatients and outpatients.
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Female; Humans; Male; Practice Guideline | 1996 |
The diagnosis and treatment of mania in the elderly.
Topics: Age of Onset; Aged; Anticonvulsants; Bipolar Disorder; Carbamazepine; Diagnosis, Differential; Dose- | 1996 |
Lithium compared to valproic acid and carbamazepine in the treatment of mania: a statistical meta-analysis.
Topics: Bipolar Disorder; Carbamazepine; Humans; Lithium; Valproic Acid | 1996 |
A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures.
Topics: Affect; Amygdala; Animals; Anticonvulsants; Bipolar Disorder; Carbamazepine; Disease Progression; Dr | 1996 |
Alopecia and mood stabilizer therapy.
Topics: Adult; Alopecia; Antimanic Agents; Bipolar Disorder; Case Management; Diethylcarbamazine; Female; Hu | 1996 |
The place of anticonvulsant therapy in bipolar illness.
Topics: Affect; Anticonvulsants; Bipolar Disorder; Calcium Channel Blockers; Carbamazepine; Clonazepam; Drug | 1996 |
Dosing strategies and time course of response to antimanic drugs.
Topics: Bipolar Disorder; Carbamazepine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Adminis | 1996 |
Health-economic implications of the onset of action of antimanic agents.
Topics: Bipolar Disorder; Carbamazepine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 1996 |
Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy.
Topics: Adenylyl Cyclases; Animals; Bipolar Disorder; Carbamazepine; Cell Line; Glioma; GTP-Binding Proteins | 1996 |
Polypharmacy in bipolar I disorder.
Topics: Bipolar Disorder; Carbamazepine; Humans; Lithium; Valproic Acid | 1996 |
Rational polypharmacy in the bipolar affective disorders.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Calcium Channel Bloc | 1996 |
Algorithms for bipolar mania.
Topics: Algorithms; Anti-Anxiety Agents; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiaze | 1997 |
Issues in the treatment of women with bipolar illness.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bipolar Disorder; Buprop | 1997 |
Mood stabilizer combinations: a review of safety and efficacy.
Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Calcium Channel Blockers; | 1998 |
Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: a review.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Drug Therapy, C | 1998 |
Drug treatment of mania: a critical review.
Topics: Anti-Anxiety Agents; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipol | 1998 |
Key treatment studies of lithium in manic-depressive illness: efficacy and side effects.
Topics: Acute Disease; Bipolar Disorder; Clinical Trials as Topic; Delayed-Action Preparations; Drug Adminis | 1998 |
Special considerations: use of lithium in children, adolescents, and elderly populations.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Age Factors; Aged; Amines; Anticonvulsants | 1998 |
[Therapy of bipolar affective illnesses with valproate. A review of the literature].
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Humans; Long-Term Care; Randomized Controlled T | 1998 |
Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder.
Topics: Acetates; Action Potentials; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipol | 1998 |
Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
Topics: Bipolar Disorder; Calcium-Calmodulin-Dependent Protein Kinases; Carbamazepine; Gene Expression; Glyc | 1999 |
Anticonvulsant therapy and suicide risk in affective disorders.
Topics: Amitriptyline; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Female; Follow | 1999 |
Management of acute mania.
Topics: Acute Disease; Algorithms; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; | 1999 |
Mood-stabilizing drugs in depression.
Topics: Acute Disease; Anticonvulsants; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bipolar Diso | 1999 |
Bipolar disorder in old age.
Topics: Acute Disease; Adult; Age Factors; Aged; AIDS Dementia Complex; Antidepressive Agents; Antimanic Age | 1999 |
Treatment of aggression in patients with bipolar disorder.
Topics: Aggression; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Combined Modality Therapy; Drug T | 1999 |
Rapid cycling bipolar affective disorder in people with intellectual disability: a systematic review.
Topics: Antimanic Agents; Bipolar Disorder; Carbamazepine; Down Syndrome; Humans; Intellectual Disability; L | 1999 |
Algorithms for the pharmacotherapy of bipolar disorder.
Topics: Acute Disease; Algorithms; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug Therapy, Combinat | 1999 |
Algorithm for the treatment of rapid cycling.
Topics: Algorithms; Antimanic Agents; Bipolar Disorder; Carbamazepine; Clonazepam; Cyclothymic Disorder; Dru | 1999 |
Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness.
Topics: Animals; Antimanic Agents; Awards and Prizes; Binding, Competitive; Bipolar Disorder; Blotting, West | 1999 |
The place of anticonvulsants and other putative mood stabilisers in the treatment of bipolar disorder.
Topics: Affect; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Hu | 1999 |
Intravenous valproate in neuropsychiatry.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Clinical Trials | 2000 |
Comprehensive review of the psychiatric uses of valproate.
Topics: Anticonvulsants; Antimanic Agents; Anxiety Disorders; Bipolar Disorder; Depressive Disorder, Major; | 2000 |
Mood stabilizers in the treatment of juvenile bipolar disorder. Advances and controversies.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Carbamazepine; Child; Clinical Trials as Topic; Drug | 2000 |
[Risk of inducing resistance upon stopping and restarting lithium after long-term usage].
Topics: Adult; Aged; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Carbamazepine; Dose-Response | 2000 |
Mood stabilizers during breastfeeding: a review.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Breast Feeding; Carbamazepine; Cyclohexanecarbo | 2000 |
The psychopharmacologic specificity of the lithium ion: origins and trajectory.
Topics: Anticonvulsants; Australia; Bipolar Disorder; Carbamazepine; Drug Therapy, Combination; History, 20t | 2000 |
Current aspects of valproate in bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Valproic Acid | 2000 |
Management of bipolar disorder.
Topics: Adolescent; Adult; Age Distribution; Antimanic Agents; Bipolar Disorder; Carbamazepine; Child, Presc | 2000 |
An ever-increasing pharmacopoeia for the management of patients with bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamaz | 2000 |
The nature of bipolar disorder.
Topics: Bipolar Disorder; Cell Death; Circadian Rhythm; Corticotropin-Releasing Hormone; Disease Models, Ani | 2000 |
New treatments for bipolar disorder: the role of atypical neuroleptic agents.
Topics: Acute Disease; Algorithms; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazep | 2000 |
Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo.
Topics: Adaptor Protein Complex alpha Subunits; Adaptor Proteins, Vesicular Transport; Animals; Bipolar Diso | 2000 |
The high affinity inositol transport system--implications for the pathophysiology and treatment of bipolar disorder.
Topics: Antimanic Agents; Biological Transport, Active; Bipolar Disorder; Carbamazepine; Carrier Proteins; D | 2000 |
Novel treatments for bipolar disorder.
Topics: Acetates; Amines; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Therapy, Combin | 2001 |
Special issues in the treatment of paediatric bipolar disorder.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Child; Humans; Lithium; Valp | 2001 |
Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: long-term effects on cell survival and transcript stability.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Cell Survival; Enoyl-CoA Hydratase; Humans; Intracellul | 2001 |
Identification of mood stabilizer-regulated genes by differential-display PCR.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Carrier Proteins; Cerebral Cortex; Endoplasmic Reticulu | 2001 |
Valproic acid overdose and haemodialysis.
Topics: Bipolar Disorder; Female; Glasgow Coma Scale; Humans; Middle Aged; Naloxone; Poisoning; Renal Dialys | 2001 |
Cognitive side effects of anticonvulsants.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cognition Disorders; Cyclohexane | 2001 |
Bipolar rapid cycling: focus on depression as its hallmark.
Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Bipolar Disorder; Comorbidity; Controlled Clinica | 2001 |
Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Lithium; Randomized Controlled Trials as Topic; Valproic | 2001 |
Developments in mood stabilisers.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Elect | 2001 |
Bipolar disorder.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Humans; Lithium Compounds; S | 2002 |
Current research on rapid cycling bipolar disorder and its treatment.
Topics: Acute Disease; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug Administration Schedule; Drug | 2001 |
Clinical correlates of therapeutic response in bipolar disorder.
Topics: Affect; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Therapy, Combi | 2001 |
Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature.
Topics: Affect; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Clinical Trial | 2002 |
Predictors of treatment response in bipolar disorders: evidence from clinical and brain imaging studies.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brain; Carbamazepine; gamma-Aminobutyric Acid; | 2002 |
The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder.
Topics: Acetates; Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2001 |
[Valproate in the treatment of bipolar disorder].
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Drug Therapy, Co | 2002 |
Regulation of ER stress proteins by valproate: therapeutic implications.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Brain; Disease Models, Animal; Endoplasmic Reticul | 2002 |
Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?
Topics: Animals; Anticonvulsants; Antimanic Agents; Arachidonic Acid; Bipolar Disorder; Brain; Brain Chemist | 2002 |
Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders?
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; gamma-Aminobutyric Acid; Gene Expression Regulatio | 2002 |
Anticonvulsants in the treatment of bipolar disorder.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Clonazepam; Drug Therapy, Combination; Electroconv | 1992 |
Synergy of carbamazepine and valproic acid in affective illness: case report and review of the literature.
Topics: Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Hum | 1992 |
Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Humans; Lithium Carbonate; Valproic Acid | 1992 |
Valproate in the treatment of bipolar disorder: literature review and clinical guidelines.
Topics: Bipolar Disorder; Humans; Valproic Acid | 1992 |
Treatment of bipolar disorder.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Humans; Lithium; Valproic Acid | 1991 |
Antiepileptic drugs in affective illness. Clinical and theoretical implications.
Topics: Acute Disease; Anticonvulsants; Benzodiazepines; Bipolar Disorder; Carbamazepine; Depression; Drug T | 1991 |
Alternative prophylactic treatments to lithium in bipolar disorders.
Topics: Alprazolam; Bipolar Disorder; Calcium Channel Blockers; Carbamazepine; Clonazepam; Humans; Lithium; | 1990 |
Non-lithium treatment for bipolar disorder.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Clonazepam; Drug Therapy | 1990 |
Valproate use in acute mania and bipolar disorder: an international perspective.
Topics: Acute Disease; Bipolar Disorder; Clinical Trials as Topic; Europe; Humans; Valproic Acid | 1989 |
U.S. experience with valproate in manic depressive illness: a multicenter trial.
Topics: Adult; Aged; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Humans; Middle Aged; P | 1989 |
Valproate in psychiatric disorders: literature review and clinical guidelines.
Topics: Bipolar Disorder; Clinical Trials as Topic; Humans; Mental Disorders; Psychotic Disorders; Valproic | 1989 |
Emerging perspectives on valproate in affective disorders.
Topics: Adult; Bipolar Disorder; Carbamazepine; Drug Therapy, Combination; Humans; Lithium; Lithium Carbonat | 1989 |
Phenomenology of rapid cycling manic depression and its treatment with valproate.
Topics: Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans | 1989 |
Drug treatment of bipolar depression and mania.
Topics: Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Bromocriptine; Carbamazepine; Choline | 1985 |
[A valproic acid-diazepam combination as an alternative to neuroleptic treatment].
Topics: Adult; Aged; Aged, 80 and over; Bipolar Disorder; Diazepam; Drug Combinations; Female; Humans; Male; | 1988 |
Alternative therapies for bipolar disorder.
Topics: Ascorbic Acid; Bipolar Disorder; Bupropion; Carbamazepine; Choline; Clonazepam; Clonidine; Clorgylin | 1985 |
298 trials available for valproic acid and Bipolar Disorder
| Article | Year |
|---|---|
Oxcarbazepine versus sodium valproate in treatment of acute mania: a double-blind randomized clinical trial.
Topics: Bipolar Disorder; Double-Blind Method; Humans; Iran; Mania; Oxcarbazepine; Psychiatric Status Rating | 2022 |
Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Comb | 2023 |
Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial.
Topics: Antipsychotic Agents; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Drug Therap | 2023 |
Does celecoxib with sodium valproate have an augmentation effect on acute mania in bipolar disorder? A double-blind controlled clinical trial in Iran.
Topics: Antipsychotic Agents; Bipolar Disorder; Celecoxib; Double-Blind Method; Humans; Iran; Mania; Psychia | 2023 |
Antisuicidal effect of lithum in bipolar disorder: is there an age-specific effect?
Topics: Adult; Age Factors; Aged; Bipolar Disorder; Humans; Lithium; Middle Aged; Suicidal Ideation; Valproi | 2023 |
A randomized controlled trial comparing lithium plus valproic acid versus lithium plus carbamazepine in young patients with type 1 bipolar disorder: the LICAVAL study.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Brazil; Carbamazepine; Drug Therapy, Combinat | 2019 |
Lithium vs valproate in the maintenance treatment of bipolar I disorder: A post- hoc analysis of a randomized double-blind placebo-controlled trial.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Canada; Double-Blind Method; Drug T | 2020 |
Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder at Any Phase of Illness and at least Mild Symptom Severity.
Topics: Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Humans; Lamo | 2020 |
A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
Topics: Adult; Aged; Antimanic Agents; Azoles; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combinat | 2020 |
A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
Topics: Adult; Aged; Antimanic Agents; Azoles; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combinat | 2020 |
A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
Topics: Adult; Aged; Antimanic Agents; Azoles; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combinat | 2020 |
A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
Topics: Adult; Aged; Antimanic Agents; Azoles; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Add-on memantine may improve cognitive functions and attenuate inflammation in middle- to old-aged bipolar II disorder patients.
Topics: Aged; Bipolar Disorder; Cognition; Double-Blind Method; Drug Therapy, Combination; Humans; Inflammat | 2021 |
Correlation between the Efficacy of Lamotrigine and the Serum Lamotrigine Level during the Remission Phase of Acute Bipolar II Depression: A Naturalistic and Unblinded Prospective Pilot Study.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Lam | 2017 |
Assessing bipolar disorder in the older adult: the GERI-BD toolbox.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Drug Ther | 2018 |
Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; C-Reactive Protein; Female; Humans; Lipids; Male; Memanti | 2017 |
Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Disease-Free Survival; Double-Blin | 2017 |
GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder.
Topics: Aged; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, C | 2017 |
Add-On Memantine Treatment for Bipolar II Disorder Comorbid with Alcohol Dependence: A 12-Week Follow-Up Study.
Topics: Alcohol Drinking; Alcoholism; Antimanic Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; | 2018 |
Bipolar Disorder Mixed Episodes: A Pragmatic Trial of a Public Health Treatment Effectiveness.
Topics: Adult; Algorithms; Antimanic Agents; Bipolar Disorder; Brazil; Carbamazepine; Female; Humans; Lithiu | 2018 |
Effect of lamotrigine on cognitive function and serum inflammatory factors in patients with depression of recurrent bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Cognition; Female; Humans; Inflammation Mediators; Interle | 2018 |
Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Double-Blind | 2019 |
Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Double-Blind Me | 2013 |
Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Double-Blind Me | 2013 |
Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Double-Blind Me | 2013 |
Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Double-Blind Me | 2013 |
Inflammation's Association with Metabolic Profiles before and after a Twelve-Week Clinical Trial in Drug-Naïve Patients with Bipolar II Disorder.
Topics: Adult; Biomarkers; Bipolar Disorder; Cytokines; Double-Blind Method; Drug Therapy, Combination; Fema | 2013 |
Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder.
Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Chi-Square Distribution; Double-Bli | 2013 |
Prescribing patterns of lithium or lithium+valproate in manic or mixed episodes: a naturalistic study.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Lithium Carbon | 2013 |
Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression.
Topics: Adult; Amygdala; Bipolar Disorder; Female; Functional Neuroimaging; Hippocampus; Humans; Lithium Com | 2013 |
Genotype variant associated with add-on memantine in bipolar II disorder.
Topics: Adult; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Double-Blind Method; Drug Therapy, Combi | 2014 |
Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Double-Blind Meth | 2014 |
A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks.
Topics: Adult; Antidepressive Agents; Biomarkers, Pharmacological; Bipolar Disorder; Cross-Over Studies; Dep | 2014 |
The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Cytokines; Double-Blind Method; Drug Therapy, Combination | 2014 |
Correlation of plasma brain-derived neurotrophic factor and metabolic profiles in drug-naïve patients with bipolar II disorder after a twelve-week pharmacological intervention.
Topics: Adult; Affect; Bipolar Disorder; Body Mass Index; Brain-Derived Neurotrophic Factor; Cholesterol; Fe | 2015 |
Oral loading of sodium valproate compared to intravenous loading and oral maintenance in acutely manic bipolar patients.
Topics: Administration, Intravenous; Administration, Oral; Adult; Analysis of Variance; Antimanic Agents; Bi | 2014 |
Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder.
Topics: Adult; Antimanic Agents; Biomarkers; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Cytokines; | 2014 |
Risperidone versus risperidone plus sodium valproate for treatment of bipolar disorders: a randomized, double-blind clinical-trial.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Femal | 2014 |
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression.
Topics: Adult; Affect; Anxiety; Anxiety Disorders; Bipolar Disorder; Cross-Over Studies; Depression; Double- | 2015 |
Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Child, Preschool; Double-Blind Meth | 2015 |
Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Child, Preschool; Double-Blind Meth | 2015 |
Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Child, Preschool; Double-Blind Meth | 2015 |
Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Child, Preschool; Double-Blind Meth | 2015 |
Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial.
Topics: Acetamides; Adult; Antidepressive Agents; Antimanic Agents; Argentina; Australia; Bipolar Disorder; | 2016 |
Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cross-Over Studies; Depressive Disorder, Treatment-R | 2015 |
Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Bipolar Disorder; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Therapy, | 2015 |
Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Female; Follow-Up Studies; Humans; Lithium | 2016 |
Depression and Suicidality Outcomes in the Treatment of Early Age Mania Study.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Depression; Female; Hum | 2015 |
Treatment of Early-Age Mania: Outcomes for Partial and Nonresponders to Initial Treatment.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Drug Therapy, Combination; Female; Humans; Li | 2015 |
Effect of lurasidone on meaningful change in health-related quality of life in patients with bipolar depression.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Femal | 2016 |
Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Computer Simulation; Depressive Dis | 2016 |
Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Computer Simulation; Depressive Dis | 2016 |
Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Computer Simulation; Depressive Dis | 2016 |
Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Computer Simulation; Depressive Dis | 2016 |
Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Chromatograp | 2016 |
Evaluating response to mood stabilizers in patients with mixed depression: A study of agreement between three different mania rating scales and a depression rating scale.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Depressive Disorder; Diagnostic and Statis | 2016 |
Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia.
Topics: Acetylcarnitine; Adolescent; Adult; Aged; Aged, 80 and over; Ammonia; Bipolar Disorder; Carnitine; E | 2016 |
Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Double-Blind Met | 2016 |
The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample.
Topics: Aged; Antidepressive Agents; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders | 2016 |
Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; H | 2016 |
Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; H | 2016 |
Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; H | 2016 |
Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; H | 2016 |
Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder.
Topics: Adolescent; Adult; Biomarkers; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Cytokines; Dextr | 2016 |
The DRD3 Ser9Gly Polymorphism Predicted Metabolic Change in Drug-Naive Patients With Bipolar II Disorder.
Topics: Bipolar Disorder; DNA; Dose-Response Relationship, Drug; Double-Blind Method; Female; GABA Agents; G | 2016 |
Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies.
Topics: Aged; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S | 2016 |
Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies.
Topics: Aged; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S | 2016 |
Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies.
Topics: Aged; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S | 2016 |
Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies.
Topics: Aged; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S | 2016 |
Treatment recommendations for DSM-5-defined mixed features.
Topics: Antipsychotic Agents; Bipolar Disorder; Comorbidity; Depressive Disorder, Major; Diagnostic and Stat | 2017 |
The correlation between plasma brain-derived neurotrophic factor and cognitive function in bipolar disorder is modulated by the BDNF Val66Met polymorphism.
Topics: Adult; Amino Acid Substitution; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Cognition; Dext | 2016 |
The COMT Val158Met Polymorphism Is Associated With Response to Add-on Dextromethorphan Treatment in Bipolar Disorder.
Topics: Antimanic Agents; Bipolar Disorder; Catechol O-Methyltransferase; Dextromethorphan; Drug Therapy, Co | 2017 |
Is valproate promising in cardiac fatal arrhythmias? Comparison of P- and Q-wave dispersion in bipolar affective patients on valproate or lithium-valproate maintenance therapy with healthy controls.
Topics: Adult; Antimanic Agents; Arrhythmias, Cardiac; Bipolar Disorder; Cross-Sectional Studies; Drug Thera | 2009 |
Time to rehospitalization in patients with bipolar I disorder on lithium or valproate with adjunctive antipsychotics.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Female; Hospita | 2008 |
Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).
Topics: Antipsychotic Agents; Bipolar Disorder; Demography; Dibenzothiazepines; Disorders of Excessive Somno | 2008 |
Brain oscillatory responses in patients with bipolar disorder manic episode before and after valproate treatment.
Topics: Action Potentials; Adult; Alpha Rhythm; Antimanic Agents; Biological Clocks; Bipolar Disorder; Brain | 2008 |
Event related oscillations in euthymic patients with bipolar disorder.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Brain; Brain Mapping; Evoked Potentials | 2008 |
A 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Femal | 2008 |
Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate.
Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Female; Humans; Hypotension | 2008 |
Comparison between lithium and valproate in the treatment of acute mania.
Topics: Antimanic Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; Lithium Carbonate; Psychiat | 2008 |
Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; | 2008 |
A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression.
Topics: Adult; Affect; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Cognition; Female; Humans; | 2008 |
A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Child; Chi | 2008 |
A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence.
Topics: Adolescent; Adult; Affect; Aged; Alcoholism; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Co | 2009 |
Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Delayed-Action Preparations; Female; Humans; | 2009 |
Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).
Topics: Adult; Affect; Antimanic Agents; Bipolar Disorder; Dibenzothiazepines; Dose-Response Relationship, D | 2009 |
Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study.
Topics: Acute Disease; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Double-Bli | 2009 |
A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents.
Topics: Adolescent; Ammonia; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Child; Delayed-Action | 2009 |
A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents.
Topics: Adolescent; Ammonia; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Child; Delayed-Action | 2009 |
A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents.
Topics: Adolescent; Ammonia; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Child; Delayed-Action | 2009 |
A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents.
Topics: Adolescent; Ammonia; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Child; Delayed-Action | 2009 |
Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adult; Antimanic Agents; Bipolar Disorder; Double-Bli | 2009 |
Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar I disorder.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Cost-Benefit Analy | 2009 |
Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diagnostic and Sta | 2009 |
[Open randomized comparative twelve-week study of lithium and valproate in manic episode].
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug | 2009 |
Efficacy of sodium valproate and haloperidol in the management of acute mania: a randomized open-label comparative study.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Dyskinesia, Drug-Induced; Female; Haloperidol | 2010 |
Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug | 2010 |
Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Femal | 2010 |
Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Double-Blind Meth | 2010 |
Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Brain; Brain Mapping; Female; Humans; Image Processing, C | 2010 |
Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Delayed-Action Preparations; Double-Blind Method; Female; | 2010 |
A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Delayed-Action Preparati | 2010 |
Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.
Topics: Adult; Antimanic Agents; Aripiprazole; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; | 2010 |
Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodes.
Topics: Adolescent; Adult; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Female; Humans; Male; Middle | 2011 |
LICAVAL: combination therapy in acute and maintenance treatment of bipolar disorder.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cognition; Drug | 2010 |
Predictors of non-stabilization during the combination therapy of lithium and divalproex in rapid cycling bipolar disorder: a post-hoc analysis of two studies.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Chi-Square Distribution; Comorbidity; Double-Blind Method | 2010 |
A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Diagn | 2010 |
Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial.
Topics: Adult; Amides; Animals; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method | 2010 |
Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antimanic Agents; Benzhydryl Compounds; Benzodiazepi | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; Ma | 2011 |
Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Double-Blind Method; Fe | 2010 |
Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Delayed-Action Preparations; Double | 2011 |
Effect of omega-3 fatty acids on valproate plasma protein binding.
Topics: Antimanic Agents; Bipolar Disorder; Blood Proteins; Fatty Acids, Omega-3; Female; Humans; Male; Midd | 2010 |
Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study.
Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Chi-Square Distribution; Depression | 2010 |
Depression symptom ratings in geriatric patients with bipolar mania.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Metho | 2011 |
Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study.
Topics: Adult; Antimanic Agents; Aripiprazole; Bipolar Disorder; Confidence Intervals; Double-Blind Method; | 2011 |
Estimation of resource utilisation difference between lithium and valproate treatment groups from the VALID study.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cost-Benefit Analysis; Female; Heal | 2011 |
Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder: fMRI outcomes.
Topics: Adolescent; Analysis of Variance; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Brain; C | 2011 |
Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Maj | 2011 |
Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; Lithium; Male; Middl | 2011 |
Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles.
Topics: Adjuvants, Immunologic; Antipsychotic Agents; Bipolar Disorder; Body Weight; Double-Blind Method; Dr | 2012 |
A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; GABA Agents; Hum | 2011 |
Pharmacotherapy impacts functional connectivity among affective circuits during response inhibition in pediatric mania.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Brain; Brain Mapping; Child; Female; Humans; Inhibit | 2012 |
Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial.
Topics: Adult; Aripiprazole; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Human | 2011 |
Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder.
Topics: Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Attention Deficit and Disruptive Beh | 2011 |
Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
Topics: Acute Disease; Adult; Affect; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disor | 2012 |
Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
Topics: Acute Disease; Adult; Affect; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disor | 2012 |
Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
Topics: Acute Disease; Adult; Affect; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disor | 2012 |
Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
Topics: Acute Disease; Adult; Affect; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disor | 2012 |
A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Female; Humans; Lithium Carbonate; Male; Psyc | 2012 |
Risperidone and divalproex differentially engage the fronto-striato-temporal circuitry in pediatric mania: a pharmacological functional magnetic resonance imaging study.
Topics: Adolescent; Affect; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Brain Mapping; Child; C | 2012 |
The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Dextromethorphan; Double-Blind Method; Drug Therapy, Comb | 2012 |
Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder.
Topics: Adult; Affect; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamazep | 2012 |
Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Wei | 2012 |
Comparing efficacy of ECT with and without concurrent sodium valproate therapy in manic patients.
Topics: Adult; Age Factors; Antimanic Agents; Bipolar Disorder; Combined Modality Therapy; Double-Blind Meth | 2012 |
Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; H | 2012 |
Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) study.
Topics: Adolescent; Age Factors; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Attention Deficit | 2012 |
Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Delayed-Action Preparations; Dibenzothiazepines; Doub | 2013 |
Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: clinical and methodological implications.
Topics: Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 2013 |
Achieving and sustaining remission in bipolar I disorder with ziprasidone : a post hoc analysis of a 24-week, double-blind, placebo-controlled study.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; H | 2012 |
Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2012 |
Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar disorder.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Comb | 2012 |
Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antimanic Agents; Basal Ganglia Diseases; Bipolar Disorder; | 2012 |
Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 2: influence of protocol-specific eligibility criteria on signal detection.
Topics: Administration, Oral; Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Diagnosis, Computer-Ass | 2012 |
Assessment of cognitive impairments and seizure characteristics in electroconvulsive therapy with and without sodium valproate in manic patients.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Cognition Disorders; Combined Modality Therapy; Double-Bli | 2013 |
Relative effectiveness of adjunctive risperidone on manic and depressive symptoms in mixed mania.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Diagnostic an | 2013 |
Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Drug | 2013 |
Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode.
Topics: Adult; Aripiprazole; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Human | 2013 |
Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamazepine; Che | 2002 |
A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania.
Topics: Acute Disease; Adolescent; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Child; Dibenzot | 2002 |
An open-label trial of divalproex in children and adolescents with bipolar disorder.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Child; Female; Humans; Logistic Models; Male; | 2002 |
Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients.
Topics: Adult; Algorithms; Antimanic Agents; Bipolar Disorder; Brain Chemistry; Female; Frontal Lobe; Humans | 2002 |
A pilot study of loading versus titration of valproate in the treatment of acute mania.
Topics: Acute Disease; Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Diagnostic and Stat | 2002 |
Initial triple therapy of acute mania, adding lithium and valproate to neuroleptics.
Topics: Acute Disease; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, | 2002 |
A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Metho | 2002 |
Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial.
Topics: Adult; Aged; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Brief | 2003 |
Initial lithium and valproate combination therapy in acute mania.
Topics: Acute Disease; Adult; Aged; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Female; H | 2002 |
Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Cerebral Cortex; Ch | 2003 |
Valproate, bipolar disorder and polycystic ovarian syndrome.
Topics: Adolescent; Adult; Anticonvulsants; Bipolar Disorder; Cross-Sectional Studies; Female; Humans; Middl | 2003 |
Acute antimanic efficacy and safety of intravenous valproate loading therapy: an open-label study.
Topics: Administration, Oral; Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Diagnostic and Statisti | 2003 |
Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes.
Topics: Acute Disease; Adult; Ambulatory Care; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipol | 2003 |
Maintenance efficacy of divalproex in the prevention of bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Chi-Square Distribution; Dose-Response Relationship, Drug | 2003 |
Combination pharmacotherapy in children and adolescents with bipolar disorder.
Topics: Adolescent; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorde | 2003 |
Risperidone in acute and continuation treatment of mania.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Administration | 2003 |
Lamotrigine in adolescent mood disorders.
Topics: Adolescent; Anticonvulsants; Bipolar Disorder; Child; Delayed-Action Preparations; Drug Therapy, Com | 2003 |
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.
Topics: Acute Disease; Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Doub | 2003 |
Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders.
Topics: Ambulatory Care; Antimanic Agents; Bipolar Disorder; Delayed-Action Preparations; Drug Administratio | 2003 |
Combination lithium and divalproex sodium in pediatric bipolarity.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Drug Therapy, Combination; Female; | 2003 |
Antipsychotic-induced weight gain: bipolar disorder and leptin.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body M | 2003 |
Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms.
Topics: Adolescent; Affective Symptoms; Anticonvulsants; Bipolar Disorder; Child; Child of Impaired Parents; | 2003 |
The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dia | 2003 |
Adjunctive topiramate in bipolar II disorder.
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug Resistance; Drug The | 2003 |
Elevated thyrotropin in bipolar youths prescribed both lithium and divalproex sodium.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Child; Child, Preschool; Female | 2004 |
Single-dose intravenous valproate in acute mania.
Topics: Acute Disease; Adult; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Female; | 2004 |
[Efficacy of depakine chrono and lithium combination in the treatment of manic states].
Topics: Adult; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Lithium Carbon | 2003 |
Long-term outcome with divalproex in children and adolescents with bipolar disorder.
Topics: Adolescent; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorders; Bipolar Disorder; | 2003 |
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone.
Topics: Adult; Aged; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind | 2004 |
Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Double-Blind Met | 2004 |
The effectiveness of divalproate in all forms of mania and the broader bipolar spectrum: many questions, few answers.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Humans; Lithium Carbonate; Valproic Acid | 2004 |
Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Brief Psychiatric Rating Scale; Doub | 2004 |
Divalproex versus valproate in patients with bipolar disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; P | 2004 |
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Benzothiazoles; Bipolar Disorder; Dopamine Agonists; | 2004 |
Psychosis in mania: specificity of its role in severity and treatment response.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cluster Analysis; Delusio | 2004 |
Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Area Under Curve; Bipolar Disorder; | 2004 |
Divalproex for the treatment of aggression associated with adolescent mania.
Topics: Adolescent; Aggression; Antimanic Agents; Bipolar Disorder; Child; Humans; Psychiatric Status Rating | 2004 |
Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder.
Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Brain; Brain Chemistry; Brain Mappi | 2004 |
Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combination; Female; H | 2004 |
A prospective 4-5 year follow-up of juvenile onset bipolar disorder.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazep | 2004 |
Prevention of postpartum episodes in women with bipolar disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Depression, Postpartum; Female; Follow-Up Studies; Humans | 2004 |
Hyperprolinemia is a risk factor for schizoaffective disorder.
Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Case-Control Studies; Chromosomes, | 2005 |
The antidepressant effects of risperidone and olanzapine in bipolar disorder.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body W | 2004 |
Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania.
Topics: Adolescent; Adult; Analysis of Variance; Bipolar Disorder; Dibenzothiazepines; Double-Blind Method; | 2004 |
Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Child, Preschool; Drug Therapy, Combinati | 2004 |
Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorde | 2004 |
Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseas | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anticonvulsants; Bipolar Disorder; Comorbidit | 2005 |
Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anticonvulsants; Bipolar Disorder; Comorbidit | 2005 |
Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anticonvulsants; Bipolar Disorder; Comorbidit | 2005 |
Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anticonvulsants; Bipolar Disorder; Comorbidit | 2005 |
Divalproex in the treatment of bipolar depression: a placebo-controlled study.
Topics: Adult; Ambulatory Care; Anticonvulsants; Antimanic Agents; Anxiety; Bipolar Disorder; Double-Blind M | 2005 |
Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Child; Child, Preschool; Double | 2005 |
Divalproex sodium for pediatric mixed mania: a 6-month prospective trial.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Female; Humans; Male; Pilot Projects; Prospec | 2005 |
Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial.
Topics: Acute Disease; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cos | 2005 |
Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial.
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug Costs; Drug Therapy, | 2005 |
Valproate attenuates dextroamphetamine-induced subjective changes more than lithium.
Topics: Adolescent; Adult; Affect; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Central Nervous Syst | 2005 |
Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Drug Evaluation; Drug Tolerance; Fem | 2005 |
Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Blood Platelets; Enzyme Activation; Female; GTP-Binding P | 2005 |
Extended-release divalproex sodium for patients with side effects from delayed-release divalproex sodium.
Topics: Adult; Ambulatory Care; Antimanic Agents; Bipolar Disorder; Delayed-Action Preparations; Drug Admini | 2005 |
Patient characteristics and treatment implications of marijuana abuse among bipolar alcoholics: results from a double blind, placebo-controlled study.
Topics: Adolescent; Adult; Affect; Aged; Alcohol Drinking; Alcoholism; Antimanic Agents; Bipolar Disorder; D | 2005 |
Differential effects of chronic lithium and valproate on brain activation in healthy volunteers.
Topics: Adult; Attention; Bipolar Disorder; Brain; Double-Blind Method; Female; Humans; Lithium; Magnetic Re | 2005 |
A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder.
Topics: Adolescent; Adult; Anticonvulsants; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination | 2005 |
Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder.
Topics: Acute Disease; Anticonvulsants; Bipolar Disorder; Drug Administration Schedule; Drug Therapy, Combin | 2005 |
A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Brief Psychiatric Rating Scale; Cholinesterase Inhibitors | 2006 |
Combination lithium and divalproex sodium in pediatric bipolar symptom re-stabilization.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Child, Preschool; Drug Therapy, Combination; | 2006 |
Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder.
Topics: Adolescent; Adult; Amenorrhea; Antimanic Agents; Bipolar Disorder; Cohort Studies; Comorbidity; Fema | 2006 |
A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Child; Dibenzothiazepines | 2006 |
Inositol augmentation of lithium or valproate for bipolar depression.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Brief Psychiatric Rating Scale | 2006 |
Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cognition; Female; Humans; Lamotrigine; Mal | 2006 |
Much improved outcome with gabapentin-divalproex combination in adults with bipolar disorders and developmental disabilities.
Topics: Adolescent; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Developm | 2006 |
Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder.
Topics: Adolescent; Affect; Aggression; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorder | 2006 |
Divalproex utility in bipolar disorder with co-occurring cocaine dependence: a pilot study.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Cocaine-Related Disorders; Counseling; | 2007 |
Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method | 2006 |
Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Body Mass Index; Carnitine; Diet, Fat-Restricted; Diet, Re | 2006 |
Valproate or olanzapine add-on to lithium: an 8-week, randomized, open-label study in Italian patients with a manic relapse.
Topics: Adult; Aged; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disor | 2007 |
A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticonvulsants; Bipolar Disorder; Delayed-Action Preparatio | 2006 |
Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Chemotherapy, Adjuvant; Double-Blind Method; Drug Therapy | 2006 |
The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s).
Topics: Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Attention Deficit and Disruptive Beh | 2006 |
Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Drug Administration Schedule; Enzyme-Linked Immunosorbent | 2007 |
Comparison of two anticonvulsants in a randomized, single-blind treatment of hypomanic symptoms in patients with bipolar disorder.
Topics: Adult; Affect; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug Therapy, Com | 2007 |
Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Double-Blind Method; Female; Genetic Predispo | 2007 |
A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Double-Blind Me | 2007 |
Treatment adherence in individuals with rapid cycling bipolar disorder: results from a clinical-trial setting.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; Lamotrigine; Lithium | 2007 |
Facial emotion processing in acutely ill and euthymic patients with pediatric bipolar disorder.
Topics: Acute Disease; Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Drug Therapy, Combination; | 2007 |
Effect of open-label lamotrigine as monotherapy and adjunctive therapy on the self-assessed cognitive function scores of patients with bipolar I disorder.
Topics: Adult; Aged; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cognit | 2007 |
A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder.
Topics: Administration, Oral; Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepine | 2007 |
Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Area Under Curve; Bipolar Disorder; Cohort Studies; D | 2007 |
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data.
Topics: Acetamides; Adult; Aged; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Female; Humans; Li | 2007 |
Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder.
Topics: Acute Disease; Adult; Anticonvulsants; Bipolar Disorder; Clinical Trials as Topic; Double-Blind Meth | 2008 |
The Bipolar Comprehensive Outcomes Study (BCOS): baseline findings of an Australian cohort study.
Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Australia; Benzodiazepines; Bipolar Disorder; Ca | 2008 |
A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex.
Topics: Adult; Aged; Antipsychotic Agents; Biological Availability; Bipolar Disorder; Delayed-Action Prepara | 2007 |
Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study.
Topics: Acute Disease; Adult; Antimanic Agents; Bipolar Disorder; Delayed-Action Preparations; Double-Blind | 2007 |
Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Bipolar Disorde | 2008 |
Family conflict moderates response to pharmacological intervention in pediatric bipolar disorder.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Drug Therapy, Combination; Family Conflict; F | 2007 |
Switching from other agents to extended-release carbamazepine in acute mania.
Topics: Acute Disease; Adult; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Carbamazepine; Delayed-Ac | 2008 |
Levetiracetam as monotherapy or add-on to valproate in the treatment of acute mania-a randomized open-label study.
Topics: Anticonvulsants; Bipolar Disorder; Drug Therapy, Combination; Humans; Levetiracetam; Piracetam; Psyc | 2008 |
Valproic acid amide in the treatment of affective and schizoaffective disorders.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as | 1984 |
Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report.
Topics: Adolescent; Adult; Analgesics; Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as | 1983 |
Treatment of mood disorders with antiepileptic medications: clinical and theoretical implications.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Clonazepam; Depressive D | 1983 |
Selective response to the anticonvulsant carbamazepine in manic-depressive illness: a case study.
Topics: Bipolar Disorder; Carbamazepine; Dose-Response Relationship, Drug; Female; Humans; Lithium; Middle A | 1984 |
Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Alcohol Withdrawal Delirium; Bipolar Disorder; Cl | 1980 |
Therapeutic effect of valproate in mania.
Topics: Affective Disorders, Psychotic; Bipolar Disorder; Clinical Trials as Topic; Double-Blind Method; Hum | 1981 |
The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults: an open clinical trial.
Topics: Acute Disease; Adolescent; Adult; Arousal; Bipolar Disorder; Dose-Response Relationship, Drug; Drug | 1995 |
Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study.
Topics: Acute Disease; Adult; Bipolar Disorder; Comorbidity; Diagnosis, Dual (Psychiatry); Female; Follow-Up | 1995 |
Divalproex sodium in the treatment of aggressive behavior.
Topics: Adult; Aggression; Bipolar Disorder; Borderline Personality Disorder; Case-Control Studies; Female; | 1994 |
Valproate oral loading in the treatment of acute mania.
Topics: Acute Disease; Administration, Oral; Adult; Bipolar Disorder; Drug Therapy, Combination; Female; Hos | 1993 |
Divalproex sodium treatment in late adolescent and young adult acute mania.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Female; Humans; Male; Psychiatric Status Rating | 1993 |
Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome.
Topics: Administration, Oral; Ambulatory Care; Bipolar Disorder; Cyclothymic Disorder; Dose-Response Relatio | 1993 |
Predictors of valproate response in bipolar rapid cycling.
Topics: Adult; Bipolar Disorder; Discriminant Analysis; Female; Humans; Male; Middle Aged; Predictive Value | 1993 |
The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay.
Topics: Adult; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Carbamazepine; Drug Therapy, Combination | 1996 |
A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania.
Topics: Acute Disease; Administration, Oral; Adult; Basal Ganglia Diseases; Bipolar Disorder; Haloperidol; H | 1996 |
Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium.
Topics: Adult; Bipolar Disorder; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Interactions | 1996 |
Relation of serum valproate concentration to response in mania.
Topics: Acute Disease; Adult; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 1996 |
Plasma GABA predicts acute response to divalproex in mania.
Topics: Adult; Aged; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Female; gamma-Aminobutyric Aci | 1996 |
Risperidone in the treatment of mania.
Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Confidence Intervals; D | 1996 |
Carbamazepine but not valproate induces bupropion metabolism.
Topics: Adult; Antidepressive Agents; Biotransformation; Bipolar Disorder; Bupropion; Carbamazepine; Cytochr | 1995 |
Depression during mania. Treatment response to lithium or divalproex.
Topics: Adult; Bipolar Disorder; Double-Blind Method; Female; Humans; Lithium; Male; Patient Dropouts; Place | 1997 |
A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder.
Topics: Adult; Aged; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Lithium Carbonate; Male; M | 1997 |
Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder.
Topics: Adult; Aged; Ambulatory Care; Bipolar Disorder; Carbamazepine; Drug Resistance; Drug Therapy, Combin | 1997 |
Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; Li | 1997 |
Lamotrigine in rapid-cycling bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Administration Schedule; Drug Therapy, Combination; F | 1997 |
Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Double-Blind Method; Female; Hu | 1997 |
Treatment algorithm use to optimize management of symptomatic patients with a history of mania.
Topics: Adult; Algorithms; Ambulatory Care; Antipsychotic Agents; Bipolar Disorder; Brief Psychiatric Rating | 1998 |
Serum levels of valproate and carbamazepine in breastfeeding mother-infant pairs.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Breast Feeding; Carbamazepine; Depression, Postpartum; Fem | 1998 |
Bipolar depression and antidepressant-induced mania: a naturalistic study.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bipolar Disorder; C | 1998 |
Anticonvulsant therapy and suicide risk in affective disorders.
Topics: Amitriptyline; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Female; Follow | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combinat | 1999 |
The use of primidone in the treatment of refractory bipolar disorder.
Topics: Adult; Ambulatory Care; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Drug Administration | 1999 |
Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania.
Topics: Acute Disease; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Humans; Lithium; Placebos; R | 1999 |
Antidepressant discontinuation-related mania: critical prospective observation and theoretical implications in bipolar disorder.
Topics: Adrenergic Uptake Inhibitors; Anticonvulsants; Antidepressive Agents; Antidepressive Agents, Tricycl | 1999 |
A history of substance abuse complicates remission from acute mania in bipolar disorder.
Topics: Acute Disease; Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Comorb | 1999 |
Tiagabine appears not to be efficacious in the treatment of acute mania.
Topics: Acute Disease; Adult; Anticonvulsants; Bipolar Disorder; Drug Therapy, Combination; Female; GABA Ant | 1999 |
Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Double-Blind Me | 2000 |
Mania: gender, transmitter function, and response to treatment.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Humans; Lithium Carbonat | 1999 |
Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Bipolar Disorder; Double-Blind Method; Drug | 1999 |
Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group.
Topics: Acute Disease; Administration, Oral; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder | 2000 |
A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group.
Topics: Ambulatory Care; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Drug Administration Schedu | 2000 |
Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report.
Topics: Adolescent; Adult; Anticonvulsants; Bipolar Disorder; Drug Administration Schedule; Drug Therapy, Co | 2000 |
Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder.
Topics: Acute Disease; Adolescent; Age Factors; Antimanic Agents; Bipolar Disorder; Carbamazepine; Child; Do | 2000 |
Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Carbamazepine; Ch | 2000 |
Mania: differential effects of previous depressive and manic episodes on response to treatment.
Topics: Antimanic Agents; Bipolar Disorder; Depression; Double-Blind Method; Drug Tolerance; Female; Humans; | 2000 |
Effects of divalproex versus lithium on length of hospital stay among patients with bipolar disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Connecticut; Cost-Benefit Analysis; Female; Humans; Lengt | 2000 |
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Body Weight; | 2000 |
Valpromide increases amplitude of heart rate circadian rhythm in remitted bipolar and unipolar disorders. A placebo-controlled study.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Circadian Rhythm; Cross-Over Studies; Depressive Disorder, | 2000 |
[Effectiveness, safety and practicality of delayed-release minitablets of valproate in bipolar affective disorders].
Topics: Adult; Antimanic Agents; Bipolar Disorder; Delayed-Action Preparations; Female; Humans; Male; Middle | 2000 |
Divalproex sodium in substance abusers with mood disorder.
Topics: Adult; Anticonvulsants; Behavior, Addictive; Bipolar Disorder; Comorbidity; Depressive Disorder; Dru | 2000 |
Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic | 2000 |
Inositol as an add-on treatment for bipolar depression.
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Blood-Brain Barrier; Carbamazepine; Drug | 2000 |
Topiramate as add-on treatment for patients with bipolar mania.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Body Mass Index; | 1999 |
Divalproex sodium in sex offenders with bipolar disorders and comorbid paraphilias: an open retrospective study.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Humans; Male; Paraphilic Disorders; Retrospec | 2001 |
Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression.
Topics: Adult; Aged; Ambulatory Care; Anticonvulsants; Antidepressive Agents, Tricyclic; Bipolar Disorder; C | 2001 |
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.
Topics: Adult; Affective Disorders, Psychotic; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; | 2001 |
Quetiapine alone and added to a mood stabilizer for serious mood disorders.
Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Brief Psychiatric Rating Scale; Dibenzothiazepi | 2001 |
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.
Topics: Acute Disease; Adult; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug | 2002 |
Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression.
Topics: Administration, Oral; Adult; Antimanic Agents; Bipolar Disorder; Drug Administration Schedule; Femal | 2001 |
The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder.
Topics: Acetates; Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2001 |
Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania.
Topics: Adult; Antimanic Agents; Behavior; Bipolar Disorder; Delusions; Double-Blind Method; Euphoria; Femal | 2002 |
Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study.
Topics: Adult; Aggression; Anger; Anticonvulsants; Bipolar Disorder; Borderline Personality Disorder; Comorb | 2002 |
Olanzapine versus divalproex in the treatment of acute mania.
Topics: Acute Disease; Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Doub | 2002 |
Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antiparkinson Agents; Antipsychotic Agents | 2002 |
Valproate treatment of mania.
Topics: Adult; Aged; Animals; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Femal | 1992 |
Synergy of carbamazepine and valproic acid in affective illness: case report and review of the literature.
Topics: Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Hum | 1992 |
Dysphoric mania.
Topics: Bipolar Disorder; Double-Blind Method; Humans; Lithium; Psychiatric Status Rating Scales; Valproic A | 1992 |
Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients.
Topics: Adult; Bipolar Disorder; Female; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Valproic | 1992 |
A double-blind comparison of valproate and lithium in the treatment of acute mania.
Topics: Analysis of Variance; Bipolar Disorder; Double-Blind Method; Female; Humans; Lithium Carbonate; Male | 1992 |
Correlates of antimanic response to valproate.
Topics: Acute Disease; Adult; Bipolar Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Psyc | 1991 |
Valproate in the treatment of acute mania. A placebo-controlled study.
Topics: Acute Disease; Adolescent; Adult; Aged; Bipolar Disorder; Double-Blind Method; Drug Administration S | 1991 |
Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Depressive | 1990 |
Non-lithium treatment for bipolar disorder.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Clonazepam; Drug Therapy | 1990 |
Valproate use in acute mania and bipolar disorder: an international perspective.
Topics: Acute Disease; Bipolar Disorder; Clinical Trials as Topic; Europe; Humans; Valproic Acid | 1989 |
U.S. experience with valproate in manic depressive illness: a multicenter trial.
Topics: Adult; Aged; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Humans; Middle Aged; P | 1989 |
Valproate in psychiatric disorders: literature review and clinical guidelines.
Topics: Bipolar Disorder; Clinical Trials as Topic; Humans; Mental Disorders; Psychotic Disorders; Valproic | 1989 |
Phenomenology of rapid cycling manic depression and its treatment with valproate.
Topics: Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans | 1989 |
Long-term use of valproate in primary psychiatric disorders.
Topics: Adult; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Drug Therapy, Combination; F | 1989 |
752 other studies available for valproic acid and Bipolar Disorder
| Article | Year |
|---|---|
Prefrontal cortical thickness and clinical characteristics of long-term treatment response to valproate in bipolar disorder.
Topics: Bipolar Disorder; Cerebral Cortex; Humans; Magnetic Resonance Imaging; Prefrontal Cortex; Valproic A | 2021 |
Lurasidone-Induced Manic Switch in an Adolescent with Bipolar I Disorder: a Case Report.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithium Compo | 2021 |
Long-term use of valproic acid reduced mortality in bipolar disorder patients in a Taiwanese population: An association analysis using the national health insurance research database (NHIRD).
Topics: Bipolar Disorder; Epilepsy; Humans; Lithium; Male; National Health Programs; Valproic Acid | 2022 |
Gender and Body Mass Index-Related Serum Level of Adipokines and Metabolic Syndrome Components in Bipolar Patients Who Received Lithium and Valproic Acid.
Topics: Adipokines; Adiponectin; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Female; Humans; Leptin | 2022 |
Mitochondrial DNA Copy Number Is Associated With Treatment Response and Cognitive Function in Euthymic Bipolar Patients Receiving Valproate.
Topics: Bipolar Disorder; Cognition; DNA Copy Number Variations; DNA, Mitochondrial; Humans; Metabolic Syndr | 2022 |
Valproate prescription to women of childbearing age in English primary care: repeated cross-sectional analyses and retrospective cohort study.
Topics: Adolescent; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cohort Studies; Contraceptio | 2022 |
Suicide death over the first year of lithium versus valproate treatment in cohorts with and without bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Lithium; Suicide; Valproic Acid | 2022 |
Bipolar disorder, mood stabilizers and cognitive flexibility: Translationally dissecting illness from drug effects.
Topics: Animals; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cognition; Humans; Lithium; Rats; Valp | 2022 |
Association between serum lithium level and incidence of COVID-19 infection.
Topics: Antimanic Agents; Bipolar Disorder; COVID-19; Humans; Incidence; Lithium; Lithium Compounds; Valproi | 2022 |
Association of Lithium Treatment With the Risk of Osteoporosis in Patients With Bipolar Disorder.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Lamotrigine; Lithiu | 2022 |
Sodium valproate continues to be prescribed in hundreds of pregnancies, data show.
Topics: Anticonvulsants; Bipolar Disorder; Female; Humans; Pregnancy; Valproic Acid | 2022 |
Response to lithium and anticonvulsants among patients with bipolar disorder with and without comorbid epilepsy - A nation-wide population-based longitudinal study.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Epilepsy; Humans; Lamotrigine; | 2022 |
Relationship between lithium carbonate and the risk of Parkinson-like events in patients with bipolar disorders: A multivariate analysis using the Japanese adverse drug event report database.
Topics: Antimanic Agents; Bipolar Disorder; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; | 2022 |
Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Hospitalization; Humans; | 2022 |
Effect of valproate and lithium on dementia onset risk in bipolar disorder patients.
Topics: Aged; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dementia; Humans; Lithium; Valproic | 2022 |
Lithium produces bi-directionally regulation of mood disturbance, acts synergistically with anti-depressive/-manic agents, and did not deteriorate the cognitive impairment in murine model of bipolar disorder.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cognitive Dysfu | 2022 |
Prescribing changes for bipolar patients discharged from two public psychiatric hospitals in Taiwan, 2006-2019.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bip | 2022 |
[French Expert advice on the management of valproate in childbearing and pregnant women with bipolar disorder].
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Child; Female; Humans; Pregnancy; Pregnant | 2022 |
Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Luras | 2022 |
Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Luras | 2022 |
Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Luras | 2022 |
Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Luras | 2022 |
Fourteen-year trends in the prescribing patterns of pediatric bipolar patients discharged from two public mental hospitals in Taiwan.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Hospitals, P | 2023 |
The development and validation of a prediction model of lithium carbonate blood concentration by artificial neural network: a retrospective study.
Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Lithium Carbonate; Neural Networks, Computer; Retros | 2022 |
[A severe, reversible encephalopathy after prolonged use of valproic acid].
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Brain Diseases; Epilepsy; Female; Hum | 2023 |
Pharmacological treatment of bipolar disorder and risk of diabetes mellitus: A nationwide study of 30,451 patients.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Diabetes Mellitus; Humans | 2023 |
Pharmacological Strategies for Bipolar Disorders in Acute Phases and Chronic Management with a Special Focus on Lithium, Valproic Acid, and Atypical Antipsychotics.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cyclothymic Disorder; Hum | 2023 |
Valproate prescription among reproductive age women with bipolar disorders-Are regulatory methods the only solution?
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Female; Humans; Prescriptions; Valproic Acid | 2023 |
The paradox of vanishing lithium.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Lithium; Lithium Compounds; Valproic Acid | 2023 |
A novel murine model of mania.
Topics: Animals; Bipolar Disorder; Disease Models, Animal; Humans; Mania; Mice; Sleep Deprivation; Valproic | 2023 |
Brief intervention reduces prescription of sodium valproate in women of childbearing age.
Topics: Anticonvulsants; Bipolar Disorder; Crisis Intervention; Female; Humans; Pregnancy; Prescriptions; Te | 2023 |
[Comment on: "French Expert advice on the management of valproate in childbearing and pregnant women with bipolar disorder"].
Topics: Anticonvulsants; Bipolar Disorder; Female; Humans; Pregnancy; Pregnant Women; Valproic Acid | 2023 |
[Recommandations to facilitate the discontinuation of valproate in women of childbearing age].
Topics: Anticonvulsants; Bipolar Disorder; Female; Humans; Valproic Acid | 2023 |
Clinical use of mood stabilizers beyond treatment for bipolar disorder: The REAP-MS study.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Humans; Pakistan; Valproi | 2023 |
[Mood Stabilizers: An Overview].
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Humans; Valproic Acid | 2023 |
Lithium and Valproic Acid in Bipolar Disorders and Beyond.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Lithium; Lithium Compounds; Valproic Acid | 2023 |
Prevalence and characteristics of polycystic ovarian syndrome in patients with bipolar disorder.
Topics: Bipolar Disorder; Female; Humans; Insulin Resistance; Polycystic Ovary Syndrome; Prevalence; Valproi | 2023 |
Valproate regulates inositol synthesis by reducing expression of myo-inositol-3-phosphate synthase.
Topics: Bipolar Disorder; Humans; Intramolecular Lyases; Protein Kinases; Valproic Acid | 2023 |
VALPROATE-QUETIAPINE INDUCED PERIPHERAL EDEMA.
Topics: Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Edema; Humans; Quetiapine Fumarate; Valp | 2023 |
Unusual case of sodium valproate-induced hyperammonaemia encephalopathy.
Topics: Bipolar Disorder; Brain Diseases; Humans; Hyperammonemia; Male; Middle Aged; Neoplasm Recurrence, Lo | 2023 |
Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016.
Topics: Adolescent; Adult; Anticonvulsants; Bipolar Disorder; Child; Cohort Studies; Databases, Factual; Epi | 2019 |
Effects of lithium and valproate on behavioral parameters and neurotrophic factor levels in an animal model of mania induced by paradoxical sleep deprivation.
Topics: Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Di | 2019 |
Indoleamine-2,3-dioxygenase-1 is a molecular target for the protective activity of mood stabilizers against mania-like behavior induced by d-amphetamine.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Calcium; Dextroamphetamine; Glutathione Peroxidase; Ind | 2020 |
Sodium valproate induced acute pancreatitis in a bipolar disorder patient: a case report.
Topics: Amylases; Antimanic Agents; Bipolar Disorder; Humans; Male; Middle Aged; Pancreatitis; Treatment Out | 2019 |
Case of significantly delayed divalproex-induced thrombocytopaenia.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Male; Middle Aged; Thrombocytopenia; Time Factors; Valpr | 2019 |
Three-year longitudinal cognitive functioning in patients recently diagnosed with bipolar disorder.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Case-Control Studies; C | 2020 |
Generalised tonic-clonic seizures on the subtherapeutic dose of olanzapine.
Topics: Administration, Intravenous; Aged; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Drug Mon | 2019 |
Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series.
Topics: Adult; Agoraphobia; Antibodies, Monoclonal, Humanized; Antidepressive Agents; Antimanic Agents; Benz | 2020 |
Clinical correlates associated with the long-term response of bipolar disorder patients to lithium, valproate or lamotrigine: A retrospective study.
Topics: Adult; Alcoholism; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Female; Fo | 2020 |
Sex difference in the progression of manic symptoms during acute hospitalization: A prospective pilot study.
Topics: Adult; Aggression; Antimanic Agents; Bipolar Disorder; Disease Progression; Female; Follow-Up Studie | 2020 |
Serum testosterone levels in bipolar and unipolar depressed female patients and the role of medication status.
Topics: Adolescent; Adult; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Middle Aged; Testos | 2020 |
Valproate intoxication in a patient with bipolar I disorder due to SGLT2 inhibitor-induced weight reduction.
Topics: Aged; Antimanic Agents; Benzhydryl Compounds; Bipolar Disorder; Diabetes Mellitus, Type 2; Drug Inte | 2020 |
Analysis of Perinatal Women Attending a Mother and Baby Unit Taking Sodium Valproate or Lithium with a Diagnosis of Bipolar Affective Disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Breast Feeding; Female; Follow-Up Studies; Humans; Lithiu | 2020 |
HDAC inhibitors reverse mania-like behavior and modulate epigenetic regulatory enzymes in an animal model of mania induced by Ouabain.
Topics: Animals; Behavior, Animal; Bipolar Disorder; Butyric Acid; Corpus Striatum; Disease Models, Animal; | 2020 |
Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder.
Topics: Ammonia; Anticonvulsants; Bipolar Disorder; Carnitine; Epilepsy; Female; Humans; Male; Middle Aged; | 2020 |
Sodium valproate prescription to women of childbearing age in a New Zealand inpatient psychiatric unit.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Clinical Audit; | 2020 |
Effects of non-peptide nociceptin/orphanin FQ receptor ligands on methylphenidate-induced hyperactivity in mice: Implications for bipolar disorders.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Female; Hyperkinesis; Imidazoles; Methylphenidate; Mice | 2020 |
Mood-Stabilizing Antiepileptic Treatment Response in Bipolar Disorder: A Genome-Wide Association Study.
Topics: Adult; Affect; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Female; Gastrointestinal Absorpt | 2020 |
[Eosinophilic pneumonia: A rare complication of sodium divalproate].
Topics: Bipolar Disorder; Dyspnea; Female; Humans; Iatrogenic Disease; Middle Aged; Pulmonary Eosinophilia; | 2020 |
Evolution and characteristics of the use of valproate in women of childbearing age with bipolar disorder: Results from the FACE-BD cohort.
Topics: Adolescent; Adult; Affect; Bipolar Disorder; Female; Humans; Middle Aged; Valproic Acid; Young Adult | 2020 |
Predictive ability of published population pharmacokinetic models of valproic acid in Thai manic patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Bipolar Disorder; Female; Humans; Male; Middle Aged; Model | 2021 |
Vanishing White Matter Hyperintensities in CADASIL: A Case Report with Insight into Disease Mechanisms.
Topics: Antimanic Agents; Bipolar Disorder; Brain; CADASIL; Disease Progression; Drug Substitution; Female; | 2020 |
Metformin, valproic acid, and starvation induce seizures in a patient with partial SLC13A5 deficiency: a case of pharmaco-synergistic heterozygosity.
Topics: Adult; Amino Acid Substitution; Ammonia; Animals; Anticonvulsants; Autistic Disorder; Bipolar Disord | 2021 |
Factors influencing lithium versus valproate prescription preference in the maintenance treatment of bipolar patients: a report from the Italian Early Career Psychiatrists (SOPSI-GG).
Topics: Adult; Antimanic Agents; Bipolar Disorder; Drug Prescriptions; Female; Health Care Surveys; Health K | 2021 |
The Relationship Between Food Craving, Appetite-Related Hormones and Clinical Parameters in Bipolar Disorder.
Topics: Acylation; Adult; Anthropometry; Appetite; Bipolar Disorder; Craving; Cross-Sectional Studies; Fast | 2020 |
Changes in striatal dopamine transporters in bipolar disorder and valproate treatment.
Topics: Animals; Bipolar Disorder; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; H | 2021 |
Bipolar Disorder and Outcomes of Monotherapy with Lithium, Valproate, Quetiapine, Olanzapine, Venlafaxine, and Citalopram.
Topics: Antipsychotic Agents; Bipolar Disorder; Citalopram; Humans; Lithium; Olanzapine; Quetiapine Fumarate | 2021 |
Pharmacological treatment profiles in the FACE-BD cohort: An unsupervised machine learning study, applied to a nationwide bipolar cohort
Topics: Antimanic Agents; Bipolar Disorder; Humans; Longitudinal Studies; Unsupervised Machine Learning; Val | 2021 |
Duration of untreated illness and bipolar disorder: time for a new definition? Results from a cross-sectional study.
Topics: Bipolar Disorder; Cross-Sectional Studies; Humans; Lamotrigine; Retrospective Studies; Valproic Acid | 2021 |
Lithium use in a patient on haemodialysis with bipolar affective disorder and lithium-induced nephropathy.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Kidney Diseases; | 2021 |
Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Cohort S | 2017 |
Valproate Intoxication in a Patient With Blood Valproate Levels Within Therapeutic Range.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Drug Monitoring; Female; Humans; Valproic Acid | 2017 |
Topics: Adult; Antimanic Agents; Bipolar Disorder; Female; Humans; Impulsive Behavior; Suicide; Valproic Aci | 2017 |
Population Pharmacokinetics of Valproic Acid in Patients with Mania: Implication for Individualized Dosing Regimens.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Body Weight; Drug Monitoring; Epilepsy; | 2017 |
[Profile of lithium carbonate use in patients with bipolar disorder in Colombia].
Topics: Bipolar Disorder; Colombia; Humans; Hypothyroidism; Lithium Carbonate; Retrospective Studies; Valpro | 2017 |
Suicidal Behavior During Lithium and Valproate Treatment: A Within-Individual 8-Year Prospective Study of 50,000 Patients With Bipolar Disorder.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Female; Humans; Information Storage and | 2017 |
Mania induced by adalimumab in a patient with ankylosing spondylitis.
Topics: Adalimumab; Adult; Antimanic Agents; Antirheumatic Agents; Aripiprazole; Bipolar Disorder; Humans; M | 2016 |
A Case of Recurrent Hypersomnia With Autonomic Dysfunction.
Topics: Antimanic Agents; Autonomic Nervous System Diseases; Bipolar Disorder; Catatonia; Disorders of Exces | 2017 |
A study on the bioequivalence of lithium and valproate salivary and blood levels in the treatment of bipolar disorder.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Female; Humans; Lithium Chloride; Male; Middle Aged; | 2017 |
Pharmacological Treatment of Bipolar Disorder with Comorbid Alcohol Use Disorder.
Topics: Alcoholism; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Humans; Quetiapin | 2017 |
Chlorpheniramine dependence presenting as mania.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Chlorpheniramine; Diagnosis, Differential; GABA Agent | 2017 |
France bans sodium valproate use in case of pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Bipolar Disorder; Female; France; Humans; Pregnancy; P | 2017 |
Antimanic activity of minocycline in a GBR12909-induced model of mania in mice: Possible role of antioxidant and neurotrophic mechanisms.
Topics: Animals; Antimanic Agents; Antioxidants; Bipolar Disorder; Brain; Disease Models, Animal; Hippocampu | 2018 |
DRESS syndrome: Addressing the drug hypersensitivity syndrome on combination of Sodium Valproate and Olanzapine.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Hypersen | 2017 |
Decreased NOX2 expression in the brain of patients with bipolar disorder: association with valproic acid prescription and substance abuse.
Topics: Adult; Bipolar Disorder; Brain; Female; Gyrus Cinguli; Humans; Male; Microglia; Middle Aged; NADPH O | 2017 |
Valproic acid-induced eosinophilic pleural effusion in a patient with pediatric bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Child; Humans; Pleural Effusion; Valproic Acid | 2017 |
Evaluation of adiponectin and leptin levels and oxidative stress in bipolar disorder patients with metabolic syndrome treated by valproic acid.
Topics: Adiponectin; Adult; Bipolar Disorder; Humans; Leptin; Male; Metabolic Syndrome; Middle Aged; Oxidati | 2017 |
Genetic disruption of ankyrin-G in adult mouse forebrain causes cortical synapse alteration and behavior reminiscent of bipolar disorder.
Topics: Animals; Ankyrins; Bipolar Disorder; Disease Models, Animal; GABAergic Neurons; Lithium; Methylpheni | 2017 |
Primary cilia formation is diminished in schizophrenia and bipolar disorder: A possible marker for these psychiatric diseases.
Topics: Adenylyl Cyclases; Adult; Bipolar Disorder; Cilia; Enzyme Inhibitors; Female; Humans; Male; Neural S | 2018 |
Prescription of Sodium Valproate as a Mood Stabiliser in Pregnancy.
Topics: Bipolar Disorder; Female; Humans; Pregnancy; Pregnancy Complications; Psychotic Disorders; Valproic | 2017 |
Associations between use of mood stabilizers and risk of cataract: A population-based nested case-control study.
Topics: Adult; Aged; Antimanic Agents; Bipolar Disorder; Carbamazepine; Case-Control Studies; Cataract; Data | 2018 |
Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Com | 2018 |
Severe recurrent hypothermia in an elderly patient with refractory mania associated with atypical antipsychotic, valproic acid and oxcarbazepine therapy.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamazepine; Drug Therapy, Combinat | 2017 |
Mood-Stabilizing Anticonvulsants, Spina Bifida, and Folate Supplementation: Commentary.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Dietary Supplements; Female; Fol | 2018 |
Proliferation and apoptosis of T lymphocytes in patients with bipolar disorder.
Topics: Adult; Anticonvulsants; Antimanic Agents; Apoptosis; Bipolar Disorder; Case-Control Studies; Cell Pr | 2018 |
Long-term use of valproic acid and the prevalence of cancers in bipolar disorder patients in a Taiwanese population: An association analysis using the National Health Insurance Research Database (NHIRD).
Topics: Adult; Aged; Anticonvulsants; Bipolar Disorder; Databases, Factual; Female; Humans; Incidence; Lithi | 2018 |
Bipolar Affective Disorder in a Patient of Profound Deafness.
Topics: Adolescent; Bipolar Disorder; Clonazepam; Female; Humans; Persons With Hearing Impairments; Psychiat | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Effect of Valproate and Antidepressant Drugs on Clozapine Metabolism in Patients With Psychotic Mood Disorders.
Topics: Adolescent; Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; | 2018 |
FGF21 Is Associated with Metabolic Effects and Treatment Response in Depressed Bipolar II Disorder Patients Treated with Valproate.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Drug Therapy, Co | 2018 |
Severe Cognitive Impairment Associated With a High Free But Therapeutic Total Concentration of Valproic Acid Due to Hypoalbuminemia in an Older Patient With Bipolar Disorder.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Cognitive Dysfunction; Female; Humans; Hypoalbuminemia; Pr | 2018 |
A UK clinical audit addressing the quality of prescribing of sodium valproate for bipolar disorder in women of childbearing age.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Antimanic Agents; Bipolar Disorder; Cli | 2018 |
Inhibition of the dopamine transporter as an animal model of bipolar disorder mania: Locomotor response, neuroimmunological profile and pharmacological modulation.
Topics: Animals; Antidepressive Agents; Aripiprazole; Bipolar Disorder; Brain; Cytokines; Disease Models, An | 2018 |
Manic Episode After a Chikungunya Virus Infection in a Bipolar Patient Previously Stabilized With Valproic Acid.
Topics: Antimanic Agents; Bipolar Disorder; Chikungunya Fever; Female; Humans; Middle Aged; Valproic Acid | 2018 |
Effects of valproate on brain volumes in pediatric bipolar disorder: A preliminary study.
Topics: Adolescent; Amygdala; Bayes Theorem; Bipolar Disorder; Brain; Child; Female; Humans; Magnetic Resona | 2018 |
Abnormal brain activation during emotion processing of euthymic bipolar patients taking different mood stabilizers.
Topics: Adult; Amygdala; Bipolar Disorder; Brain; Brain Mapping; Cross-Sectional Studies; Emotions; Facial E | 2019 |
[Prescribing valproate to girls and women of childbearing age in Germany : Analysis of trends based on claims data].
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Drug Prescriptions; Drug Utilization; Ep | 2018 |
Rate of Serum Valproate Concentration Monitoring in Patients with Bipolar Disorder Type I at Srinagarind Hospital Outpatient Clinic.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2016 |
Regulation of Glycogen Content in Astrocytes via Cav-1/PTEN/AKT/GSK-3β Pathway by Three Anti-bipolar Drugs.
Topics: Animals; Animals, Newborn; Antimanic Agents; Astrocytes; Bipolar Disorder; Carbamazepine; Caveolin 1 | 2018 |
Rare cause of manic period trigger in bipolar mood disorder: testosterone replacement.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Chorionic Gonadotropin; Hormone Rep | 2018 |
Serotonin depletion causes valproate-responsive manic-like condition and increased hippocampal neuroplasticity that are reversed by stress.
Topics: Animals; Anticonvulsants; Anxiety; Bipolar Disorder; Brain; Gene Expression Profiling; Hippocampus; | 2018 |
Combine these screening tools to detect bipolar depression.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Humans; Interview, Psychological; Male; Mass Screening; P | 2018 |
Diacylglycerol kinase (DGKA) regulates the effect of the epilepsy and bipolar disorder treatment valproic acid in
Topics: Amino Acid Sequence; Anticonvulsants; Bipolar Disorder; Diacylglycerol Kinase; Dictyostelium; Diglyc | 2018 |
Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test.
Topics: Aggression; Agonistic Behavior; Animals; Anxiety; Bipolar Disorder; Carbamazepine; Cycloheptanes; De | 2019 |
Cortical thickness and subcortical volumes alterations in euthymic bipolar I patients treated with different mood stabilizers.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Cerebral Cortex; Female; Humans; Image Processing, Comput | 2019 |
Severe hair loss associated with psychotropic drugs in psychiatric inpatients-Data from an observational pharmacovigilance program in German-speaking countries.
Topics: Adult; Alopecia; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Austria; Bipolar Dis | 2018 |
[Valproic acid toxicity due to misinterpretation of plasma levels: increase in unbound fraction caused by hypoalbuminaemia and renal dysfunction].
Topics: Aged; Anticonvulsants; Bipolar Disorder; Humans; Hypoalbuminemia; Male; Mobility Limitation; Muscle | 2018 |
Mood stabilisers and risk of stroke in bipolar disorder.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cross-O | 2019 |
Lithium, valproate, and carbamazepine prescribing patterns for long-term treatment of bipolar I and II disorders: A prospective study.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug Prescriptions; Drug Therapy, Combinat | 2018 |
Blood Lithium Monitoring Practices in a Population-Based Sample of Older Adults.
Topics: Aged; Biomarkers; Bipolar Disorder; Calcium; Case-Control Studies; Cohort Studies; Creatinine; Drug | 2018 |
Gene expression effects of lithium and valproic acid in a serotonergic cell line.
Topics: Animals; Bipolar Disorder; Cell Adhesion; Cell Line; Chemotaxis; Extracellular Matrix; Gene Ontology | 2019 |
Reversible taste and smell dysfunction associated with sodium valproate and quetiapine in bipolar depression: a case report.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Male; M | 2019 |
Peripheral Oxidative Stress Markers in Patients with Bipolar Disorder during Euthymia and in Siblings.
Topics: Adult; Antimanic Agents; Biomarkers; Bipolar Disorder; Case-Control Studies; Cross-Sectional Studies | 2020 |
Association between electroencephalogram changes and plasma clozapine levels in clozapine-treated patients.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Clozapine; Drug Monitoring; Electroencephalography; F | 2019 |
A Case of Stevens-Johnson Syndrome After Exposure to Valproic Acid.
Topics: Antipsychotic Agents; Bipolar Disorder; Female; Humans; Stevens-Johnson Syndrome; Valproic Acid | 2019 |
Timing of onset of lithium relapse prevention - how early, how late?
Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Lithium; Secondary Prevention; Valproic Acid | 2019 |
Use of Suvorexant for Sleep Regulation in an Adolescent with Early-Onset Bipolar Disorder.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Azepines; Bipolar Disorder; Humans; Lurasidone Hy | 2019 |
Current status and progress of electroencephalogram study in patients with bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Deep Brain Stimulation; Electroencephalography; Humans; Levetira | 2020 |
Prevalence and clinical presentation of HIV positive female psychiatric inpatients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Cross-Sectional Studie | 2013 |
Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control study.
Topics: Adolescent; Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar | 2013 |
[Acute pancreatitis induced by valproic acid].
Topics: Anticonvulsants; Bipolar Disorder; Cooperative Behavior; Diagnosis, Differential; Drug Substitution; | 2013 |
The valproate serum level in maintenance therapy for bipolar disorder in Japan.
Topics: Adult; Aged; Ambulatory Care; Antimanic Agents; Bipolar Disorder; Chi-Square Distribution; Drug Moni | 2013 |
Valproate prescriptions for nonepilepsy disorders in reproductive-age women.
Topics: Adolescent; Adult; Anticonvulsants; Bipolar Disorder; Congenital Abnormalities; Drug Prescriptions; | 2013 |
Valproate as a risk factor for lamotrigine discontinuation.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Drug Therapy, Combination; Female; | 2013 |
An evaluation of inpatient treatment continuation and hospital readmission rates in patients with bipolar disorder treated with aripiprazole or quetiapine.
Topics: Adolescent; Adult; Age Factors; Aged; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodia | 2013 |
Hyperammonemia induced by interaction of valproate and quetiapine.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Drug Interactio | 2013 |
Monotherapy with lithium or valproate or respectively combination therapy with quetiapine have similar effect on cognitive functions in Chinese euthymic patients with bipolar disorder: a cross-sectional survey.
Topics: Adult; Antimanic Agents; Bipolar Disorder; China; Cognition Disorders; Cross-Sectional Studies; Dibe | 2013 |
Bipolar disorder - from endophenotypes to treatment.
Topics: Acute Disease; Adult; Bipolar Disorder; Depressive Disorder, Major; Endophenotypes; Female; Humans; | 2013 |
Teaching neuroimages: reversible paradoxical lithium neurotoxicity.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Gadolinium; Humans; Lithium; Magnetic Resonance Imaging; | 2013 |
A case report that suggested that aspirin's effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aspirin; Bipolar Disorder; Clozapine; Dose-Response R | 2013 |
Fenproporex increases locomotor activity and alters energy metabolism, and mood stabilizers reverse these changes: a proposal for a new animal model of mania.
Topics: Amphetamines; Animals; Antimanic Agents; Bipolar Disorder; Disease Models, Animal; Dose-Response Rel | 2014 |
SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties.
Topics: Actin-Related Protein 2-3 Complex; Actins; Adult; Animals; Behavior, Animal; Bipolar Disorder; Chrom | 2013 |
Sodium valproate may be a treatment for sleep bruxism.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Follow-Up Studies; GABA Agents; Humans; Male; Sleep | 2013 |
Lurasidone and bipolar disorder.
Topics: Bipolar Disorder; Female; Humans; Isoindoles; Lithium Compounds; Lurasidone Hydrochloride; Male; Thi | 2014 |
Evaluation of reproductive function in women treated for bipolar disorder compared to healthy controls.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Menstruation Disturbances | 2014 |
Lithium use for bipolar disorder post renal transplant: is mood stabilization without toxicity possible?
Topics: Biopsy; Bipolar Disorder; Cyclosporine; Female; Glomerular Filtration Rate; Humans; Kidney Transplan | 2014 |
One-year rehospitalization rates of patients with first-episode bipolar mania receiving lithium or valproate and adjunctive atypical antipsychotics.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Female; | 2014 |
A case of late-onset bipolar disorder with severely abnormal behavior and neuroimaging observations very similar to those of frontotemporal dementia.
Topics: Antimanic Agents; Bipolar Disorder; Frontal Lobe; Frontotemporal Dementia; Humans; Magnetic Resonanc | 2014 |
rTMS in resistant mixed states: an exploratory study.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Female; Humans; Male; Middle Aged; Prefrontal Cortex; Tra | 2014 |
Bipolar disorder in Pendred syndrome: a case report of two siblings.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Goiter, Nodular; Hearing Loss, Sens | 2014 |
Rapid development of severe skin rash after adding valproic acid in a case of bipolar depression treated with low-dose lamotrigine.
Topics: Antimanic Agents; Bipolar Disorder; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Fe | 2014 |
Valproate-related hyperammonemic encephalopathy: report of 1 case.
Topics: Antimanic Agents; Bipolar Disorder; Female; Humans; Hyperammonemia; Neurotoxicity Syndromes; Valproi | 2014 |
Development of acute pancreatitis caused by sodium valproate in a patient with bipolar disorder on hemodialysis for chronic renal failure: a case report.
Topics: Abdominal Pain; Acute Disease; Anticonvulsants; Bipolar Disorder; Humans; Japan; Kidney Failure, Chr | 2014 |
The effectiveness of high-dosage amisulpride combined with moderate-dosage sodium valproate treatment for an overweight patient with psychotic bipolar disorder.
Topics: Amisulpride; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Fe | 2014 |
First manic episode due to discontinuation of valproic acid in a patient with epilepsy.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Administration Schedule; Epilepsy; Female; Humans; Va | 2014 |
Peripheral mononeuropathy associated with valproic acid poisoning in an adult patient.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Drug Overdose; Humans; Male; Mononeuropathies; Neurologic | 2014 |
Increased platelet intracellular calcium ion concentration is specific to bipolar disorder.
Topics: Adult; Antipsychotic Agents; Biomarkers; Bipolar Disorder; Blood Platelets; Calcium; Case-Control St | 2014 |
Hyperammonemia associated with valproic acid concentrations.
Topics: Adolescent; Adult; Ammonia; Bipolar Disorder; Carnitine; Child; Dietary Supplements; Dose-Response R | 2014 |
Secondary mania in a patient with solitary red nucleus lesion.
Topics: Antimanic Agents; Bipolar Disorder; Brain Infarction; Humans; Male; Middle Aged; Red Nucleus; Treatm | 2014 |
International prescribing patterns for mood illness: the International Mood Network (IMN).
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Asia; Bipolar Disorder; Carbamazepine | 2014 |
Clinical outcome of valproate maintenance treatment in bipolar I disorder at Srinagarind Hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Disease-Free Surviva | 2014 |
Effect of valproate on the plasma concentrations of aripiprazole in bipolar patients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Therapy, Combina | 2014 |
Cognitive change in the year after a first manic episode: association between clinical outcome and cognitive performance early in the course of bipolar I disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; British Columbia; Cognition Disorders; Di | 2014 |
Alterations in BDNF (brain derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum levels in bipolar disorder: The role of lithium.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Depression; Enzyme-Lin | 2014 |
DNA methylation and expression of KCNQ3 in bipolar disorder.
Topics: Adult; Aged; Animals; Antimanic Agents; Base Sequence; Bipolar Disorder; Brain; Case-Control Studies | 2015 |
Divalproex sodium and quetiapine treatment of a pedophile with bipolar spectrum disorder.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Humans; Male; P | 2014 |
Are cognitive deficits similar in remitted early bipolar I disorder patients treated with lithium or valproate? Data from the STOP-EM study.
Topics: Antimanic Agents; Bipolar Disorder; Cognition Disorders; Female; Humans; Lithium Compounds; Male; Ne | 2015 |
Long-term treatment of bipolar disorder: the controversial role of antidepressants.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Clomipramine; Humans; Lithium Compounds; Male; Recur | 2014 |
Effects of mood-stabilizing drugs on dendritic outgrowth and synaptic protein levels in primary hippocampal neurons.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Cell Adhesion Molecu | 2015 |
Predominant polarity in bipolar disorder and validation of the polarity index in a German sample.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Bipolar | 2014 |
Histone deacetylase inhibitors reverse manic-like behaviors and protect the rat brain from energetic metabolic alterations induced by ouabain.
Topics: Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Brain; Butyric Acid; Citric Acid Cycl | 2015 |
Sodium butyrate and mood stabilizers block ouabain-induced hyperlocomotion and increase BDNF, NGF and GDNF levels in brain of Wistar rats.
Topics: Affect; Animals; Antimanic Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Butyric Acid | 2015 |
Alcohol withdrawal delirium manifested by manic symptoms in an elderly patient.
Topics: Alcohol Withdrawal Delirium; Alcoholic Intoxication; Bipolar Disorder; Drug Therapy, Combination; He | 2015 |
Gender differences in the treatment of patients with bipolar disorder: a study of 7354 patients.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Pr | 2015 |
Serum uric acid levels and different phases of illness in bipolar I patients treated with lithium.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug Therapy, Combination; Female; Humans; | 2015 |
Mixed myoclonic-absence status epilepticus in juvenile myoclonic epilepsy.
Topics: Anticonvulsants; Bipolar Disorder; Catatonia; Clonazepam; Electroencephalography; Epilepsies, Myoclo | 2015 |
Pulmonary embolism in a psychiatric patient.
Topics: Adult; Aggression; Antipsychotic Agents; Autopsy; Benzodiazepines; Bipolar Disorder; Catatonia; Deat | 2014 |
[Use of valproic acid in long stay units of psychiatry].
Topics: Adult; Aged; Antimanic Agents; Bipolar Disorder; Cross-Sectional Studies; Epilepsy; Female; Humans; | 2015 |
Manic illness associated with right temporo-thalamic arteriovenous malformation: A rare presentation.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Cerebral Angiography; Female; Functional Laterality; | 2015 |
A critical interaction between ertapenem and valproic acid.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Antimanic Agents; beta-Lactams; Bipolar Disorder; Drug Int | 2015 |
Effects of Mood Stabilizers on Brain Energy Metabolism in Mice Submitted to an Animal Model of Mania Induced by Paradoxical Sleep Deprivation.
Topics: Adenosine Triphosphate; Affect; Animals; Antimanic Agents; Bipolar Disorder; Brain Chemistry; Citrat | 2015 |
Analysis of variability of concentrations of valproic acid (VPA) and its selected metabolites in the blood serum of patients treated with VPA and patients hospitalized because of VPA poisoning.
Topics: Anticonvulsants; Bipolar Disorder; Drug Overdose; Epilepsy; Female; Humans; Male; Peripheral Nervous | 2014 |
Decreased right hippocampal volumes and neuroprogression markers in adolescents with bipolar disorder.
Topics: Adolescent; Antidepressive Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Disease Prog | 2015 |
Correlations between amygdala volumes and serum levels of BDNF and NGF as a neurobiological markerin adolescents with bipolar disorder.
Topics: Adolescent; Adult; Amygdala; Biomarkers; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Cross- | 2015 |
Preclinical Evidences for an Antimanic Effect of Carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Antimanic Agents; Bipolar Disorder; Brain; Brain-Derived Neuro | 2015 |
Mice heterozygous for cathepsin D deficiency exhibit mania-related behavior and stress-induced depression.
Topics: Adaptation, Ocular; Animals; Antidepressive Agents; Bipolar Disorder; Cathepsin D; Corticosterone; D | 2015 |
Acute renal and neurotoxicity in older lithium users: How can we manage and prevent these events in patients with late-life mood disorders?
Topics: Acute Kidney Injury; Aged; Bipolar Disorder; Humans; Lithium Compounds; Male; Neurotoxicity Syndrome | 2015 |
Transcriptome sequencing of the anterior cingulate in bipolar disorder: dysregulation of G protein-coupled receptors.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Case-Control Studies; Cell Line; Female; G | 2015 |
Treatment of comorbid bipolar disorder and anxiety disorders: A great challenge to modern psychiatry.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Citalopram; Comorbidity; Humans; Mal | 2016 |
Psychopharmacological treatment of 1650 in-patients with acute mania-data from the AMSP study.
Topics: Acute Disease; Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; | 2016 |
A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate.
Topics: Adult; Antimanic Agents; Biomarkers; Bipolar Disorder; Body Mass Index; Case-Control Studies; Dyslip | 2017 |
Changes in mood stabilizer prescription patterns in bipolar disorder.
Topics: Adult; Aged; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar | 2016 |
Editorial.
Topics: Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Humans; Psych | 2016 |
LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; Lithium Compound | 2016 |
The rapid suicide protection of mood stabilizers on patients with bipolar disorder: A nationwide observational cohort study in Taiwan.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cohort Studies; Female; | 2016 |
Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disor | 2016 |
Targeting astrocytes in bipolar disorder.
Topics: Animals; Antidepressive Agents; Astrocytes; Bipolar Disorder; Carbamazepine; Humans; Valproic Acid | 2016 |
Safety and effectiveness of divalproex sodium extended release containing regimen in Indian patients with bipolar I disorder in continuation phase: Results of EASED registry.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Delayed-Action Preparations; Female; Humans; India; Male; | 2016 |
Valproate-induced hyperammonemic encephalopathy associated with urinary tract infection and urinary retention in the psychiatric setting.
Topics: Antimanic Agents; Bipolar Disorder; Brain Diseases; Humans; Hyperammonemia; Male; Middle Aged; Urina | 2016 |
Should women of childbearing potential be prescribed valproate? a call to action.
Topics: Abnormalities, Drug-Induced; Bipolar Disorder; Contraception Behavior; Epilepsy; Female; Humans; Inf | 2016 |
Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study.
Topics: Adult; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Cohort Studies; Cross-Sectional Studies; | 2016 |
Emerging Hyperkalemia Following Valproic Acid Use in an Elderly Patient With Late-Onset Mania.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Female; Humans; Hyperkalemia; Valproic Acid | 2016 |
Atypical neuroleptic malignant syndrome in a young male precipitated by oral sodium valproate.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Humans; Male; Neuroleptic Malignant Syndrome; Valproic Ac | 2016 |
Effect of valproic acid on dementia onset in patients with bipolar disorder.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Bipolar Disorder; Cohort Studies; Databases, Factua | 2016 |
Omega-3 Fatty Acids and Mood Stabilizers Alter Behavioural and Energy Metabolism Parameters in Animals Subjected to an Animal Model of Mania Induced by Fenproporex.
Topics: Amphetamines; Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Citrate (si)-Synthase; | 2017 |
Lithium and valproate prevent methylphenidate-induced mania-like behaviors in the hole board test.
Topics: Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Central Nervous System Stimulants; Di | 2016 |
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cardiovascular Diseases; Chemical an | 2016 |
A population-based study of the comparative effectiveness of second-generation antipsychotics vs older antimanic agents in bipolar disorder.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cohort Studi | 2016 |
Aripiprazole-related hyponatremia and consequent valproic acid-related hyperammonemia in one patient.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Hyper | 2017 |
Reversible Valproic Acid-Induced Parkinsonism and Cognitive Impairment in an Elderly Patient With Bipolar Disorder I.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Cognition Disorders; Diagnostic and Statistical Manual of | 2016 |
Valproic Acid and Hepatic Steatosis: A Possible Link? About a Case Report.
Topics: Anticonvulsants; Bipolar Disorder; Fatty Liver; Humans; Male; Middle Aged; Valproic Acid | 2016 |
Clinical and treatment-related predictors of cognition in bipolar disorder: focus on visual paired associative learning.
Topics: Adult; Analysis of Variance; Association Learning; Attention; Bipolar Disorder; Cognition Disorders; | 2017 |
Lithium and valproate act on the GSK-3β signaling pathway to reverse manic-like behavior in an animal model of mania induced by ouabain.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Disease Models, Animal; Frontal Lobe; Glycogen Synthase | 2017 |
Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; | 2016 |
[Caution and warning: About valproate and pregnancy].
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Epilepsy; Female; Humans; Pregnancy; Pre | 2016 |
Current psychotropic medication prescribing patterns in late-life bipolar disorder.
Topics: Age of Onset; Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; | 2017 |
Antipsychotic adjunctive therapy to mood stabilizers and 1-year rehospitalization rates in bipolar disorder: A cohort study.
Topics: Adult; Affect; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cohort Studies; Drug Therap | 2016 |
Protection against hormone-mediated mood symptoms.
Topics: Affect; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Lithium; Lurasidone Hydrochloride; M | 2017 |
Inositol Depletion Induced by Acute Treatment of the Bipolar Disorder Drug Valproate Increases Levels of Phytosphingosine.
Topics: Acetyltransferases; Antimanic Agents; Bipolar Disorder; Ceramides; Down-Regulation; Humans; Inositol | 2017 |
Lymphocyte Phospho-Ser-9-GSK-3β/Total GSK-3β Protein Levels Ratio Is Not Affected by Chronic Lithium or Valproate Treatment in Euthymic Patients With Bipolar Disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Female; Glycogen Synthase Kinase 3 beta; Humans; Lithium | 2017 |
Affective Recurrences in Bipolar Disorder After Switching From Lithium to Valproate or Vice Versa: A Series of 57 Cases.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Drug Substitution; Female; Humans; Lithium Compounds; Mal | 2017 |
Treating an Adolescent with Long QT Syndrome for Bipolar Disorder: A Case Presentation.
Topics: Adolescent; Bipolar Disorder; Female; Humans; Long QT Syndrome; Lorazepam; Risperidone; Valproic Aci | 2017 |
Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report.
Topics: Antimanic Agents; Bipolar Disorder; Brain Diseases; Female; Humans; Hyperammonemia; Middle Aged; Val | 2017 |
Pharmacological agents to reduce readmissions in bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Lithium Compounds | 2017 |
Acute treatment of patients with bipolar mixed episodes.
Topics: Algorithms; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Drug Administration Sched | 2008 |
Indications.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Child; Drug Approval; Evidence- | 2008 |
Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Body Weight; Child; Child, Pres | 2008 |
Treatment emergent mania responding to valproate in a Chinese female adolescent population with eating disorders: a case series.
Topics: Adolescent; Anorexia Nervosa; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Bulimia Nervosa; | 2008 |
Unilateral rubral tremor following treatment with risperidone.
Topics: Anticonvulsants; Antipsychotic Agents; Ataxia; Behavior Therapy; Bipolar Disorder; Brain; Carbamazep | 2009 |
Valproate: do formulations matter?
Topics: Antimanic Agents; Bipolar Disorder; Drug Administration Schedule; Humans; Valproic Acid | 2008 |
Revised Korean medication algorithm for bipolar disorder.
Topics: Algorithms; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar D | 2009 |
Oral divalproex sodium loading for adolescent outpatients with acute mania/hypomania: a report of 2 cases.
Topics: Administration, Oral; Adolescent; Ambulatory Care; Antipsychotic Agents; Bipolar Disorder; Female; H | 2008 |
Valproate and babies.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Bipolar Disorder; Cross-Sectional Studies; Dose-Respon | 2008 |
Health-related quality of life in Thai bipolar disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cross-Sectional | 2008 |
The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study.
Topics: Acetaminophen; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Case-Contr | 2008 |
Bipolar drug development: are we getting closer to the real world?
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Therap | 2008 |
Reliability and validity of the Korean version of UKU-SERS-Pat in patients with bipolar disorder.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Anticonvulsants; Antidepressive Agents; Antimanic Ag | 2008 |
Mood stabilizer loading versus titration in acute mania: audit of clinical practice.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Dr | 2008 |
Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a "recovered" status in the systematic treatment enhancement program for bipolar disorder.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antidepressive Agents; Antimanic Agents; Bipol | 2008 |
Yeast bioassay for identification of inositol depleting compounds.
Topics: Anticonvulsants; Antimanic Agents; Biological Assay; Bipolar Disorder; Brain; Carboxylic Acids; Cell | 2009 |
Effects of mood stabilizers on DNA damage in an animal model of mania.
Topics: Amphetamine; Animals; Antimanic Agents; Antioxidants; Bipolar Disorder; Central Nervous System Stimu | 2008 |
Ethylbutyrate, a valproate-like compound, exhibits inositol-depleting effects--a potential mood-stabilizing drug.
Topics: Affect; Bipolar Disorder; Butyrates; Cell Proliferation; Humans; Inositol; Intramolecular Lyases; Sa | 2009 |
Methylphenidate in attention deficit hyperactivity disorder and bipolar disorder.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous Sy | 2008 |
Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.
Topics: Adiponectin; Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Comorb | 2009 |
The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; | 2008 |
Medical and substance use comorbidity in bipolar disorder.
Topics: Adult; Affect; Aging; Antimanic Agents; Bipolar Disorder; Comorbidity; Drug Resistance; Drug Therapy | 2009 |
Valproate, a mood stabilizer, induces WFS1 expression and modulates its interaction with ER stress protein GRP94.
Topics: Animals; Antimanic Agents; Biomarkers; Bipolar Disorder; Cell Line; Endoplasmic Reticulum; Gene Expr | 2009 |
Expression of mitochondrial complex I subunit gene NDUFV2 in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Cell Line, Transformed; Female; | 2009 |
[Catatonic syndrome associated with mixed bipolar disorder: a case report and therapeutic considerations].
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Catatonia; Clonazepam; Female; Humans; Middle A | 2008 |
[Gilles de la Tourette syndrome in a child with bipolar disorder].
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Drug Therapy, Combination; Humans; | 2008 |
Improvement of obsessive-compulsive disorder with divalproex and lamotrigine in two patients with bipolar II disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Female; Humans; Lamotrigine; Male; Obsessive-Compulsive Di | 2009 |
Aripiprazole-induced sialorrhea.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disor | 2009 |
Histone deacetylase inhibitors and candidate gene expression: An in vivo and in vitro approach to studying chromatin remodeling in a clinical population.
Topics: Acetylation; Adult; Bipolar Disorder; Blotting, Western; Cell Culture Techniques; Enzyme Inhibitors; | 2009 |
High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan.
Topics: Adult; Analysis of Variance; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Blood Glucose | 2009 |
Effect of divalproex on brain morphometry, chemistry, and function in youth at high-risk for bipolar disorder: a pilot study.
Topics: Adolescent; Amygdala; Antimanic Agents; Bipolar Disorder; Brain; Brain Chemistry; Child of Impaired | 2009 |
Na+,K+-ATPase activity in an animal model of mania.
Topics: Amphetamine; Analysis of Variance; Animals; Antimanic Agents; Bipolar Disorder; Disease Models, Anim | 2009 |
Schizencephaly associated with bipolar II disorder.
Topics: Bipolar Disorder; Brain; Citalopram; Depression; Diagnosis, Differential; Dibenzothiazepines; Humans | 2009 |
The supra-additive hyperactivity caused by an amphetamine-chlordiazepoxide mixture exhibits an inverted-U dose response: negative implications for the use of a model in screening for mood stabilizers.
Topics: Affect; Amphetamine; Animals; Antimanic Agents; Anxiety; Bipolar Disorder; Chlordiazepoxide; Disease | 2009 |
Refractory restless legs syndrome likely caused by olanzapine.
Topics: Anticonvulsants; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Drug Therapy | 2009 |
Valproate-induced reversible pseudoatrophy of the brain and hyperammonemic encephalopathy in a bipolar patient.
Topics: Atrophy; Bipolar Disorder; Brain; Female; Humans; Hyperammonemia; Middle Aged; Neurotoxicity Syndrom | 2009 |
Differential modulation of intracellular Ca2+ responses in B lymphoblasts by mood stabilizers.
Topics: Adult; Antimanic Agents; B-Lymphocytes; Bipolar Disorder; Calcium; Cell Line, Transformed; Drug Inte | 2010 |
Valproate-related peripheral oedema: a manageable but probably neglected condition.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Edema; Female; Humans; Middle Aged; | 2009 |
Maintenance treatment received by patients with bipolar I and II disorders--a naturalistic prospective study.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipol | 2010 |
Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study.
Topics: Adult; Affect; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cognition Disorders; Female; Fol | 2010 |
Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Chi-Square Distribution; DNA-Binding Proteins; Drosophila | 2009 |
Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Female; Gastroint | 2009 |
Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder.
Topics: Adult; Affect; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar | 2008 |
[Inadequate vasopressin secretion and valproate].
Topics: Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Comorbidity; Humans; Hyponatremia; Inappropri | 2009 |
Pedal edema associated with addition of low-dose quetiapine to valproate treatment in bipolar disorder.
Topics: Aged; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Edema; Female; F | 2009 |
An initial report of a new biological marker for bipolar disorder: P85 evoked brain potential.
Topics: Acoustic Stimulation; Adult; Antimanic Agents; Biomarkers; Bipolar Disorder; Electroencephalography; | 2009 |
Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis.
Topics: Affect; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cost-Benefit Analysis; Dibenzothiaz | 2009 |
Divalproex is not effective for children with bipolar disorder.
Topics: Adolescent; Anticonvulsants; Bipolar Disorder; Child; Humans; Treatment Outcome; Valproic Acid | 2009 |
PtdIns(3,4,5)P(3) and inositol depletion as a cellular target of mood stabilizers.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Carbamazepine; Chemotaxis; Humans; Inositol; Lithium Co | 2009 |
Valproic acid- and lithium-sensitivity in prs mutants of Saccharomyces cerevisiae.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Humans; Intracellular Signaling Peptides and Pr | 2009 |
Combination treatment with quetiapine in bipolar disorder patients.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Drug Therapy, Combinat | 2009 |
Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.
Topics: Adult; Aging; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzo | 2009 |
Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Bod | 2010 |
Rhabdomyolysis associated with mania in late life.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Humans; Male; Rhabdomyolysis; Treatment Outcome; Valproic | 2009 |
Divalproex extended-release in acute bipolar II depression.
Topics: Acute Disease; Adult; Anticonvulsants; Bipolar Disorder; Delayed-Action Preparations; Dose-Response | 2010 |
Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain.
Topics: Amygdala; Analysis of Variance; Animals; Antimanic Agents; Bipolar Disorder; Brain-Derived Neurotrop | 2010 |
The role of divalproex plus olanzapine in outpatient mixed-episode bipolar I disorder.
Topics: Ambulatory Care; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug The | 2009 |
The role of valproate in metabolic disturbances in bipolar disorder patients.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Blood Glucose; Body Mass Index; Cholesterol, HDL; Choleste | 2010 |
A new BALANCE in bipolar I disorder.
Topics: Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithium Compounds; Randomized | 2010 |
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; C | 2010 |
[Valproate induced hypoactive delirium in a bipolar disorder patient with psychotic features].
Topics: Antimanic Agents; Bipolar Disorder; Blood Chemical Analysis; Delirium; Female; Humans; Middle Aged; | 2010 |
[Inappropriate antidiuretic hormone secretion induced by sodium valproate].
Topics: Antimanic Agents; Bipolar Disorder; Humans; Inappropriate ADH Syndrome; Male; Middle Aged; Valproic | 2010 |
Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year "open" follow-up study.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Comorbidity; Female; Humans; Longi | 2010 |
Quetiapine as add-on treatment for bipolar I disorder with comorbid compulsive buying and physical exercise addiction.
Topics: Antipsychotic Agents; Bipolar Disorder; Compulsive Behavior; Dibenzothiazepines; Drug Therapy, Combi | 2010 |
Galactorrhea - side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Ther | 2010 |
Infection or idiosyncratic reaction to antiepileptic drugs?
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Clozapine; Diagnosis, Differential; | 2010 |
Bipolar affective disorder presenting as failure of parenting.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Child; Female; Humans; Male; Parent-Child Relations; | 2010 |
Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Comorbidity; Diagnostic and Statisti | 2010 |
Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Brain; Corpus Striatum; Dextroamphetamine; Disease Mode | 2010 |
Pharmacological response in juvenile bipolar disorder subtypes: A naturalistic retrospective examination.
Topics: Adolescent; Age Factors; Antimanic Agents; Bipolar Disorder; Child; Drug Therapy, Combination; Femal | 2010 |
Disturbance in long distance gamma coherence in bipolar disorder.
Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Cerebral Cortex; Electroencephalogr | 2010 |
The BALANCE trial.
Topics: Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithium Carbonate; Valproic A | 2010 |
The BALANCE trial.
Topics: Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithium Carbonate; Valproic A | 2010 |
Use of valproate in women of childbearing potential: pre- and post-NICE bipolar guidelines.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Contraindications; Female; Guideline Adherenc | 2010 |
Can we prevent fatal liver failure under valproate?
Topics: Anticonvulsants; Bipolar Disorder; Fatal Outcome; Female; Humans; Liver; Liver Failure, Acute; Liver | 2010 |
Preventing relapse in bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithium Compounds; Secondary | 2010 |
Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.
Topics: Absenteeism; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder | 2010 |
Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania.
Topics: Analysis of Variance; Animals; Antimanic Agents; Bipolar Disorder; Brain; Catalase; Disease Models, | 2011 |
Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome.
Topics: Adult; Bipolar Disorder; Body Mass Index; Comorbidity; Endocrine System Diseases; Female; Humans; Li | 2010 |
Efficacy of olanzapine and sodium valproate given alone or as add-on therapy in acute mania. A comparative study.
Topics: Acute Disease; Adult; Aged; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combination; Female; Hu | 2010 |
Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied.
Topics: Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamazepine; Dose-Respon | 2010 |
Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness.
Topics: Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Bipolar Disorder; Carbamazepine; Cotinine; Cy | 2010 |
C825T polymorphism of the GNB3 gene on valproate-related metabolic abnormalities in bipolar disorder patients.
Topics: Adult; Alleles; Bipolar Disorder; Body Mass Index; Female; Genetic Carrier Screening; Heterotrimeric | 2010 |
Child Mania Rating Scale-Parent Version: a valid measure of symptom change due to pharmacotherapy.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Diagnosis, Differential; Dopamine Antagonists | 2011 |
Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder.
Topics: Adult; Ambulatory Care; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Antimanic Agent | 2010 |
Bipolar disorder and valproate-induced hyperammonemic encephalopathy in an adolescent with diabetes.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Diabetes Mellitus, Type 1; Humans; Hyperammonemia; M | 2010 |
Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dr | 2011 |
Lithium neurotoxicity at normal serum levels.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Lithium Chloride; Male; Middle Aged; Neurotoxicity Syndr | 2010 |
Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity.
Topics: Adolescent; Adult; Amino Acid Substitution; Bipolar Disorder; Child; Child, Preschool; Diffuse Cereb | 2010 |
Commentary: the Bipolar Affective Disorder: Lithium/Anticonvulsant Evaluation (BALANCE) study.
Topics: Anticonvulsants; Bipolar Disorder; Humans; Lithium Chloride; Randomized Controlled Trials as Topic; | 2010 |
A much needed BALANCE.
Topics: Anticonvulsants; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithium Chloride; Valproic Aci | 2010 |
Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Brain Mappin | 2011 |
Valproate uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: relevance to valproate's efficacy against bipolar disorder.
Topics: Acylation; Animals; Anticonvulsants; Arachidonic Acid; Arachidonic Acids; Bipolar Disorder; Brain; C | 2011 |
Valproate prescription prevalence among women of childbearing age.
Topics: Adolescent; Adult; Age Factors; Antimanic Agents; Bipolar Disorder; Female; Humans; Male; Middle Age | 2011 |
Valproate-induced encephalopathy related to concurrent antimanic medications.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Drug Interactions; Encephalitis; Female; Humans; Valproic | 2011 |
Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling.
Topics: Animals; Apoptosis; Bipolar Disorder; Humans; Intercellular Signaling Peptides and Proteins; Lithium | 2012 |
Magnesium sulfate and sodium valproate block methylphenidate-induced hyperlocomotion, an animal model of mania.
Topics: Animals; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Central Nervous System Stimulants; Dis | 2011 |
Bipolar disorder presenting as stalking--a case report.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cognitive Behavioral Therapy; Combined Modality | 2011 |
Adherence to guidelines by French psychiatrists in their real world of clinical practice.
Topics: Adult; Age Factors; Aged; Antimanic Agents; Bipolar Disorder; Female; France; Guideline Adherence; H | 2011 |
Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Cognition Disorders; Cytochrome P-450 CYP3A; Dibenzothiaze | 2011 |
Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study.
Topics: Adult; Aged; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Denmark; Drug Substitution; E | 2011 |
Detrimental effects of divalproex on warfarin therapy following mechanical valve replacement.
Topics: Adult; Anticoagulants; Antimanic Agents; Bipolar Disorder; Drug Interactions; Drug Therapy, Combinat | 2011 |
Pharmacological treatment of deep brain stimulation-induced hypomania leads to clinical remission while preserving motor benefits.
Topics: Antimanic Agents; Bipolar Disorder; Clozapine; Deep Brain Stimulation; Humans; Male; Middle Aged; Pa | 2012 |
Successful reintroduction of valproic acid after the occurrence of pancytopenia.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Drug Administration Schedule; Drug Monitoring; Humans; Mal | 2011 |
Observational BALANCE.
Topics: Antimanic Agents; Bipolar Disorder; Female; Humans; Lithium Compounds; Male; Outcome Assessment, Hea | 2011 |
Hard outcomes: clinical trials to reduce suicide.
Topics: Antimanic Agents; Bipolar Disorder; Female; Humans; Lithium; Male; Suicide Prevention; Suicide, Atte | 2011 |
Predictors of relapse or recurrence in bipolar I disorder.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Top | 2012 |
Effectiveness of valproate for the treatment of manic-like behavior in X-linked adrenoleukodystrophy.
Topics: Adrenoleukodystrophy; Antimanic Agents; Bipolar Disorder; Humans; Male; Valproic Acid; Young Adult | 2012 |
Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; | 2011 |
Genome-wide association study meta-analysis of European and Asian-ancestry samples identifies three novel loci associated with bipolar disorder.
Topics: Ankyrins; Antidepressive Agents; Asian People; Bipolar Disorder; Cell Line, Transformed; Cytokines; | 2013 |
A rare occurrence of isolated neutropenia with valproic acid: a case report.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Female; Humans; Neutropenia; Valproic Acid | 2011 |
Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Female; Humans; Lamotrigine; Lithium Compou | 2012 |
Valproic Acid-related anticonvulsant hypersensitivity syndrome and subsequent olanzapine-related neutropenia and thrombocytopenia: a case report.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; C | 2012 |
Ammonemia in bipolar patients on maintenance treatment with valproic acid.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Female; Humans; Hyperammonemia; Male; Mood Diso | 2012 |
Early life stress exacerbates cognitive dysfunction induced by d-amphetamine: amelioration by valproic acid.
Topics: Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Body Weight; Central Nervous System S | 2012 |
Serum protein levels of brain-derived neurotrophic factor and tropomyosin-related kinase B in bipolar disorder: effects of mood stabilizers.
Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; | 2012 |
Additional effect size measures helpful in understanding lithium and valproate trial results.
Topics: Antimanic Agents; Bipolar Disorder; Female; Humans; Lithium; Male; Suicide Prevention; Suicide, Atte | 2012 |
Differential lithium efficacy in reducing suicidal behaviors compared with suicidal thoughts.
Topics: Antimanic Agents; Bipolar Disorder; Female; Humans; Lithium; Male; Suicide Prevention; Suicide, Atte | 2012 |
This is your brain. This is your brain on treatment. Any questions?
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Corpus Striatum; Female; Frontal Lobe; Huma | 2012 |
Anti-NMDA receptor encephalitis with the initial presentation of psychotic mania.
Topics: Adolescent; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antimanic Agents; Bipolar Disorder; Ele | 2012 |
Effects of lithium and valproate on oxidative stress and behavioral changes induced by administration of m-AMPH.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Brain; Disease Models, Animal; Dose-Response Relationsh | 2012 |
Amygdala functional connectivity predicts pharmacotherapy outcome in pediatric bipolar disorder.
Topics: Adolescent; Age Factors; Amygdala; Bipolar Disorder; Child; Female; Humans; Lamotrigine; Male; Nerve | 2011 |
Sulpiride-associated torsade de pointes in a woman with bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Electrocardiogr | 2012 |
Levocarnitine-induced hypophosphatemia in a hemodialysis patient with acute valproic acid toxicity.
Topics: Adolescent; Anticonvulsants; Bipolar Disorder; Carnitine; Drug-Related Side Effects and Adverse Reac | 2012 |
Valproate in acute mania: is our practice evidence based?
Topics: Acute Disease; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Chemistry, Pharmaceu | 2012 |
Mortality risk with the use of atypical antipsychotics in later-life bipolar disorder.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diben | 2012 |
Three medication pathways for bipolar disorder.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Interactions; Hu | 2012 |
Neutropenia associated with the comedication of quetiapine and valproate in 2 elderly patients.
Topics: Aged, 80 and over; Antimanic Agents; Antipsychotic Agents; Asian People; Bipolar Disorder; Dementia, | 2012 |
A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone.
Topics: Adult; Anti-Anxiety Agents; Antimanic Agents; Antipsychotic Agents; Anxiety Disorders; Bipolar Disor | 2012 |
Carbamazepine treatment of bipolar disorder: a retrospective evaluation of naturalistic long-term outcomes.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamazepine; Fem | 2012 |
A functional magnetic resonance imaging study of risperidone and divalproex.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Corpus Striatum; Female; Frontal Lobe; Huma | 2012 |
Glutamatergic effects of divalproex in adolescents with mania: a proton magnetic resonance spectroscopy study.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Cerebral Cortex; Female; Glutamic Acid; Humans; Magn | 2012 |
Atypical presentation of tardive dyskinesia associated with risperidone long-acting injection as maintenance treatment in bipolar affective disorder: a case report.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Delayed-Action Preparations; Drug Therapy, | 2012 |
What works for delirious catatonic mania?
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Catatonia; Combined Modality Therapy; Deli | 2010 |
Coexistence and independence between a mental disorder and female stalking.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Commitment of Mentally Ill; Dibenzo | 2013 |
Abnormal semen parameters in bipolar men treated with valproate.
Topics: Anticonvulsants; Bipolar Disorder; Humans; Infertility, Male; Male; Semen; Valproic Acid | 2012 |
Suicide attempts in veterans with bipolar disorder during treatment with lithium, divalproex, and atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Lithium Compounds; Male; Middle Aged; | 2013 |
What we can all learn from the Treatment of Early Age Mania (TEAM) trial.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Lithium C | 2012 |
[Unipolar mania: a distinct entity or characteristic of manic preponderance?].
Topics: Anticonvulsants; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Humans; Li | 2012 |
Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
Topics: Adult; Alcoholism; Antidepressive Agents; Bipolar Disorder; Cross-Over Studies; Double-Blind Method; | 2012 |
Evaluation of behavioral and neurochemical changes induced by ketamine in rats: implications as an animal model of mania.
Topics: Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Disease Models, Animal; Drug Interact | 2012 |
Lithium and valproate modulate energy metabolism in an animal model of mania induced by methamphetamine.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Brain; Citric Acid Cycle; Creatine Kinase; Disease Mode | 2013 |
The prevalence of metabolic syndrome in drug-naïve bipolar II disorder patients before and after twelve week pharmacological intervention.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Body Mass Index; Diagnostic and Statistical Manual of Men | 2013 |
Serum levels of sodium valproate in patients suffering from bipolar disorders: comparing acute and maintenance phases of mania.
Topics: Adult; Bipolar Disorder; Depression; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Sc | 2013 |
Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice.
Topics: Analysis of Variance; Animals; Antimanic Agents; Bipolar Disorder; Disease Models, Animal; Dopamine | 2013 |
Methodologies to avoid the enrollment of ineligible patients in clinical trials.
Topics: Antimanic Agents; Bipolar Disorder; Female; Humans; Lithium Carbonate; Male; Patient Selection; Pipe | 2012 |
Valproate-associated reproductive hormone abnormalities: do bipolar men have the same risk as epileptic men?
Topics: Adolescent; Adult; Animals; Anticonvulsants; Bipolar Disorder; Disease Models, Animal; Endocrine Sys | 2012 |
Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Australia; B | 2012 |
Evaluation of acetylcholinesterase in an animal model of mania induced by D-amphetamine.
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Antimanic Agents; Bipolar Disorder; Brain; Cent | 2013 |
Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: a potential drug for bipolar disorder.
Topics: Acylation; Animals; Antimanic Agents; Arachidonic Acid; Bipolar Disorder; Coenzyme A Ligases; Molecu | 2013 |
Neural correlates of treatment response in depressed bipolar adolescents during emotion processing.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Diso | 2013 |
Another look at the Treatment of Early-Age Mania (TEAM) trial.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Lithium C | 2013 |
Dr. Vitiello et al. reply.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Lithium C | 2013 |
New trial should clarify lithium use in bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithium Compounds; Valproic A | 2002 |
Treatment of bipolar disorder in older adults.
Topics: Aged; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; | 2002 |
Charcoal enhancement of treatment for tricyclic-induced mania.
Topics: Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Antidotes; Bipolar Disorder; Charcoal; Depres | 2002 |
Low glial numbers in the amygdala in major depressive disorder.
Topics: Amygdala; Anticonvulsants; Bipolar Disorder; Cell Count; Cell Size; Depressive Disorder, Major; Ento | 2002 |
PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania.
Topics: Adolescent; Adult; Anticonvulsants; Bipolar Disorder; Brain; Cerebellum; Corpus Striatum; Female; Hu | 2002 |
Sibutramine-induced mania episode in a bipolar patient.
Topics: Adolescent; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cyclobutanes; Humans; Male; V | 2002 |
Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization.
Topics: Adolescent; Aged; Antimanic Agents; Biological Availability; Bipolar Disorder; Carbamazepine; Drug T | 2002 |
Lamotrigine use in geriatric patients with bipolar depression.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Dose-Response Rela | 2002 |
Can we conduct some large simple trials in bipolar disorder?
Topics: Anticonvulsants; Bipolar Disorder; Humans; Lithium; Randomized Controlled Trials as Topic; Research | 2002 |
Expression of G-proteins and regulators of G-protein signalling in neutrophils of patients with bipolar disorder: effects of mood stabilizers.
Topics: Antimanic Agents; Bipolar Disorder; Case-Control Studies; GTP-Binding Protein alpha Subunits, Gs; He | 2002 |
Valproate-associated reproductive and metabolic abnormalities: are epileptic women at greater risk than bipolar women?
Topics: Adult; Antimanic Agents; Bipolar Disorder; Cross-Sectional Studies; Endocrine System; Epilepsy; Fema | 2003 |
Re: "Cades disease" and beyond.
Topics: Antidepressive Agents; Bipolar Disorder; Female; Hospitalization; Humans; Middle Aged; Valproic Acid | 2003 |
Attenuation of N-methyl-D-aspartate-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cell Survival; Cells, Cultured; Cytoplas | 2003 |
Enhancing treatment of bipolar disorder using the patient's belief system.
Topics: Adult; Bipolar Disorder; Health Knowledge, Attitudes, Practice; Humans; Lithium Carbonate; Male; Pat | 2003 |
Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Dementia; Humans; Lithium Carbonate; Practice Patterns, Ph | 2003 |
Electroencephalogram changes and its improvement with sodium valproate in a patient with electrocution-induced chronic mania.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Electric Injuries; Electroencephalography; Humans; Male; | 2003 |
Gabapentin in geriatric mania.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cycl | 2003 |
Two case studies of hypothermia induced by an increased dosage of zotepine in a combination therapy.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Diazepam; Diben | 2003 |
Levetiracetam in the treatment of rapid cycling bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Female; Humans | 2003 |
Ammonia induced encephalopathy from valproic acid in a bipolar patient: case report.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Coma; Diagnosis, Dual (Psychiatry); Electroencephalograph | 2003 |
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation.
Topics: Affect; Aminoacetonitrile; Animals; Antidepressive Agents; Antimanic Agents; Behavior, Animal; Bipol | 2003 |
Older patients are eligible for trial of lithium and valproate.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Humans; Lithium Carbonate; Valpr | 2003 |
Adjunctive quetiapine in bipolar patients partially responsive to lithium or valproate.
Topics: Adult; Aged; Bipolar Disorder; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Lithiu | 2003 |
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepi | 2003 |
Mood stabilizers in hospitalized children with bipolar disorder: a retrospective review.
Topics: Analysis of Variance; Anticonvulsants; Bipolar Disorder; Carbamazepine; Child; Child, Hospitalized; | 2003 |
Suicide risk in bipolar disorder during treatment with lithium and divalproex.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Female; Humans; Lithium Compou | 2003 |
Somnambulism due to probable interaction of valproic acid and zolpidem.
Topics: Bipolar Disorder; Citalopram; Depression; Drug Interactions; Drug Therapy, Combination; Humans; Male | 2003 |
Thrombocytopenia during valproic acid treatment in young patients with new-onset bipolar disorder.
Topics: Adult; Bipolar Disorder; Female; Humans; Male; Normal Distribution; Platelet Count; Prospective Stud | 2003 |
Yellow nail pigmentation following Depakote therapy.
Topics: Antimanic Agents; Bipolar Disorder; Female; Humans; Middle Aged; Nail Diseases; Pigmentation Disorde | 2003 |
Evidence-based mental health use of anticonvulsants during pregnancy.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Clinical Trials as Topic; Evidence-Based Medicine; Female; | 2003 |
[Fast control of manic or mixed episodes. Atypical neuroleptics for bipolar patients].
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical T | 2003 |
[Long-term therapy with intuition].
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical T | 2003 |
Oxcarbazepine vs. valproate in the treatment of mood and schizoaffective disorders.
Topics: Adult; Akathisia, Drug-Induced; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brief Psychiatr | 2003 |
Mood-stabilizers: the archeology of the concept.
Topics: Affect; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Concept Formation; Forec | 2003 |
"Mood-stabilizers: the archeology of the concept"--by M Harris, S Chandran, N Chakraborty and D Healy: a commentary.
Topics: Affect; Antimanic Agents; Bipolar Disorder; Carbamazepine; Concept Formation; Forecasting; History, | 2003 |
Divalproex versus olanzapine in mania.
Topics: Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bias; Bipolar Disorder; Clinical Trials as T | 2003 |
Exacerbation of mania secondary to right temporal lobe astrocytoma in a bipolar patient previously stabilized on valproate.
Topics: Anticonvulsants; Antimanic Agents; Astrocytoma; Bipolar Disorder; Brain Neoplasms; Disease Progressi | 2003 |
Modafinil treatment of excessive sedation associated with divalproex sodium.
Topics: Adult; Antimanic Agents; Benzhydryl Compounds; Bipolar Disorder; Central Nervous System Stimulants; | 2004 |
Clinical case presentation: therapeutic challenges in adolescent-onset bipolar disorder.
Topics: Adolescent; Aggression; Anti-Anxiety Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorde | 2003 |
Lithium the lifesaver.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Lithium; Suicide; Suicide Prevention; Valproic Acid | 2004 |
Pharmacotherapy and risk of suicidal behaviors among patients with bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Confounding Factors, Epidemiologic; Humans; Lithium Compounds; R | 2004 |
Pharmacotherapy and risk of suicidal behaviors among patients with bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithiu | 2004 |
Valproic Acid and hypersensitivity syndrome.
Topics: Anticonvulsants; Bipolar Disorder; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combination; | 2004 |
Risperidone plus lithium versus risperidone plus valproate in acute and continuation treatment of mania.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Com | 2004 |
Mood stabilizers: protecting the mood...protecting the brain.
Topics: Affect; Anticonvulsants; Apoptosis; Bipolar Disorder; Brain; Cyclic AMP; Humans; Lithium Carbonate; | 2004 |
Olanzapine: new indication. New indication in acute mania: just another neuroleptic.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cost-Benefit Analysis; France; Haloperidol; | 2004 |
Case of bipolar disorder successfully stabilized with clonazepam, valproate and lithium after numerous relapses for 47 years.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Clonazepam; Drug Resistance; Drug Therapy, Combination; Fe | 2004 |
Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Bipolar Disorder; Brain; Cells, Cultured | 2004 |
Key developments in psychiatry.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cognitive Behavioral Therapy; Dementia; Hu | 2004 |
Olanzapine for injection: new formulation. No advantage in agitated patients.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cost-Benefit Analysis; France; Haloperidol; | 2004 |
Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels.
Topics: Affect; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Therapy, Combin | 2004 |
Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach.
Topics: Animals; Antimanic Agents; Bayes Theorem; Bipolar Disorder; Brain; Central Nervous System Stimulants | 2004 |
Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania.
Topics: Adolescent; Adult; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; | 2004 |
Successful treatment of sexual dysfunction with dronabinol: a case report.
Topics: Adult; Benzodiazepines; Bipolar Disorder; Dronabinol; Female; Humans; Libido; Olanzapine; Paroxetine | 2004 |
Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures.
Topics: Adult; Aged; Bipolar Disorder; Enzyme Inhibitors; Female; Gene Expression; Humans; Male; Middle Aged | 2004 |
Intravenous valproate in acute adolescent mania: a preliminary report.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Humans; Injections, Intravenous; Male; Valproic | 2004 |
Lamotrigine therapy in treatment-resistant menstrually-related rapid cycling bipolar disorder: a case report.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Chronobiology Phenomena; Cyclohexanols; Drug Resistance; | 2004 |
Cytokine production in bipolar affective disorder patients under lithium treatment.
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cytokines; Down-Regulatio | 2004 |
Antidepressant-associated mania with escitalopram.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Citalopram; Depressive Disorder; Humans; Male; Selective S | 2004 |
A mood stabilizer with risperidone or haloperidol for mania.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combinat | 2004 |
A mood stabilizer with risperidone or haloperidol for mania.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combinat | 2004 |
Predictors of response to treatment of acute bipolar manic episodes with divalproex sodium or placebo in 2 randomized, controlled, parallel-group trials.
Topics: Adult; Bipolar Disorder; Chi-Square Distribution; Female; Humans; Linear Models; Male; Middle Aged; | 2004 |
[Study on the mechanism to maintain calcium mobilization in platelets of patients with bipolar affective disorders--the relationship with the protein kinase C system].
Topics: Adult; Bipolar Disorder; Blood Platelets; Calcium; Calcium Chloride; Female; Humans; Lactones; Male; | 2004 |
The diagnosis of preschool bipolar disorder presenting with mania: open pharmacological treatment.
Topics: Affect; Age of Onset; Antimanic Agents; Bipolar Disorder; Child, Preschool; Diagnosis, Differential; | 2004 |
Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting.
Topics: Antimanic Agents; Bipolar Disorder; Brain Diseases; Confusion; Female; Humans; Hyperammonemia; Middl | 2005 |
Acute pancreatitis and diabetic ketoacidosis in non-diabetic person while on treatment with sodium valproate, chlorpromazine and haloperidol.
Topics: Acute Disease; Adult; Antimanic Agents; Bipolar Disorder; Chlorpromazine; Diabetic Ketoacidosis; Dia | 2004 |
Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Bipolar Disorder; Carbamazepine; Central Nervous Syst | 2005 |
Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure.
Topics: Animals; Bipolar Disorder; Cell Line; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glycogen Synt | 2005 |
Molecular studies probe bipolar disorder.
Topics: Animals; Benzothiazoles; Bipolar Disorder; Carrier Proteins; Central Nervous System Agents; DNA-Bind | 2005 |
Co-existence of lycanthropy and Cotard's syndrome in a single case.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Combined Modality Therapy; Diagnostic and Statistical | 2005 |
Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Carbamazepine; De | 2005 |
Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus type 1 in a patient treated with valproate and lithium.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ke | 2005 |
Improvement in tardive dyskinesia with aripiprazole use.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Interactions; Drug Therapy, Combination; | 2005 |
New thyroxine treatment in older adults beginning lithium therapy: implications for clinical practice.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Cohort Studies; Dr | 2005 |
Drug treatments for bipolar disorder: 1--Acute manic or depressive episodes.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disor | 2005 |
NICE recommendations for valproate treatment are unhelpful.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Practice Guidelines as Topic; Valproic Acid | 2005 |
Anticonvulsant hypersensitivity syndrome from addition of lamotrigine to divalproex.
Topics: Anticonvulsants; Bipolar Disorder; Drug Hypersensitivity; Drug Therapy, Combination; Exanthema; Fema | 2005 |
Reproductive function and risk for PCOS in women treated for bipolar disorder.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Endocrine System Diseases; Female; Humans; Me | 2005 |
A psychotic episode associated with the Atkins diet in a patient with bipolar disorder.
Topics: Antimanic Agents; Anxiety; Bipolar Disorder; Confusion; Diet Fads; Humans; Ketosis; Male; Middle Age | 2005 |
How can the mood stabilizer VPA limit both mania and depression?
Topics: Animals; Animals, Newborn; Antimanic Agents; Bipolar Disorder; Brain; Brain Chemistry; Cells, Cultur | 2005 |
Potential risks associated with high-dose valproate in pregnancy in psychiatric patients.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, D | 2005 |
Neuroleptic malignant syndrome due to three atypical antipsychotics in a child.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Temperature; Child; Dibenz | 2005 |
Lamotrigine add-on to valproate therapy for paediatric bipolar affective disorder.
Topics: Antimanic Agents; Bipolar Disorder; Child; Drug Therapy, Combination; Humans; Lamotrigine; Male; Tri | 2005 |
Outcome measurement, outcome management and monitoring.
Topics: Anticonvulsants; Antipsychotic Agents; Australia; Benzodiazepines; Bipolar Disorder; Carbamazepine; | 2005 |
Cingulate cortex anatomical abnormalities in children and adolescents with bipolar disorder.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Atrophy; Bipolar Disorder; Brain; Brain Mapping; Ch | 2005 |
Interactive case conference. First episode: depression and panic disorder.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Citalopram; Clonazepam; Depression; | 2005 |
Bipolar depression.
Topics: Antipsychotic Agents; Bipolar Disorder; Combined Modality Therapy; Female; Humans; Lithium Carbonate | 2005 |
Impulsive aggression with irritability and responsive to divalproex: a pediatric bipolar spectrum disorder phenotype?
Topics: Adolescent; Aggression; Antimanic Agents; Bipolar Disorder; Child; Female; Humans; Impulsive Behavio | 2005 |
Longitudinal evaluation of reproductive function in women treated for bipolar disorder.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cross-Sectional Studies | 2005 |
Intravenous valproate use in bipolar II disorder after gastric bypass surgery.
Topics: Adult; Bipolar Disorder; Enzyme Inhibitors; Female; Gastric Bypass; Humans; Injections, Intravenous; | 2005 |
A positron emission tomography study of the effects of treatment with valproate on brain 5-HT2A receptors in acute mania.
Topics: Acute Disease; Adult; Antimanic Agents; Bipolar Disorder; Brain; Contrast Media; Female; Humans; Lit | 2005 |
Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Lamotrigine; St | 2006 |
Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Female; Follow- | 2005 |
Efficiency of the Genius batch hemodialysis system with low serum solute concentrations: the case of lithium intoxication therapy.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Diffusion; Equipment Design; Equipment Failure; Female; H | 2005 |
Conclusions inconsistent with results with amphetamines and divalproex.
Topics: Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Cent | 2005 |
Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Community Mental Hea | 2005 |
Suicidal ideation and pharmacotherapy among STEP-BD patients.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Di | 2005 |
Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder.
Topics: Acyl Coenzyme A; Animals; Antimanic Agents; Arachidonic Acid; Bipolar Disorder; Brain; Coenzyme A Li | 2006 |
Adjunctive topiramate in ultradian cycling bipolar disorder: case report with 3-year follow-up.
Topics: Activity Cycles; Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benztropine; Bipola | 2006 |
Possible interaction between lopinavir/ritonavir and valproic Acid exacerbates bipolar disorder.
Topics: Adult; Antiretroviral Therapy, Highly Active; Bipolar Disorder; Dose-Response Relationship, Drug; Dr | 2006 |
Macrocytosis associated with divalproex treatment.
Topics: Anemia, Macrocytic; Anticonvulsants; Bipolar Disorder; Child; Dose-Response Relationship, Drug; Eryt | 2005 |
Adjunctive lamotrigine as a possible mania inducer in bipolar patients.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Drug Thera | 2006 |
Sodium-myo-inositol co-transporter (SMIT-1) mRNA is increased in neutrophils of patients with bipolar 1 disorder and down-regulated under treatment with mood stabilizers.
Topics: Adult; Aged; Antimanic Agents; Bipolar Disorder; Case-Control Studies; Down-Regulation; Female; Heat | 2007 |
Epigastric pain.
Topics: Abdominal Pain; Adult; Antimanic Agents; Bipolar Disorder; Diagnosis, Differential; Female; Gastriti | 2006 |
What is bipolar disorder?
Topics: Bipolar Disorder; Disease Susceptibility; Frontal Lobe; Humans; Lithium; Recurrence; Regional Blood | 2006 |
Risk and resilience markers in bipolar disorder: brain responses to emotional challenge in bipolar patients and their healthy siblings.
Topics: Adult; Biomarkers; Bipolar Disorder; Brain; Cohort Studies; Depressive Disorder; Emotions; Female; F | 2006 |
Neurocognitive function in unmedicated manic and medicated euthymic pediatric bipolar patients.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bi | 2006 |
Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania.
Topics: Affect; Amphetamine; Animals; Antimanic Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; | 2006 |
Screening for bipolar disorder in women with polycystic ovary syndrome: a pilot study.
Topics: Adolescent; Adult; Anticonvulsants; Bipolar Disorder; Epilepsy; Female; Humans; Mass Screening; Midd | 2006 |
[Transient central diabetes insipidus during a valproic acid poisoning].
Topics: Adult; Bipolar Disorder; Coma; Diabetes Insipidus; Fluid Therapy; Humans; Intubation, Intratracheal; | 2006 |
[Ergenyl chronospheres in bipolar disorders].
Topics: Antimanic Agents; Bipolar Disorder; Chronotherapy; Controlled Clinical Trials as Topic; Delayed-Acti | 2005 |
Use of intravenous valproate in a patient with neuroleptic malignant syndrome.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Creatine Kinase; Diagnosis, Differen | 2006 |
Safety and tolerability of mood-stabilising anticonvulsants in the elderly.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug In | 2006 |
Sustained attention deficits in manic and euthymic patients with bipolar disorder.
Topics: Adult; Anticonvulsants; Antimanic Agents; Arousal; Attention Deficit Disorder with Hyperactivity; Bi | 2006 |
A retrospective analysis of changing from alternative agents to carbamazepine extended-release capsules in bipolar disorder.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Capsul | 2006 |
Preliminary study of relationships among measures of depressive symptoms in adolescents with bipolar disorder.
Topics: Adolescent; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clinica | 2006 |
Hypomania as an aura in migraine.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Electroencephalography; Humans; Male; Migraine with Aura; | 2006 |
Reduced valproate plasma levels possible after introduction of efavirenz in a bipolar patient.
Topics: Adult; Alkynes; Anti-HIV Agents; Anticonvulsants; Benzoxazines; Bipolar Disorder; Cyclopropanes; Dos | 2006 |
A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder.
Topics: Adolescent; Adult; Aggression; Antidepressive Agents; Bipolar Disorder; Carbamazepine; Child; Drug A | 2006 |
Lithium increases nerve growth factor levels in the rat hippocampus in an animal model of mania.
Topics: Amphetamine; Animals; Antimanic Agents; Bipolar Disorder; Central Nervous System Stimulants; Hippoca | 2006 |
Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: A preliminary report.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Body Mass Index; Female; Follow-Up Studies; H | 2006 |
Cingulate gyrus volumetry in drug free bipolar patients and patients treated with valproate or valproate and quetiapine.
Topics: Adolescent; Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenz | 2007 |
Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania.
Topics: Animals; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Catalase; Dextroamphetamine; Disease M | 2006 |
Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes.
Topics: Animals; Anticonvulsants; Astrocytes; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Cell Comm | 2006 |
Atypical antipsychotics related metabolic syndrome in bipolar patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Carbama | 2007 |
Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis.
Topics: Adult; Aggression; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Case-Control Studies; Dr | 2006 |
Regional cerebral glucose metabolic abnormalities in bipolar II depression.
Topics: Amygdala; Antimanic Agents; Bipolar Disorder; Blood Glucose; Brain; Brain Mapping; Depression; Femal | 2007 |
Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Topics: Adult; Akathisia, Drug-Induced; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Basal Gangl | 2006 |
Hippocampal 1H MRS in patients with bipolar disorder taking valproate versus valproate plus quetiapine.
Topics: Adult; Analysis of Variance; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiaze | 2007 |
Lamotrigine combined with divalproex or lithium for bipolar disorder: a case series.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combinat | 2006 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.
Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Bipo | 2006 |
Lamotrigine added to valproate successfully treated a case of ultra-rapid cycling bipolar disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Calcium Channel Blockers; Drug Therapy, Combination; Huma | 2007 |
Cognitive functioning and instrumental activities of daily living in late-life bipolar disorder.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anticonvulsants; Antimanic Agents; Bipolar Diso | 2007 |
Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Cardiovascular Diseases; Drug Monitori | 2007 |
Characteristics of psychotic patients with foreign accent syndrome.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; C | 2007 |
Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania.
Topics: Antipsychotic Agents; Asperger Syndrome; Attention Deficit Disorder with Hyperactivity; Bipolar Diso | 2007 |
Drug-induced Brugada syndrome with ST-T wave alternans and long QT.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Arrhythmias, Cardiac; | 2007 |
Health-related quality of life in adolescents with bipolar I disorder.
Topics: Activities of Daily Living; Adolescent; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Di | 2007 |
Effects of lithium and valproate on hippocampus citrate synthase activity in an animal model of mania.
Topics: Amphetamine; Analysis of Variance; Animals; Antimanic Agents; Bipolar Disorder; Citrate (si)-Synthas | 2007 |
Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine.
Topics: Adult; Aggression; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clinical Trials, Phase | 2007 |
Quetiapine in the treatment of acute mania: target dose for efficacious treatment.
Topics: Acute Disease; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; | 2007 |
Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Double- | 2007 |
Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania.
Topics: Acute Disease; Affect; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; | 2007 |
Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Double- | 2007 |
Polypharmacy and suicide attempts in bipolar disorder.
Topics: Adolescent; Adult; Age of Onset; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipo | 2007 |
Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study.
Topics: Adult; Aged; Aged, 80 and over; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Dis | 2007 |
Response and remission in adolescent mania: signal detection analyses of the young mania rating scale.
Topics: Acute Disease; Adolescent; Antimanic Agents; Bipolar Disorder; Dibenzothiazepines; Female; Humans; M | 2007 |
Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Drug A | 2008 |
Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania.
Topics: Amphetamine; Animals; Antimanic Agents; Bipolar Disorder; Disease Models, Animal; Hippocampus; Lithi | 2008 |
Polypharmacy and EPS in a child; a case report.
Topics: Attention Deficit Disorder with Hyperactivity; Benztropine; Bipolar Disorder; Child; Comorbidity; Do | 2007 |
Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Cognition Disorders; Diagnostic and Statistic | 2007 |
Adherence to pharmacological treatment for juvenile bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Child; Child of Impaired Parents; Female; Humans; Lithium Carbon | 2007 |
Bipolar pharmacotherapy and suicidal behavior Part 3: impact of antipsychotics.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Thera | 2007 |
A closer look: the benefits and effectiveness of cognitive behavioral therapy on a female-specific unit for treatment of bipolar disorder.
Topics: Adult; Bipolar Disorder; Cognitive Behavioral Therapy; Female; Health Knowledge, Attitudes, Practice | 2007 |
Bipolar pharmacotherapy and suicidal behavior. Part I: Lithium, divalproex and carbamazepine.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Female; Hospitalization; Humans; | 2007 |
Addition of lamotrigine to valproic acid: a successful outcome in a case of rapid-cycling bipolar affective disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Lamotrigine; | 2007 |
Cost analysis of divalproex sodium extended-release compared to valproic acid in the treatment of bipolar disorder.
Topics: Bipolar Disorder; Delayed-Action Preparations; Drug Costs; Gastrointestinal Tract; Humans; Monte Car | 2007 |
Reduction of dominant or submissive behaviors as models for antimanic or antidepressant drug testing: technical considerations.
Topics: Animals; Antidepressive Agents; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Data Interpret | 2007 |
Dosing of divalproex extended release.
Topics: Acute Disease; Administration, Oral; Antimanic Agents; Bipolar Disorder; Delayed-Action Preparations | 2007 |
Divalproex, lithium and suicide among Medicaid patients with bipolar disorder.
Topics: Adult; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Emerge | 2008 |
Chronic valproic acid intoxication: reversal by naloxone.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Female; Humans; Naloxone; Narcotic Antagonists; Poisoning; | 2007 |
Resolution of haloperidol-induced hyperprolactinemia with aripiprazole.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clonazepam; Dose-Resp | 2007 |
Menopause manifesting as bipolar symptoms.
Topics: Antipsychotic Agents; Bipolar Disorder; Depressive Disorder, Major; Dibenzothiazepines; Estrogen Rep | 2007 |
Psychiatric use and utility of divalproex sodium in Connecticut prisons.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Connecticut; Drug Utilization; Female; Humans | 2008 |
A case of catatonia resembling frontotemporal dementia and resolved with electroconvulsive therapy.
Topics: Anti-Arrhythmia Agents; Anticonvulsants; Antimanic Agents; Atrophy; Atropine; Bipolar Disorder; Cata | 2009 |
[Lithium intoxications at normal serum levels].
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Delirium; Dose-Response Relationship, Drug | 2008 |
Secondary bipolar disorder and Diogenes syndrome in frontotemporal dementia: behavioral improvement with quetiapine and sodium valproate.
Topics: Antipsychotic Agents; Behavioral Symptoms; Bipolar Disorder; Dementia; Dibenzothiazepines; Female; H | 2007 |
Divalproex sodium vs. valproic acid: drug utilization patterns, persistence rates and predictors of hospitalization among VA patients diagnosed with bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Cohort Studies; Drug Utilization; Drugs, Generic; Hospitalizatio | 2007 |
A successful outcome with valproic acid in a case of mania secondary to stroke of the right frontal lobe.
Topics: Anticonvulsants; Bipolar Disorder; Female; Frontal Lobe; Humans; Middle Aged; Stroke; Treatment Outc | 2008 |
Comments on "Addition of lamotrigine to valproic acid: a successful outcome in a case of rapid-cycling bipolar affective disorder".
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Lamotrig | 2008 |
Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid.
Topics: Adolescent; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bipolar Disorder; | 2009 |
The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior.
Topics: Animals; Antimanic Agents; Behavior, Animal; Benzodiazepines; Bipolar Disorder; Cells, Cultured; Dis | 2008 |
Brain creatine kinase activity in an animal model of mania.
Topics: Amphetamine; Animals; Antimanic Agents; Bipolar Disorder; Brain; Central Nervous System Stimulants; | 2008 |
Valproate-induced subclinical hypothyroidism.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Hypothyroidism; Male; Valproic Acid | 2008 |
Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Drug | 2008 |
Changes in outpatient lithium treatment in the Netherlands during 1996-2005.
Topics: Ambulatory Care; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Cohort Studies; Drug | 2008 |
Deconstructing a medication regimen.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Benztropine; Biotransformation; Bipolar Disorder | 2008 |
[Secondary delirium due to the use of lamotrigine with abrupt increase valproic acid's dose].
Topics: Adult; Anticonvulsants; Bipolar Disorder; Delirium; Drug Interactions; Drug Therapy, Combination; Hu | 2008 |
Growing evidence to support early intervention in early onset bipolar disorder?
Topics: Adolescent; Age of Onset; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Child; Child, Pre | 2008 |
Sustained low-efficiency dialysis with filtration (SLEDD-f) in the management of acute sodium valproate intoxication.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Drug Overdose; Female; Hemodiafiltration; Humans; Valproi | 2008 |
Pediatric bipolar disorder: evidence-based psychopharmacological treatments.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Drug Therapy, Combination; Humans; | 2008 |
Neuronal peroxisome proliferator-activated receptor gamma signaling: regulation by mood-stabilizer valproate.
Topics: Acyl-CoA Oxidase; Animals; Antimanic Agents; Bipolar Disorder; Catalase; Epilepsy; Gene Expression; | 2008 |
Risperidone and valproate for mania following stroke.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Humans; Male; Middle Aged; Risperidone; Str | 2008 |
A case of hyperammonemic encephalopathy after 11 years of valproate therapy.
Topics: Aged; Anticonvulsants; Bipolar Disorder; Delayed-Action Preparations; Drug Therapy, Combination; Hum | 2008 |
New drugs for mania?
Topics: Affective Disorders, Psychotic; Bipolar Disorder; Humans; Propranolol; Psychotic Disorders; Valproic | 1983 |
[Prevention of phases in manic-depressive disorder with dipropylacetamide (Depamide)].
Topics: Adult; Bipolar Disorder; Female; Humans; Male; Valproic Acid | 1983 |
Valproic acid amide as a prophylactic agent in affective and schizoaffective disorders.
Topics: Adult; Bipolar Disorder; Humans; Middle Aged; Mood Disorders; Psychotic Disorders; Recurrence; Valpr | 1984 |
The role of sodium valproate as an anti-manic agent.
Topics: Adult; Bipolar Disorder; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Valpro | 1984 |
On a possible role of GABA in mania. Therapeutic efficacy of sodium valproate.
Topics: Affective Disorders, Psychotic; Bipolar Disorder; Double-Blind Method; Drug Evaluation; gamma-Aminob | 1981 |
Relapse and impairment in bipolar disorder.
Topics: Adaptation, Psychological; Adult; Ambulatory Care; Bipolar Disorder; Carbamazepine; Drug Therapy, Co | 1995 |
Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Cholecystitis; Comorbidity; Epilepsy; Humans; Intellectual | 1995 |
Sucralfate in bipolar patients with valproate intolerance.
Topics: Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Lithium; Middle Aged; Sucralfate; Valpr | 1995 |
Valproate and carbamazepine join lithium as primary treatments for bipolar disorder.
Topics: Bipolar Disorder; Carbamazepine; Electroconvulsive Therapy; Humans; Lithium; Valproic Acid | 1995 |
A clinically significant interaction between clozapine and valproate.
Topics: Adult; Arousal; Bipolar Disorder; Clozapine; Confusion; Dose-Response Relationship, Drug; Drug Inter | 1995 |
Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders.
Topics: Bipolar Disorder; Brain Damage, Chronic; Cohort Studies; Double-Blind Method; Electroencephalography | 1994 |
Lithium: the present and the future.
Topics: Acute Disease; Bipolar Disorder; Carbamazepine; Depressive Disorder; Drug Interactions; Female; Huma | 1995 |
Choosing lithium, anticonvulsant, or electroconvulsant therapy for mood disorders.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Controlled Clinical Trials as Topic; Electroconvul | 1995 |
History of the development of valproate for treatment of bipolar disorder.
Topics: Animals; Bipolar Disorder; Clinical Trials as Topic; Drug Approval; Eye Movements; Female; History, | 1995 |
Anticonvulsant therapy for mood disorders.
Topics: Affect; Anticonvulsants; Bipolar Disorder; Carbamazepine; Humans; Lithium; Valproic Acid | 1994 |
Valproate/nortriptyline interaction.
Topics: Adult; Bipolar Disorder; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Nortrip | 1994 |
Response to anticonvulsant substitution among refractory bipolar manic patients.
Topics: Adult; Aged; Bipolar Disorder; Female; Humans; Male; Middle Aged; Valproic Acid | 1994 |
Valproate prophylaxis against steroid induced psychosis.
Topics: Adult; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans | 1994 |
Valproate for bipolar disorder.
Topics: Adult; Bipolar Disorder; Clinical Trials as Topic; Humans; Valproic Acid | 1994 |
Combining lithium and sodium valproate for bipolar disorder.
Topics: Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Lithium; Male; Middle Aged; Valproic Ac | 1994 |
Safety and efficacy of divalproex sodium in elderly bipolar patients.
Topics: Aged; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Lithium; Male; Treatment Outcome; | 1994 |
Manic depressive disorder and lithium over the decades: the very educational case of Mrs. L.
Topics: Aged; Aged, 80 and over; Bipolar Disorder; Drug Administration Schedule; Electroconvulsive Therapy; | 1994 |
Efficacy of divalproex vs lithium and placebo in mania.
Topics: Bipolar Disorder; Humans; Lithium; Valproic Acid | 1994 |
Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders.
Topics: Adult; Bipolar Disorder; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1994 |
Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients.
Topics: Adult; Alcoholism; Bipolar Disorder; Comorbidity; Depressive Disorder; Dose-Response Relationship, D | 1994 |
Valproate as a loading treatment in acute mania.
Topics: Acute Disease; Adult; Bipolar Disorder; Female; Humans; Male; Middle Aged; Psychotic Disorders; Valp | 1993 |
The effect of valproate on bipolar spectrum temperamental disorders.
Topics: Adult; Bipolar Disorder; Cyclothymic Disorder; Female; Humans; Male; Middle Aged; Personality Disord | 1993 |
Divalproex sodium in the treatment of refractory affective disorders.
Topics: Adult; Aged; Bipolar Disorder; Carbamazepine; Depressive Disorder; Drug Therapy, Combination; Female | 1993 |
Valproic acid-induced truncal weakness and respiratory failure.
Topics: Aged; Bipolar Disorder; Drug Therapy, Combination; Humans; Male; Muscular Diseases; Respiratory Insu | 1993 |
Clinical correlates of valproate augmentation in refractory bipolar disorder.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Drug Therapy, Combination; Female; Hospitalization; | 1993 |
New onset rapid cycling bipolar disorder in an 87 year old woman.
Topics: Aged; Aged, 80 and over; Bipolar Disorder; Cerebral Infarction; Female; Humans; Hypothyroidism; Lith | 1993 |
Expanding uses of anticonvulsants in the treatment of bipolar disorder.
Topics: Bipolar Disorder; Carbamazepine; Clonazepam; Humans; Valproic Acid | 1993 |
Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium.
Topics: Adult; Aged; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 1993 |
Valproic acid for dysphoric mania in a mentally retarded adolescent.
Topics: Adolescent; Bipolar Disorder; Drug Administration Schedule; Female; Humans; Intellectual Disability; | 1995 |
Acute manic episodes in pregnancy.
Topics: Adult; Bipolar Disorder; Chlorpromazine; Comorbidity; Diabetes Mellitus, Type 1; Drug Therapy, Combi | 1996 |
Tolerability of divalproex sodium in elderly psychiatric patients with mixed diagnoses.
Topics: Aged; Anticonvulsants; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Tolerance; Female; H | 1995 |
Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs.
Topics: Affect; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Depressive | 1995 |
Trends in pharmacotherapy of Schizoaffective and bipolar affective disorders: a 5-year naturalistic study.
Topics: Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Drug Therapy, Combination; Drug Utilizati | 1996 |
Treatment of dysphoric mania with nefazodone.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Drug Therapy, Combination; Female | 1996 |
A pharmacoeconomic model of divalproex vs. lithium in the acute and prophylactic treatment of bipolar I disorder.
Topics: Acute Disease; Ambulatory Care; Bipolar Disorder; Costs and Cost Analysis; Decision Support Techniqu | 1996 |
Valproic acid in ultra-rapid cycling: a case report.
Topics: Bipolar Disorder; Humans; Male; Middle Aged; Valproic Acid | 1995 |
ECT-valproic acid interaction.
Topics: Aged; Bipolar Disorder; Combined Modality Therapy; Drug Therapy, Combination; Electroconvulsive Ther | 1995 |
Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.
Topics: Adult; Bipolar Disorder; Cognition Disorders; Creativity; Drug Administration Schedule; Drug Therapy | 1996 |
Valproate treatment of alcohol withdrawal and mania.
Topics: Adult; Alcoholism; Bipolar Disorder; Ethanol; Humans; Male; Psychotic Disorders; Substance Withdrawa | 1996 |
National Institute of Mental Health Workshop Report on the Treatment of Bipolar Disorder.
Topics: Antidepressive Agents; Bipolar Disorder; Carbamazepine; Education; Humans; Lithium; Valproic Acid | 1996 |
Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Therapy, Combination; Humans; Lamotrigine; Male; Tria | 1996 |
Hormonal effects of valproic acid?
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Child; Female; Follow-Up Studies; Humans; Hyp | 1996 |
Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain?
Topics: Animals; Bipolar Disorder; Blotting, Western; Carbamazepine; Cell Line; Dose-Response Relationship, | 1996 |
Acute treatment of bipolar disorder with adjunctive risperidone in outpatients.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Therapy, Combination; Female; Hum | 1997 |
Response of kleptomania and mixed mania to valproate.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Comorbidity; Di | 1997 |
Extrapyramidal syndrome due to valproate administration as an adjunct to lithium in an elderly manic patient.
Topics: Aged; Antimanic Agents; Basal Ganglia Diseases; Bipolar Disorder; Drug Therapy, Combination; Female; | 1997 |
Dose-related thrombocytopenia and macrocytic anemia associated with valproate use in bipolar disorder.
Topics: Anemia, Macrocytic; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Middle Aged; Myelod | 1997 |
Drugs for psychiatric disorders.
Topics: Aged; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety; Benzodi | 1997 |
The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates.
Topics: Animals; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cerebral Cortex; Drug Interactio | 1997 |
Combined valproate or carbamazepine and electroconvulsive therapy.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 1997 |
Chronic neuroleptic exposure in bipolar outpatients.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Communi | 1997 |
Valproic acid for Kleine-Levin syndrome.
Topics: Adolescent; Anger; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; | 1997 |
Comparison of valproic acid and lithium in mania.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Administration Schedule; Drug Industry | 1997 |
Mania.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Lithium; Valproic Acid | 1997 |
Carnitine for valproic acid-induced hyperammonemia.
Topics: Adult; Ammonia; Bipolar Disorder; Carbamoyl-Phosphate Synthase (Ammonia); Carnitine; Depressive Diso | 1997 |
Lamotrigine treatment of rapid cycling bipolar disorder.
Topics: Adult; Aged; Anticonvulsants; Bipolar Disorder; Drug Administration Schedule; Drug Eruptions; Drug T | 1997 |
Borderline personality and bipolar disorder.
Topics: Bipolar Disorder; Borderline Personality Disorder; Diagnosis, Differential; Humans; Psychotherapy; T | 1997 |
Association between mood-stabilizing medication and mental health resource use in the management of acute mania.
Topics: Acute Disease; Adult; Aged; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug | 1997 |
Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission.
Topics: 5-Hydroxytryptophan; Adult; Animals; Bipolar Disorder; Dose-Response Relationship, Drug; Female; Hum | 1997 |
Bipolar disorder in children and adolescents: current challenges.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Clom | 1997 |
Toxic effects of nefazodone.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Female; Humans; | 1997 |
An open study of lamotrigine in refractory bipolar depression.
Topics: Adolescent; Adult; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Cohort Studies; Depress | 1997 |
Is divalproex a cost-effective alternative in the acute and prophylactic treatment of bipolar I disorder?
Topics: Acute Disease; Bipolar Disorder; Cost-Benefit Analysis; Drug Costs; Health Care Costs; Hospitalizati | 1997 |
Valproate and polycystic ovaries.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Female; Humans; Polycystic Ovary Syndrome; Va | 1998 |
Divalproate augmentation in lithium-resistant rapid cycling mania in four geriatric patients.
Topics: Age Factors; Aged; Aged, 80 and over; Bipolar Disorder; Confusion; Drug Administration Schedule; Dru | 1998 |
Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy.
Topics: Adolescent; Adult; Affect; Aged; Agoraphobia; Anxiety Disorders; Bipolar Disorder; Cognitive Behavio | 1998 |
Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combination; Female; H | 1998 |
Cost-effectiveness of divalproex versus lithium.
Topics: Bipolar Disorder; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Hospitalization; | 1997 |
Medication-induced hypomania in Asperger's disorder.
Topics: Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Bipolar Disorder | 1998 |
[Injectionable valproate: experiences in neurology pediatrics and psychiatry. Workshop at Hamburg, 8 November 1997].
Topics: Analgesics; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Child; Critical Care; Female; Human | 1998 |
Rapid titration of mood stabilizers predicts remission from mixed or pure mania in bipolar patients.
Topics: Adult; Analysis of Variance; Bipolar Disorder; Carbamazepine; Drug Administration Schedule; Drug The | 1998 |
Medication compliance among patients with bipolar disorder and substance use disorder.
Topics: Adult; Benzodiazepines; Bipolar Disorder; Carbamazepine; Comorbidity; Female; Humans; Lithium; Male; | 1998 |
Treatment of a case of comorbid bipolar disorder and attention-deficit/hyperactivity disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Attention Deficit Disorder with H | 1998 |
Tolerability of oral loading of divalproex sodium in the treatment of acute mania.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Antimanic Agents; Bipolar Disorder; Dose-Response | 1998 |
Dose-dependent valproic acid thrombocytopenia in bipolar disorder.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Female; Human | 1998 |
Divalproex treatment of mania in elderly patients.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Resistance; Evaluat | 1998 |
Possible risks associated with valproate treatment of AIDS-related mania.
Topics: Acquired Immunodeficiency Syndrome; Bipolar Disorder; Cytomegalovirus; Drug Costs; HIV-1; Humans; In | 1998 |
Comment on Vadney and Kraushaar's "Effect of switching from Depakene to generic valproic acid on individuals with mental retardation".
Topics: Anticonvulsants; Bipolar Disorder; Humans; Intellectual Disability; Valproic Acid | 1998 |
Use of mood stabilizers by hospitalized geriatric patients with bipolar disorder.
Topics: Aged; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Carbamazepine; Female; Geriatric Psy | 1998 |
Generalized edema with risperidone: divalproex sodium treatment.
Topics: Adult; Bipolar Disorder; Comorbidity; Edema; Epilepsy, Temporal Lobe; Humans; Male; Risperidone; Val | 1996 |
New perspectives in the treatment of acute mania: a single case report.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Infusions | 1998 |
Classic mania: treatment response to divalproex or lithium.
Topics: Bipolar Disorder; Depressive Disorder; Humans; Lithium; Psychiatric Status Rating Scales; Randomized | 1998 |
Delirium and persistent dyskinesia induced by a lithium-neuroleptic interaction.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Delirium; Dyskinesia, Drug-Induced; Female | 1998 |
The naturalistic course of pharmacologic treatment of children with maniclike symptoms: a systematic chart review.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; | 1998 |
Valproate robustly enhances AP-1 mediated gene expression.
Topics: Animals; Anticonvulsants; Bipolar Disorder; DNA-Binding Proteins; Gene Expression Regulation; Genes, | 1999 |
Clinical correlates of response to valproate in geriatric inpatients.
Topics: Age Factors; Aged; Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Drug Administration Schedu | 1998 |
Valproic acid intoxication in a patient with bipolar disorder and chronic uremia.
Topics: Antimanic Agents; Bipolar Disorder; Depression; Female; Humans; Hypokinesia; Kidney Failure, Chronic | 1999 |
Introduction: the use of mood stabilizers in the treatment of psychiatric disorders.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Humans; Li | 1999 |
Efficacy of lithium vs. valproate in the treatment of mania in the elderly: a retrospective study.
Topics: Age Factors; Age of Onset; Aged; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Female; Hospit | 1999 |
Valproate with lithium and carbamazepine in bipolar disorder.
Topics: Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Cross-Over Studies; Dose-Response Relatio | 1999 |
Mania onset while using dehydroepiandrosterone.
Topics: Acute Disease; Bipolar Disorder; Dehydroepiandrosterone; Drug Therapy, Combination; Haloperidol; Hum | 1999 |
Mood stabilizer combinations for bipolar disorder.
Topics: Acetates; Adolescent; Age Factors; Amines; Antimanic Agents; Bipolar Disorder; Child; Cyclohexanecar | 1999 |
Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters.
Topics: Adaptation, Physiological; Adult; Aged; Aged, 80 and over; Bayes Theorem; Bipolar Disorder; Case-Con | 1999 |
Divalproex for the treatment of geriatric bipolar disorder.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Male; Middle Ag | 1999 |
Therapeutic drug monitoring of mood stabilizers in Medicaid patients with bipolar disorder.
Topics: Adolescent; Adult; Bipolar Disorder; Blood Chemical Analysis; Carbamazepine; Case Management; Drug M | 1999 |
Valproate for alcoholics with bipolar disorder.
Topics: Adult; Alcoholism; Anticonvulsants; Bipolar Disorder; Comorbidity; Female; gamma-Glutamyltransferase | 1999 |
Isotretinoin treatment of a woman with bipolar disorder.
Topics: Acne Vulgaris; Adult; Bipolar Disorder; Comorbidity; Drug Therapy, Combination; Female; Humans; Isot | 1999 |
Sodium valproate increases pupillary responsiveness to a cholinergic agonist in responders with mania.
Topics: Adult; Bipolar Disorder; Cholinergic Agonists; Humans; Male; Middle Aged; Muscarinic Agonists; Piloc | 1999 |
Extrapyramidal symptoms associated with the adjunct of nortriptyline to a venlafaxine-valproic acid combination.
Topics: Aged; Anticonvulsants; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; B | 1999 |
Intravenous valproate loading in acutely manic and depressed bipolar I patients.
Topics: Acute Disease; Administration, Oral; Adult; Antimanic Agents; Bipolar Disorder; Dose-Response Relati | 1999 |
Valproate-induced hyperammonemia in the psychiatric setting: 2 cases.
Topics: Adult; Ammonia; Anticonvulsants; Bipolar Disorder; Humans; Male; Mental Disorders; Middle Aged; Psyc | 1999 |
Modulation of carbachol-stimulated AP-1 DNA binding activity by therapeutic agents for bipolar disorder in human neuroblastoma SH-SY5Y cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antipsychotic Agents; Bipolar Disorder; Calcium; Calc | 1999 |
Lamotrigine as prophylaxis against steroid-induced mania.
Topics: Adult; Anti-Inflammatory Agents; Antimanic Agents; Bipolar Disorder; Contraindications; Female; Huma | 1999 |
Diabetic ketoacidosis with clozapine treatment.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clozapine; Diabetic Ketoacidosis; Drug The | 1999 |
[Pharmacotherapy in manic-depressive disorder].
Topics: Antimanic Agents; Bipolar Disorder; Drug Approval; Humans; Netherlands; Psychotropic Drugs; United S | 1999 |
Fifty years of treatments for bipolar disorder: a celebration of John Cade's discovery.
Topics: Antimanic Agents; Bipolar Disorder; History, 20th Century; Humans; Lithium Carbonate; Suicide, Attem | 1999 |
Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations.
Topics: Antimanic Agents; Astrocytoma; Bipolar Disorder; Brain; Brain Neoplasms; Carbamazepine; Dose-Respons | 2000 |
Pancytopenia and valproic acid: a dose-related association.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Humans; Male; Pancytopen | 2000 |
Visual and auditory hallucinations with the association of bupropion and valproate.
Topics: Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Bupropion; Hallucinations; Humans; Male; M | 2000 |
Mood stabilizer augmentation with olanzapine in acutely manic children.
Topics: Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzodiazepin | 2000 |
Correlation of valproate plasma concentrations and dose in bipolar affective disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration Sch | 2000 |
Maintenance treatment in bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Follow-Up Studies; Humans; Lithium Carbonate; Patient Selection; | 2000 |
Divalproex sodium to treat concomitant substance abuse and mood disorders.
Topics: Adolescent; Adult; Alcoholism; Bipolar Disorder; Comorbidity; Female; Humans; Male; Middle Aged; Moo | 2000 |
Serum valproate levels in 6 breastfeeding mother-infant pairs.
Topics: Age Factors; Animals; Bipolar Disorder; Breast Feeding; Female; Humans; Infant; Infant, Newborn; Pos | 2000 |
Low-dose lithium augmentation of divalproex in geriatric mania.
Topics: Acute Disease; Aged; Antimanic Agents; Bipolar Disorder; Cognition Disorders; Dose-Response Relation | 2000 |
Parenteral valproate for control of acute mania.
Topics: Acute Disease; Aged; Aged, 80 and over; Bipolar Disorder; Female; Humans; Infusions, Intravenous; Tr | 2000 |
[Valproic acid in prophylaxis of bipolar disorder. A case of valproate-induced encephalopathy].
Topics: Adult; Antimanic Agents; Ataxia; Bipolar Disorder; Brain Diseases, Metabolic; Dyskinesias; Epilepsy, | 2000 |
Lamotrigine and clozapine for bipolar disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Clozapine; Drug Therapy, Combination; | 2000 |
Clinical and biological findings in a case with 48-hour bipolar ultrarapid cycling before and during valproate treatment.
Topics: Aged; Bipolar Disorder; Depressive Disorder; Functional Laterality; Human Growth Hormone; Humans; Ma | 2000 |
Possible risperidone-induced visual hallucinations.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diagnosis, Du | 2000 |
Treatment of comorbid bipolar disorder and epilepsy with valproate.
Topics: Anticonvulsants; Bipolar Disorder; Epilepsy; Humans; Valproic Acid | 2000 |
Influence of chronic barbiturate administration on sleep apnea after hypersomnia presentation: case study.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Disorders of Excessive Somnolence; Dose-Response Relations | 2000 |
Chronic valproate treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Calcium-Binding Proteins; Calreticulin; Cerebral Cortex | 2000 |
Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness.
Topics: Affect; Antimanic Agents; Atrophy; Bipolar Disorder; Brain; Calcium-Calmodulin-Dependent Protein Kin | 2000 |
Periodic motor impairments in a case of 48-hour bipolar ultrarapid cycling before and under treatment with valproate.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Handwriting; Humans; Male; Movement D | 2000 |
Valproate and other anticonvulsants for psychiatric disorders.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar | 2000 |
Clozapine therapy for a patient with a history of Hodgkin's disease.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Clozapine; Drug Therapy, Combination; Female; Hodgkin | 2001 |
Valproate-induced tinnitus misinterpreted as psychotic symptoms.
Topics: Antimanic Agents; Bipolar Disorder; Diagnosis, Differential; Hallucinations; Humans; Male; Middle Ag | 2000 |
Difficulties in diagnosis and management of bipolar disorder: three case presentations.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Combined Modality The | 2000 |
Evaluating the tolerability of the newer mood stabilizers.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Central Nervous System Diseases; Cyclohexanecar | 2001 |
Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antimanic Agents; Bipolar Disorder; Carbamazepine; De | 2001 |
Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex.
Topics: Adult; Affect; Bipolar Disorder; Brain Mapping; Choline; Dominance, Cerebral; Female; Gyrus Cinguli; | 2000 |
Pharmacologic loading in the treatment of acute mania.
Topics: Acute Disease; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Dose-Response Rel | 2000 |
The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes.
Topics: Adult; Anti-HIV Agents; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; HIV Seroposit | 2001 |
The use of intravenous valproate in psychiatry.
Topics: Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, | 2001 |
Effect of lithium and sodium valproate ions on resting membrane potentials in neurons: an hypothesis.
Topics: Bipolar Disorder; Dose-Response Relationship, Drug; Humans; Ion Channels; Lithium Carbonate; Membran | 2001 |
Mood stabilizers in Asperger's syndrome.
Topics: Adult; Antimanic Agents; Asperger Syndrome; Bipolar Disorder; Drug Therapy, Combination; Humans; Lit | 2001 |
Retrospective analysis of serum valproate levels and need for an antidepressant drug.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Chi-Square Distribution; Female; H | 2001 |
Introduction: the role of anticonvulsants as mood stabilizers.
Topics: Anticonvulsants; Bipolar Disorder; Depressive Disorder; Humans; Lamotrigine; Lithium; Terminology as | 2001 |
[Hypernatremia as a rare complication in change from lithium to valproate].
Topics: Antimanic Agents; Bipolar Disorder; Diabetes Insipidus, Nephrogenic; Drug Therapy, Combination; Fema | 2001 |
Uses of intravenous valproate in geriatric psychiatry.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antimanic Agents; Bipolar Disorder; Female; Geriatric Ps | 2001 |
Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depression; Drug Therapy, Combinat | 2001 |
Does EEG predict response to valproate versus lithium in patients with mania?
Topics: Acute Disease; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brain; Electroencephalogr | 2001 |
Pharmacokinetics of valproic acid in patients with bipolar disorder.
Topics: Adult; Antimanic Agents; Biological Availability; Bipolar Disorder; Dose-Response Relationship, Drug | 2001 |
Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency.
Topics: Acetylcarnitine; Acute Disease; Antimanic Agents; Bipolar Disorder; Carnitine O-Palmitoyltransferase | 2001 |
Disodium valproate: new preparation. An alternative for acute mania after lithium failure or intolerance.
Topics: Antimanic Agents; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Drug Approval; France; | 2001 |
Corticosteroid-induced acute mania during a cluster headache episode.
Topics: Acute Disease; Adolescent; Age of Onset; Antimanic Agents; Bipolar Disorder; Cluster Headache; Gluco | 2001 |
Agitation as a paradoxical effect of divalproex sodium: a case report.
Topics: Adult; Akathisia, Drug-Induced; Bipolar Disorder; Dose-Response Relationship, Drug; Humans; Male; Va | 2001 |
[Manic syndrome: diagnostic trends and principles of treatment].
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Chl | 1998 |
Consensus guidelines outline drug selection and sequencing options for bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cyclohexanols; Depr | 2000 |
Valproate in very young children: an open case series with a brief follow-up.
Topics: Affect; Age Factors; Antimanic Agents; Bipolar Disorder; Child; Child, Preschool; Female; Humans; In | 2001 |
Intravenous valproate treatment: some observations.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Injections, Intravenous; Valproic Acid | 2002 |
Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder.
Topics: Administration, Oral; Animals; Anticonvulsants; Bipolar Disorder; Brain; Carbamazepine; Disease Mode | 2002 |
Lithium in bipolar mood disorder.
Topics: Antimanic Agents; Bipolar Disorder; Evidence-Based Medicine; Humans; Lithium Compounds; Valproic Aci | 2002 |
Cerebellar ataxia with intravenous valproate and haloperidol.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cerebellar Ataxia; Haloperidol; Hum | 2002 |
Divalproex in the management of neuropsychiatric complications of remote acquired brain injury.
Topics: Adolescent; Adult; Anticonvulsants; Bipolar Disorder; Brain Injuries; Child; Child, Preschool; Depre | 2002 |
PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium.
Topics: Adult; Age Factors; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Corpus Striatum; Dihydr | 2002 |
Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder.
Topics: Adolescent; Adult; Age Factors; Ambulatory Care; Anticonvulsants; Bipolar Disorder; Female; Health S | 2002 |
A common mechanism of action for three mood-stabilizing drugs.
Topics: Animals; Animals, Newborn; Antimanic Agents; Bipolar Disorder; Calcium-Calmodulin-Dependent Protein | 2002 |
Nonadherence with mood stabilizers: prevalence and predictors.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Attitude of Health Personnel; Attitude to Health; Bip | 2002 |
[Manic-depressive psychoses. Chronic treatment with tricyclic antidepressive agents].
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Bipolar Disorder; Female; Humans; Lithium; Male; Midd | 1977 |
Augmentation of valproate with lithium in a case of rapid cycling affective disorder.
Topics: Aged; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy | 1992 |
Clinical experience with valproic acid in 22 patients with refractory bipolar mood disorder.
Topics: Adult; Aged; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 1992 |
Mania and anticonvulsant therapy.
Topics: Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Epilepsy, Absence; Ethosuxim | 1992 |
Combined valproate and carbamazepine treatment of bipolar disorder.
Topics: Adult; Bipolar Disorder; Carbamazepine; Drug Therapy, Combination; Humans; Lithium Carbonate; Male; | 1992 |
Algorithm for patient management of acute manic states: lithium, valproate, or carbamazepine?
Topics: Acute Disease; Algorithms; Bipolar Disorder; Carbamazepine; Humans; Lithium; Valproic Acid | 1992 |
Verapamil and valproic acid treatment of prolonged mania.
Topics: Adolescent; Arousal; Bipolar Disorder; Drug Therapy, Combination; Humans; Intellectual Disability; M | 1992 |
A potential drug interaction between fluoxetine and valproic acid.
Topics: Bipolar Disorder; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Intellec | 1991 |
Alternatives to lithium in the treatment of bipolar disorder.
Topics: Bipolar Disorder; Carbamazepine; Humans; Valproic Acid | 1991 |
Life events and the course of bipolar disorder.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Female; Follow-Up Stu | 1990 |
Valproate use in the older manic patient.
Topics: Age Factors; Aged; Antipsychotic Agents; Bipolar Disorder; Combined Modality Therapy; Drug Evaluatio | 1990 |
Four cases of obstructive sleep apnea associated with treatment-resistant mania.
Topics: Adult; Bipolar Disorder; Clonazepam; Female; Follow-Up Studies; Hospitalization; Humans; Lithium; Mi | 1991 |
Divalproex-responsive rapid cycling bipolar disorder in a patient with Down's syndrome: implications for the Down's syndrome-mania hypothesis.
Topics: Adult; Affect; Bipolar Disorder; Diarrhea; Humans; Intellectual Disability; Male; Valproic Acid | 1991 |
On the use of anticonvulsants for manic depression during pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Bipolar Disorder; Carbamazepine; Female; Humans; Infan | 1990 |
Valproic acid in bipolar disorder.
Topics: Bipolar Disorder; Humans; Valproic Acid | 1990 |
Valproic acid in the treatment of refractory bipolar disorder.
Topics: Adolescent; Bipolar Disorder; Humans; Male; Valproic Acid | 1990 |
Use of anticonvulsants for manic depression during pregnancy.
Topics: Bipolar Disorder; Female; Humans; Neural Tube Defects; Pregnancy; Pregnancy Complications; Valproic | 1990 |
The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders.
Topics: Adult; Autistic Disorder; Bipolar Disorder; Chronic Disease; Female; Follow-Up Studies; Fragile X Sy | 1989 |
Valproate in the treatment of rapid-cycling bipolar disorder.
Topics: Bipolar Disorder; Humans; Hypnosis; Valproic Acid | 1989 |
Carbamazepine auto- and hetero-induction complicating clinical care.
Topics: Bipolar Disorder; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female | 1989 |
GABA and circadian timekeeping: implications for manic-depression and sleep disorders.
Topics: 4-Aminobutyrate Transaminase; Acetylcholine; Aldehyde Oxidoreductases; Animals; Benzodiazepines; Bip | 1986 |
The use of alternative drug therapy in nine patients with recurrent affective disorder resistant to conventional prophylaxis.
Topics: Adult; Aged; Bipolar Disorder; Carbamazepine; Drug Therapy, Combination; Female; Humans; Lithium; Mi | 1986 |
New developments in long-term preventive therapy.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Diethylcarbamazine; Dose-Response Rela | 1986 |
[Preventive effect of dipropylacetamide in bipolar manic-depressive psychoses].
Topics: Anticonvulsants; Bipolar Disorder; Humans; Valproic Acid | 1987 |
[Personal experience with the prophylactic effect of dipropylacetamide].
Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; Humans; Male; Middle Aged; Psychotic Disorders | 1988 |
Lithium-induced downbeat nystagmus.
Topics: Adult; Bipolar Disorder; Electrooculography; Female; Haloperidol; Humans; Lithium; Middle Aged; Nyst | 1988 |
Valproate in the treatment of rapid-cycling bipolar disorder.
Topics: Adult; Bipolar Disorder; Female; Humans; Male; Middle Aged; Schizotypal Personality Disorder; Valpro | 1988 |
A clinically significant interaction between carbamazepine and valproic acid.
Topics: Adult; Bipolar Disorder; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1988 |
Treatment of bulimia and rapid-cycling bipolar disorder with sodium valproate: a case report.
Topics: Adolescent; Bipolar Disorder; Feeding and Eating Disorders; Female; Humans; Hyperphagia; Valproic Ac | 1985 |